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Abstract 
Protozoan parasites of the genus Leishmania are the causative agents of a 
complex of diseases referred to as leishmaniasis. Leishmania have a digenetic life 
cycle that involves a sand fly vector (promastigote stage) and a mammalian host 
(amastigote stage). The parasites reside within very different environmental niches 
in the two different hosts, and therefore must be able to adapt their energy 
metabolism to the available carbon and nitrogen sources. 
Lipoic acid (LA) is a multifaceted molecule, and plays an important role as a water- 
and fat-soluble antioxidant. LA is also an essential cofactor of the α-ketoacid 
dehydrogenase complexes (α-KADHs) and of the glycine cleavage complex 
(GCC). The α-KADHs include the pyruvate dehydrogenase (PDH), branched-chain 
α-ketoacid dehydrogenase (BCKDH) and α-ketoglutarate dehydrogenase (α-
KGDH), each of which is integral to cellular energy metabolism. In some 
organisms, LA can be acquired through salvage and biosynthesis pathways, and 
yet others only encode enzymes that permit one of the two pathways. Lipoylation 
of the PDH has been demonstrated in a parasite related to Leishmania called 
Trypanosoma brucei; however there have not been any investigations into the 
enzymes involved in LA metabolism in either Leishmania or Trypanosoma brucei.  
In silico analyses identified genes encoding for proteins involved in both LA 
biosynthesis and salvage (lipoic acid synthase (LIPA), octanoyl-[acyl carrier 
protein]: protein N-octanoyltransferase (LIPB) and lipoate protein ligase (LPLA), 
respectively), and it was predicted that all three proteins possess mitochondrial 
targeting peptides. Targeting of these proteins to the mitochondrion was verified 
by a green fluorescence protein (GFP) reporter system, and by subcellular pre-
fractionation using digitonin followed by western blotting. Functionality of L. major 
putative LIPA, LIPB and LPLA genes was determined by showing that the genes 
complemented the no-growth phenotype of bacteria deficient in either lipA or lipB 
genes on minimal medium. 
Bioinformatics analyses also showed that L. major possesses genes encoding all 
of the subunits comprising the different α-KADHs and the GCC, and the subunits 
were predicted to possess mitochondrial targeting peptides. Western blotting of 
promastigote protein with an antibody recognising protein-bound LA (α-LA 
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antibody) identified four proteins, which based upon predicted molecular sizes, 
correspond to the lipoylated transacylase subunits of the three α-KADHs and the 
H-protein of the GCC. Interestingly, the lipoylation pattern changes throughout 
promastigote growth in vitro, with α-KGDH being lipoylated throughout 
promastigote life while PDH and BCKDH are not lipoylated and presumably not 
active in metacyclic promastigotes. These findings indicate that modification of α-
KADHs and the GCC by lipoylation is a dynamic process, possibly reflecting 
adaptations in the parasite’s energy metabolism during their developmental cycle. 
Three approaches were taken to study the relative importance of the LA 
biosynthesis and salvage pathways in L. major promastigotes. First, LA analogues 
8’ bromooctanoic acid (8-BOA) and octanoic acid (OA) were tested for their effects 
on growth in L. major maintained in lipid-depleted medium. The IC50 for 8-BOA 
was relatively high when compared to that determined in other organisms, 
suggesting that LA biosynthesis can compensate for a decrease in LA salvage in 
medium deficient in LA. Second, attempts to replace either LIPA or LPLA genes 
with selectable markers were unsuccessful. LPLA could however, be knocked-out 
when an extra copy of the gene was introduced into the parasite’s genome. These 
data suggest that both LA acquisition pathways might be essential for 
promastigote growth and development. Third, overexpression of C-terminal His-
tagged versions of LIPB (LIPB-His), LPLA (LPLA-His) and a LPLA active site 
mutant, LPLAH118A (LPLAH118A-His), resulted in slow-growth phenotypes. 
Overexpression of LIPB-His and LPLAH118A-His resulted in lipoylation of the PDH 
and BCKDH in metacyclic promastigotes, which is not observed in wild-type 
metacyclic promastigotes. It is hypothesised that LA biosynthesis and salvage 
enzymes could have differential substrate-specificities in L. major. 
A number of avenues require further investigation, including the mechanism that 
permits a relatively rapid turnover of lipoylated protein, and whether lipoylation 
patterns differ depending upon the carbon sources that are provided in the growth 
medium. Also, it will be interesting to determine whether LIPB and LPLA have 
intrinsic substrate-specificities, and whether this is sufficient to explain the fact that 
both LIPA and LPLA are essential in the promastigote stage in vitro. 
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1 Introduction 
1.1 Leishmania 
1.1.1 Aetiology 
The leishmaniases describe a spectrum of zoonotic diseases that are caused by 
obligate intracellular protozoa of the genus Leishmania (family Trypanosomatidae, 
order Kinetoplastida), which are transmitted to a vertebrate host through the bite of 
an infected sandfly (Herwaldt, 1999). Leishmaniasis is a complex of diseases, 
which are classified into four clinical forms: 
i. Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis, and 
results in cutaneous sores, which are localised to the vector bite site. It is caused 
mainly by Leishmania major, Leishmania tropica and Leishmania aethiopica in the 
Old World, and by Leishmania mexicana complex species, Leishmania 
guyanensis and Leishmania panamensis in the New World. The lesions caused by 
infection with these species generally self-heal within a few months after the onset 
of symptoms, without the need for drug intervention (Desjeux, 2004). 
ii. Diffuse cutaneous leishmaniasis (DCL) is a more extensive and chronic form of 
CL; the sores that form are non-ulcerative (Herwaldt, 1999) and do not self-heal, 
due to an inefficient cell-mediated immune response (Desjeux, 2004). It is caused 
by L. aethiopica in the Old World and by L. mexicana complex species (most 
notably, by Leishmania amazonensis) in the New World. 
iii. Mucocutaneous leishmaniasis (MCL) is another type of CL defined by the 
development of sores on the naso-oropharyngeal mucosal membranes, which 
result in severe disfigurement (Herwaldt, 1999). It is caused by Leishmania 
braziliensis subspecies. 
iv. Visceral leishmaniasis (VL), commonly referred to as kala azar, is the most 
severe form of the disease; symptoms include fever, extreme weight loss, 
anaemia, hepatosplenomegaly, pancytopenia and hypergammaglobulinaemia. 
The primary species responsible for VL in the Old Word is Leishmania donovani, 
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particularly on the Indian subcontinent and Eastern Africa. In the Mediterranean 
and the New World, Leishmania infantum is the principal cause of VL. 
Humans are susceptible to infection from approximately 20 species of Leishmania, 
and leishmaniasis is endemic to 88 countries on four continents 
(http://www.who.int/leishmaniasis/burden/en/), as illustrated in Figure 1.1. 
 
Figure 1.1 Global distribution of cutaneous and visceral leishmaniasis 
Maps showing the global distribution of cutaneous (A) and visceral (B) leishmaniasis. Maps were 
taken from http://www.who.int/leishmaniasis/leishmaniasis_maps/en/index.html. 
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1.1.2 Life cycle 
Leishmania require two hosts to complete their life cycle; the definitive female, 
haematophagous sandfly vector (subfamily Phlebotominae) and the mammalian 
host (including dogs and humans). 
When a sandfly bites an infected mammal it acquires a bloodmeal containing 
Leishmania amastigotes. In order to survive within the sandfly midgut, these 
amastigotes must differentiate into the promastigote form. Species of the 
subgenus Leishmania are suprapylarian parasites, restricted to the midgut of the 
sandfly, whereas species belonging to the Viannia subgenus from the New World 
are peripylarian parasites, entering the hindgut before migrating towards the 
midgut (Kamhawi, 2006). Studies of L. mexicana in its sandfly host Lutzomyia 
longipalpis have illustrated the existence of at least six different promastigote sub-
types (Rogers et al., 2002). Firstly, amastigotes ingested within the bloodmeal 
differentiate into procyclic promastigotes, which then develop into nectomonad 
promastigotes, then into leptomonad promastigotes and finally into metacyclic 
promastigotes, which are the mammal-infective form (see Figure 1.2). The two 
other promastigote sub-types observed are haptomonad promastigotes and 
paramastigotes, yet the precursors of these have not been determined (Kamhawi, 
2006; Rogers et al., 2002). Of the six promastigote sub-types, only the procyclic 
promastigotes (in the abdominal midgut) and leptomonad promastigotes (in the 
thoracic midgut and foregut) are replicative (Gossage et al., 2003). 
In the sandfly vector, the time taken for ingested amastigotes to develop into 
metacyclic promastigotes ranges from six to nine days, depending upon the 
species of Leishmania (Kamhawi, 2006). The mode of transmission of metacyclic 
promastigotes into the mammalian host is via regurgitation. The cause of this 
regurgitation is the promastigote secretory gel (PSG), which is secreted by the 
parasites into the thoracic midgut to form a PSG plug, which in turn forces open 
the stomodeal valve where metacyclic promastigotes accumulate (Rogers et al., 
2002; Stierhof et al., 1999) (see Figure 1.2). Upon regurgitation by the sandfly, 
approximately 1000 metacyclic promastigotes are inoculated into the mammalian 
host, most of which were derived from just behind the stomodeal valve. 
Interestingly, the PSG plug is also transmitted into the mammalian host, and the 
main component of this plug, filamentous proteophosphoglycan (fPPG), has been 
shown to aid disease progression (Rogers et al., 2002; Stierhof et al., 1999). 
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A lot of focus has recently been on the events that proceed as metacyclic 
promastigotes enter the mammalian host. These experiments have illustrated that 
even though amastigote development is restricted to the phagolysosomal 
compartment of macrophages, polymorphonuclear neutrophil granulocytes (PMN) 
appear to be key in establishing infection (Nauseef, 2007; Peters et al., 2008; 
Segal, 2005; van Zandbergen et al., 2004). An interesting theory has been 
proposed, whereby PMNs act as a 'Trojan horse' vehicle for Leishmania infection 
of macrophages. It was demonstrated that metacyclic promastigotes are 
phagocytosed by PMNs, and that PMNs do not kill the internalised parasites by 
the oxidative burst (Laufs et al., 2002; Muller et al., 2001; van Zandbergen et al., 
2004). Additionally, the phagocytosed metacyclic promastigotes do not multiply or 
differentiate into amastigotes inside PMNs (Laufs et al., 2002; Muller et al., 2001; 
van Zandbergen et al., 2004). The 'Trojan horse' theory was proposed because it 
was observed in vitro that infected PMNs are phagocytosed by macrophages (van 
Zandbergen et al., 2004). However, recent in situ mouse data show that PMNs 
undergoing apoptosis in fact release their parasite load, which is then in turn 
phagocytosed by macrophages (Peters et al., 2008). Thus, the current hypothesis 
is concurrent with the idea that PMNs are essential to establishment of Leishmania 
infection, however the results do not indicate that PMNs act as 'Trojan horses'; 
instead, parasites exposed to the internal milieu of PMNs are conferred 
subsequent resistance somehow after being internalised by macrophages (Peters 
et al., 2008). 
After being phagocytosed by macrophages, Leishmania metacyclic promastigotes 
reside within the acidic phagolysosomal compartment (or parasitophorous vacuole 
(PV)), and prevent the fusion of the phagolysosome with the lysosome (Bogdan & 
Rollinghoff, 1999). It is in the PV that metacyclic promastigotes differentiate into 
the amastigote form, and the nature of the PV niche varies, depending upon the 
species of Leishmania (Handman & Bullen, 2002; Rittig & Bogdan, 2000). 
Amastigotes are aflagellate and round-oval in shape with a diameter of 4 µm 
(Herwaldt, 1999) (see Figure 1.2). Amastigotes multiply within the PV and are 
released and subsequently infect further macrophages, although the exact 
mechanism of amastigote escape from macrophages is not fully understood. 
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Figure 1.2 Digenetic life cycle of Leishmania 
A, Schematic representation of a Leishmania-infected sandfly, indicating time-dependent 
appearance of distinct morphological forms. The promastigote secretory gel (PSG) fills the thoracic 
midgut, and in doing so holds open the stomodeal valve. (Image taken from (Kamhawi, 2006) with 
permission from Elsevier.) B, The life cycle of Leishmania is initiated by the uptake of amastigotes 
in a bloodmeal from the mammalian host by the sandfly vector. Amastigotes differentiate into 
promastigotes, which migrate to the proboscis, where the promastigotes are inoculated into the 
mammalian host upon taking another bloodmeal. The promastigotes are ultimately phagocytosed 
by macrophages, where they multiply within the phagolysosomal compartment. Amastigotes are 
released and then the free amastigotes are taken up by another macrophage. (Image taken from 
http://commons.wikimedia.org/wiki/File:Leishmaniasis_life_cycle_diagram_en.svg.) 
1.1.3 Ultrastructure of Leishmania 
Leishmania belong to the order Kinetoplastida, the members of which each 
possess a unique organelle called the kinetoplast, comprising the mitochondrial 
DNA. Similar to Leishmania, other kinetoplastids such as species within the genus 
Trypanosoma, have complex digenetic life cycles. Kinetoplastid species have 
adapted in various ways to the very different environments found within the fly and 
mammalian hosts. Trypanosoma brucei for example, has evolved to derive its 
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nutrition from mammalian blood, and as such bears a flagellum and has adapted 
to the problem of immune recognition by varying the antigen type (variable surface 
glycoprotein (VSG)) presented on its plasma membrane (Donelson, 2003). 
Leishmania however, have evolved to survive and replicate within the acidic 
environment of the macrophage phagolysosome. Amastigotes are small in length 
(4 µm) and amotile (aflagellate). By contrast, promastigotes have long thin cell 
bodies that are 5-20 µm in length, and possess a flagellum up to 20 µm in length. 
As such, a large amount of cellular remodelling is required in the process of 
promastigote-to-amastigote differentiation (Besteiro et al., 2006; Clayton et al., 
1995) (see Figure 1.3). This involves rearrangement of the array of cross-linked 
subpellicular microtubules that are located underneath the plasma membrane 
(McConville et al., 2002), which govern the characteristic shapes of Leishmania 
promastigotes and amastigotes. 
1.1.3.1 Plasma membrane 
Leishmania synthesise a family of glycoconjugates that are either attached to the 
extracellular face of the plasma membrane or secreted from the cell. The base 
molecule of these glycolipids is phosphoglycan (PG), and important members of 
this family include membrane-bound lipophosphoglycan (LPG) and 
proteophosphoglycan (PPG) (Beverley & Turco, 1998; Ilg et al., 1999; McConville 
& Ferguson, 1993). These molecules make up a thick glycocalyx in procyclic 
promastigotes, however metacyclic promastigotes and amastigotes possess a 
much thinner layer. It was demonstrated that LPG is essential for survival of L. 
major within the sandfly (Sacks et al., 2000) and for infection of macrophages and 
mice (Spath et al., 2000). Interestingly, LPG does not seem to be essential for L. 
mexicana infection of macrophages or mice (Ilg et al., 2001). It is not apparent 
whether the contrasting results observed for L. major and L. mexicana are intrinsic 
to using mouse as a model, or whether the two species indeed do use different 
surface glycoconjugates to survive within the mammalian host (Turco et al., 2001). 
1.1.3.2 Flagellar pocket 
In kinetoplastids, endocytosis and exocytosis are restricted to a single portion of 
the plasma membrane at the anterior of the cell called the flagellar pocket. The 
flagellar pocket is a specialised invagination of the plasma membrane, and is the 
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only region in the cell that is not subtended by microtubules which make up the 
cytoskeletal network (Clayton et al., 1995; Overath et al., 1997) (see Figure 1.3). 
1.1.3.3 Flagellum 
Leishmania promastigotes possess a single flagellum, which is derived from one 
of the two basal bodies located within the kinetoplast (see Figure 1.3). The 
flagellum consists of a classical 9+2 microtubule double axoneme and the 
trypanosomatid-specific paraflagellar rod (Bastin et al., 2000) (see Figure 1.3). 
In Leishmania promastigotes, the flagellum has several roles: the first and most 
obvious is to enable promastigotes to migrate from the sandfly midgut towards the 
stomodeal valve. L. mexicana promastigotes were shown to swim at a velocity of 
29.5 ± 5.9 µm sec-1 in culture conditions (Santrich et al., 1997). The flagellum 
length varies between different promastigote sub-types, and metacyclics possess 
the greatest flagellum-to-cell body ratio and are highly motile. It has been shown 
that Leishmania are able to use positive chemotaxic cues including sugar and 
saliva (Barros et al., 2006; Charlab et al., 1995). The flagellum has also been 
shown to be involved in anchoring promastigotes to the sandfly gut epithelium 
(Wakid & Bates, 2004). Interestingly, the promastigote plasma membrane 
glycolipid, LPG, is important for interactions of promastigotes with the gut in 
certain sandfly species, but not others. It was discovered that LPG is essential for 
the attachment of L. major promastigotes in the specific vector Phlebotomus 
papatasi, however LPG was not essential for adherence of promastigotes in the 
permissive vectors Phlebotomus arabicus or Lutzomyia longipalpis (Myskova et 
al., 2007). 
1.1.3.4 Kinetoplast 
The kinetoplast is a disc-shaped sub-structure located within the mitochondrion, 
which contains kinetoplast DNA (kDNA). kDNA accounts for 10-20 % of the total 
cellular DNA content, and can be observed by microscopy using DAPI stain 
(Bastin et al., 2000). kDNA is found in the form of a few dozen maxicircles and 
thousand of minicircles. The maxicircles have some functions of higher eukaryote 
mitochondrial DNA. The minicircles encode guide RNAs, which carry out the post-
transcriptional editing of maxicircle RNA species by extensive uridylate insertions 
(Liu et al., 2005). 
Chapter 1  8 
 
1.1.3.5 Mitochondrion 
Leishmania possess a single mitochondrion, which is large and stretches 
throughout most of the cell body (Bienen et al., 1981; Coombs et al., 1986). In 
terms of structure, the mitochondrion in Leishmania is similar to that found in other 
eukaryotes; it consists of outer and inner membranes and tubular cristae. The 
Leishmania mitochondrion is structurally similar in both promastigote and 
amastigote forms, whereas the T. brucei mitochondrion lacks extensive tubular 
cristae in the mammalian blood stream form stage, and has greatly reduced 
activity (Bienen et al., 1981).  
1.1.3.6 Glycosomes 
Glycosomes are spherical shaped peroxisome-like organelles with a diameter of 
approximately 0.7 µm (Michels et al., 2006). A key feature of these organelles is 
the compartmentalisation of the first seven enzymes involved in glycolysis; 
interestingly, the enzymes involved in net production of adenosine triphosphate 
(ATP) are located in the cytosol (see Figure 1.4). In other organisms in which all 
glycolytic enzymes are localised to the cytosol, two ATP-dependent kinases 
hexokinase (HXK) and phosphofructokinase (PFK) are negatively regulated by 
intermediate metabolites of glycolysis. This has been shown to be essential in 
yeast, since removal of inhibition results in uncontrolled glycolysis and build-up of 
unacceptably high levels of hexose phosphate glycolytic intermediates (Thevelein 
& Hohmann, 1995). In T. brucei, regulation of HXK and PFK has not been 
practically demonstrated. Indeed, systems biology modelling and practical data 
have illustrated that the reason for glycosomal compartmentalisation is to prevent 
a 'lethal turbo charge of glycolysis'; it seems therefore that T. brucei, and possibly 
other kinetoplastids, have evolved a glycolytic system that has no need for 
regulation of HXK and PFK enzymes (Haanstra et al., 2008). 
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Figure 1.3 Schematic representation of the ultrastructure of Leishmania promastigotes and 
amastigotes 
Promastigote on left and amastigote on right. Organelles are labelled. (Image taken from (Besteiro 
et al., 2007) with permission from Elsevier.) 
1.1.4 Chemotherapies 
There is currently no vaccine against leishmaniasis and the drugs currently 
available to treat leishmaniasis are the pentavalent antimonials, that is, sodium 
stibogluconate (Pentostam) and meglumine antimonate (Glucantime); 
amphotericin B; pentamidine amd miltefosine (Croft and Coombs, 2003). Aside 
from miltefosine, all of the other drugs require parenteral administration, which 
results in a long period of hospitalisation. The drugs also have a range of side 
effects and drug resistance is increasing (Croft et al., 2005; Murray et al., 2005; 
Sundar et al., 2000). 
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In the treatment of visceral leishmaniasis, the pentavalent antimonials have been 
the first-line treatment for over 60 years (Croft and Coombs, 2003).  Antimonials 
can give rise to severe toxic side effects, including cardiac arrhythmia and 
pancreatitis.  Levels of resistance to these drugs have been reported to be very 
high in endemic regions, particularly in Bihar, India (Sundar and Rai, 2002).  
Pentamidine is highly toxic, and as such has generally only been used as a 
second-line therapy after ineffective antimonial treatment, and resistance to 
pentamidine treatment has been reported in India (Sundar and Rai, 2002).  In 
some areas of Bihar, Amphotericin B has replaced antimonials as the first-line 
treatment Amphotericin B is highly effective at treating antimony-resistant cases, 
but is toxic, with nephrotoxicity and first-dose anaphylaxis reported.  The lipid 
formulation, AmBisome, has much reduced toxicity, but its high cost has limited its 
use in developing countries until recently (Chappuis et al., 2007). 
Miltefosine has been used to treat visceral leishmaniasis in India since 2002 
(Davies et al., 2003).  Miltefosine has been shown to be safe for both adults and 
children in India and although gastrointestinal side effects are common, these do 
not generally prevent completion of treatment (Sundar et al., 2002). It has not 
however, been established whether miltefosine will be as effective against L. 
infantum/chagasi as it is against L. donovani (Croft and Coombs, 2003).  
As discussed in Section 1.1.1, cutaneous leishmaniasis often self-heals; as such, 
drug treatment is not always necessary, and is normally only used if there is a risk 
of mucocutaneous leishmaniasis.  For patients with disfiguring lesions or diffuse or 
mucocutaneous leishmaniasis, treatment with pentavalent antimonials is the most 
common route of action (Davies et al., 2003).  It is known that there is a difference 
in the susceptibility of different Leishmania species to pentavalent antimonials; L. 
donovani and L. braziliensis are more sensitive compared to L. major, L. tropica 
and L. mexicana (Croft et al., 2002).  Pentamidine is used to treat cutaneous and 
mucocutaneous leishmaniasis (Sundar and Rai, 2002), and amphotericin B is 
often used as a first-line treatment for travellers (Schwartz et al., 2006).   
Miltefosine is effective against L. panamensis, less so against L. mexicana, and 
shows a large variation in its efficacy against L. braziliensis (Soto et al., 2004; Soto 
et al., 2007).  Miltefosine has also been tested against Old World cutaneous 
species and found to give similar cure levels as antimonials (Mohebali et al., 2007).   
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1.2 Energy metabolism in Leishmania and other 
trypanosomatids 
1.2.1 Introduction to energy metabolism 
The production of the energy storage compound ATP is essential for active cellular 
function. There are two methods by which organisms generally produce ATP; 
substrate-level phosphorylation and oxidative phosphorylation. Substrate-level 
phosphorylation is defined as the catalysis of phosphoryl transfer from a reactive 
intermediate to adenosine diphosphate (ADP), resulting in ATP (Nelson & Cox, 
2000). For example, as illustrated in Figure 1.4, succinate dehydrogenase (SDH) 
catalyses the breakage of the high-energy thioester bond between succiante and 
Coenzyme A (CoA), and in the process itself becomes phosphorylated. SDH then 
transfers the phosphoryl-group to ADP to produce ATP and succinate (Nelson & 
Cox, 2000). Oxidative phosphorylation describes an aerobic process (respiration) 
whereby certain nutrients (for example glucose) are completely oxidised to CO2 
and H2O (Nelson & Cox, 2000). In the process, electrons of oxidised intermediates 
are transferred to electron acceptors such as NAD+ and FAD+. In eukaryotes, 
electrons are fed through the electron transport chain, which is located in the inner 
mitochondrial membrane; the result is the generation of a transmembrane 
potential and ultimately the production of ATP from the phosphorylation of ADP, 
and  the generation of H2O from the reduction of O2 (Nelson & Cox, 2000). 
Organisms have adapted their energy metabolisms in different ways, depending 
upon the nutrients that are available to them as well as the aerobic conditions. 
Parasites, on the other hand, especially those with multiple hosts within their life 
cycle, may have also been restricted to certain microenvironments within each 
host, based on the metabolic machinery that they encode. In terms of energy 
metabolism in trypanosomatids, most work has been carried out on T. brucei (for 
review see (Bringaud et al., 2006)), and although there are some studies with 
regards to Leishmania promastigote energy metabolism, there are still many 
questions remaining, especially in terms of amastigote energy metabolism (for 
review see (Opperdoes & Coombs, 2007)). The aim of this section is to summarise 
what is known about the nutritional requirements of Leishmania with reference to 
other trypanosomatids (mainly T. brucei), and to give an appreciation of how these 
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organisms have adapted to cope with their digenetic life cycles on a metabolic 
level. 
1.2.2 Nutrition in the fly vector 
Trypanosomatids are exposed for part of their life cycles to different compartments 
within their permissive haematophagous fly vectors. Whereas Leishmania 
promastigotes are restricted to the fly midgut (with the exception of the braziliensis 
complex of Leishmania), trypanosomes also invade the fly hindgut and salivary 
glands. In conjunction with differential geographical locations within the fly vector, 
the sandfly differs from the vectors of trypanosomes in its feeding habits. For 
example, it has been shown that the tsetse fly (the vector of T. brucei) relies upon 
amino acids for energy generation during flight (Bursell, 1960; Bursell, 1963). 
Notably, it was shown that proline is the principal amino acid used as a carbon 
source, and that proline is partially oxidised via glutamate to alanine (Bursell, 
1967). However, sandflies have been reported to feed primarily on nectar and as 
such Leishmania promastigotes in the midgut are thought to have a sugar-rich diet 
(Schlein, 1986), and Leishmania encode glycosidases to digest complex 
polysaccharides (Jacobson & Schlein, 2001; Jacobson et al., 2001). Interestingly 
however, in vitro studies indicate that T. brucei procyclic form (PCF) preferentially 
use glucose as an energy source when grown in the presence of both glucose and 
proline (Hellemond et al., 2005; Lamour et al., 2005; van Weelden et al., 2003; van 
Weelden et al., 2005), yet Leishmania promastigotes preferentially use amino 
acids (Cazzulo et al., 1985). Nevertheless, in the absence of glucose in the 
medium, proline has been shown to be the principle carbon source for T. brucei 
PCF (Lamour et al., 2005). It is also generally accepted that proline is an important 
carbon source for energy generation in Leishmania in the sandfly (for review see 
(Bringaud et al., 2006). 
1.2.3 Parasite energy metabolism in the fly vector 
Although there are likely to be differences between energy metabolism in T. brucei 
PCF and Leishmania promastigotes, T. brucei has been used as a model for 
trypanosomatid energy metabolism in the fly stage, primarily due to the fact that 
this organism is amenable to RNA interference (RNAi), whereas this technique 
has not been successfully applied in Leishmania. As will be discussed in Section 
6.3.3.3, gene replacement in Leishmania can be a lengthy and unsuccessful tactic 
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to study certain genes, and RNAi sometimes permits a more subtle dissection of 
molecular pathways. As such, this section will have a bias towards T. brucei. 
In Leishmania promastigotes and trypanosomatid PCF, energy generation 
involves both glycolysis and mitochondrial metabolism. As described in Section 
1.1.3.6, the ATP-expending reactions of glycolysis occur in peroxisome-like 
organelles called glycosomes (see Figure 1.3), and the later ATP-yielding 
reactions of glycolysis occur in the cytosol (see Figure 1.4) (Michels et al., 2006). 
The end-product of glycolysis – pyruvate – can be decarboxylated to produce 
acetyl-CoA via the mitochondrial pyruvate dehydrogenase complex (PDH). In 
yeast, mammals and bacteria, under aerobic conditions acetyl-CoA is completely 
oxidised through the tricarboxylic acid (TCA) cycle to CO2, H2O and ATP. The TCA 
cycle generates energy through substrate-level phosphorylation (via succinate 
dehydrogenase; SDH) and through oxidative phosphorylation, feeding reducing 
equivalents in the form of NADH and FADH2 into the electron transport chain. 
Trypanosomatids seem to be an exception, since acetyl-CoA is not used in the 
TCA cycle (Coustou et al., 2008; van Weelden et al., 2003), but is instead 
converted to acetate by a two-enzyme cycle involving acetate: succinate CoA 
transferase (ASCT) and succinyl-CoA synthetase (SCS), with concomitant ATP 
production (see Figure 1.4) (Van Hellemond et al., 1998). Such partial 
fermentation occurs even in the presence of oxygen, and as such is referred to as 
aerobic fermentation (for review see (Bringaud et al., 2006)). Acetate is not the 
only end-product of aerobic fermentation; others include succinate and alanine, 
and to a lesser extent pyruvate, lactate and ethanol (see Figure 1.4) (for review 
see (Bringaud et al., 2006)). 
It has been shown that in the absence of high concentrations of glucose, T. brucei 
PCF cultured in vitro rely upon proline as a carbon source. When cultured in 
glucose-depleted/proline-containing conditions, the major end products excreted 
by PCF are alanine (64.2 %) and glutamate (28.2 %) (Coustou et al., 2008). 
Coustou et al. (2008) propose a metabolic pathway, whereby proline is oxidised 
via glutamate to α-ketoglutarate, which is then fed into the TCA cycle through the 
action of the α-ketoglutarate dehydrogenase complex (α-KGDH) to produce 
succinyl-CoA, and ultimately malate. Malate is converted into pyruvate, which is 
subsequently transaminated with glutamate by alanine aminotransferase (ALAT) 
to produce alanine. The authors make the potentially intriguing observation that 
proline metabolism in T. brucei PCF mimics that which occurs in the tsetse fly 
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flight muscle, in that alanine is the principal end-product (Bursell, 1967; Coustou et 
al., 2008). Interestingly, under glucose-depleted/proline-containing conditions, the 
electron transport chain was shown to be essential. Leishmania promastigotes, 
however, are semi-tolerant to anoxic conditions, and although they do not 
proliferate in the absence of oxygen, they do persist. Indeed, after 40 h of anoxia, 
replenishing the oxygen supply permits a release of the metabolic arrest such that 
Leishmania promastigotes proliferate again (Van Hellemond & Tielens, 1997; Van 
Hellemond et al., 1997). The slowing of promastigote motility during hypoxic 
conditions in the sandfly is hypothesised to be important for the simple reason that 
a reduction in energy expenditure will allow the parasites to persist for longer (Van 
Hellemond & Tielens, 1997). T. brucei PCF are completely intolerant of anaerobic 
conditions, and start dying after a few days of anoxia (van Weelden et al., 2003). 
In comparison to T. brucei, little is known in Leishmania promastigotes with 
regards to the relative levels of contribution of glucose and proline in energy 
metabolism. However, one study illustrates that a L. mexicana promastigote 
mutant line, which lacks three genes that are integral to glucose transport, is able 
to establish an infection in L. longipalpis sandflies, albeit less efficiently 
(Burchmore et al., 2003). However, the mutant line is unable to replicate within 
macrophages in the mammalian host (see Section 1.2.5) (Rodriguez-Contreras et 
al., 2007). Another study illustrated that gluconeogenesis is essential for L. major 
promastigotes in the absence of glucose, since a mutant line lacking the gene 
encoding the important gluconeogenesis enzyme fructose 1,6-bisphosphatase 
(FBP) is unable to proliferate on glucose-depleted/glycerol-containing medium 
(see Figure 1.4) (Naderer et al., 2006). It was also demonstrated that acetyl-CoA 
derived from β-oxidation of fatty acids (FAs) is not a gluconeogenic substrate in 
promastigotes (Naderer et al., 2006). This was expected to be the case, since 
analysis of the L. major genome indicates that this parasite lacks the glyoxylate 
cycle genes encoding isocitrate lyase (ICL) and malate synthase (MLS), and as 
such is unable to convert acetyl-CoA into malate, and subsequently oxaloacetate, 
which is used in gluconeogenesis (Ivens et al., 2005). Instead, in conditions of low 
glucose concentration, amino acids have been shown to be used for 
gluconeogenesis (Burchmore et al., 2003). Overall, in promastigotes it is likely that 
glucose plays an important role as a substrate for the pentose phosphate pathway 
(PPP) to generate precursors for DNA and RNA biosynthesis (Maugeri et al., 
2003), and is also likely to be used for the production of carbohydrate, such as 
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β1,2-mannan reserve oligosaccharides (see Figure 1.4) (Ralton et al., 2003). 
However, in terms of Leishmania energy metabolism, proline is thought to be more 
important than glucose (see Figure 1.4) (Opperdoes & Coombs, 2007). 
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Figure 1.4 The pathways of core metabolism in L. major 
Figure shows reactions taking place in the glycosome, that are involved in carbohydrate 
metabolism, and in the mitochondrion, with its tricarboxylic acid cycle, and the flux of metabolites 
between these two organelles. Boxed metabolites are substrates (grey) or end products (black) of 
metabolism. Thick arrows represent major metabolite fluxes. Pathways in blue are thought to be 
more important in promastigotes and pathways in red are thought to be more important in the 
amastigote. Abbreviations: Fru, fructose; GAP, glyceraldehyde 3 phosphate; Glc, glucose; H-5-P, 
hexose 5-phosphate; Man, mannose; PEP, phosphoenolpyruvate; PGA, phosphoglyceric acid; 
PPP, pentose-phosphate pathway. Enzymes: 1, hexokinase; 2, phosphoglucose isomerase; 3, 
phosphofructokinase;4, fructosebisphosphate aldolase; 5, triosephosphate isomerase; 6, 
glyceraldehyde-3-phosphate dehydrogenase; 7, phosphoglycerate kinase; 8, glycerol-3-phosphate 
dehydrogenase; 9, glycerol kinase; 10, adenylate kinase; 11, glucosamine-6-phosphate 
deaminase; 12, mannose-6-phosphate isomerase; 13, phosphomannomutase; 14, GDP-mannose 
pyrophosphorylase; 15, phosphoglycerate mutase; 16, enolase; 17, pyruvate kinase; 18, 
phosphoenolpyruvate carboxykinase; 19, malate dehydrogenase; 20, fumarate hydratase; 21, 
NADH-dependent fumarate reductase; 22, malic enzyme; 23, alanine aminotransferase; 24, 
aspartate aminotransferase; 25, pyruvate phosphate dikinase; 26, citrate synthase; 27, 2-
ketoglutarate dehydrogenase; 28, succinyl-CoA ligase; 29, succinate dehydrogenase; 30, acetate–
succinate CoA transferase; 31, pyruvate dehydrogenase; 32, citrate lyase; 33, acetyl-CoA 
synthetase; 34, proline oxidation pathway; 35, threonine oxidation pathway; 36, ribulokinase; 37, 
ribokinase; 38, xylulokinase; 39, amylase-like protein; 40, sucrase-like protein. (Image taken from 
(Opperdoes & Coombs, 2007) with permission from Elsevier.) 
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1.2.4 Nutrition in the mammalian host 
In the mammalian host (human), Leishmania amastigotes and Trypanosoma cruzi 
amastigotes have an intracellular life style, whereas T. brucei BSF lives in the 
blood. T. cruzi trypomastigotes infect a variety of cell types, including 
cardiomyocytes, and once within the cell, trypomastigotes differentiate into 
amastigotes, which multiply in the cytosol. Both T. cruzi and T. brucei thus inhabit 
hexose sugar-rich environments. 
Leishmania amastigotes reside within the acidic phagolysomal compartment of 
macrophages, which is also referred to as the PV. In fact, different species of 
Leishmania are known to infect different populations of macrophages, and the 
morphology of the phagolysosome differs depending upon the species of 
Leishmania (Antoine et al., 2004). For example, L. mexicana induce spacious 
vacuoles, rather than tight-fitting phagolysosomes found in L. major infections 
(Russell et al., 1992). Interestingly, aside from the Gram-negative bacterium 
Coxiella burnetii (Voth & Heinzen, 2007), no other microbial pathogen is known to 
replicate within the phagolysosomal compartment. Unlike the hexose-rich cytosolic 
compartment that T. cruzi inhabits, the phagolysosome lumen is hexose-poor, and 
the main carbon sources for energy generation are thought to come from host 
amino acids and FAs (Bringaud et al., 2006; McConville et al., 2007; Naderer & 
McConville, 2008; Opperdoes & Coombs, 2007). Lastly, there is some evidence to 
suggest that the metabolic and activation status of the infected macrophage has a 
significant influence upon amastigote growth (Gordon, 2003; Sacks & Anderson, 
2004).  
1.2.5 Parasite energy metabolism in the mammalian host 
Given the very different tissue-specificities of the different trypanosomatids, it is 
not surprising that their energy metabolism differs much more drastically than in 
the fly host. T. brucei BSF lacks most of the mitochondrial enzymes found in the 
PCF and completely relies upon glycolysis for energy generation (Bakker et al., 
2000; Fairlamb & Opperdoes, 1986). 
Leishmania amastigotes acquire energy via β-oxidation of FAs (see Figure 1.4) 
(Hart & Coombs, 1982). It is thought that the acetyl-CoA produced from β-
oxidation is fed into a fully functional TCA cycle (Hart & Coombs, 1982), however 
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this needs reanalysis given that trypanosomatid promastigotes and PCF do not 
fully oxidise acetyl-CoA via the TCA cycle (Opperdoes & Coombs, 2007). A recent 
proteomic study highlighted the fact that during the in vitro differentiation of L. 
donovani metacyclic promastigotes into amastigotes, enzymes involved in the 
glycosomal-restricted portion of glycolysis are down-regulated, whereas key 
enzymes involved in β-oxidation of FAs were significantly up-regulated 
(Rosenzweig et al., 2008). The authors also reported increases in the levels of 
TCA cycle enzymes and of enzymes involved in the catabolism of amino acids 
(Rosenzweig et al., 2008). 
Despite the fact that the phagolysosomal compartment is hexose-poor, an L. 
mexicana mutant lacking three glucose transporters is unable to proliferate when 
inoculated into mice (Burchmore et al., 2003). It was shown that the mutant 
promastigotes are taken up by host macrophages and differentiate into 
amastigotes, yet do not persist (Rodriguez-Contreras et al., 2007). To further 
strengthen the case that glucose uptake is essential for L. mexicana amastigote 
development, a reversion of this mutant line has been reported, in which an 
alternative hexose transporter has been amplified on a circular extrachromosomal 
element (Feng et al., 2009b). This naturally occurring selection for an up-
regulation of an alternative hexose transporter reverted the avirulent phenotype of 
the glucose transporter mutant in mice, thus highlighting the importance of 
hexoses like glucose for amastigote survival and replication (Feng et al., 2009b). 
On the other hand, gluconeogenesis has been reported to be essential for the 
survival of L. major within macrophage phagolysosomes (Naderer et al., 2006). If 
the uptake of hexoses is also essential to L. major amastigote fitness, it would 
appear that gluconeogenesis is not sufficient to provide enough hexose for PPP or 
for carbohydrate biosynthesis (or for other purposes), and that uptake of even 
small concentrations of hexoses in the hexose-poor PV niche is critical for the 
survival of the amastigote stage. 
1.3 Production of fatty acids 
Leishmania have a very robust energy metabolism, with the capacity to partially 
oxidise sugars, amino acids and FAs in order to generate energy (see Section 
1.2). Key to several of the important enzymes within the TCA cycle is the molecule 
lipoic acid (LA), which is the topic of this thesis. LA can be synthesised from FAs 
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(see Section 1.4.3), and as such the aim of this section is to give an appreciation 
of the different systems that exist in trypanosomatids to produce FAs. 
FAs are carboxylic acids with unbranched aliphatic tails that are either saturated or 
unsaturated. The process of FA synthesis involves the extension of a ‘primer’ FA 
building block by addition of a 2 carbon (2C) FA unit. FAs are bound to either acyl 
carrier protein (ACP) or to CoA. ACP and CoA are covalently modified with a 4'-
phosphopantetheine group (Magnuson et al., 1993). FAs are bound to ACP and 
CoA through a thioester linkage with the 4'-phosphopantetheine group. One cycle 
of 2C addition requires four steps; condensation, reduction, dehydration and 
reduction. These steps are catalysed by either type I or type II fatty acid synthase 
(FAS). The type I FAS is found in mammals and yeast, is localised to the cytosol, 
and arranges its different catalytic activities on separate domains spanning either 
one or two polypeptide chains (Smith, 1994). The type II FAS occurs in plants and 
bacteria, and each catalytic activity is associated with an individual polypeptide 
chain (Rock & Jackowski, 2002; White et al., 2005). Recent data indicate that 
mammals (Witkowski et al., 2007) and yeast (Hiltunen et al., 2005) also contain a 
mitochondrial type II FAS, which is not merely a relict of the endosymbiont, but is 
essential to respiration and cellular fitness in mammals (Feng et al., 2009a) and 
yeast (Brody et al., 1997; Schonauer et al., 2008; Sulo & Martin, 1993). In both 
type I and type II FAS, the growing acyl chain is esterified to ACP (White et al., 
2005). 
In addition to de novo biosynthesis of FAs via type I or type II FAS, a set of 
elongase enzymes also exist, whose role in mammals and yeast is to elongate 
long-chain FAs (C14-18) to make very long-chain FAs (C20 or longer).  
1.3.1 Endoplasmic reticulum elongase system 
Elongase enzymes carry out the same four condensation, reduction, dehydration 
and reduction reactions that are catalysed by FAS (Leonard et al., 2004). Unlike 
FAS, elongases (ELOs) are localised to the endoplasmic reticulum (ER) and are 
membrane-bound (Moon et al., 2001; Oh et al., 1997; Toke & Martin, 1996). 
Another difference is that the growing acyl chain is esterified to CoA instead of to 
ACP. In yeast and mammals, ELOs incrementally increase the length of an acyl 
chain using malonyl-CoA as the 2C donor (Leonard et al., 2004). Multiple 
elongase systems exist (Cinti et al., 1992), each with different chain length 
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specificity, in order to permit the production of various types of polyunsaturated 
fatty acids (PUFAs). 
In T. brucei, a membrane-associated FA synthesis was discovered in a cell-free 
system (Morita et al., 2000), which was interesting for several reasons. Firstly, a 
soluble mitochondrial type II FAS had been predicted (and since shown to be 
active) (Stephens et al., 2007), and as such it was peculiar that FA synthesis was 
associated with the membrane fraction. Secondly, whereas malonyl-CoA or acetyl-
CoA were expected to serve as a primer for FA synthesis, only butyryl-CoA 
worked as a primer (Morita et al., 2000). Thirdly, knock-down of ACP by RNAi had 
no effect on bulk FA synthesis in the cell-free system (Lee et al., 2006). 
It was recently shown that the membrane-associated FA synthesis in T. brucei is 
due to the action of ELO 1-4. However, unlike yeast and mammalian ELOs, T. 
brucei ELO1 and ELO2 were shown to primarily synthesise myristate (C14) de 
novo from a butyryl-CoA primer in T. brucei BSF (Lee et al., 2006). The authors 
also identified 13 potential ELOs in the L. major genome and five potential ELOs in 
the T. cruzi genome. Preliminary data from the cell-free system illustrated that like 
T. brucei, both L. major and T. cruzi possess membrane-associated FA synthesis 
activity (Lee et al., 2006). So far, T. brucei is the only organism that has been 
experimentally shown to have adopted the microsomal ELO system for the 
purpose of de novo FA synthesis (Lee et al., 2006; Lee et al., 2007). 
1.3.2 Mitochondrial type II FAS 
Type II FAS uses ACP to extend an acyl chain, using acetyl-CoA (1C) as a primer 
and malonyl-CoA as the 2C donor (for review see (White et al., 2005)). Acetyl-CoA 
can be derived from the glycolytic product pyruvate via the action of mitochondrial 
pyruvate dehydrogenase. Alternatively, the amino acid threonine can be converted 
to pyruvate via threonine dehydrogenase, and an intermediate in this pathway can 
undergo thiolysis with CoA to produce acetyl-CoA and glycine. 
The first enzyme involved in type II FAS is acetyl-CoA carboxylase (ACC), which is 
a biotin-dependent enzyme that catalyses the conversion of acetyl-CoA to 
malonyl-CoA. The malonyl-moiety is subsequently transferred onto ACP by 
malonyl-CoA: ACP transferase. The addition of malonyl-ACP to a growing acyl 
chain is catalysed by the sequential action of four enzymes. Firstly, condensation 
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of acetyl-CoA/acetyl-ACP and malonyl-CoA to form 3-ketoacyl-ACP is catalysed 
by 3-ketoacyl-ACP synthase. Next, 3-ketoacyl-ACP is reduced to 3-hydroxyacyl-
ACP by 3-ketoacyl: ACP-reductase. The dehydration reaction producing trans-2-
enoyl-ACP is catalyzed by 3-hydroxyacyl thioester dehydratase. Lastly, trans-2-
enoyl-ACP is reduced by 2-enoyl thioester reductase to produce the acyl-ACP 
molecule that has been extended by two carbon atoms. The acyl-ACP species can 
then be used as a substrate by ketoacyl-ACP synthase and the type II FAS cycle 
continues. 
Interestingly, it has been noted in fungi (Wada et al., 1997), plants (Wada et al., 
1997), yeast (Brody et al., 1997; Schonauer et al., 2008) and mammals (Feng et 
al., 2009a; Witkowski et al., 2007) that the principal end product of type II FAS is 
the 8 carbon (8C) FA octanoyl-ACP (see Section 1.4.3). Type II FAS also 
produces FA chains up to myristate (14C) in Neurospora crassa (Mikolajczyk & 
Brody, 1990), up to palmitate (16C) in T. brucei (Stephens et al., 2007) and up to 
stearate (18C) in plants (Gueguen et al., 2000), however much less is known with 
regards to the role of acyl-chains longer than 8C. 
The trypanosomatids T. brucei, T. cruzi and L. major all possess genes that 
potentially encode all components of a type II FAS (Lee et al., 2007; Stephens et 
al., 2007). Research on T. brucei has shown that all components of type II FAS 
are localised to the mitochondrion (Autio et al., 2008a; Stephens et al., 2007). T. 
brucei mitochondrial type II FAS is essential, since RNAi of ACP causes cell death 
in PCF and BSF parasites (Guler et al., 2008; Stephens et al., 2007). It was shown 
that T. brucei RNAi resulted in a significant decrease in LA (Stephens et al., 2007). 
However, the principal cause of a decrease in parasite fitness was found to be due 
to a significant decrease in the production of certain phospholipids, resulting in 
altered mitochondrial ultrastructure, mitochondrial membrane potential, and 
ultimately a decrease in cytochrome-mediated respiration (Guler et al., 2008). 
A recent surge of publications have received much attention recently, since they 
illustrate that type II FAS in fungi, yeast, mammals, plants and T. brucei is pivotal 
to cellular survival. As will be discussed in Section 6.3.3.3, evidence is 
accumulating that one of the main functions of type II FAS is to produce octanoyl-
ACP, which is the precursor of LA (Hiltunen et al., 2009). 
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1.4 Lipoic acid 
LA (6,8-thioctic acid or 1,2-dithiolane-3-pentanoic acid) was first isolated from 
bovine liver in 1951 (Reed et al., 1951). LA is an eight-carbon fatty acid with two 
sulphur atoms linked to carbons 6 and 8 that form a disulphide 1,2-dithiolane ring 
in the oxidised form (see Figure 1.5), which can be reduced to form dihydrolipoic 
acid (DHLA) (Atmaca, 2004). R-LA is the naturally occurring enantiomer of LA, 
and from now on will simply be referred to as LA. From bacteria to mammals, LA is 
an essential cofactor in several multienzyme complexes that are involved in key 
metabolic processes (Perham, 2000). Additionally, LA is a potent antioxidant, and 
there have been a plethora of recent studies into the potential therapeutic 
applications of LA (Estrada et al., 1996) (Beitner, 2003) (Hager et al., 2001). LA 
can be synthesised from the type II FAS product octanoyl-ACP (see Sections 1.3.2 
and 1.4.3), or can be salvaged from the external milieu (see Section 1.4.3.2). 
 
Figure 1.5 Schematic representations of LA and DHLA 
Diagrams showing the structure of the oxidised form (A) and reduced form, DHLA (B) of LA. 
1.4.1 Antioxidant properties of the lipoic acid/dihydrolipoic acid 
redox pair 
An antioxidant is defined by several criteria, which include specificity of free radical 
quenching, metal chelating activity, interactions with other antioxidants, and effects 
on gene expression. Additional criteria that are important when considering 
therapeutic applications are bioavailability, concentration and solubility. Vitamin E, 
for example, is soluble only in the lipid phase and its main role is to quench lipid 
peroxyl radicals (Burton & Ingold, 1981). On the other hand, the LA/DHLA redox 
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pair fulfil most of the above criteria, and for this reason have been described as a 
'universal antioxidant' (Kagan et al., 1992).  
The LA/DHLA redox pair has a redox potential of -0.32 V (Searls & Sanadi, 1960); 
as a comparison, the redox potential of the glutathione (GSH)/glutathione 
disulphide (GSSG) pair is -0.24 V (Scott et al., 1963). This low electronegativity 
means that DHLA is a very strong reductant. As well as being able to reduce 
GSSG to GSH (Jocelyn, 1967), DHLA is an antioxidant of ascorbate (vitamin C), 
and due to its solubility in lipid as well as water (Roy & Packer, 1998), DHLA can 
also reduce lipid-soluble tocopherol (vitamin E) (Podda et al., 1994; Rosenberg & 
Culik, 1959). 
In addition to the recycling of antioxidants as described above, LA is able to 
scavenge hydroxyl radicals (Scott et al., 1994; Suzuki et al., 1991), hypochlorous 
acid (Haenen & Bast, 1991) and singlet oxygen (Devasagayam et al., 1991). 
DHLA is able to scavenge hypochlorous acid (Haenen & Bast, 1991), and unlike 
LA, DHLA is also an effective buffer of peroxyl radicals (Kagan et al., 1992; Suzuki 
et al., 1993). DHLA, but not LA, is also able to chelate redox active metal ions 
such as iron, thus minimising the production of highly reactive hydroxyl radicals 
through the Fenton reaction (Suh et al., 2004). 
Given the important nature of LA/DHLA as an antioxidant, much attention has 
recently been focused on understanding whether this thiol could be of therapeutic 
usefulness. It was, for example, demonstrated that LA has beneficial effects in the 
treatment of diabetes type 1 and type 2, which are both associated with elevated 
levels of oxidative stress. In both type 1 and type 2 diabetes, the problem is a lack 
of insulin-mediated glucose uptake into cells. Insulin is ordinarily made within β 
cells of the pancreas, however type 1 diabetes is an autoimmune disease that 
results in the destruction of these insulin-generating β cells. The main problem 
associated with type 2 diabetes is resistance to insulin. In vitro, it has been 
demonstrated that LA stimulated glucose uptake into muscle cells in a manner 
similar to that induced by insulin (Estrada et al., 1996). In a study whereby 74 
patients with type 2 diabetes were administered 600 mg LA or 'placebo' once, 
twice or three times daily for four weeks, patients that received LA had a 
significant increase in insulin-stimulated glucose uptake compared to the placebo 
control (Jacob et al., 1999). 
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In terms of therapeutic applications, LA/DHLA is also being tested for its 
protective/regenerative potential in other diseases, such as cataract (Maitra et al., 
1995) and Alzheimer's disease (Hager et al., 2001), as well as gaining the 
attention of cosmetologists and dermatologists (Beitner, 2003). 
In addition to its role as an antioxidant, LA has also been shown to affect 
transcription of certain genes, by regulating redox-sensitive transcription factors 
present in the cytosol. For example, LA is known to inhibit the translocation of the 
transcription factor NF-κB from the cytosol to the nucleus (Zhang & Frei, 2001). 
More recent data indicate the intriguing observation that LA is directly or indirectly 
involved in RNA processing in yeast (Schonauer et al., 2008) and vertebrate (Autio 
et al., 2008b) mitochondria, marking an evolutionarily conserved intersection of 
positive feedback loops between type II FAS and RNA processing. 
Overall, LA is a multifaceted molecule, with roles as an antioxidant and as a 
signalling molecule. The focus of this thesis however, is on the role of LA in energy 
metabolism, in which it acts as a cofactor for four enzyme complexes, with each 
playing a key role in either substrate level/oxidative phosphorylation or in the 
creation of C1 units for folate metabolism. 
1.4.2 Role of LA in energy metabolism 
1.4.2.1 α-Ketoacid dehydrogenase complexes 
LA plays a key role in energy metabolism, since it acts as an essential cofactor of 
α-KADH complexes (α-KADHs) (Perham, 2000). α-KADHs consist of multimers of 
three proteins that are strongly (but not covalently) associated; a substrate-specific 
α-ketoacid decarboxylase (E1), an acyltransferase (E2) and a dihydrolipoamide 
dehydrogenase (E3) (see Figure 1.6). Mammals (De Marcucci & Lindsay, 1985) 
and yeast (Maeng et al., 1994) also encode a protein that is structurally-similar to 
E2, called E3 binding protein (E3BP). Three types of KADHs are found in 
eukaryotes; pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (α-
KGDH) and branched-chain α-ketoacid dehydrogenase (BCKDH). These 
multienzyme complexes can be up to 10 MDa in size. Recent data indicate that 
the BCKDH may even exist as a part of an even larger supramolecular complex 
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with the branched-chain aminotransferase (BCAT), referred to as the branched-
chain amino acid metabolon (BCAA metabolon) (Islam et al., 2007).  
α-KADHs catalyse the conversion of α-ketoacid, NAD+ and coenzyme A (CoA) 
into CO2, NADH and acyl-CoA (see Figure 1.6). The substrate-specific E1 subunit 
contains a thiamine pyrophosphate (TPP) cofactor, and catalyses the 
decarboxylation of an α-ketoacid, generating CO2 and an acyl-TPP moiety, which 
remains bound to the E1 subunit. The E2 subunit contains the LA cofactor, which 
is covalently bound via an amide linkage to the N6-amino group of a specific lysine 
residue of the E2 subunit. The lipoamide acts as a swinging arm in the E2-
catalysed transfer of the acyl group from acyl-TPP to coenzyme A to form acyl-
CoA (see Figure 1.6). The high-energy acyl-CoA thioester is either fed into the 
TCA cycle or used as a precursor in fatty acid biosynthesis. The last step in the 
reaction is the re-oxidation of dihydrolipoamide by the FAD-containing E3 subunit, 
which results in lipoamide and NADH (see Figure 1.6) (Perham, 1991; Perham, 
2000; Reed & Hackert, 1990). The reduced NADH derived from the reaction can 
be used in the electron-transport chain with production of ATP (Voet & Voet, 
2005). 
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Figure 1.6 Reaction mechanism of α-KADHs 
1, The E1 subunit catalyses the decarboxylation of an α-ketoacid to form an acyl group, in a TPP-
dependent manner. The E2 subunit catalyses transfer of the acyl group (2) onto a CoA receptor (3) 
to form acyl CoA, and in the process the lipoyl-moiety becomes reduced. The E3 subunit catalyses 
the oxidation of the lipoyl-group (4), with the electron acceptor being NAD+ (5). Abbreviations: TPP, 
thiamin diphosphate; LipS2 and Lip(SH) 2, lipoyl moiety and its reduced form. (Image taken from 
(Reed & Hackert, 1990) with permission from Elsevier.) 
In every α-KADH, the E2 components are assembled into either a cubic (24-mer) 
or a dodecahedral (60-mer) inner core, around which E1 and E3 components bind 
(Perham, 1991; Perham, 2000; Reed & Hackert, 1990). The E2 protein consists of 
three structurally- and functionally distinct domains. The N-terminal portion is the 
lipoyl-domain, which contains the signature lysine residue that is post-
translationally modified by LA. Depending upon the species and the α-KADH, 
there may be up to three lipoyl-domains, each spanning approximately 80 amino 
acid residues (Packman et al., 1984). However, the reason for the existence of 
more than one lipoyl-domain is not fully understood, since computer modelling 
(Hackert et al., 1983a; Hackert et al., 1983b) and experimental evidence (Allen et 
al., 1989; Guest et al., 1985) indicate that only one lipoyl-domain is required for 
optimal α-KADH activity. The lipoyl-domain is followed by a subunit-binding 
domain, which confers binding of E1 and E3 subunits to the E2 core. 
Nevertheless, the PDH E2 subunit in mammals (De Marcucci & Lindsay, 1985) 
and some yeast (Maeng et al., 1994) (but not bacteria) is not able to bind E3 
directly, and instead requires the accessory E3BP; E3 binds to E3BP and is 
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inserted into the E2p scaffold (Sanderson et al., 1996a; Sanderson et al., 1996b). 
After the subunit-binding domain is the C-terminal catalytic domain, which 
catalyses the transfer of the acyl-moiety from the E1 subunit onto the CoA 
acceptor, to produce acyl-CoA (see Figure 1.6). 
The three domains that comprise the E2 subunit are separated by linker regions, 
which are approximately 20-30 amino acids in length, and are typically rich in 
amino acids alanine and proline, which gives these structures flexibility (Packman 
et al., 1984; Perham et al., 1981). These flexible linkers permit the lipoyl-domain to 
act as a 'swinging domain', shuttling reaction intermediates between E1, E2 and 
E3 subunits (Fries et al., 2007; Green et al., 1992; Perham et al., 1981; Perham, 
1991; Reed & Hackert, 1990).  
The role of the E1 subunit is to confer substrate-specificity to the α-KADH, and 
requires TPP and Mg2+ cofactors for activity (see Figure 1.6). The E3 protein is a 
flavoprotein, which is responsible for the re-oxidation of dihydrolipoamide to 
lipoamide (see Figure 1.6). In most organisms, the E3 protein is shared between 
different complexes (Bourguignon et al., 1996). The situation is different in 
organisms that possess α-KADHs localised to different organelles, such as plants 
and P. falciparum; in such cases more than one E3 protein exists, in order to serve 
α-KADHs in an organellar-specific manner (Lutziger & Oliver, 2000; McMillan et 
al., 2005). 
The PDH catalyses the oxidative decarboxylation of pyruvate to acetyl-CoA (see 
Figure 1.7). The enzyme complex is generally found in the mitochondrion, where it 
forms the link between glycolysis and the TCA cycle. Plants possess an additional 
PDH enzyme complex, which is present in the plastid, where it provides acetyl-
CoA and NADH for fatty acid biosynthesis (Mooney et al., 2002). 
The BCKDH complex catalyses the oxidative decarboxylation of branched-chain 
α-ketoacids, namely 2-ketoisocaproate, 2-keto-3-methylvalerate and 2-
ketoisovalerate (derived from leucine, isoleucine and valine, respectively) to form 
an acyl-group (isovaleryl, 2-methylbutyryl or isobutyryl, respectively), in a TPP-
dependent process (Massey et al., 1976) (see Figure 1.7). Eventually, the acyl-
CoA products can be converted to acetyl-CoA and/or succinyl-CoA for usage in 
the TCA cycle (Anderson et al., 1998). 
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The α-KGDH is also found in the mitochondrion, where it catalyses the oxidative 
decarboxylation of α-ketoglutarate to succinyl-CoA. The production of succinyl-
CoA is another branch point into the TCA cycle, other than acetyl-CoA. In 
Leishmania and T. brucei insect stage forms, proline (and glutamine) is thought to 
be a key carbon source. Proline is ultimately catabolised to α-ketoglutarate, which 
is fed into the TCA cycle through the action of the α-KGDH (see Figure 1.7). As 
such, α-KGDH is likely to be a key enzyme in Leishmania energy metabolism. 
 
Figure 1.7 Schematic representation of the reactions catalysed by different α-KADHs 
This figure is based upon the information presented in Figure 1.4, and highlights the relevance of 
the different α-KADHs in mitochondrial energy metabolism. Abbreviations: Glu, glutamate. 
1.4.2.2 Glycine cleavage complex 
LA is also an essential cofactor of the glycine cleavage complex (GCC). The GCC 
consists of multiple copies of four protein subunits; a decarboxylase (P-protein), an 
aminomethyltransferase (T-protein), a dihydrolipoamide dehydrogenase (L-
protein) and a carrier protein (H-protein). The GCC is present in the mitochondria, 
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plastids and cytosol of plant photosynthetic cells, and in the mitochondria of 
mammals (Cossins & Chen, 1997; Douce et al., 2001). 
The GCC catalyses the oxidative decarboxylation and deamination of glycine, 
generating CO2, NH3, NADH and N5,N10-methylene tetrahydrofolate (5,10-CH2-
THF) (see Figure 1.8 for reaction mechanism). C1 units provided by 5,10-CH2-THF 
are used by folate coenzymes to synthesise essential cellular compounds, 
including pyrimidines and mitochondrial protein (Appling, 1991). 
The P-protein catalyses the decarboxylation of glycine and the reductive 
methylamination of lipoamide, which is covalently attached to the H-protein. The T-
protein is a THF-dependent enzyme, and catalyses the transfer of methylene to 
THF and the subsequent release of NH3. The H-protein then reacts with the L-
protein, the dihydrolipoamide dehydrogenase described above, to oxidise the 
dihydrolipoamide, with NAD+ as the final electron acceptor. The released 5,10-
CH2-THF reacts with another glycine molecule, resulting in the formation of serine, 
a reaction that is catalysed by serine hydroxymethyltransferase (SHMT) (Douce et 
al., 2001). 
The GCC and α-KADH share similar mechanisms of action, most relevant of which 
is the parallel between α-KADH E2 subunits and GCC H-protein. Like the E2 
subunit, the H-protein is lipoylated, and the bound LA shuttles reaction 
intermediates between different catalytic subunits, itself being reduced and 
oxidised. Nevertheless, whereas the E2 subunit bears catalytic activity, the H-
protein does not, and is just a carrier protein. 
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Figure 1.8 Reaction mechanism of the GCC 
Outline of the reactions involved in oxidative decarboxylation and deamination of glycine in plant 
mitochondria. P-, H-, T- and L- are the protein components of the glycine-decarboxylase 
multienzyme system. The key enzyme in the entire sequence of reactions is the lipoamide-
containing H-protein, which undergoes a cycle of reductive methylamination (catalysed by the P-
protein), methylamine transfer (catalysed by the T-protein) and electron transfer (catalysed by the 
L-protein). SHMT: serine hydroxymethyltransferase involved in the conversion of CH2–THF to THF 
at the expense of a second molecule of glycine. Note that the methylamine moiety deriving from 
glycine is passed to the distal sulphur of the dithiolane ring. Hmet, Hred and Hox: methylaminated, 
reduced and oxidized forms of the H protein, respectively. (Image taken from (Douce et al., 2001) 
with permission from Elsevier.) 
1.4.3 LA metabolism 
As discussed in Section 1.4.2, LA is an essential cofactor of α-KADHs and the 
GCC. LA is ligated to the E2 subunits of α-KADHs and to the H-protein of the GCC 
in a process referred to as lipoylation. Specifically, LA is attached to the ε-amino 
group of a strictly conserved lysine residue of apoproteins (Douce et al., 2001; 
Reche & Perham, 1999). 
Two pathways exist to carry out lipoylation of α-KADHs and the GCC (see Figure 
1.9). Firstly, LA can be synthesised de novo, which necessitates the sequential 
action of two enzymes; octanoyl-[acyl carrier protein]: protein N-
octanoyltransferase (LipB) covalently attaches ACP to the apoproteins (Cronan et 
al., 2005; Zhao et al., 2005). The octanoyl-ACP used as a precursor for LA 
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synthesis is provided by mitochondrial type II FAS, as discussed in Section 1.3.2 
(Gueguen et al., 2000; Jordan & Cronan, 1997b; Miller et al., 2000). Following 
ligation of OA to the apoprotein, two sulphurs are inserted at carbon positions six 
and eight, to form the lipoyl-arm. This reaction is catalysed by lipoic acid synthase 
(LipA), an S-adenosyl-methionine (SAM)-dependent, [Fe-S] cluster-containing 
enzyme (Cicchillo & Booker, 2005; Miller et al., 2000; Zhao et al., 2003). LA can 
also be salvaged from the environment, and scavenged LA is ligated directly to the 
enzyme complexes by either of the two known salvage pathways. Salvage of LA in 
E. coli requires just one enzyme, lipoate protein ligase (LplA) (Morris et al., 1994; 
Reed et al., 1994), which catalyses the formation of an activated intermediate, 
lipoyl-AMP, and the subsequent transfer of the lipoyl moiety to the apoprotein. The 
mammalian system necessitates the sequential action of two enzymes for 
activation and transfer of LA to the apoprotein; medium-chain acetyl-CoA 
synthetase 1 (ACSM1) (Fujiwara et al., 2001) and lipoyltransferase (LT) (Fujiwara 
et al., 1997a; Fujiwara et al., 1999), respectively. 
 
Figure 1.9 Schematic representation of LA metabolism pathways 
LA can be acquired through biosynthesis or salvage pathways. In the biosynthesis pathway, 
octanoyl-ACP from mitochondrial type II FAS is used a substrate for LipB, which transfers the 
octanoyl-moiety to the E2 subunit of a α-KADH or to the H-protein of the GCC. LipA catalyses the 
insertion of two sulphur atoms into the octanoyl-moiety to form the lipoyl-moiety. LA is salvaged by 
bacteria and mammals in an ATP-dependent reaction. In E. coli, one enzyme – LplA – catalyses 
the activation of LA to form lipoyl-AMP, and the subsequent transfer of the lipoyl-moiety to the apo-
E2-protein or apo-H-protein. In mammals, salvage of LA necessitates the sequential action of two 
enzymes; lipoate-activating enzyme (medium-chain acyl-CoA synthetase) catalyses the activation 
of LA and lipoyltransferase catalyses the transfer of the lipoyl-moiety to the apo-E2-protein or apo-
H-protein. 
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1.4.3.1 LIPA 
LipA catalyses the production of LA from OA by inserting two sulphur atoms at 
carbon position six and eight (see Figure 1.9). As described in Section 1.3.2, 
octanoyl-ACP is provided by mitochondrial type II FAS. In E. coli, it was 
demonstrated that LipA has significantly higher preference for the apoprotein-
bound octanoyl-moiety (octanoamide) as a substrate rather than free octanoyl-
ACP (Zhao et al., 2003). LipA is a member of the radical SAM superfamily, which 
use SAM and a specialised [4Fe-4S]+ cluster to cleave non-activated carbon 
hydrogen (C-H) bonds (Hayden et al., 1992; Miller et al., 2000; Reed & Cronan, 
1993; Sofia et al., 2001). All members of this superfamily possess a strictly 
conserved Cx3Cx2C motif; the three cysteine residues within this motif nucleate 
three of the Fe atoms within the [4Fe-4S]+ cluster, and the fourth Fe atom is bound 
to SAM (Frey et al., 2008). Radical SAM enzymes catalyse the reductive cleavage 
of SAM to produce [4Fe-4S] 2+-Met and a 5'-deoxyadenosyl radical (5'-dA●). 5'-dA● 
abstracts hydrogen atoms linked to non-activated carbon hydrogen (C-H) bonds. 
In the case of LipA, the 5'-dA● abstracts hydrogen atoms linked to C6 and C8 of 
octanoamide, forming C6- and C8 alkyl radicals (Douglas et al., 2006). It was 
established that the production of one molecule of lipoamide from octanoamide 
requires two SAM molecules (Cicchillo et al., 2004a). Interestingly, LipA also 
possesses a second LipA -specific cysteine-rich motif Cx4Cx5C (Cicchillo & 
Booker, 2005; Frey et al., 2008). A second [4Fe-4S]+ cluster is bound to this motif; 
the C6 and C8 alkyl radicals formed from hydrogen abstraction by the action of 5'-
dA● attack µ-sulphido atoms attached to the Cx4Cx5C cluster, and the final result is 
production of a lipoyl-group (Booker et al., 2007; Cicchillo et al., 2004b) (see 
Figure 1.9). 
LipA shares some mechanistic features with biotin synthase (BioB). LA 
metabolism and biotin metabolism are closely related in terms of reaction 
mechanisms carried out by the respective enzymes (Reche, 2000). Biotin is an 
essential cofactor of several enzyme complexes including acetyl-CoA carboxylase 
and pyruvate carboxylase (Nikolau et al., 2003; Pacheco-Alvarez et al., 2002). 
Mammals are not able to synthesise biotin, and as such rely upon uptake of this 
vitamin, which is synthesised in bacteria, plants and some fungi. BioB belongs to 
the radical SAM superfamily and catalyses the generation of biotin from 
desthiobiotin (Lotierzo et al., 2005; Sofia et al., 2001). During this reaction, two C-
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H bonds are cleaved and one sulphur atom is inserted. Similar to LipA, BioB 
requires two SAM molecules to form one molecule of biotin (Shaw et al., 1998). 
The protein also contains a second cysteine-rich motif (Ugulava et al., 2001a), 
which binds to a [2Fe-2S]+ cluster that contributes a sulphur atom to the formation 
of biotin (Jarrett, 2005; Ugulava et al., 2001b). 
1.4.3.2 Octanoic acid and lipoic acid transferases 
The enzymes LipB and LplA possess a moderate degree of similarity on the amino 
acid sequence level to biotin protein ligase (BPL) (Reche, 2000). LipB, LplA and 
BPL all possess a strictly conserved lysine residue that was thought to be involved 
in the transfer of LA/biotin to the ε-amino group of a conserved lysine residue on 
the apoprotein, and this was indeed shown to be the case for LplA and BPL 
(Bagautdinov et al., 2005; McManus et al., 2005). 
However, the reaction catalysed by LipB differs in several respects from those 
carried out by LplA and BPL. Firstly, E. coli LipB (EcLipB) uses ACP-bound OA or 
LA as substrate and is unable to transfer free OA or LA to apo-E2 or apo-H-protein 
(Jordan & Cronan, 1997b; Jordan & Cronan, 2003) (see Figure 1.9). Although 
EcLipB is able to transfer lipoyl-ACP as well as octanoyl-ACP, the fact that E. coli 
LipA (EcLipA) has a significantly higher preference for protein-bound octanoamide 
(Zhao et al., 2003) dictates that the substrate of LipB under physiological 
conditions is likely to be octanoyl-ACP. Secondly, unlike LplA and BPL, EcLipB 
was shown to catalyse octanoylation of apoproteins in a two-step manner, 
whereby octanoyl-ACP is covalently attached to LipB as an acyl-intermediate 
before being transferred to the apo-lipoyl-domain (Zhao et al., 2005). Crystal 
structure data of LipB from Mycobacterium tuberculosis has revealed the nature of 
this two-step reaction, and indicates that M. tuberculosis LipB (MtLipB) is a 
cysteine-lysine acyltransferase (Ma et al., 2006). In the first step of catalysis, 
octanoyl-ACP forms a thioester linkage with a conserved cysteine residue in 
MtLipB, and the conserved lysine residue in LipB activates the ε-amino group of 
the target lysine residue in the apoprotein by deprotonation (Ma et al., 2006). In 
the second step, MtLipB catalyses the nucleophilic attack of the activated ε-amino 
group of the target (apoprotein) lysine residue; the result is cleavage of the 
thioester linkage between the octanoyl-moiety and MtLipB, and the formation of an 
amide bond between the octanoyl-moiety and the apoprotein (Ma et al., 2006). 
Chapter 1  34 
 
The reaction mechanisms of LplA and BPL are similar to one another, yet very 
different to that of LipB. E. coli LplA (EcLplA) is able to use octanoyl-ACP or lipoyl-
ACP as substrates, which is based on evidence that an E. coli line lacking the lipB 
gene is able to proliferate (albeit poorly) without the provision of exogenous LA 
(Jordan & Cronan, 2003). Free LA is the optimal substrate for EcLplA (Green et 
al., 1995; Jordan & Cronan, 2003), and the lipoylation reaction occurs in two steps. 
The first step involves activation of LA by ATP to form the lipoyl-AMP intermediate, 
and the release of pyrophosphate (PPi). Subsequently, the activated intermediate 
is ligated onto the ε-amino group of the target lysine residue in the apoprotein 
(Fujiwara et al., 2005; Kim do et al., 2005; McManus et al., 2005) (see Figure 1.9). 
In mammals, salvage of LA necessitates the sequential action of two enzymes. 
The first step is activation of LA by ATP or guanosine triphosphate (GTP) to form 
lipoyl-AMP or lipoyl-GMP (Fujiwara et al., 2007), respectively, which is carried out 
by a lipoic acid activating enzyme that was shown to be the ACSM (Fujiwara et al., 
2001). Secondly, the lipoyl-AMP intermediate is ligated to apoproteins by LT 
(Fujiwara et al., 1997a; Fujiwara et al., 1999; Fujiwara et al., 2007). 
LplA, BPL and LT share a conserved mechanism of ligation of the lipoyl/biotinoyl-
moiety to apoproteins from a tightly-bound acyl-adenylate intermediate (Fujiwara 
et al., 2005; Fujiwara et al., 2007; Kim do et al., 2005; McManus et al., 2005; 
Reche & Perham, 1999; Reche, 2000; Wilson et al., 1992). Nevertheless, LT is 
unable to catalyse the first step in the reaction carried out by LplA; LA activation 
(Fujiwara et al., 2007). Crystal structure data of EcLplA (Fujiwara et al., 2005), the 
archaebacterium Thermoplasma acidophilum LplA (Kim do et al., 2005; McManus 
et al., 2005), E. coli BPL (Wilson et al., 1992) and Bos taurus LT (BtLT) (Fujiwara 
et al., 2007) have helped to better understand how the similarities between these 
enzymes contribute to common modes of action, and how the differences between 
these enzymes permit substrate specificity (Kim do et al., 2005; McManus et al., 
2005). The N-terminal domains of EcLplA, TaLplA and BtLT were shown to 
possess three highly conserved sequence motifs, which contain key residues 
involved in the formation of the lipoyl-AMP binding pocket (see Figure 3.4) 
(Fujiwara et al., 2005; Fujiwara et al., 2007; Kim do et al., 2005; McManus et al., 
2005). LA is bound within a hydrophobic cavity, and it is believed that the binding 
and activation of LA with ATP occurs at the same site, since no large 
conformational changes were observed after LA binding and activation, and ATP 
was located in the same position as AMP (Fujiwara et al., 2007; Kim do et al., 
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2005). A conserved lysine residue is present in EcLplA, TaLplA and BtLT, which 
directly interacts with the carboxyl-group of LA (Fujiwara et al., 2005; Fujiwara et 
al., 2007; Kim do et al., 2005; McManus et al., 2005). 
Based on size, two types of LplA were uncovered; a shorter form found in T. 
acidophilum (circa 260-270 amino acids) (Kim do et al., 2005; McManus et al., 
2005) and a longer form found in E. coli (circa 330-340 amino acids) (Fujiwara et 
al., 2005). Of the two structural reports on T. acidophilum LplA (TaLplA) (Kim do et 
al., 2005; McManus et al., 2005), one of them illustrated that recombinant TaLplA 
is able to activate LA, yet is unable to ligate it to a lipoate-acceptor protein 
(McManus et al., 2005). Interestingly, T. acidophilum possesses the conserved N-
terminal domain that has been shown to be involved in activation of LA, yet 
completely lacks the C-terminal domain found in EcLplA (McManus et al., 2005), 
thus explaining why it is considerably shorter than EcLplA. The authors 
hypothesised that salvage of LA in T. acidophilum necessitates the sequential 
action of two enzymes, in a similar fashion to LT (McManus et al., 2005). 
Unlike TaLplA however, BtLT does not lack a C-terminal domain, and is unable to 
catalyse the activation of LA (Fujiwara et al., 2007). As discussed above, the N-
terminal domain of LplA has been shown to be important in binding and activation 
of LA (Fujiwara et al., 2005; McManus et al., 2005), and given that the LT N-
terminal domain contains conserved motifs that permit the binding of lipoyl-AMP 
(Fujiwara et al., 2007), one might expect BtLT to have the capacity to activate LA. 
Interestingly, upon protein purification of recombinant BtLT, LA was bound within 
the active site, yet LA has never been reported to be bound to purified 
recombinant EcLplA or TaLplA (Fujiwara et al., 2007). The authors that solved the 
BtLT crystal structure hypothesise that the reason BtLT is unable to activate LA is 
due to its C-terminal domain (Fujiwara et al., 2007). The C-terminal domain of 
BtLT has the same overall fold as that of EcLplA, but importantly, they are rotated 
by approximately 180° relative to each other (Fujiw ara et al., 2007). Both EcLplA 
and BtLT proteins possess a loop linking beta strand 12 and alpha helix 6 (β12-α6 
loop, or the 'adenylate binding loop'), and this loop is unordered in EcLplA. In BtLT 
however, the C-terminal domain anchors the adenylate binding loop to the active 
site, which restricts access of ATP to the active site (Fujiwara et al., 2007). 
Given that LplA/LT and BPL enzymes catalyse the post-translational ligation of LA 
or biotin, respectively, to certain apoproteins, the question arises as to how this 
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event is so specific. An interesting study showed that a single point mutation 
introduced into the active site of EcBPL resulted in promiscuous biotin addition 
(biotinylation) to lysine residues on proteins that were not ordinarily biotinylated 
(Choi-Rhee et al., 2004; Cronan, 2005). The most likely explanation for this 
"promiscuous biotinylation" was found to be due to the activated biotin 
intermediate (biotinoyl-AMP) escaping more easily from the active site of mutant 
EcBPL and biotinylating lysine residues on non-specific substrates by chemical 
(not enzymatic) acylation, in a concentration-dependent manner (Choi-Rhee et al., 
2004; Cronan, 2005). 
In order to avoid lipoylation/biotinylation of the wrong proteins, activated lipoyl-
AMP and biotinoyl-AMP intermediates are bound tightly to the active site of 
LplA/LT and BPL, respectively. Also, the exact positioning of the target lysine 
residue on the apoprotein is pivotal to being recognised by lipoylating/biotinylating 
enzymes (Reche et al., 1998; Wallis & Perham, 1994). The target lysine residue is 
located within a lipoyl-domain or biotinoyl-domain, whereby it is found in the 
DKA/V motif or MKM motif, respectively. However, the most important factor in 
LplA/LT and BPL substrate specificity is the subtle structural differences found 
between the lipoyl/biotinoyl domains (Jones & Perham, 2008).  
1.5 Aims of project 
a. Determine whether genes coding for subunits of α-KADHs and of the GCC are 
present within the L. major genome, and subsequent in silico analyses of the 
predicted proteins. 
b. Assess whether α-KADH E2 subunits and the H-protein of the GCC are 
lipoylated in vivo. 
c. Determine whether genes coding for enzymes involved in LA metabolism are 
present within the L. major genome, and subsequent in silico analyses of the 
predicted proteins. 
d. Assess whether the proteins predicted to be involved in LA metabolism are 
functional. 
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e. Confirmation that the proteins predicted to be involved in LA metabolism 
localise to the mitochondrion. 
f. Attempt gene replacement of one gene from the LA biosynthesis pathway and 
one from the LA salvage pathway, in order to gain an insight into the level of 
redundancy between the two metabolic pathways. 
This thesis is divided into three results chapters covering points a-d (Chapter 3), 
points e-f for the LA salvage pathway (Chapter 4) and points e-f for the LA 
biosynthesis pathway (Chapter 5). The results and their implications relative to 
published work will be discussed in Chapter 6. 
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2 Materials and Methods 
2.1 Biological and chemical reagents 
General chemicals were purchased from either Sigma or Fisher Scientific. 
Abgene   2x Reddymix 
BD Biosciences  α-His-tag monoclonal antibody 
Bio-Rad Precision plus all blue standards, Bradford protein 
assay reagent, econo-columns 
Biosera Lipid-containing- and lipid-depleted foetal calf serum 
(FCS) 
Calbiochem   α-Lipoic acid polyclonal antibody 
Eurogentec Custom DNA oligonucleotides, custom polyclonal 
antibody production 
Fisher Scientific  10x phosphate buffered saline (PBS) 
GE Healthcare Alk phos direct Southern blot kit, N+ membrane, ECL 
films 
IBA α-Strep-tag monoclonal antibody, strep-tactin 
sepharose, d-desthiobiotin, strep-tactin regeneration 
buffer 
ICN Biomedicals Inc. R-lipoic acid 
Invitrogen Accuprime Pfx supermix, zero blunt cloning kit, 
chemically-competent TOP10 E. coli, sybr safe, low 
melting point agarose, HOMEM medium 
Melford Ampicillin, carbenicillin, isopropyl-β-D-
thiogalactopyranoside (IPTG), dithiothreitol (DTT) 
Millipore  Immobilon western detection kit, Centricon Plus-20 
centrifugal filter device 
Molecular Probes  Mitotracker CMXRos 
New England Biolabs All restriction endonucleases, 1 kb DNA ladder 
Novagen Bugbuster protein extraction reagent, benzonase 
nuclease, chemically-competent E. coli BLR (DE3) 
cells 
PAA     G418, puromycin, hygromycin 
Promega α-Mouse IgG (HRP-conjugated) antibody, α-rabbit IgG 
(HRP-conjugated) antibody 
Qiagen Qiaprep spin DNA miniprep kit, Qiaquick gel extraction 
kit, hi-speed maxi kit, Qiaamp DNA mini kit 
Roche    Rapid ligation kit 
Sigma Acrylamide 30 %, Ponceau-S solution, L-polylysine, 
bovine serum albumin (BSA), lysozyme, 
phenylmethylsulfonylfluoride (PMSF), pepstatin A, E-
64, 1, 10-phenanthroline, 4' -6-diamidino-2-
phenylindole dihydrochloride (DAPI), tetracycline 
hydrochloride, digitonin, peanut agglutinin, propidium 
iodide 
Stratagene Quickchange lightning mutagenesis kit 
Schleicher Schuell  Protran nitrocellulose membrane 
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Thermo Scientific Restore western blot stripping buffer, aminolink 
coupling resin, IgG binding buffer, IgG elution buffer 
Upstate   Mouse α-T. brucei EF1α antibody 
2.1.1 Buffers, solutions and media 
General buffers 
1x PBS 140 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.4 
1x TAE    40 mM Tris-acetate, 1 mM EDTA, pH 8.0 
DNA analyses 
DNA loading dye 0.25 % (w/v) bromophenol blue, 0.25 % (w/v) orange-
G, 40 % (w/v) sucrose 
Depurination solution 0.25 N HCl 
Denaturation solution 1.5 M NaCl and 0.5 M NaOH 
20x SSC   0.3 M tri-sodium citrate, 3 M NaCl, pH 7.0 
Protein analyses 
6x loading buffer   62.5 mM Tris/HCl pH 6.8, 2% (w/v) SDS, 10% (v/v) 
glycerol, 0.001% (w/v) bromophenol blue, 5% (v/v) 2-
mercaptoethanol 
1x running buffer  25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS 
1x MOPS buffer  50 mM 3-[N-morpholino] propane sulphonic acid, 50 
mM Tris, 3.5 mM SDS, 1 mM EDTA 
Coomassie stain  40 % (v/v) methanol, 10 % (v/v) acetic acid, 0.1 % (w/v) 
coomassie brilliant blue R-250 
Destain    20 % (v/v) methanol, 10% (v/v) acetic acid 
Towbin transfer buffer  25 mM Tris, 192 mM glycine, 20 % (v/v) methanol 
Buffer W   100 mM Tris-HCl, 150 mM NaCl, pH 8.0 
Buffer E 100 mM Tris-HCl, 150 mM NaCl, 2.5 mM desthibiotin, 
pH 8.0 
Quenching buffer 1 M Tris-HCl, pH 7.4 
Wash buffer 1 M NaCl 
Neutralisation buffer 1 M Tris-HCl, pH 9.0 
Bacteria culture 
Luria-Bertani (LB) medium 10 g L-1 tryptone, 5 g L-1 yeast extract, 5 g L-1 NaCl 
(add 15 g L-1 agar for LB plates) 
M9 minimal medium 10x M9 salt stock: 58 g L-1 Na2HPO4, 30 g L-1 
Na2HPO4, 5 g L-1 NaCl, 10 g L-1 NH4Cl 
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Working solution: 1x M9 salts, 0.2% (w/v) glucose, 1 
mM MgSO4, 0.001 % (w/v) thiamine (add 15 g L-1 agar 
for M9 plates) 
Ampicillin    100 mg ml-1 in ddH20; stored at -20°C 
Carbenicillin    100 mg ml-1 in ddH20; stored at -20°C 
Kanamycin    50 mg ml-1 in ddH20; stored at -20°C 
Tetracycline   5 mg ml-1 in ethanol; stored at -20°C 
TfbI 100 mM RbCl, 50 mM MnCl2-4H2O, 30 mM KNa, 10 
mM CaCl2-2H2O, 15 % glycerol 
TfbII 10 mM MOPS, 10 mM RbCl, 75 mM CaCl2-2H2O, 15 % 
glycerol 
L. major culture 
HOMEM + 10 % FCS: Modified eagle's medium supplemented with 10 % 
heat-inactivated FCS (Berens et al., 1976). HOMEM is 
purchased from GIBCO (Invitrogen), and FCS from 
Biosera 
Electroporation buffer 120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4, 25 mM 
HEPES, 2 mM EDTA, 2 mM MgCl2, pH 7.6 
Freezing solution 30 % (v/v) glycerol in FCS 
TELT buffer 50 mM Tris-HCl, 62.5 mM EDTA; 2.5 M LiCl; 4% (v/v) 
Triton X-100, pH 8.0 
Lysis buffer 0.25 M sucrose, 0.25 % Triton x-100, 10 mM EDTA, 10 
µM EDTA, 10 µM E-64, 2 µM 1, 10-phenanthroline, 4 
µM pepstain A, 1 mM PMSF 
TSE buffer 0.025 M Tris-HCl, 0.25 M Sucrose, 1 mM EDTA, 10 µM 
E-64, 2 µM 1, 10 phenanthroline, 2 µM Pepstatin A, 1 
mM PMSF, 0.3 – 5.0 mg ml-1 digitonin, pH 7.4 
 
2.1.2 Bacteria strains 
TOP10 (Invitrogen) 
F– mcrA∆(mrr-hsdRMS-mcrBC) ø 80lacZ∆M15∆lacX74 recA1 arcD139 ∆(arcleu)  
7697 galU galK rpsL (StrR) endA1 nubG 
 
BLR(DE3) (Novagen) 
F– ompT hsdSB(rB- mB-) gal dcm (DE3) ∆(srl-recA)306::Tn10 (TetR) 
 
XL10-Gold ultracompetent (Stratagene) 
Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 
relA1 lac Hte [F’ proAB lacIqZ∆M15 Tn10 (Tetr) Amy Camr]a 
 
KER184 (lipB–) (Vanden Boom et al., 1991) 
F– rpsL lipB182::Tn1000dKn 
 
KER176 (lipA–) (Vanden Boom et al., 1991) 
F– rpsL lipA150::Tn1000dKn 
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2.1.3 L. major strain 
MHOM/IL/80/Friedlin 
2.1.4 Oligonucleotide primers 
2.1.4.1 For transfection in L. major 
Lm1  GCGCATCGATATGCTGCGCTGCTGCTCTGC (ClaI) 
Lm2  GCGCACCGGTTCACGCAATCGCAGTACCTGCG (AgeI) 
Lm3  GCGCAAGCTTGTTGTGTGTTCGCTGGCAGCG (HindIII) 
Lm4  GCGCGTCGACGCTGACGTTCACGAG (SalI) 
Lm5  GCGCCCCGGGAGAGGAGGTGCATGTGCAATGAGC (SmaI) 
Lm6  GCGCAGATCTCAAGGGTGCGCGCCTATCTC (BglII) 
Lm13  GCGCATCGATATGTGGCAGACTGTCGTGCG (ClaI) 
Lm14  GCGCACCGGTTTAGGTCGCGATGTCGAAC (AgeI) 
Lm15  GCGCAAGCTTCGACTTCCTCGGCTCCCAGC (HindIII) 
Lm16  GCGCGTCGACGGTTGCACACGATCCAGTTGC (SalI) 
Lm17  GCGCCCCGGGTCCGTCGAGCCTTCGCGTCG (SmaI) 
Lm18  GCGCAGATCTCGTAGGGGGGAGGAGTTGCC (BglII) 
Lm19  GCGCCATATGCTGCGCTGCTGCTCTGCTCTG (NdeI)   
Lm20  GCGCGGTACCCGCAATCGCAGTACCTGCGTTG (KpnI) 
Lm21  GCGCGGTACCGGGCGTTGAAATGCCTGCAG (KpnI) 
Lm22  GCGCCATATGAAGGCATTTTTCATCGGCAAAC (NdeI) 
Lm23  GCGCCATATGTGGCAGACTGTCGTGCGGCG (NdeI) 
Lm24  GCGCAGATCTGGTCGCGATGTCGAACACATT (BglII) 
Lm64  GTGCCGTTTTCGCAGACGAGGG 
Lm65  CCCTCGTCTGCGAAAACGGCAC 
 
2.1.4.2 For recombinant protein expression 
Lm25  ATGGTAGGTCTCAAATGCTGCGCTGCTGCTCTGCTCTG 
Lm26  ATGGTAGGTCTCAAATGTCTGCTCTGATGTGCCCGACG 
Lm27  ATGGTAGGTCTCAAATGCCGGTTGCTGCTGCTGCCGC 
Lm28  ATGGTAGGTCTCAAATGCAGTCGGACAAGACGGGCATG 
Lm29  ATGGTAGGTCTCAGCGCTCGCAATCGCAGTACCTGCGTTG 
Lm30  ATGGTAGGTCTCAAATGAAGGCATTTTTCATCGGCAAACGC 
Lm31  ATGGTAGGTCTCAAATGAGTGTGCGCCGCGGCGCG 
Lm32  ATGGTAGGTCTCAAATGGGCGCGTCGAAGCTGCCGC 
Lm33  ATGGTAGGTCTCAGCGCTGGGCGTTGAAATGCCTGCAGTG 
Lm34  ATGGTAGGTCTCAAATGTGGCAGACTGTCGTGCGGCG 
Lm35  ATGGTAGGTCTCAAATGCCCACGTCCCTCGCAGCCTT 
Lm36  ATGGTAGGTCTCAAATGGACTCGAACCTTGTCGTCGCTG 
Lm37  ATGGTAGGTCTCAGCGCTGGTCGCGATGTCGAACACATTC 
 
All primers used for PCR of DNA fragments to be used in recombinant protein 
expression contain directional BsaI restriction endonuclease sites.  
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2.1.5 Antibodies 
1ary antibody Animal Clonality Dilution Source Reference
α-Lipoic acid Rabbit Polyclonal 1/6,000 Calbiochem Gunther et al.  (2007)
α-Strep-tag Mouse Monoclonal 1/7,500 IBA N/A
α-His-tag(6x) Mouse Monoclonal 1/10,000 BD Biosciences N/A
α-GFP Mouse Monoclonal 1/5,000 Roche N/A
α-Lm LIPA Rabbit Polyclonal 1/20 Ryan Bissett (Eurogentec) N/A
α-Lm LIPB Rabbit Polyclonal 1/1000 Ryan Bissett (Eurogentec) N/A
α-Lm CS Rabbit Polyclonal 1/7,500 Dr Rod Williams N/A
α-Tb EF1α Mouse Polyclonal 1/10,000 Upstate Besteiro et al.  (2008)
α-Lm HASPB Rabbit Polyclonal 1/4,000 Prof. Debbie Smith Flinn et al.  (1994)
2ary antibody Animal Clonality Dilution Source Reference
α-Mouse (H + L), HRP Goat Polyclonal 1/10,000 Promega N/A
α-Rabbit (H + L), HRP Goat Polyclonal 1/10,000 Promega N/A
 
Table 2.1 Primary and secondary antibodies and their dilutions 
Table of all primary and secondary antibodies used in this thesis. The 'Animal' field indicates the 
origin of the antibodies. 'Lm' and 'Tb' indicate that the antigens used for antibody production are of 
L. major or T. brucei origin. 'HRP' is an abbreviation for 'horseradish peroxidise', to which 
secondary antibodies are conjugated. 'N/A' is an acronym for 'not applicable.'  
2.2 L. major cell culture 
2.2.1 L. major promastigote culture 
L. major cultures were initiated by purification of amastigotes from a BALB/c 
mouse by Mrs Denise Candlish (University of Glasgow) and differentiated into 
promastigotes by inoculation into HOMEM medium supplemented with 10 % (v/v) 
heat-inactivated FCS, which will be referred to as HOMEM + 10 % FCS. In order 
to maintain L. major promastigotes, cultures were incubated at 25 °C an d sub-
passaged to a density of 105 parasites ml-1 on a weekly basis. 
Parasite numbers were determined by transferring the parasites into 1 % 
formaldehyde in PBS, and counting them using a Neubauer haemocytometer with 
an objective magnification of 400 x on an inverted light microscope (Zeiss Wetzlar, 
Germany). Growth rates through promastigote development were examined by 
determining parasite numbers daily for up to 120 h, starting from a parasite density 
of 5 x 105 cells ml-1.  
Chapter 2  43 
 
When necessary, antibiotics were added to transgenic promastigote cell lines as 
follows: G418 at 10- or 50 µg ml-1; hygromycin B at 50 µg ml-1; neurseothricin at 75 
µg ml-1; puromycin at 100 µg ml-1.  
Stabilates of parasites were generated by transferring 500 µl of exponentially 
growing cells into 500 µl of 30 % glycerol (v/v) in FCS and transferring the mixture 
into – 80 ºC for 24 h before the stabilate was transferred into liquid nitrogen for 
long-term storage. 
2.2.2 Isolation of concentrated L. major metacyclic promastigotes 
Isolation of metacyclic promastigotes was carried out based upon a negative 
selection (of procyclic promastigotes) protocol described by Sacks (Sacks et al., 
1985). Briefly, L. major stationary culture promastigotes were incubated with sterile 
peanut agglutinin dissolved in PBS, pH 7.2 at a concentration of 100 µg ml-1 and 
incubated for 30 min at room temperature. The parasites were then centrifuged for 
5 min at 100 g at room temperature in order to fractionate non-metacyclic 
promastigotes (pellet fraction) from metacyclic promastigotes (supernatant 
fraction). 
2.2.3 Harvest, lysis and fractionation of parasites 
2.2.3.1 Isolation of genomic DNA from L. major 
Genomic DNA (gDNA) was isolated from parasites by one of two methods. For 
PCR analyses, gDNA was isolated by phenol-chloroform extraction (as described 
in (Sambrook et al., 1989)) after lysis with TELT buffer (see Section 2.1.1). For 
Southern blotting, gDNA was isolated using the QIAamp DNA mini kit according to 
instructions provided by the manufacturer (Qiagen). 
2.2.3.2 Isolation of protein from L. major 
Protein was extracted from parasites by cell lysis in lysis buffer (see Section 
2.1.1). Soluble- and pellet fractions were separated by centrifugation for 30 min at 
13,000 rpm (Fisher Scientific accuSpin MicoR with 24-plate motor) at 4 °C. The 
protein concentration in the soluble fraction was determined using the Bradford 
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method with BSA as a standard (Bradford, 1976). Then, 6x sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) loading dye was added 
and aliquots were denatured at 100 ºC for 5 min before the samples were stored 
at – 20 °C. 
2.2.3.3 Cellular pre-fractionation 
Parasites were permeabilised with increasing quantities of digitonin in order to pre-
fractionate (or concentrate) different organelles. Previous digitonin-titration 
experiments in L. mexicana showed that cytosolic-, glycosomal- or mitochondrial 
protein markers could be detected by western blotting (see Section 2.5.3) when 
cells were treated with 0.3 mg ml-1, 1.5 mg ml-1 or 3.0 mg ml-1 to 5.0 mg ml-1 
digitonin, respectively (Leroux et al., 2006). The same digitonin concentrations 
were used here. Briefly, 2 x 109 stationary phase parasites were harvested by 
centrifugation for 15 min at 1000 g at room temperature. Cells were washed twice 
at room temperature in TSE buffer (TSEB) (see Section 2.1.1) (Leroux et al., 
2006). Cells were then resuspended in 200 µl TSEB supplemented with the lowest 
concentration of digitonin (dissolved in sterile water) and incubated for 5 min at 
room temperature. 40 µl of 0.3 M sucrose was added to the cells, which were then 
centrifuged for 10 min at 18,000 g at 4 °C. The pellet fraction was subsequently 
treated in the same way as described above except the second lowest 
concentration of digitonin was added. Soluble fractions from each digitonin-titration 
step were used to extract soluble protein for SDS-PAGE and western blotting. 
2.2.4 Targeted gene replacement in L. major 
Gene replacement by double homologous recombination is the method of choice 
for gene knockout studies in L. major (Cruz & Beverley, 1990; Cruz et al., 1991). 
The plasmids used consist of an antibiotic resistance gene (for selection of 
transgenic parasites), flanked by regions of DNA specific to the gene under study. 
The knockout plasmid is linearised either side of the flanking regions of the target 
gene to give rise to the knockout cassette, which is then introduced into 
Leishmania by electroporation (see Section 2.2.8). The fact that Leishmania is a 
diploid organism means that two rounds of homologous recombination with 
different selectable markers are necessary in order to ablate both endogenous 
alleles of the gene (Cruz & Beverley, 1990; Cruz et al., 1991).  
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2.2.4.1 Gene knockout 
In order to create an L. major LIPA (LmjLIPA) gene knockout construct, the 534 bp 
5' flanking region (using primer pairs Lm3-Lm4) and the 550 bp 3' flanking region 
(using primer pairs Lm5-Lm6) were cloned into plasmid into pGL158 (see Figure 
2.1 and Section 2.1.4.1) to give rise to LIPA-SAT. The LPLA-SAT gene knockout 
construct was created by cloning the 516 bp 5' flanking region (using primer pairs 
Lm15-Lm16) and the 545 bp 3' flanking region (using primer pairs Lm17-Lm18) 
into the pGL158 plasmid (see Figure 2.1 and Section 2.1.4.1). In both cases, 5' 
and 3' flanking regions were cloned into pGL158 by directional cloning with 
HindIII/SalI and SmaI/BglII, respectively (see Section 2.4.2). 
The pGL158 plasmid contains the neurseothricin-resistance gene; streptothricin-
acetyl-transferase (SAT) (Joshi et al., 1995). LIPA-HYG and LPLA-HYG were 
generated by replacing the SpeI/BamHI cassette containing the neurseothricin-
resistance gene with a SpeI/BamHI cassette containing the hygromycin-resistance 
gene; hygromycin B phosphotransferase (HYG) (Cruz et al., 1991), which was 
derived from plasmid pGL345 (see Figure 2.2).  
Knockout cassettes were created by HindIII/BglII linearisation of knockout 
constructs; the cassettes were gel purified, precipitated into a smaller volume and 
then transfected into parasites (see Section 2.2.8).  
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Figure 2.1 pGL158 plasmid 
The pGL158 plasmid contains the following features: 5' of gene, the 5' FR of the gene of interest; 3' 
of gene, the 3' FR of the gene of interest; SAT, streptothricin acetyltransferase gene conferring 
resistance to neurseothricin; Amp, ampicillin-resistance gene. Restriction endonucleases are 
illustrated, and numbers in brackets mark the cut sites of the restriction endonucleases. 
 
Figure 2.2 pGL345 plasmid 
The pGL345 plasmid contains the following features: 5' of gene, the 5' FR of the gene of interest; 3' 
of gene, the 3' FR of the gene of interest; SAT, streptothricin acetyltransferase gene conferring 
resistance to neurseothricin; Amp, ampicillin-resistance gene. Restriction endonucleases are 
illustrated, and numbers in brackets mark the cut sites of the restriction endonucleases. 
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2.2.5 Re-expression of the target gene 
In order to assess the functionality of genes in Leishmania, it is necessary to 
create a parasite line re-expressing the gene of interest, before or after ablating 
the endogenous gene copies. The pGL631 (or pRB vector) (see Figure 2.3) was 
chosen for this purpose, which is designed to replace (knock-in) one of the twelve 
copies of the 18S SSU ribosomal rRNA (rRNA) gene (Misslitz et al., 2000). 
Additionally, a re-expression construct that integrates is more likely to mimic 
expression levels of the endogenous gene, compared to the (typically) very high 
expression/over-expression observed from episomal expression constructs (see 
Section 5.4.1). 
The pRB vector (see Figure 2.3) contains DNA sequences corresponding to 5' and 
3' regions within the 18S SSU rRNA gene, in order to permit replacement of one of 
the 12 18S SSU rRNA gene copies by homologous recombination (Misslitz et al., 
2000). The puromycin resistance gene, puromycin N-acetyltransferase (PAC) 
(Freedman & Beverley, 1993), is upstream of the intergenic region of the L. 
mexicana cysteine peptidase B 2.8 (CPB 2.8) gene, in order to permit high 
expression of the resistance marker if the transfected line is to be used in 
amastigotes (Misslitz et al., 2000). In the pRB vector, open reading frames (ORFs) 
to be expressed in parasites are located downstream of a splice acceptor site 
(SAS), which is necessary in order to permit trans-splicing of the pre-messenger 
RNA (mRNA) into monocistronic units (Agabian, 1990). 
LIPA-pRB and LPLA-pRB re-expressor constructs were created by directional 
cloning of the respective ORFs into the pRB vector, using ClaI/AgeI. The LIPA and 
LPLA genes were amplified from L. major gDNA using primer pairs Lm1-Lm2 and 
Lm13-Lm14, respectively (see Section 2.1.4.1), and then cloned into plasmid pRB 
(also referred to as pGL631) (see Figure 2.3).  
Knockout cassettes were created by PacI/PmeI linearisation of knockout 
constructs; the cassettes were gel purified, precipitated into a smaller volume and 
then transfected into parasites (see Section 2.2.8).  
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Figure 2.3 pGL631 (pRB) plasmid 
The pGL631/pRB plasmid contains the following features: 5' 18S SSU, the 5' FR of the 18S SSU 
locus; SL, splice leader sequence; PAS, polyadenylation site; SAS, splice acceptor site; 5' CPB 
2.8, intergenic region of the L. mexicana cysteine peptidase B 2.8 (CPB 2.8) gene; PAC, puromycin 
N-acetyltransferase gene conferring resistance to puromycin; 3' 18S SSU, the 3' FR of the 18S 
SSU locus; Amp, ampicillin-resistance gene. Restriction endonucleases are illustrated, and 
numbers in brackets mark the cut sites of the restriction endonucleases. The gene of interest to be 
expressed in L. major is directionally cloned into pGL631 using ClaI and AgeI restriction sites. 
2.2.6 Episomal gene expression in L. major 
Stable extrachromosomal expression of genes in Leishmania is possible using a 
series of expression vectors, named pNUS vectors, which have been designed for 
the trypanosomatids Crithidia and Leishmania (Tetaud et al., 2002). These vectors 
contain a rRNA promoter, intergenic sequences from the Crithidia fasciculata (C. 
fasciculata) phosphoglycerate kinase (PGK) locus at the 5' and 3 ends of the 
target gene, and the 3' untranslated sequence of the C. fasciculata glutathionyl-
spermidine synthetase (GSPS) locus 3' to the antibiotic resistance gene. Two 
variations of the vectors were used in this thesis: pGL1132 adds a C-terminal 
green-fluorescent protein (GFP)-tag to the insert gene (see Figure 2.4), and 
pGL1137 adds a C-terminal His6x-tag (see Figure 2.5). The antibiotic resistance 
gene used in all studies was neomycin phosphotransferase (NEO), which confers 
resistance to neomycin (Curotto de Lafaille et al., 1992). 
In order to create LIPA-GFP and LPLA-GFP constructs, full-length LIPA and LPLA 
genes lacking their stop codons, were amplified from L. major gDNA using primer 
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pairs Lm19-Lm20 and Lm23-Lm24 (see Section 2.1.4.1), and cloned into plasmid 
pGL1132 (see Figure 2.4). The LIPB-His construct was created by amplifying the 
full-length LIPB gene lacking its stop codons from L. major gDNA using primer pair 
Lm21-Lm22 (see Section 2.1.4.1), and cloning into plasmid pGL1137 (see Figure 
2.5). The LPLA-His construct was created by excision (NdeI/BglII digest) of the 
LPLA gene from pGL1132, and sub-cloning into NdeI/BglII-digested pGL1137. The 
LPLAH118A-His construct was created by site-directed mutagenesis PCR (see 
Section 2.4.1.3), using the LPLA-His construct as a DNA template.  
 
Figure 2.4 pGL1132 plasmid 
The pGL1132 plasmid contains the following features: 5' PGKB, the 5'FR of the C. fasciculata 
phosphoglycerate kinase B (PGKB) gene; GFP, GFP gene; 3' PGKB, the 3'FR of the C. fasciculata 
phosphoglycerate kinase A (PGKA) gene; 3' GSPS, the 3'FR of the C. fasciculata glutathionyl-
spermidine synthetase (GSPS) gene; NEO, neomycin phosphotransferase gene conferring 
resistance to G418; Amp, ampicillin-resistance gene. Restriction endonucleases are illustrated, and 
numbers in brackets mark the cut sites of the restriction endonucleases. The gene of interest to be 
expressed in L. major is directionally cloned into pGL631 using NdeI and KpnI (or BglII) restriction 
sites. 
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Figure 2.5 pGL1137 plasmid 
The pGL1137 plasmid contains the following features: 5' PGKB, the 5'FR of the C. fasciculata 
phosphoglycerate kinase B (PGKB) gene; GFP, GFP gene; 3' PGKB, the 3'FR of the C. fasciculata 
phosphoglycerate kinase A (PGKA) gene; 3' GSPS, the 3'FR of the C. fasciculata glutathionyl-
spermidine synthetase (GSPS) gene; NEO, neomycin phosphotransferase gene conferring 
resistance to G418; Amp, ampicillin-resistance gene. Restriction endonucleases are illustrated, and 
numbers in brackets mark the cut sites of the restriction endonucleases. The gene of interest to be 
expressed in L. major is directionally cloned into pGL631 using NdeI and KpnI (or BglII) restriction 
sites. 
2.2.7  Resistance markers 
In order to select for transgenic Leishmania parasites, six resistance markers have 
been developed, four of which were used in this thesis (see Table 2.2). 
Gene Protein Antibiotic Reference
NEO Neomycin phosphotransferase G418 Cruz et al.  (1990)
SAT Streptothricin acetyltransferase Neurseothricin Joshi et al.  (1995)
PAC Puromycin N -acetyltransferase Puromycin Freedman & Beverley (1993)
HYG Hygromycin B phosphotransferase Hygromycin B Cruz et al.  (1991)
 
Table 2.2 Antibiotic resistance genes used for genetic manipulation of Leishmania 
 
2.2.8 Transfection of L. major 
For constructs designed to integrate into the L. major genome, 100 µg of plasmid 
was digested with the appropriate restriction enzymes (HindIII/BglII for knockout 
plasmids and PacI/PmeI for pRB plasmids). The knock-out cassettes were 
separated by gel electrophoresis, gel-extracted and –purified, and then 
precipitated with ethanol according to standard procedures (Sambrook et al., 
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1989) before resuspension in 15 µl sterile water, with a final DNA concentration of 
about 1 – 2 µg µl-1. For ectopic constructs, 20 µg of circular plasmid was used for 
transfections, in a final volume of 15 µl.  
For transfections, mid-log phase (at a density of 8 x 106 – 1 x 107 parasites ml-1) 
promastigote cultures were used. Each transfection necessitated 5 x 107 cells and 
10 – 20 µg of purified plasmid/linear DNA in 15 µl sterile water. Two different 
transfection methods were used. The first is using the protocol developed by 
Robinson and Beverley (Robinson & Beverley, 2003). Briefly, cells were counted 
and the appropriate number centrifuged for 10 min at 1,000 g at 4 °C and washed 
with electroporation buffer (EPB: 120 mM KCl, 015 mM CaCl2, 10 mM K2HPO4, 25 
mM HEPES, 2 mM EDTA, 2 mM MgCl2 at pH 7.6). Cells were resuspended in 500 
µl EPB to a concentration of 1 x 108 parasites ml-1, and added to 15 µl of 
appropriate plasmid/linear DNA in an ice-cold 4 mm gap cuvette (Gene Pulse, Bio-
Rad, Hemel Hempstead, UK) and incubated on ice for 10 min. The cuvette was 
exposed to two electroporation pulses at 25 µF, 1.5 kV (3.75 kV cm-1), pausing 10 
sec between pulses, using a Bio-Rad Gene Pulser II machine.  
The second method was only used for transfection of integration cassettes. Briefly, 
cells were counted and the appropriate number centrifuged for 10 min at 1,000 g 
at 4 °C and resuspended in Nucleofactor Solution fr om the Amaxa Human T Cell 
Nucleofactor Kit (Amaxa AG, Cologne, Germany) to give 5 x 107 cells 100 µl-1. The 
resuspended cells were mixed with 15 µl linear DNA in the cuvette from the 
Nuclefeofactor kit. Program U-033 was used to electroporate the cells using the 
Amaxa Nucleofactor Device.  
In both methods, electroporated cells were incubated on ice for 10 min before 
transferring into a flask containing 10 ml HOMEM + 10 % FCS. Drug selection and 
cloning (of integrative constructs) was commenced the following day. In order to 
generate a population of cells for ectopic expression of a plasmid, the appropriate 
antibiotic(s) was added directly to the flask of cells.  
2.2.9 Cloning of L. major by limiting dilution 
In order to generate clones, three dilutions of the transfected cells were made (1/6, 
1/72 and 1/864) in HOMEM + 10 % FCS including appropriate antibiotic(s), and 
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plated in 96-well plates. After approximately 2–3 weeks of incubation, plates 
containing ≤ 10 wells with parasite growth (equating to ≤ 0.1 parasite well-1) were 
used for further analysis; the clones were sub-passaged into 3 ml HOMEM + 10 % 
FCS in 12-well plates and incubated until parasite density was sufficient to extract 
gDNA. 2 ml of the clonal cultures were used for gDNA extraction and PCR to 
screen for knock-out/knock-in cassette integration and/or for the presence of the 
endogenous gene. The remaining 1 ml of clonal culture with the desired genotype 
was sub-passaged into 10 ml HOMEM + 10 % FCS with appropriate drugs, and 
once parasite density was high enough, stabilates were made and gDNA was 
extracted for Southern blot analysis. 
2.2.10 Fluorescence microscopy 
Sub-cellular localisation of LIPA-GFP and LPLA-GFP fusion proteins expressed in 
L. major was determined by fluorescence microscopy using an AxioScop-2 mot 
plus microscope (Zeiss) equipped with a Hamamatsu C4742-95 CCD camera. 
Preparation of cells to be analysed involved adding 10 µg ml-1 DAPI to 10 ml of 
mid-log phase culture and immediately centrifuging for 1 minute at 1000 g at room 
temperature. Cells were washed twice with 20 ml PBS, and to the second wash 1 
nM Mitotracker CMXRos was added. Finally, pelleted cells were resuspended in 
20 µl PBS and loaded on a microscope slide with cover slip sealed with nail 
varnish to avoid drying-out of specimen.  
Images were captured at 100x magnification using differential interference contrast 
(DIC) microscopy. The GFP-fusion proteins were observed using the fluorescent 
filter FITC (λexcitation = 494 nm and λemission = 518 nm). The mitochondrion was 
selectively stained using Mitotracker CMXRos (Invitrogen), and was visualised 
using the fluorescent filter for rhodamine (λexcitation = 570 nm and λemission = 590 
nm). The nucleus and kinetoplast DNA of parasites were visualised using DAPI 
(Sigma) and the fluorescent filter for DAPI (λexcitation = 345 nm and λemission = 458 
nm). 
2.2.11 Cell viability assay 
The alamar blue assay was employed in order to determine the 
leishmanicidal/leishmanistatic effects of a compound on Leishmania cells. 
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Metabolising parasites reduce resazurin (alamar blue) and the fluorescence can 
be detected; the higher the level of fluorescence, the less effect the compound has 
at that specific concentration. 
Promastigotes were cultured in the appropriate medium to a density of 5 x 106 ml-1 
and then diluted to 2 x 106 ml-1 in medium. In a 96-well plate, 100 µl of neat 
compounds (lipoid acid, octanoic acid or 8’ bromooctanoic acid) dissolved in 100 
% EtOH were added to wells in the first columns; each treatment was carried out 
in duplicate and a negative solvent (EtOH) control included in order to normalise 
the data; the concentration of the EtOH solvent control was the same as the 
concentration of EtOH in the well containing the most concentrated of each 
compound, which was 0.5 % EtOH. 100 µl medium was added to each well, and 
then serial dilutions of drug were carried out along rows. 100 µl of cells at a density 
of 2 x 106 ml-1 were added to each well, thus giving a final density of 1 x 106 
parasites ml-1. Plates were incubated at 25 °C for 120 h. After the incubation 
period, 20 µl resazurin was added to each well (to a final concentration of 12.5 µg 
ml-1), followed by further incubation for 48 h at 25 °C. Plates were then read using 
an LS 55 luminescence spectrometer with λemission = 535 nm and λexcitation = 620 
nm. All data were normalised against respective column negative controls and 
expressed as bar charts using the software Prism.  
2.3 Bioinformatics 
2.3.1 Identifying genes in the L. major genome 
Genes were identified in the L. major GeneDB database 
(http://www.genedb.org/genedb/leish/) by performing TBLASTN searches using 
known protein sequences from Escherichia coli or H. sapiens. Predicted 
translations of the sequences identified were queried back against the 
SWISSPROT protein database at NCBI using BLASTP 
(http://www.ncbi.nlm.nih.gov/blast).  
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2.3.2 Multiple sequence alignments 
Protein sequence analyses were performed using VECTOR NTI Suite (Invitrogen), 
and sequence alignments carried out using the program ClustalW (Thompson et 
al., 1994). 
2.3.3 Subcellular localisation predictions 
Predictions of N-terminal targeting sequences were performed using TARGETP 
(http://www.cbs.dtu.dk/services/TargetP) (Emanuelsson et al., 2000) and 
MITOPROT (http://mips.biochem.mpg.de/cgi-bin/proj/medgen/mitofilter) (Claros & 
Vincens, 1996). 
Based on predicted mitochondrial targeting peptides, different N-terminal truncated 
constructs of the three genes (LIPA, LIPB and LPLA) were created for expression 
in E. coli (see Section 2.5.6). 
2.4 Methods in molecular biology 
2.4.1 Polymerase chain reaction 
2.4.1.1 AccuPrime Pfx SuperMix 
L. major genes/flanking regions were amplified from L. major gDNA using 
AccuPrime Pfx SuperMix (Invitrogen), which contains 1.1 mM MgSO4, 330 µM 
deoxyribonucleotide triphosphate (dNTPs) and 22 U ml-1 Pfx DNA polymerase. 
Polymerase chain reaction (PCR) was set up using 100 ng gDNA and 10 µM of 
each primer. The final volume per PCR reaction was 25 µl and PCR was carried 
out under the following conditions: 
Initial denaturation  95 °C, 5 min 
30 cycles of: 
Denaturation   95 °C, 15 sec 
Annealing   primer-specific temperature, 30 sec 
Elongation   68 °C, 2 min kb -1 amplified  
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Final elongation  68 °C, 10 min 
The PCR products were analysed on a 1 % agarose gel containg Sybr Safe at a 
1/10,000 dilution, and fragments of the expected size were cloned into pCR-
BluntII-TOPO using the Zero Blunt TOPO PCR cloning kit (Invitrogen).  
2.4.1.2 ReddyMix PCR Master Mix 
In order to screen for bacterial clones possessing the desired insert in plasmid, 
and for L. major clones having correct knockout cassette integration (and for the 
presence/absence of the endogenous gene), PCR was carried out using 
ReddyMix PCR Master Mix (Thermo Scientific). Individual PCR reactions contain 
0.625 U of ThermoPrime Taq DNA polymerase, 1.5 mM MgCl2 and 0.2 mM of 
each of the four dNTPs. The PCR was set up using bacterial colony/up to 100 ng 
gDNA and 10 µM of each primer. The final volume per PCR reaction was 10 µl 
and PCR was carried out under the following conditions: 
Initial denaturation  95 °C, 5 min 
30 cycles of: 
Denaturation   95 °C, 15 sec 
Annealing   primer-specific temperature, 30 sec 
Elongation   72 °C, 2 min kb -1 amplified  
Final elongation  72 °C, 10 min 
The PCR products were analysed on a 1 % agarose gel. 
2.4.1.3 Site-directed mutagenesis PCR 
Site-directed mutagenesis was used to introduce three point mutations into LPLA 
in order to produce the mutant LPLAH118A. The LPLA-His construct (see Section 
2.2.6) was used as a DNA template for mutagenesis PCR using primer pair Lm64-
Lm65 (see Section 2.1.4.1). PCR was carried out using the QuickChange 
Lightning Site-Directed Mutagenesis Kit (Stratagene). The reaction contained 50 
ng of plasmid DNA, 125 ng of each primer, 1x reaction buffer, 1.5 µl of 
QuickSolution reagent, 1 µl of dNTP mix and 1 µl of 'QuickChange Lightning' DNA 
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polymerase (provided with kit). The PCR was carried out under the following 
conditions: 
Initial denaturation  95 °C, 2 min 
18 cycles of: 
Denaturation   95 °C, 20 sec 
Annealing   69 °C, 10 sec 
Elongation   68 °C, 4 min (for 7.8 kb plasmid)  
Final elongation  68 °C, 5 min 
2 µl of the provided DpnI enzyme (Stratagene) was added to the finished PCR 
reaction, and incubated at 37 °C for 5 min in order  to degrade methylated 
(plasmid) DNA. The PCR products were then transformed into XL-10 
Ultracompetent bacteria (Stratagene). Bacterial colonies containing the plasmid 
with insert were verified by restriction digestion and then mutagenesis of the LPLA 
insert was confirmed by sequencing (Dundee Sequencing Centre). The LPLAH118A-
His construct (see Section 2.2.6) was then transfected into WT parasites to create 
the WT[LPLAH118A-His] line.  
2.4.2 Cloning techniques 
2.4.2.1 TOPO cloning of PCR products 
In order to facilitate the cloning of PCR products into their destination vectors, 
inserts were firstly ligated into an intermediate vector. Given that PCR products 
amplified with Pfx polymerase have blunt ends, the Zero Blunt TOPO PCR cloning 
kit containing the vector pCR-BluntII-TOPO was chosen for intermediate vector 
cloning (see Figure 2.6). Ligations were carried out according to instructions 
provided by the manufacturer (Invitrogen) and 1 µl of the ligation transformed into 
TOP10 cells (see Section 2.1.2). 
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Figure 2.6 Vector map of pCR-BluntII-TOPO 
This figure displays the important features of the pCR-Blunt II-TOPO plasmid, which was used to 
clone PCR products amplified with polymerases with proofreading abilities. The plasmid contains 
the kanamycin resistance cassette (KanR; 795 bp) for selection in E. coli. The topoisomerase I is 
covalently bound to the TOPO binding sites. After cloning, the generated construct was analysed 
by diagnostic digests using the EcoRI restriction sites shown, and the sequence of the cloned PCR 
product was verified by sequencing using the primers M13F and M13R. 
2.4.2.2 Sub-cloning into destination plasmids 
Bacterial clones containing TOPO plasmid with the correct insert (as determined 
by colony PCR (see Section 2.4.1.2) or by restriction endonuclease digest (see 
Section 2.4.6) were used in subsequent cloning steps, after verification of the 
correct DNA sequence (see Section 2.4.9). The insert was isolated from the TOPO 
plasmid using the appropriate restriction endonucleases (see Section 2.4.6). The 
destination plasmid was linearised using the same restriction enzymes and the 
DNA fragments were separated by agarose gel electrophoresis (see Section 
2.4.10). The digested insert and destination plasmid were excised from the gel and 
purified using the Qiagen Gel Extraction kit as per manufacturer’s instructions. The 
insert was then ligated into the destination plasmid using the Rapid DNA Ligation 
kit, according to instructions provided by the manufacturer (Roche). A molar 
vector: insert ratio of 1: 3 was used in the ligation reactions. 10 µl of the ligation 
reactions were transformed into competent TOP10 E. coli and plated on LB-plates 
containing the appropriate antibiotics. Individual colonies were analysed by DNA 
plasmid miniprep (see Section 2.4.5) and restriction endonuclease digestion (see 
Section 2.4.6). Plasmids containing the correct insert size were analysed by DNA 
sequencing (see Section 2.4.9). 
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2.4.3 Preparation of chemically-competent bacteria 
Competent bacteria used during this work were either bought from Invitrogen 
(TOP10), Novagen (BLR (DE3)) or Stratagene (XL10-Gold Ultracompetent) (see 
Section 2.1.2), or were made chemically competent. Briefly, a 5 ml overnight 
culture of the appropriate E. coli strain was set up and then used to inoculate 200 
ml LB-medium with the appropriate (if necessary at all) antibiotics. The culture was 
grown at 37 °C at 220 rpm until OD 600 reached 0.6. The culture was transferred 
into a sterile centrifuge tube and incubated for 15 min at 4 °C. The cells were then 
pelleted for 10 min at 6,000 g at 4 °C. The pellet was resuspended in 30 ml of ic e-
cold TfbI buffer (100 mM RbCl, 50 mM MnCl2-4H2O, 30 mM KNa, 10 mM CaCl2-
2H2O and 15 % glycerol) and incubated at 4 °C for 30 m in. The cells were then 
centrifuged for 5 min at 6,000 g at 4 °C and resuspended in 6 ml of ice-cold TfbII 
buffer (10 mM MOPS, 10 mM RbCl, 75 mM CaCl2-2H2O and 15 % glycerol). 
Aliquots of competent cells were snap frozen in dry ice and immediately 
transferred to – 80 °C for storage. 
2.4.4 Transformation of competent bacteria 
Chemically-competent E. coli were used to transform plasmid DNA and ligation 
reactions. The bacteria were removed from storage at – 80 °C and thawed on ice 
for 10 min. The DNA (1 µl of 1/10 diluted miniprep plasmid DNA or 10 µl of 
ligation) was added to the bacteria and then incubated on ice for 30 min. Heat 
shock was carried out for 45 sec at 42 °C and then the bacteria were kept on ice 
for 10 min. 250 µl LB was added to the bacteria, which were then incubated for 30 
min to 1 h shaking at 37 °C at 250 rpm. Finally, th e cells were pelleted and 
resuspended in 50 µl LB and plated onto agar plates supplemented with the 
appropriate antibiotic (see Section 2.1.1).  
2.4.5 Plasmid DNA isolation from bacteria 
Plasmid DNA was isolated from E. coli by one of two methods, depending upon 
the amount of DNA required. In order to purify small amounts of DNA to screen for 
correct insert ligation into a plasmid, 5 ml LB with the appropriate antibiotics was 
inoculated with a single bacterial colony overnight at 37 °C at 250 rpm. The 
bacteria were pelleted and DNA purification carried out using the Qiaprep Spin 
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Miniprep kit according to manufacturer's instructions (Qiagen). Large quantities of 
DNA to be used in transfection of Leishmania were isolated using a similar silica 
column-based method, but using a higher volume of culture (250 ml) and the Hi-
Speed Plasmid Maxi kit (Qiagen). DNA was precipitated into a volume of 500 µl 
using the QiaPrecipitator module (Qiagen), and the concentration determined by 
spectrophotometric means (see Section 2.4.8).  
DNA obtained from miniprep and maxiprep protocols was subjected to restriction 
endonuclease digestion (see Section 2.4.6) in order to determine/verify that the 
plasmid contained the correct insert in the correct orientation.  
2.4.6 Restriction endonuclease digestion 
Restriction endonuclease digestion was routinely carried out on miniprep DNA in 
order to verify the correct cloning of an insert into an intermediate/destination 
vector. Unless stated otherwise, 3 µl of miniprep DNA was digested with 1 U of 
restriction enzyme in the appropriate buffer (NEB). Reactions were typically 
incubated for 2 h at 37 °C (or 50 °C for BsaI). Restriction patterns were visualised 
by mixing with 6xDNA loading dye and subjection to agarose (1 % w/v) 
electrophoresis (see Section 2.4.10) 
2.4.7 Ethanol precipitation of gDNA 
DNA was precipitated using 0.1 volumes of 3 M Na-acetate pH 5.2 and three 
volumes of ice-cold ethanol. Additionally, 1 µl of glycogen (20 mg ml-1 stock) was 
added in order to visualise the DNA pellet throughout centrifugation steps. The 
mixture was incubated for 20 min at – 80 °C and the n the precipitated DNA 
pelleted at 13,000 rpm (Fisher Scientific accuSpin MicoR with 24-plate motor) at 4 
°C for 30 min. The DNA was washed with ice-cold 70 % (v/v) ethanol, and then 
allowed to air-dry (under a sterile hood if the DNA was to be used for transfections 
in Leishmania). Finally, the DNA was re-suspended in water or an appropriate 
buffer. 
2.4.8 Determining DNA concentration 
DNA concentration was measured using a UV-spectrophotometer (Shimadzu) at 
OD260 nm. OD260 nm = 1 corresponded to 50 µg ml-1 for double-stranded DNA. DNA 
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purity was determined by calculating the ratio of DNA (OD260 nm) to protein (OD280 
nm). 
2.4.9 DNA sequencing 
DNA sequencing was carried out externally by the Dundee Sequencing Centre 
(www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 chemistry on an 
Applied Biosystems model 3730 automated capillary DNA sequencer. It was 
necessary to provide 200 – 300 ng of DNA template, along with 3.2 pmoles of 
sequencing primer, per sequencing reaction. 
2.4.10 Agarose gel electrophoresis 
DNA quantity and quality was routinely examined by agarose gel electrophoresis 
using the Sub-Cell GT system (Bio-Rad). 1 % (w/v) agarose was dissolved in 1x 
TAE buffer by boiling the mixture in a microwave. SYBR safe (Invitrogen) DNA 
stain was added at 1/10,000 and the agarose poured into gel trays with the 
appropriate size comb. The DNA samples were mixed with 6x DNA loading dye 
and electrophoresis was performed at 100 V in 1x TAE buffer until DNA fragments 
were sufficiently separated. 1 kb DNA ladder (NEB) was run alongside DNA 
samples to permit size determination of the bands visualised by UV illumination at 
302 nm or 365 nm using the Gel Doc XR system (Bio-Rad). 
2.4.11 Southern blot analysis 
In order to analyse the genotypes of genetically-manipulated parasite lines, firstly 
their gDNA was isolated (see Section 2.2.3.1), and then subjected to diagnostic 
digests with NruI overnight at 37 °C. Fully-digested gDNA was separ ated on a 0.8 
% agarose gel overnight at 20 V. The DNA was transferred onto positively-
charged nylon membrane Hybond-N+ (GE Healthcare). For the transfer the 
membrane was placed on the VacuGene XL apparatus (GE Healthcare) and was 
covered with 0.25 N HCl depurination- (0.25 N HCl), denaturation- (1.5 M NaCl 
and 0.5 M NaOH) and transfer (20x  SSC) solutions were incubated on the gel for 
30 min, 30 min and 1 h, respectively. DNA was subsequently cross-linked to the 
membrane. Blocking, probe-making, hybridisation, washing and detection steps 
were all carried out using the AlkPhos Direct Kit according to instructions provided 
by the manufacturer (GE Healthcare). Pre-hybridisation-, hybridisation- and 
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primary wash steps were carried out at 61 °C and th e probes used recognised L. 
major LIPA and LPLA genes and HYG and SAT genes. LIPA- and LPLA gene 
probes were made using full-length LIPA and LPLA genes amplified from L. major 
gDNA using primer pairs Lm1-Lm2 and Lm13-Lm14, respectively (see Section 
2.1.4.1). HYG and SAT gene probes were derived from digesting (BamHI/SpeI) 
HYG and SAT genes from plasmids pGL435 and pGL158, respectively (see 
Figure 2.1 and Figure 2.2). The gene fragments were gel extracted and purified 
(see Section 2.4.2.2) and then used to make probes. 
2.5 Biochemical methods 
2.5.1 SDS-PAGE 
Proteins were separated by SDS-PAGE (Laemmli, 1970). The NuPAGE 
electrophoresis system (Invitrogen) was used with either 4 – 12 % Novex Bis-Tris 
pre-cast gels or with non-gradient polyacrylamide gels. Gradient gels were utilised 
for the analyses of parasite extract whereas non-gradient polyacrylamide gels 
were used for examining purity of recombinant protein. In non-gradient gels, the 
running gel consisted of 6 ml running gel buffer (375 mM Tris pH 8.9, 0.1 % (w/v) 
SDS, 10 – 15 % (v/v) acrylamide) which was polymerised by addition of 5 ml 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) and 25 µl ammonium 
persulphate (APS) (10 mg ml-1 stock). The gel was poured into empty plastic 
cassettes (Invitrogen) and allowed to set. The stacking gel, consisting of 2 ml 
stacking gel buffer (122 mM Tris pH 6.7, 0.1 % (w/v) SDS and 5 % (v/v) 
acrylamide) was poured on top of the running gel and an appropriate comb was 
placed in the stacking gel. Protein samples were prepared while the stacking gel 
was in the process of setting. 10 µg parasite extract or 1 µg recombinant protein 
was mixed with 6x loading buffer and denatured at 100 °C for 5 min. The samples 
were loaded and the non-gradient polyacrylamide gels were run in 1x running 
buffer (25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS) and pre-cast gels in 1x 
MOPS buffer (Invitrogen) at 40 mA (200 V maximum). Following electrophoresis, 
gels were either stained with Coomassie blue (see Section 2.5.2) or were 
analysed by western blotting (see Section 2.5.3). 
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2.5.2 Coomassie blue staining 
Coomassie blue staining was carried out in order to determine the purity of elution 
fractions from protein purification (see Section 2.5.6). After SDS-PAGE (see 
Section 2.5.1), the gel was removed from the cassette and covered with 
Coomassie blue stain (40 % (v/v) methanol, 10 % (v/v) acetic acid, 0.1 % (w/v) 
and coomassie brilliant blue R-250) for at least 1 h at room temperature. For 
destaining, the Coomassie blue solution was removed and the gel was incubated 
in destain solution (20 % (v/v) methanol and 10% (v/v) acetic acid) for at least 1 h, 
changing the destain solution two times in the process. 
2.5.3 Western blotting 
Proteins were transferred from gel to membrane using the Trans-Blot SD Semi-
Dry Electrophoretic Transfer Cell (Bio-Rad) for 1 h at 20 V at room temperature. 
Ponceau-S (reversible) staining was used to visualise equal loading in all lanes, 
before continuing the experiment. Blots were blocked for 1 h in 5 % (w/v) milk in 
PBS (5 % MPBS) at room temperature, followed by incubation with primary, and 
secondary antibodies, in 2 % (w/v) MPBS with 0.1 % (v/v) Tween-20 (2 % 
MPBST). In between primary- and secondary antibody incubations, and after the 
secondary antibody step, blots were washed 3 x 10 min in PBS containing 0.1 % 
(v/v) Tween-20 (PBST). Detection of secondary antibody (linked to horseradish 
peroxidase)-bound protein was carried out using Immobilon Western Blot 
Detection Kit (Millipore) for 5 min at room temperature. The resulting 
chemiluminescence was detected on autoradiography film (Kodak). 
Quantification of western blot band density was carried out by using a ChemiDoc 
XRS machine (Bio-Rad) to detect chemiluminescence signal generated by 
western blotting. Subsequently, Quantity One software (Bio-Rad) was used to 
determine band density. A standard curve was produced with band intensity as a 
function of the quantity of recombinant protein, in order to determine the quantity 
of a specific protein in promastigote protein lysate. 
2.5.4 Determining protein concentration  
The protein concentration of parasite extract and recombinant protein was 
determined by the Bradford assay (Bradford, 1976), using the Bio-Rad protein 
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assay reagent. The absorbance of a protein solution mixed with Bradford reagent 
(Bio-Rad) was measured at 595 nm and the protein concentration was determined 
relative to a standard curve of known BSA concentrations. 
2.5.5 Estimation of protein molecular mass 
After SDS-PAGE and Coomassie staining or western blotting, a standard curve 
was made by calculating the relative mobility (Rf) of standard proteins and then 
logging the values. The values were used to construct a standard curve, which 
was used to calculate the molecular mass of bands of an unknown size. 
2.5.6 Expression and purification of proteins with a Strep-tag 
2.5.6.1 Cloning of expression constructs 
In order to express L. major LIPA, LIPB and LPLA in E. coli, different truncated 
versions of the genes were cloned into the vector pASK-IBA3 (see Figure 2.7 and 
Section 2.3.3), which adds a C-terminal Strep-tag to the translated transgene. The 
Strep-tag is a stretch of 8 amino acids that specifically binds to a modified version 
of streptavidin called Strep-Tactin, and as such a recombinant protein bearing a 
Strep-tag can be purified by affinity chromatography using Strep-Tactin resin 
(IBA). 
The genes of interest were cloned into pASK-IBA3 by directional BsaI cloning (see 
Section 2.1.4.2). Table 2.3 highlights the primers used in order to amplify the 
different versions of LIPA, LIPB and LPLA by PCR, and the size of the N-terminal 
truncation. N-terminal truncations were based upon targeting predictions made by 
MitoProt and/or TargetP software as well as by alignments with E. coli 
homologues (see Sections 2.3.3 and 3.4). PCR fragments were cloned into the 
intermediate vector pCR-BluntII-TOPO (see Section 2.4.2.1), and correct 
sequences were verified by DNA sequencing (see Section 2.4.9). DNA inserts 
were then sub-cloned into pASK-IBA3 by directional BsaI cloning; correct ligation 
of insert into vector was confirmed via XbaI/HindIII double digest and restriction 
digest analysis by agarose electrophoresis (see Sections 2.4.6 and 2.4.10). The 
nomenclature of the final constructs will be referred to as the name of the DNA 
fragment (see Table 2.3) followed by IBA3 (representing vector pASK-IBA3).  
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Name of DNA fragment Primer pairs used in PCR Size of PCR fragment (kbp)
LIPAFL Lm25-Lm29 1.250
LIPAT1 Lm26-Lm29 1.235
LIPAT2 Lm27-Lm29 1.193
LIPAT3 Lm28-Lm29 1.067
LIPBFL Lm30-Lm33 0.791
LIPBT1 Lm31-Lm33 0.704
LIPBT2 Lm32-Lm33 0.689
LPLAFL Lm34-Lm37 1.535
LPLAT1 Lm35-Lm37 1.499
LPLAT2 Lm36-Lm37 1.430
 
Table 2.3 Cloning genes into pASK-IBA3 for protein expression 
Table providing information about the cloning of full-length (FL) and N-terminally truncated versions 
(T1-T3) of LIPA, LIPB and LPLA to be used in protein expression trials. All primers in this table 
have BsaI restriction sites (see Section 2.1.4.2). 
2.5.6.2 Trial protein expression 
In order to determine the most yielding conditions for expression of recombinant 
proteins, trial expressions were carried out. Variables included: full-length or N-
terminally truncated expression construct (see Section 2.5.6.1); temperature of 
incubation after induction of protein expression (15 °C, 30 °C or 37 °C); length of 
incubation after induction of protein expression (1 h, 2 h, 3 h or overnight). Briefly, 
5 ml of LB supplemented with appropriate antibiotic(s) was inoculated with a single 
colony from a transformation with a protein expression construct and incubated 
overnight at 37 °C at 250 rpm. This starter culture  was diluted 1/100 into 50 ml LB 
with appropriate antibiotics and incubated at 37 °C  at 250 rpm until OD600 nm = 
0.6. Protein expression from the expression construct was then induced (with 
anhydrotetracycline (ATc) for pASK-IBA3 constructs (see Section 2.5.6.3). Post-
induction, cultures incubated at different temperatures and for different lengths of 
time were centrifuged at for 1 min at 13,000 rpm (Eppendorf microcentrifuge with 
F45-24-11 rotor) at room temperature, the supernatant was discarded and the 
pellet was resuspended in 100 µl BugBuster Protein Extraction Reagent 
(Novagen). 0.5 µl benzonase (Novagen) was also included in order to degrade 
DNA. The mixture was incubated at 4 °C with constan t shaking. After 15 min, the 
mixture was centrifuged for 15 min at 13,000 rpm (Fisher Scientific accuSpin 
MicroR with 24-place rotor) at 4 °C. The supernatan t was transferred into a fresh 
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tube, and the pellet was resuspended in 100 µl PBS. For analyses, 5 µl of the 
pellet fractions and 10 µl of the supernatant fractions were separated by SDS-
PAGE (see Section 2.5.1) and evaluated by western blotting using specific 
antibodies against the protein-tag (see Table 2.1). 
2.5.6.3 Protein purification 
Trial expressions indicated that of all the constructs tested, LIPAT3-IBA3, LIPBFL-
IBA3 and LPLAT2-IBA3 resulted in the production of the highest level of the 
respective proteins, LIPAT3-Strep, LIPBFL-Strep and LPLAT2-Strep. The expression 
of these constructs in BLR (DE3) cells was carried out as described in Section 
2.5.6.2. The plasmid contains the ampicillin-resistance gene (AMP) to allow 
selection of the transfected plasmid with ampicillin. At optical density (OD)600 nm = 
0.6, the expression of recombinant protein was induced by addition of 200 ng ml-1 
ATc. The protein was expressed at optimal conditions, which were determined 
previously using the BugBuster protein extraction kit (see Section 2.5.6.2), and 
which are outlined for LPLA, LIPB and LIPA in Section 3.5. After the optimal time 
of expression, the culture was centrifuged for 15 min at 6,000 g at 4 °C. The 
bacterial pellet was resuspended in a small volume of chilled buffer W (100 mM 
Tris-HCl (pH 8.0), 150 mM NaCl). The resuspended pellet was stored at – 20 °C 
with protease inhibitors at the same concentration as used in L. major lysis buffer 
(see Section 2.1.1).  
For purification, the pellet was thawed and 50 mg ml-1 lysozyme was added. The 
pellet was incubated for 30 min on ice. Additional protease inhibitors were added 
(at the same concentrations as above). Bacterial cells were lysed using the One 
Shot Cell Disrupter (Constant Systems) at 15 kPsi. Disrupted bacteria were 
centrifuged for 30 min at 20,000 rpm (Beckman J2-H5 centrifuge with a JA- 20 
rotor) at 4 °C. The cleared lysate was subsequently  filtered through a 0.4 µm 
disposable filter unit (Satorius) in order to remove any remaining particulate 
matter. Affinity chromatography with Strep-Tactin Sepharose (IBA) was used to 
purify Strep-tagged recombinant protein, according to instructions provided by the 
manufacturer. Briefly, 2 ml Strep-Tactin slurry was transferred to an Econo-Pac 
column (Bio-Rad) to give a column volume (CV) of 1 ml Strep-Tactin Sepahorse. 
The sepharose was equilibrated with two CV of buffer W. The cleared lysate was 
then added to the column and allowed to pass through by gravity flow. The column 
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was then washed with five CV of buffer W. Cleared lysate, flow-through and wash 
fractions were retained for analysis by SDS-PAGE and Coomassie blue staining. 
Elution of recombinant protein was carried out with buffer E (buffer W with 2.5 mM 
desthiobiotin), and six fractions were collected. The protein concentration of each 
elution fraction was determined by Bradford assay (see Section 2.5.4). Finally, 
SDS-PAGE (see Section 2.5.1) of all samples taken during the purification and 
elution fractions was carried out and analysed by Coomassie blue staining (see 
Section 2.5.2) or western blotting with α-Strep-tag antibody (see Section 2.5.3). 
 
Figure 2.7 pASK-IBA3 plasmid 
The pASk-IBA3 plasmid contains the following features: Tet promoter, anhydrotetracycline-
inducible promoter; Amp, ampicillin-resistance gene; Tet repressor, repressor of Tet promoter. 
Restriction endonucleases are illustrated, and numbers in brackets mark the cut sites of the 
restriction endonucleases. The gene of interest to be expressed in E. coli is directionally cloned into 
pASK-IBA3 using BsaI restriction sites. 
2.5.7 Antibody production and purification 
Rabbit polyclonal antibodies were raised against recombinant LIPAT3-Strep, 
LIPBFL-Strep and LPLAT2-Strep proteins, by Eurogentec (Belgium), following their 
standard immunization protocols. 400 µg of each antigen was subjected to SDS-
PAGE and Coomassie blue staining, the band excised and injected into rabbit; two 
rabbits were inoculated per antigen.  
Antibodies specific to the recombinant proteins were purified from antisera by 
affinity chromatography purification using AminoLink Coupling resin, according to 
instructions provided by the manufacturer (Thermo Scientific). Briefly, 1 mg of 
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recombinant protein used to inoculate rabbits for antibody production was dialysed 
into 1 ml PBS using a Centricon Plus-20 centrifugal filter device (Millipore), in 
order to dilute out any amines from the elution fraction. The protein was then 
covalently linked to 2 ml AminoLink Coupling slurry (1 ml CV of resin) by treatment 
with cyanoborohydride. Any remaining binding sites were blocked by treatment 
with a quenching buffer (1 M Tris-HCl, pH 7.4). The covalently bound protein was 
then washed with wash buffer (1 M NaCl) and equilibrated with 5 CV of Protein A 
IgG binding buffer. 5 ml of antiserum to be purified was added to 2.5 ml Protein A 
IgG binding buffer before transferring the mixture to the prepared column. The 
column was washed with 20 ml Protein A IgG binding buffer. Ten 500 µl elutions 
were carried out with Protein A IgG elution buffer into tubes containing 25 µl of 
neutralisation buffer (1 M Tris-HCl, pH 9.0).  
2.6 DNA content analysis 
Fluorescence activated cell sorting (FACS) analysis was used in order to 
determine the DNA content of transgenic parasites. Mid-log promastigotes were 
centrifuged for 5 min at 1,000 g at 4 °C, washed with PBS and then resuspended 
in 1 ml of 70 % (v/v) methanol in PBS. Fixation in methanol was carried out at 4 °C 
for at least 1 h to overnight. Prior to analysis, the cells were washed once in PBS 
and then resuspended in 1 ml of PBS containing 10 µg ml-1 propidium iodide and 
10 µg ml-1 RNAse A, and DNA labeling was carried out at 37 °C for 1 h in a light-
protected box. 
FACS analysis was carried out with a Becton Dickinson FACSCalibur, using the 
FL2-A (fluorescence intensity at 585/642 nm, note λemission propidium iodide = 620 
nm under an λexcitation = 488 nm (blue, Uniphase Argon Ion Laser)), the Forward 
Scatter (FSC, relative cell size) and the Side Scatter detectors (SSC, cell 
granulometry or internal complexity). For each sample, at least 10,000 events 
(cells) were counted. Data was interpreted with CellQuestPro software (BD 
Bioscience).  
2.7 Statistical analyses 
All graphs and statistical analyses were carried out using the program Prism 3.0 
(GraphPad), unless otherwise stated. All experiments with statistical data attached 
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were carried out in duplicate, and one-way ANOVA with Tukey post-test used to 
determine the significance of results; p-values < 0.05 were considered to be 
significant.  
2.8 Functionality assays 
As discussed in Section 2.5.6, full-length- and different truncated versions of LIPA, 
LIPB and LPLA were cloned into pASK-IBA3, in order to test for the optimal 
expression construct for recombinant protein purification. In order to determine 
whether the different constructs encoded functional proteins, LIPA-IBA3 constructs 
were transformed into the lipA deficient E. coli strain KER176 (Vanden Boom et 
al., 1991), and LIPB-IBA3 and LPLA-IBA3 constructs were transformed into the 
lipB deficient E. coli strain KER184 (Vanden Boom et al., 1991). Functionality was 
assessed by whether the constructs would complement the growth defect of the 
bacterial lines when grown on minimal medium (see Section 2.1.1). Both cell lines 
were grown on M9 minimal plates containing 100 mg ml-1 ampicillin (to select for 
the construct), 50 mg ml-1 kanamycin (to select for the transgenic cell line) and 200 
ng ml-1 ATc (to induce recombinant protein expression) and without- or with 
supplementation of 10 µM LA. 
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3 In silico and functionality studies 
3.1 Introduction 
In all organisms, α-KADHs and the GCC are intricately linked to energy 
metabolism (Perham, 2000) and (Douce et al., 2001). LA is an essential 
component of these complexes, covalently linked to the acyl transferase subunits 
of α-KADHs and to the H-protein of the GCC. The post-translational event that 
transfers LA to apoproteins is referred to as lipoylation. Two pathways exist to 
carry out lipoylation; LA biosynthesis and LA salvage. Biosynthesis enzymes LIPA 
and LIPB have been studied to varying degrees in E. coli (Jordan & Cronan, 
1997a; Reed & Cronan, 1993), M. tuberculosis (Sassetti et al., 2003), P. 
falciparum (Wrenger & Muller, 2004), T. gondii (Thomsen-Zieger et al., 2003), A. 
thaliana (Yasuno & Wada, 2002) and H. sapiens (Morikawa et al., 2001). Salvage 
of LA in E. coli requires just one enzyme, LPLA (Morris et al., 1994; Reed et al., 
1994), which catalyses the formation of an activated intermediate, lipoyl-AMP, and 
the subsequent transfer of the lipoyl moiety to the apoprotein. The mammalian 
system necessitates the sequential action of two enzymes for activation and 
transfer of LA to the apoprotein; ACSM1 (Fujiwara et al., 2001) and LT (Fujiwara 
et al., 1997a; Fujiwara et al., 1999), respectively. 
In this chapter, an in silico approach was employed in order to identify and analyse 
potential components comprising α-KADHs, the GCC and the enzymes involved in 
LA acquisition and ligation in L. major. The next aim was to determine whether 
lipoylation of the acyl transferase and H-protein subunits occurs in L. major 
promastigotes. Subsequently, the genes encoding L. major LIPA, LIPB and LPLA 
were heterologously expressed in E. coli deficient in either lipA or lipB, in order to 
ascertain whether L. major encodes active lipoylating machinery. Finally, the 
effects of LA analogues on promastigote growth and lipoylation were studied. 
3.2 Sequence analyses of lipoylated protein complexes 
In order to identify potential homologues of α-KADH subunits and subunits of the 
GCC, the L. major genome database was searched by TBLASTN using H. sapiens 
and E. coli amino acid sequences as queries (as described in Section 2.3). 
Potential homologues of α-KADH subunits were identified (see Table 3.1): 
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1. Four genes encoding the α-ketoglutarate dehydrogenase (α-KGDH) 
complex; two α-ketoglutarate dehydrogenase isoenzymes (designated E1k-
A and E1k-B) and one succinyl transferase (E2k). 
2. Four genes encoding the pyruvate dehydrogenase (PDH) complex; two 
pyruvate dehydrogenase heteromers (E1p-α and E1p-β) and one acetyl 
transferase (E2p). 
3. Four genes encoding the branched-chain α-ketoacid dehydrogenase 
(BCKDH) complex; two branched-chain dehydrogenase heteromers (E1b-α 
and E1b-β) and one branched-chain transacylase (E2b). 
4. One gene encoding the lipoamide dehydrogenase subunit (LipDH), which is 
presumably common to all α-KADHs. 
In addition, potential homologues of components of the GCC were identified (see 
Table 3.1): 
1. One lipoyl-domain protein (H-protein). 
2. One glycine dehydrogenase (P-protein). 
3. Two aminomethyl transferase isoenzymes (T-protein-A and T-protein-B). 
4. One gene encoding the LipDH subunit, which is presumably the same as 
that used by α-KADHs. 
 
   
 
Predicted Sizes (kDa) Systematic Name Targeting Predictions (%) Identity of L. major to other species (%) 
Subunit E. coli H. sapiens L. major L. major Mitoprot Target P H. sapiens E. coli
E1p 99.7 (AAC73225) N/A N/A N/A N/A N/A N/A N/A
E1p-α N/A 43.3 (NP_000275) 42.9 LmjF18.1380 79 MT 47 MT 43 N/A
E1p-β N/A 39.2 (NP_000916) 37.9 LmjF25.1710 99 MT 87 MT 57 N/A
E1k 105.1 (ACB01934) 115.9 (NP_002532) N/A N/A N/A N/A N/A N/A
E1k-like N/A 114.5 (NP_060715) N/A N/A N/A N/A N/A N/A
E1k-A N/A N/A 114.4 LmjF36.3470 97 MT 92 MT 35 33
E1k-B N/A N/A 112.7 LmjF27.0880 95 MT 78 MT 34 (36  to LmE1k -A) 32
E1b-α N/A 50.5 (NP_000700) 53.3 LmjF21.1430 80 MT 85 MT 36 N/A
E1b-β N/A 43.1 (NP_000047) 40 LmjF35.0050 84 MT 73 MT 49 N/A
P-protein 104.4 (AAC75941) 112.7 (NP_000161) 108.5 LmjF26.0030 95 MT 86 MT 47 46
E2p 66.1 (AAC73226) 68.9 (NP_001922) 48.7 LmjF36.2660 86 MT 52 MT 24 18
62 SP
E2p-like N/A 54.1 (NP_001128496) 46.1 LmjF21.0550 61 MT 5 MT 15 to Hs  pE2 N/A
85 SP 16 to Hs  E3BP**
E2k 44 (AAA23898) 48.6 (NP_001924) 41.7 LmjF28.2420 96 MT 78 MT 38 39
E2b N/A 53.5 (NP_001909) 50.2 LmjF05.0180 100 MT 92 MT 41 N/A
H-protein 13.8 (AAC75942) 18.9 (NP_004474) 15.2 LmjF35.4720 76 MT 50 MT 36 37
LipDH 50.7 (AAC73227) 54.2 (NP_000099) 50.6 LmjF32.3310 9 MT (ATG start) 21 MT (ATG start) 47 38
16 SP, 57 OT (ATG start)
23 MT (GTG start) 83 MT (GTG start)*
T-protein 40.1 (AAC75943) 43.9 (NP_000472) N/A N/A N/A N/A N/A N/A
T-protein A N/A N/A 43.2 LmjF36.3800 17 MT 12 MT 29 38
25 SP, 38 OT
T-protein B N/A N/A 41.3 LmjF36.3810 17 MT 12 MT 29 39
25 SP, 38 OT
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Table 3.1 Sequence analyses of subunits of L. major α-KADHs and of the GCC 
L. major homologues of subunits of α-KADHs and of the GCC were identified as described in 
Section 2.3. Red subunits are those which catalyse the oxidative decarboxylation of substrates. 
Blue subunits are those that carry out transferase reactions. The green subunit is common to both 
α-KADHs and the GCC and catalyses the re-oxidation of dihydrolipoic acid (DHLA) to oxidised LA. 
In the 'Protein Size' column, accession numbers of E. coli and H. sapiens proteins are shown in 
brackets. Mitochondrial targeting predictions were carried out by analysing L. major protein 
sequences with MitoProt or TargetP. The results obtained indicate the percent likelihood of 
mitochondrial targeting (MT). Some proteins were predicted to possess signal peptides (SP), or an 
alternative processing type (OT). The mitochondrial targeting for the LipDH subunit was 
unexpectedly low. However, by starting the ORF at a GTG 75 bp upstream of the predicted ATG 
start, the likelihood of mitochondrial targeting was significantly increased (*). Amino acid sequence 
identity of L. major α-KADH- and GCC subunits to E. coli and H. sapiens homologues was 
determined using Vector NTI (see Section 2.3). In the case of the L. major E2p-like protein, in 
addition to aligning with H. sapiens E2p, an alignment was also performed with the human E3 
binding protein (E3BP) (**). 
3.2.1 α-Ketoglutarate dehydrogenase (α-KGDH) complex  
3.2.1.1 α-Ketoglutarate dehydrogenase isoenzymes (E1k-A and E1k-
B)  
The E1k subunit of the α-KGDH complex catalyses the oxidative decarboxylation 
of α-ketoglutarate to form CO2 and a succinyl group, in a TPP-dependent manner 
(Perham, 1991; Perham, 2000). Whereas the PDH E1 (E1p) and BCKDH E1 (E1b) 
subunits in most organisms studied tend to form heterotetramers, E1k proteins are 
active as homodimers. Recent in silico analyses indicate that mammalian species 
such as H. sapiens and M. musculus possess an E1k isoenzyme, E1k-like (E1kL) 
(Bunik & Degtyarev, 2008). H. sapiens E1k (HsE1k) and E1kL (HsE1kL) share 75 
% sequence identity. Experimental evidence has shown HsE1kL to have different 
kinetic properties from HsE1k, and different tissue specificity (Bunik et al., 2008). 
L. major encodes two potential E1k proteins, LmjE1k-A and LmjE1k-B (see Table 
3.1). The genes are located on chromosomes 36 and 27, respectively (see Table 
3.1). LmjE1k-A and LmjE1k-B are predicted to be 114.4 kDa and 112.7 kDa, 
respectively, and as such are both similar in size to HsE1k (115.9 kDa) and 
HsE1kL (114.5 kDa). Unlike the high sequence identity shared between HsE1k 
and HsE1kL (75 %), LmjE1k-A shares only 36 % identity to LmjE1k-B, and both 
have similar identities to HsE1k (35 % and 34 %, respectively) and E. coli E1k 
(EcE1k) proteins (33 % and 32 %, respectively) (see Table 3.1 and Appendix 
Figure 7.1 and Table 7.1). The two potential LmjE1k isoenzymes are predicted to 
be mitochondrial by prediction programmes MitoProt (95 % and 75 % confidence 
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levels, respectively) and TargetP (78 % and 92 % confidence levels, respectively) 
(see Table 3.1). 
The fact that H. sapiens possesses the functional E1k isoenzyme E1kL has been 
discussed two paragraphs above. In human, in silico analyses resulted in the 
identification of another E1k-like protein named dehydrogenase E1 and 
transketolase domain-containing 1 (HsDHTDK1) protein (Bunik & Degtyarev, 
2008). HsDHTDK1 lacks three conserved motifs that are required for Ca2+ 
activation, and in this sense is more similar to bacterial E1k proteins (Bunik & 
Degtyarev, 2008). ClustalW alignment of LmjE1k-A and LmjE1k-B with different 
vertebrate E1k, E1kL and DHTDK1 proteins revealed some potentially interesting 
differences (see Appendix Figure 7.1). Firstly, LmjE1k-A and LmjE1k-B possess 
most of the required motifs for α-ketoacid dehydrogenase activity, such as lipoyl-
domain-binding motifs and TPP-binding motifs (see Appendix Figure 7.1). 
However, LmjE1k-A and LmjE1k-B lack all three conserved motifs required for 
binding of Ca2+. In addition, as for DHTDK1, LmjE1k-A and LmjE1k-B have altered 
α-ketoglutarate substrate binding motifs (see Appendix Figure 7.1). Bunik et al. 
(2008a) discuss this phenomenon in the context of DHTDK1, and hypothesise that 
DHTDK1 could use substrates other than α-ketoglutarate, such as glyoxylate. 
3.2.1.2 Succinyl transferase subunit (E2k) 
The E2k subunit of the α-KGDH complex catalyses the transfer of the succinyl 
group from E1k onto CoA, in a LA-dependent manner (Perham, 1991; Perham, 
2000). In all α-KADHs, the E2 components are assembled into either a cubic (24-
mer) or a dodecahedral (60-mer) inner core, around which E1 and E3 components 
bind. 
Bioinformatics analyses indicate that L. major possesses a single E2k gene 
encoding the succinyl transferase, LmjE2k. LmjE2k has a relatively high sequence 
identity to H. sapiens E2k (HsE2k) (38 %) and E. coli E2k (EcE2k) (39 %) (see 
Table 3.1). LmjE2k is predicted to be mitochondrial by prediction programmes 
MitoProt and TargetP (96 % and 78 % confidence levels, respectively) (see Table 
3.1). 
ClustalW alignment with H. sapiens and E. coli homologues illustrates that LmjE2k 
has a single lipoyl-domain at the N-terminus. However, the strictly conserved motif 
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42TDK44 in EcE2k is 64SDK66 in LmjE2k (see Appendix Figure 7.7), and this is the 
same for all other trypanosomatid species with sequenced genomes available (L. 
infantum, L. braziliensis, T. brucei and T. cruzi). This seemingly kinetoplastid-
specific anomaly could be of significance given that the Thr42 residue of the 
42TDK44 motif has been shown to be very important in the reductive succinylation 
of the E2k-bound lipoyl moiety by E1k (Jones & Perham, 2008). On the other 
hand, threonine and serine are similar residues in that both are polar and 
uncharged, and as such may be interchangeable. 
LmjE2k has the conserved 358DHRxxDG364 motif at the C-terminus (see Appendix 
Figure 7.7), the His359 of which is required for succinyl transferase catalytic activity 
(Reed & Hackert, 1990). 
However, unlike bacterial and mammalian E2k and E2b proteins, LmjE2k lacks a 
strictly conserved Arg140 residue (Ciszak et al., 2006) that permits binding to both 
E1 and E3 proteins, and instead has Lys141, which given its similarity in size and 
charge to arginine, may fulfil a similar role (see Appendix Figure 7.9). 
3.2.2  Pyruvate dehydrogenase (PDH) complex 
3.2.2.1 Pyruvate dehydrogenase subunits (E1p-α and E1p-β) 
The E1p subunit of the PDH complex catalyses the oxidative decarboxylation of 
pyruvate to form CO2 and an acetyl group in a TPP-dependent manner (Perham, 
1991; Perham, 2000). Eukaryotic E1p subunits (Wexler et al., 1991) and those 
from gram-positive bacteria such as Bacillus species (Lessard & Perham, 1994) 
are comprised of heterotetramers, whereas E1p subunits from gram-negative 
bacteria such as E. coli are homodimers (de Kok et al., 1998). 
Searching the L. major genome for homologues resulted in the identification of two 
genes, the products of which have been designated LmjE1p-α and LmjE1p-β (see 
Table 3.1). LmjE1p-α and LmjE1p-β are predicted to be 42.9 kDa and 37.9 kDa, 
respectively, and are therefore more similar in size to H. sapiens E1p-α (HsE1p-α) 
and H. sapiens E1p-β (HsE1p-β) (43.2 kDa and 39.2 kDa, respectively) than to the 
single E. coli E1p (EcE1p) (99.7 kDa) (see Table 3.1). This information (combined 
with that provided below) is in accordance with LmjE1p-α and LmjE1p-β forming 
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heteromers. Both L. major E1p proteins have high identities to the respective 
HsE1p-α and HsE1p-β subunits (43 % and 57 %, respectively) (see Table 3.1 and 
Appendix Figure 7.2 and Figure 7.3). Both proteins are predicted to be 
mitochondrial by MitoProt and TargetP programmes, with confidence values of 79 
% and 47 % respectively, for LmjE1p-α, and 99 % and 87 % respectively, for 
LmjE1p-β (see Table 3.1). 
ClustalW alignment of LmjE1p-α and LmjE1p-β with mammalian homologues 
revealed that some of the amino acids within conserved motifs are different in L. 
major E1p proteins, however the overall conservation is high. For example, the 
conserved motif in E1p-α proteins involved in interacting with the thiamine 
diphosphate (TPP) cofactor, catalysing the decarboxylation of pyruvate, and 
interacting with the lipoyl-domain of the E2p subunit (285TYRY(H/g)GHSMSDPG298 
in HsE1p-α) is instead 276CYRYMGHSMSDPD289 in LmjE1p-α (see Appendix 
Figure 7.2). Another example is a motif found in E1p-β proteins that is involved in 
binding the lipoyl-domain of the E2p subunit (109EFM(T/s)FNFSMQAID121 in 
HsE1p-α), which is instead 101EFMTFNFAMQAID113 in LmjE1p-β (see Appendix 
Figure 7.3). The significance of such differences remains unknown, yet they could 
reflect subtle species-specific adaptations to different substrates for example. 
3.2.2.2 Acetyl transferase (E2p) and E3-binding protein (E3BP) 
subunits 
The E2p subunit of the α-PDH complex catalyses the transfer of the acetyl group 
from E1p onto the acceptor protein coenzyme A (CoA), in a LA-dependent manner 
(Perham, 1991; Perham, 2000). In all α-KADHs, the E2 components are 
assembled into either a cubic (24-mer) or a dodecahedral (60-mer) inner core, 
around which E1 and E3 components bind. Mammals (De Marcucci & Lindsay, 
1985) and some yeast (Maeng et al., 1994) (but not bacteria) also encode a 
structurally similar protein, E3-bindng protein (E3BP). In these organisms, the E2p 
subunit cannot bind the E3 subunit directly. As such, E3 binds to E3BP and is 
inserted into the E2p scaffold (Sanderson et al., 1996a; Sanderson et al., 1996b). 
Querying the L. major genome with H. sapiens E2p (HsE2p) and E. coli E2p 
(EcE2p) protein sequences resulted in the identification of a single LmjE2p-
encoding gene, and a gene encoding an E2p-like protein (LmjE2pL). The 
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predicted size of LmjE2p is 48.7 kDa, which is 20 kDa smaller than the HsE2p and 
EcE2p proteins (see Table 3.1). The size discrepancy can be explained by 20 kDa 
N-terminal extensions in HsE2p and EcE2p proteins compared to LmjE2p (see 
Appendix Figure 7.8). The large N-terminal extensions in EcE2p and HsE2p 
consist of two additional lipoyl-domains (L1 and L2 lipoyl-domains) (Guest et al., 
1985). LmjE2p has 24 % and 18 % sequence identity to HsE2p and EcE2p 
proteins, respectively (see Table 3.1). Subcellular targeting prediction programmes 
give different results with regards to LmjE2p subcellular localisation; MitoProt 
predicts mitochondrial targeting (86 % confidence level), yet TargetP predicts with 
only moderate confidence that LmjE2p is mitochondrial (52 % confidence level) 
and with higher confidence (62 %) that LmjE2p possesses a secretory signal 
peptide (see Table 3.1). Given that E2p is integral to the formation and function of 
the PDH complex, one would expect LmjE2p to be mitochondrial, and indeed 
evidence is provided that this is probably the case in L. major (see Section 5.4.1). 
LmjE2p possesses a single lipoyl-domain with the motif 60TDKA63, as well as the 
C-terminal motif 619DHRxxDG625; the former is involved in binding LA and the latter 
is integral to the transfer of the acetyl group from the E1p subunit to a CoA 
acceptor protein (see Appendix Figure 7.8) (Reed & Hackert, 1990). 
As mentioned, a second gene that shares some homology to LmjE2p, LmjE2pL, is 
predicted in the L. major genome (see Table 3.1). The most obvious candidate for 
the LmjE2pL protein would be the E3BP. Human and yeast E3BP have 
reasonable sequence identities to their respective E2p proteins (30 % and 20 %, 
respectively). Similarly, LmjE2p and LmjE2pL share 18 % amino acid sequence 
identity. The sequence identities of LmjE2pL to HsE2p and HsE3BP are low (15 % 
and 16 %, respectively) (see Table 3.1). As for LmjE2p, the mitochondrial targeting 
prediction by MitoProt is reasonably high (61 % confidence level), whereas 
TargetP predicts with high confidence (85 %) that LmjE2pL has a secretory signal 
sequence (see Table 3.1).  
In yeast and humans, E3BP has the conserved 80TDKA83 motif (HsE3BP 
numbering), the Lys82 of which can be lipoylated by lipoyl transferases (Sanderson 
et al., 1996b). LmjE2pL also possesses the conserved 51TDKA54 motif, and 
possibly a second functional motif 177TDKA180 (see Appendix Figure 7.8). Yeast 
and human E3BP do not possess acetyl transferase activity, since the strictly 
conserved His620 residue within the motif 619DHRxxDG625 (HsE2p numbering), is 
instead Ser460 (HsE3BP numbering) (Neagle et al., 1989). LmjE2pL also lacks this 
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histidine residue and the motif is instead 366YKSxxDT372 (with bold residues 
representing those residues that are not conserved in LmjE2pL) (see Appendix 
Figure 7.8). The H. sapiens PDH (HsPDH) complex requires E3BP to insert E3 
into the E2p scaffold, since HsE2p only has the capacity to interact with E1 and 
E3BP (Ciszak et al., 2006). Interestingly, LmjE2p has Val175 and Arg177 residues 
(see Appendix Figure 7.9), which could permit binding of both E1 and E3 subunits 
according to predictions made by Cizak et al. (2006). However, LmjE2pL does not 
possess the strictly conserved 170SPAxRNxxE178 motif, or the Pro192 and Ile195 
residues (see Appendix Figure 7.9) that have been shown in HsE3BP to make 
important contacts with the E3 subunit (Ciszak et al., 2006). As such, although in 
silico analyses generally infer that LmjE2pL may be E3BP, experimental evidence 
would be required to confirm the localisation of LmjE2pL, as well as the nature of 
its interactions with other subunits of the PDH complex. 
3.2.3 Branched chain α-ketoacid dehydrogenase (BCKDH) 
3.2.3.1 Branched chain ketoacid dehydrogenase subunits (E1b-α and 
E1b-β) 
The E1b subunit of the BCKDH complex catalyses the oxidative decarboxylation of 
branched-chain α-ketoacids 2-ketoisocaproate, 2-keto-3-methylvalerate and 2-
ketoisovalerate (derived from leucine, isoleucine and valine, respectively) to form 
CO2 and an acyl group (isovaleryl, 2-methylbutyryl or isobutyryl, respectively), in a 
TPP-dependent process (Massey et al., 1976). E1b subunits in human (Aevarsson 
et al., 2000) and gram-negative bacterium Pseudomonas putida (Aevarsson et al., 
1999) are heterotetrameric. 
Searching the L. major genome for homologues resulted in the identification of two 
genes, LmjE1b-α and LmjE1b-β (see Table 3.1). LmjE1b-α and LmjE1b-β are 
predicted to be 53.3 kDa and 40.0 kDa, respectively, and are therefore similar in 
size to H. sapiens E1p-α (HsE1p-α) and E1p-β (HsE1p-β) (50.5 kDa and 43.1 
kDa, respectively) (see Table 3.1). This information (combined with that provided 
below) is in accordance with LmjE1b-α and LmjE1b-β forming heteromers. Both L. 
major E1b proteins have high identities to the respective HsE1b-α and HsE1b-β 
subunits (36 % and 49 %, respectively) (see Table 3.1 and Appendix Figure 7.4 
and Figure 7.5). Both proteins are predicted to be mitochondrial by MitoProt and 
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TargetP programmes, with confidence values of 80 % and 84 %, respectively, for 
LmjE1b-α, and 85 % and 73 %, respectively, for LmjE1b-β (see Table 3.1). 
ClustalW alignment of LmjE1b-α and LmjE1b-β with mammalian homologues 
revealed that some of the amino acids within conserved motifs of LmjE1b-β are 
different to those found in mammalian E1b-β proteins; however, the overall 
conservation is high. For example, the conserved motif in E1b-β proteins involved 
in interacting with the TPP cofactor (146E[I/m]QF149 in HsE1b-β) is instead 
123EVQF126 in LmjE1b-β (see Appendix Figure 7.5). The significance of such 
differences remains unknown. 
3.2.3.2 Branched-chain transacylase subunit (E2b) 
The E2b subunit of the BCKDH complex catalyses the transfer of the acyl group 
(either isovaleryl, 2-methylbutyryl or isobutyryl) from E1b onto the acceptor protein 
CoA, in a LA-dependent manner (Perham, 1991; Perham, 2000). In all α-KADHs, 
the E2 components are assembled into either a cubic (24-mer) or a dodecahedral 
(60-mer) inner core, around which E1 and E3 components bind.  
Bioinformatics analyses indicate that L. major possesses a single gene encoding 
the branched-chain transacylase, LmjE2b. LmjE2b has a relatively high sequence 
identity to H. sapiens E2b (HsE2b) (40 %) (see Table 3.1). LmjE2b is predicted to 
be mitochondrial by prediction programmes MitoProt and TargetP (100 % and 92 
% confidence levels, respectively) (see Table 3.1). 
ClustalW alignment with mammalian homologues illustrates that LmjE2b has a 
single lipoyl-domain at the N-terminus, with the diagnostic motif 86SDKA89, the 
Lys88 of which is lipoylated by lipoyl transferases (see Appendix Figure 7.10). 
LmjE2b is likely to be catalytically active, given that the 446DHRxxDG452 motif is 
present, the His447 of which is required for acyl transferase catalytic activity (Reed 
& Hackert, 1990). 
However, unlike bacterial and mammalian E2k and E2b proteins, LmjE2k lacks a 
conserved Arg199 residue (Ciszak et al., 2006) that permits binding to both E1 and 
E3 proteins, and instead has Lys297, which given its similarity in size and charge to 
arginine, may fulfil a similar role (see Appendix Figure 7.9). 
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3.2.4 Glycine cleavage complex (GCC) 
3.2.4.1 Lipoyl-domain subunit (H-protein) 
In the GCC, H-protein is monomeric (Nakai et al., 2003a; Pares et al., 1994), 
unlike the E2 subunits of α-KADHs, which form 24-mers or 60-mers (Perham, 
1991; Reed & Hackert, 1990). However, 27 H-protein monomers are found within 
the GCC of Pisum satisvum (PsGCC) (Oliver et al., 1990). Similarly to E2 
subunits, H-protein possesses a lipoyl-domain which binds LA and acts as a 
"swinging arm" domain that permits access of each catalytic subunit in turn, to the 
essential lipoyl moiety. Nevertheless, unlike E2 subunits, H-protein bears no 
catalytic activity (Macherel et al., 1992). 
Bioinformatics analyses indicate that L. major encodes a single lipoyl-domain 
protein, LmjH-protein. LmjH-protein has a reasonable sequence identity to H. 
sapiens H-protein (HsH-protein) (36 %) and E. coli H-protein (EcH-protein) (37 %) 
(see Table 3.1). LmjH-protein is predicted to be mitochondrial by prediction 
programmes MitoProt and TargetP (76 % and 50 % confidence levels, 
respectively) (see Table 3.1). 
ClustalW alignments with mammalian homologues reveals that LmjH-protein 
possesses the motif 76SVKA79, the strictly conserved Lys78 of which becomes 
lipoylated by lipoyl transferases (see Appendix Figure 7.11). Additionally, strongly 
conserved negatively-charged residues Glu48, Asp52 and Glu75 that make contacts 
with P-protein and T-protein (Nakai et al., 2003a) are present, however one 
glutamate residue is instead Asn81 (see Appendix Figure 7.11). 
3.2.4.2 Glycine dehydrogenase subunit (P-protein) 
The P-protein subunit of the GCC complex is a pyridoxal 5'-phosphate (PLP)-
dependent enzyme that catalyses the oxidative decarboxylation of glycine to form
 
CO2 and aminomethylated H-protein (Douce et al., 2001). Eukaryotic P-proteins 
(for example, human) (Kume et al., 1991) and some prokaryotic P-proteins (for 
example, E. coli) (Okamura-Ikeda et al., 1993) occur as homodimers, whereas 
most prokaryotic P-proteins typically form heterotetramer P-protein complexes (for 
example, Thermus thermophilus) (Nakai et al., 2003b). In the PsGCC two 
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homodimers of P-protein are necessary and sufficient for glycine decarboxylase 
activity (Oliver et al., 1990). 
The L. major genome possesses one gene encoding LmjP-protein. The L. major 
homologue has relatively high sequence identity to E. coli P-protein (EcP-protein) 
(46 %) and H. sapiens protein (HsP-protein) (47 %) (see Table 3.1). LmjP-protein 
is predicted to be mitochondrial by MitoProt and TargetP, with confidence levels of 
95 % and 86 %, respectively (see Table 3.1). The mitochondrial localisation of 
LmjP-protein has been verified experimentally in L. major promastigotes by over-
expression of an LmjP-protein-GFP reporter construct (Scott et al., 2008). 
LmjP-protein contains all of the residues known to be important in lining the active 
site (such as the 541PLGSCTMKLN550 motif), and for interaction with lipoamide 
(Gln354 and His638) (see Appendix Figure 7.6). The only potentially important 
differences are two changes in residues involved in binding H-protein, whereby 
LmjP-protein has Lys357 instead of Arg326, and at another position has Arg360 
instead of Lys329 (see Appendix Figure 7.6). However, the most important factor 
involved in binding H-protein is thought to be the positive charge within this motif 
(Nakai et al., 2005), and the changes just outlined would keep the charge the 
same as that found in EcP-protein and HsP-protein. Indirect evidence has proven 
that LmjP-protein (and as such the GCC in L. major) is active (Scott et al., 2008); 
inactivation of the LmjP-protein gene in promastigotes resulted in a significant loss 
of [2-14C] glycine incorporation into DNA, which is ordinarily derived from 5,10-
methylene-tetrahydofolate (5,10-CH2-THF) produced via the GCC (Scott et al., 
2008). 
3.2.4.3 Aminomethyl transferase subunit isoenzymes (T-protein-A and 
T-protein-B) 
The T-protein subunit of the GCC complex catalyses the transfer of the methylene 
group (CH2) from aminomethylated H-protein to a tetrahydrofolate (THF) acceptor, 
to produce 5,10-CH2-THF and ammonia (NH3) (Douce et al., 2001). T-protein is a 
monomeric protein, and forms a 1:1 ratio with H-protein (Okamura-Ikeda et al., 
1993). A total of 9 T-protein monomers have been determined for the PsGCC 
(Oliver et al., 1990). 
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Searching the L. major genome revealed two potential T-protein genes, which are 
arranged in tandem on chromosome 36. The GCC studied in all other organisms 
involves one T-protein. As such, it is possible that there is an 
annotation/sequencing mistake in the L. major genome project. However, L. 
infantum has two predicted T-protein genes, yet L. braziliensis has only one, which 
potentially indicates that a gene duplication event occurred in L. major and L. 
infantum but not in L. braziliensis. The two L. major T-proteins, LmjT-protein-A and 
LmjT-protein-B, are identical, except that LmjT-protein-A has a C-terminal 
extension of 17 amino acids, which is not present in either the human or E. coli 
homologues. The two L. major homologues share moderate sequence identity to 
E. coli T-protein (EcT-protein) (29 %) and H. sapiens T-protein (HsT-protein) (38 
%) (see Table 3.1). Given that both LmjT-protein-A and LmjT-protein-B are 
identical apart from the terminal 17 amino acids, they possess exactly the same N-
terminal sequences involved in subcellular targeting. Mitochondrial targeting 
predictions by MitoProt and TargetP are poor (17 % and 12 %, respectively) (see 
Table 3.1). However, given the experimentally-proven mitochondrial localisation 
and function of LmjP-protein (Scott et al., 2008), one would certainly expect LmjT-
protein (isoform A or B) to also be mitochondrial. 
Both LmjT-protein-A and LmjT-protein-B possess the conserved motifs (Lee et al., 
2004) involved in binding H-protein, such as the 195GYTGExGxE203 motif (see 
Appendix Figure 7.12). Additionally, the 225GLGARDx2RxEAx3LYG244 motif that 
surrounds the aliphatic portion of LA, is present in LmjT-protein-A and LmjT-
protein-B (see Appendix Figure 7.12). Lastly, LmjT-protein-A and LmjT-protein-B 
possess the conserved motif 318Gx2TSGx2SPxL329 that makes key contacts with 
the T-protein cofactor, THF (see Appendix Figure 7.12). 
3.2.5 Dihydrolipoamide dehydrogenase subunit (LipDH) 
Most eukaryotic organisms and bacteria possess a single gene encoding lipDH. 
The LipDH protein is a subunit of α-KADHs (E3 subunit) and the GCC (L-protein) 
(Perham, 2000). In both complexes, the role of LipDH is to re-oxidise DHLA to LA 
with the concomitant generation of reduced NADH, in a process that requires the 
cofactor flavin adenine dinucleotide (FAD). Eukaryotic (for example, human) 
(Ciszak et al., 2006) and prokaryotic (for example, Azotobacter vinelandii) (Mattevi 
et al., 1991) LipDH proteins form tightly-bound homodimers. One L-protein dimer 
is associated with the GCC (Oliver et al., 1990), whereas α-KADHs require 12 
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copies of E3. Unlike in the α-KGDH and BCKDH complexes (and the PDH 
complex in bacteria), where E3 homodimers directly bind to the E2 scaffold, 
interaction of E3 with E2p in the mammalian PDH complex requires E3BP. There 
is a 1:1 stoichiometry of E3 homodimer binding to E3BP monomer, and 12 E3BP 
monomers bind to E2p (Ciszak et al., 2006).   
Querying the L. major genome with H. sapiens LipDH (HsLipDH) and E. coli LipDH 
(EcLipDH) proteins resulted in four significant hits. Analysis of all four L. major 
predicted proteins revealed that only one – LmjF32.3310 – possessed all motifs 
diagnostic of LipDH enzymes (see Appendix Figure 7.13). LmjLipDH has relatively 
high sequence identity to human and E. coli LipDH homologues (47 % and 38 %, 
respectively). However, the confidence of mitochondrial targeting is very low if one 
assumes the open reading frame of the gene to begin at a classical ATG codon (9 
% for MitoProt and 21 % for TargetP) (see Table 3.1). If the ORF is presumed to 
start at a GTG codon that is 75 bp upstream of the ATG start codon, the resulting 
protein is predicted to be mitochondrial with higher confidence values (23 % for 
MitoProt and 83 % for TargetP) (see Table 3.1). Nevertheless, I was not able to 
identify any studies indicating that GTG is a valid start codon in Leishmania. Given 
the high degree of confidence in mitochondrial localisation predicted by MitoProt 
and TargetP for the majority of components of the α-KADHs and GCC in L. major, 
combined with the experimental evidence showing LmjP-protein to be 
mitochondrial (Scott et al., 2008), one would expect LmjLipDH to be mitochondrial 
also.  
ClustalW alignment of LmjLipDH with HsLipDH and EcLipDH proteins revealed 
that LmjLipDH possesses all motifs diagnostic of LipDH enzymes. Firstly, 
LmjLipDH possesses the 43GxGx2G48 motif, which is involved in binding of the 
pyrophosphate moiety of FAD (see Appendix Figure 7.13) (Mattevi et al., 1991). 
Secondly, the redox active 75CLNVGC80 motif is present in LmjLipDH (see 
Appendix Figure 7.13) (Thorpe & Williams, 1976). Thirdly, LmjLipDH has the 
conserved glycine-rich 215GxGxIGxEx3Vx4G231 motif, which is important in binding 
NADH (see Appendix Figure 7.13) (Mattevi et al., 1992). Lastly, LmjLipDH 
possesses the acid/base catalyst motif 480HPTx2E485, which is an integral 
component of the active site (see Appendix Figure 7.13). 
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3.2.6 α-KADH kinases and phosphatases 
In mammals, but not lower eukaryotes such as yeast or prokaryotes, α-KADH 
complex activities are regulated by specific mitochondrial kinases and 
phosphatases.  
3.2.6.1 α-KADH kinases 
In human, four highly homologous isoforms of PDH kinase (PDK-1–4), and one 
BCKDH kinase (BCKDK) have been identified, although the α-KGDH complex has 
no known associated kinases or phosphatases. PDK forms homodimers, whereas 
BCKDK is more stable in a tetrameric formation (Machius et al., 2001; Wynn et al., 
2000). PDK and BCKDK are mitochondrial serine kinases belonging to the 
ATPase/kinase superfamily (Bowker-Kinley & Popov, 1999; Dutta & Inouye, 2000), 
and are distantly related to the protein histidine kinase (PHK) family (Koretke et al., 
2000). 
PDK and BCKDK down-regulate the activity of their respective α-KADHs by 
phosphorylating specific serine residues on E1 subunits (Roche et al., 2001; 
Roche & Hiromasa, 2007). It has been shown that α-KADH kinases bind to the 
lipoyl-domain of E2p (specifically to the second lipoyl-domain, L2) and E2b 
subunits (Bao et al., 2004; Roche et al., 2003; Wynn et al., 2000), and that the 
level of phosphorylation of E1 subunits is dependent upon the lipoylation state of 
the lipoyl-domain (Roche & Hiromasa, 2007). 
In order to identify potential homologues of α-KADH kinases, the L. major genome 
database was queried with H. sapiens PDK-1-4 and BCKDK protein sequences. In 
total, two potential genes encoding PDK/BCKDK were identified; PDH kinase 
(lipoamide) (LmjF24.0010) and a phosphoprotein-like protein (LmjF20.0280) (see 
Table 3.2). For simplicity, the genes and gene products will be referred to as 
LmjF24.0010 and LmjF20.0280. LmjF24.0010 (50.9 kDa) and LmjF20.0280 (55.2 
kDa) predicted proteins are larger than H. sapiens PDK-1-4 (49.2 kDa, 46.2 kDa, 
46.9 kDa and 46.5 kDa, respectively) and BCKDK (46.4 kDa) (see Table 3.2). 
LmjF20.0280 protein has higher sequence identity (20 – 22 %) to the five human 
α-KADH kinases than does LmjF24.0010 protein (15 – 17 %) (see Table 3.2). 
Mitochondrial targeting predictions for LmjF20.0280 and LmjF24.0010 proteins by 
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MitoProt and Target P are high (92 % and 82 % compared to 83 % and 48 %, 
respectively) (see Table 3.2). 
ClustalW alignment of the LmjF20.0280 protein with the five human α-KADH 
kinases revealed that LmjF20.0280 possesses the strictly conserved N-, G1- and 
G2 boxes (see Appendix Figure 7.14), which constitute the ATP domain that is 
characteristic of the ATPase/kinase superfamily (Bilwes et al., 1999). However, the 
F-box, which is present in all human α-KADH kinases (Bowker-Kinley & Popov, 
1999; Wynn et al., 2000), is not found in the LmjF20.0280 protein. LmjF24.0010 
lacks strictly conserved residues comprising the N-, G1- and G2 boxes; Asp364 
instead of Asn (N box), Ala404 instead of glycine (G1 box) and 438SxPxR442 instead 
of GxGxG (G2 box) (see Appendix Figure 7.15). As such, contrary to the current 
GeneDB annotation of LmjF24.0010 as the PDH kinase, it is more likely, based on 
the conservation of ATP-binding motifs, that LmjF20.0280 is a PDH/BCKDH 
kinase. 
However, compared to human PDK-1-4, both LmjF20.0280 and LmjF24.0010 
proteins completely lack the C-terminal portion containing the motif 
416EAxDWx2PSxEP427 (see Appendix Figure 7.14 and Figure 7.15), which is 
involved in binding the L2 domain of the PDH E2 (Kato et al., 2005). Interestingly, 
human BCKDK also lacks the C-terminal tail that is found in all four PDK isoforms 
(Kato et al., 2005). Unfortunately, structural information is not available with 
regards to how human BCKDK binds to the lipoyl-domain of E2b. As such, the key 
residues involved are not known, and therefore it is not possible to predict whether 
LmjF20.0280 may be a BCKDH kinase. 
 
  
Predicted sizes (kDa) Systematic Name (GeneDB) Targeting Predictions Identity (%) to H. sapiens
Subunit H. sapiens L. major L. major Mitoprot Target P PDK-1 PDK-2 PDK-3 PDK-4 BCKDK
PDK-1 49.2 (NP_002601) N/A N/A N/A N/A N/A 64 62 61 27
PDK-2 46.2 (NP_002602) N/A N/A N/A N/A 64 N/A 65 63 25
PDK-3 46.9 (NP_005382) N/A N/A N/A N/A 62 65 N/A 61 23
PDK-4 46.5 (NP_002603) N/A N/A N/A N/A 61 63 61 N/A 24
BCKDK 46.4 (NP_005872) N/A N/A N/A N/A 27 25 23 24 N/A
Phosphoprotein-like N/A 50.9 LmjF20.0280 92 % MT 82 % MT 22 21 21 20 21
PDH (lipoamide) kinase N/A 55.2 LmjF24.0010 83 % MT 48 % MT, 79 % SP 16 15 15 15 17
 
 
Table 3.2 Sequence analyses of potential L. major PDH/BCKDH kinases 
Predicted L. major homologues of subunits of PDK/BCKDK were identified as described in Section2.3. Red proteins are those which have been identified in human. Blue 
proteins are predicted L. major homologues of the human kinases. In the 'Protein Size' column, accession numbers of H. sapiens proteins are shown in brackets. 
Mitochondrial targeting predictions were carried out by analysing L. major protein sequences with MitoProt or TargetP. The results obtained indicate the percent likelihood 
of mitochondrial targeting (MT). Some proteins were predicted to possess signal peptides (SP). Sequence identities shared between human PDK/BCKDK proteins and L. 
major predicted kinases were determined using Vector NTI (See Section2.3). ‘N/A’ is an acronym for ‘non applicable’.  
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3.2.6.2 α-KADH phosphatases  
In human, two PDH phosphatases (PDP) exist; each shares the same regulatory 
subunit (PDPr), but differs in the catalytic subunit (PDP-1c or PDP-2c) (Huang et 
al., 1998; Lawson et al., 1993; Lawson et al., 1997; Teague et al., 1982). BCKDH 
phosphatase (BCKDP or PTMP) activity was first documented in 1984 (Damuni et 
al., 1984; Damuni & Reed, 1987), yet only recently has the human BCKDP been 
cloned and partially characterised; although only one isoform of the catalytic 
subunit has been identified, and no regulatory subunit is known (Joshi et al., 
2007). The role of PDP and BCKDP is to catalyse the dephosphorylation of their 
respective enzyme complexes, and as such to repress the down-regulation 
imposed upon PDH and BCKDH by PDK and BCKDK, respectively. Based upon 
some strictly conserved motifs and the crystal structure of PDP-1c (Vassylyev & 
Symersky, 2007), PDP-1c, PDP-2c and BCKDP are related to the PPM family of 
serine/threonine phosphatases, whose defining member is PP2C (Barford et al., 
1998; Bork et al., 1996). Although the sequence identities shared between human 
PP2C-1/PP2C-2 and PDP-1c/PDP-2c/BCKDP are low (21 – 24 %), 10/11 of the 
sequence motifs characteristic of PP2C enzymes are conserved. Information is 
available with regards to the binding of PDP-1c to the L2 domain of E2p 
(Vassylyev & Symersky, 2007); however the residues involved are not conserved 
in BCKDP. As such, no structural data exists describing the mode of BCKDP 
substrate binding and catalysis. 
In order to identify potential homologues of α-KADH phosphatases, the L. major 
genome database was queried with H. sapiens PDP-1c, PDP-2c, PDPr and 
BCKDP protein sequences. Interestingly, significant hits were not obtained from 
BLAST analysis with PDP subunit sequences. However, querying with the human 
BCKDP sequence retrieved seven significant hits from L. major GeneDB 
(LmjF34.2510, LmjF30.0380, LmjF36.0530, LmjF25.0750, LmjF32.1690, 
LmjF15.0170 and LmjF27.2320) (see Table 3.3). The seven predicted proteins are 
all PP2C-like or PP2C-putative, which infers that some of the residues involved in 
PP2C activity are conserved in these proteins. Although overall sequence 
identities to PDP-1c, PDP-2c and BCKDP are low (7 – 20 %), the predicted 
proteins have a high degree of conservation within the 10/11 domains known to be 
important in the functioning of PP2C and PP2C-like enzymes (data not shown) 
(Barford et al., 1998; Bork et al., 1996), and catalytically-important residues are 
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conserved. Mitochondrial targeting predictions vary, although confidence values 
are high for LmjF30.0380 and LmjF32.1690 (see Table 3.3).
  
Predicted sizes (kDa) Systematic Name (GeneDB) Targeting Predictions Identity (%) to H. sapiens
Subunit H. sapiens L. major L. major Mitoprot Target P PDP-1c PDP-2c BCKDP
PDP-1c 61.0 kDa (NP_060914) N/A N/A N/A N/A N/A 47 15
PDP-2c 60.0 kDa (NP_065837) N/A N/A N/A N/A 47 N/A 17
PDPr 99.4 kDa (NP_060460) N/A N/A N/A N/A N/A N/A N/A
BCKDP 41.0 kDa (NP_689755) N/A N/A N/A N/A 15 17 N/A
PP2C-like N/A 29.8* LmjF34.2510 0 % MT 4 % MT, 92 % OT 12 10 16
N/A 47.7** 0 % MT 9 % MT, 88 % OT 13 11 15
PP2C-putative N/A 41.7* LmjF30.0380 86 % MT 35 % MT, 56 % OT 10 9 16
N/A 64.6** 99 % MT 88 % MT 12 9 15
PP2C-like N/A 32.6 LmjF36.0530 3 % MT 11 % MT, 88 % OT 10 10 20
PP2C-putative N/A 45 LmjF25.0750 41 % MT 21 %, 79 % OT 12 7 11
PP2C-putative N/A 68.3 LmjF32.1690 97 % MT 24 % MT, 71 % SP 15 11 12
PP2C-putative N/A 44.3 LmjF15.0170 40 % MT 24 % MT, 84 % OT 14 12 19
PP2C-like N/A 34.4* LmjF27.2320 45 % MT 20 % MT, 81 % OT 13 11 17
N/A 45.7** 0 % MT 6 % MT, 94 % SP 17 13 17
 
Table 3.3 Sequence analyses of potential L. major PDH/BCKDH phosphatases 
Predicted L. major homologues of subunits of PDP/BCKDP were identified as described in Section2.3. Red proteins are those which have been identified in human. Blue 
proteins are predicted L. major homologues of the human phosphatases. In the 'Protein Size' column, accession numbers of H. sapiens proteins are shown in brackets. 
Three of the L. major genes predicted by GeneDB do not correlate with ORFs predicted by Vector NTI. In such cases, translated protein from GeneDB predictions (*) as 
well as translated protein from Vector NTI predictions (**) were analysed. A possible explanation for these size discrepancies is that the predicted ATG start codon 
provided by GeneDB is wrong, and is in fact located further upstream. Mitochondrial targeting predictions were carried out by analysing L. major protein sequences with 
MitoProt or TargetP. The results obtained indicate the percent likelihood of mitochondrial targeting (MT). Some proteins were predicted to possess signal peptides (SP), or 
an alternative processing type (OT). Sequence identities shared between human PDP/BCKDP proteins and L. major predicted phosphatases were determined using 
Vector NTI (See Section2.3). ‘N/A’ is an acronym for ‘non applicable’. 
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3.3 Lipoylation patterns in L. major 
The in silico analyses discussed in Section 3.2 indicate that L. major encodes 
machinery to form functional α-KADHs and the GCC. In addition, it was 
determined that the E2 subunits of α-KADHs and the H-protein of the GCC all 
have one lipoyl-domain at their N-termini. Lipoylation of the E2 subunits and H-
protein is essential for activity of these complexes. Therefore, in order to address 
the question as to whether α-KADHs and the GCC were potentially active in L. 
major, protein lysates of promastigotes and amastigotes were probed by western 
blot with a polyclonal antibody that specifically detects protein-bound LA. This 
assay has previously been used successfully in other organisms, for example, T. 
gondii and P. falciparum (Allary et al., 2007; Crawford et al., 2006; Gunther et al., 
2007). 
In order to correlate promastigote growth phase with lipoylation pattern, wild-type 
parasites were cultured in standard HOMEM + 10 % FCS medium and growth 
readings were taken every 24 h (see Figure 3.1A), and soluble protein was 
harvested every 24 h during 48–120 h growth (see Figure 3.1B). In order to 
analyse the lipoylation pattern in amastigotes, lesions from two mice infected with 
L. major were isolated and amastigotes purified (isolations carried out by Mrs 
Denise Candlish, University of Glasgow) and soluble protein was extracted, as 
described in Section 2.2.3.2. Western blotting with α-LA antibody, which detects 
protein-bound LA, resulted in just four prominent bands in promastigotes. The 
observed band sizes (calculations are described in Section 2.5.5) are 14.4 kDa, 
40.6 kDa and 47.3 kDa (see Figure 3.1B), which combined with predicted sizes 
after cleavage of mitochondrial targeting peptides (see Table 3.4), correlates well 
with the predicted sizes of LmjH-protein (15.2 kDa), LmjE2k (41.7 kDa) and 
LmjE2p (48.7 kDa). The 55 kDa band does not correlate with the predicted size of 
LmjE2b (50.2 kDa), although this band will be referred to as LmjE2b henceforth as 
it is the only remaining protein that has the capacity to be lipoylated (see Section 
6.2.3).  
The banding patterns observed in each of the two amastigote protein lysates are 
similar to one another, and share some similarities with those observed in 
promastigotes (see Figure 3.1C). The 47.8 kDa band most likely corresponds to 
the LmjE2p (which is 47.3 kDa in the promastigote blot), although a band larger 
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than 50 kDa (assumedly corresponding to LmjE2b) is not present in amastigote 
protein lysates (see Figure 3.1C). One of two bands (39.4 kDa and 41.4 kDa) 
could be LmjE2k (which is 40.6 kDa in the promastigote blot). Although the nature 
of the second band is not clear, it could correspond to the LmjE2pL protein (similar 
to the human E3BP), since sequence analyses identified LmjE2pL as possessing 
at least one lipoyl-domain (see Section 3.2.2.2). Two bands of 15.5 kDa and 13.4 
kDa are similar in size to the 14.4 kDa band observed in promastigote lysates, 
which most likely corresponds to LmjH-protein (see Table 3.4). It should also be 
noted that the protocol for isolating L. major amastigotes from an infected mouse 
is such that the final amastigote preparation contains some contamination with 
mouse proteins. On the other hand, none of the expected band sizes of mouse α-
KADH E2 subunits (see Table 3.4) are observed in Figure 3.1C; suggesting that all 
lipoylated proteins observed are derived from L. major.  
Figure 3.1 shows that during exponential growth (48 h) promastigotes primarily 
lipoylate E2k. Also, lipoylation of H-protein is very low. During early (72 – 96 h) 
and late-stationary phase (120 h), lipoylation of all three α-KADH E2 subunits and 
H-protein is apparent. Metacyclic promastigotes purified from mixed promastigote 
cultures have a similar lipoylation pattern to exponential growth phase parasites; 
only E2k being lipoylated to an appreciable extent. This indicates that metacyclic 
promastigotes are metabolically different from procyclic promastigotes. The 
consistent lipoylation of E2k throughout the 120 h time course indicates that α-
ketoglutarate (derived from proline or glutamine) is an important carbon source for 
energy production, and most likely represents an important entry point into the 
tricarboxylic acid (TCA) cycle. Pyruvate and branched-chain α-ketoacids could be 
important during stationary phase, whereas metacyclic promastigotes apparently 
do not require BCKDH or PDH activity. Lipoylation of H-protein follows a similar 
pattern to that of E2b and E2p, potentially indicating that production of one-carbon 
CH2 units via the GCC is important only at specific times during promastigote 
development. In fact, it has been experimentally determined that the GCC is not 
essential in L. major promastigotes grown in a similar medium to HOMEM + 10 % 
FCS (importantly, with the same glycine and serine concentrations) (Scott et al., 
2008). In terms of amastigotes, the lipoylation profile is not as clear, although if the 
bands predicted to be E2p and E2k are correct, the lipoylation intensities of these 
two proteins are similar, which is in contrast to the situation observed in 
promastigotes.  
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Figure 3.1 Lipoylation of α-KADH E2 subunits and H-protein of GCC in L. major 
promastigotes and amastigotes 
A, In order to observe lipoylation patterns in promastigotes, cultures were initiated with starting 
densities of 5 x 105 parasites ml-1. Growth readings were taken every twenty-four hours to produce 
a growth curve. B, Approximately 1 x 108 cells were harvested from the cultures at time points from 
48 – 120 h. Cells were lysed, and the protein concentration of soluble fractions determined by 
Bradford assay. At 120 h, in addition to preparing soluble protein from mixed cultures, metacyclic 
promastigotes were purified from the cultures using peanut agglutinin negative selection, and 
soluble protein isolated. 10 µg protein from each time point was loaded on a 4 – 12 % SDS-PAGE 
gradient gel. Western blotting was carried out with α -LA antibody at 1/6,000 and α-cysteine 
synthase (α-CS) antibody to assess loading, at 1/5,000. Each time point was carried out in 
duplicate. C, Western blot of 30 µg of two different amastigote protein lysates using α-LA antibody 
at 1/6,000. Observed band sizes (shown in brackets) were calculated as described in Section 
2.5.5. Predicted (full-length) sizes of E2k, E2p and E2b are 41.7 kDa, 48.7 kDa and 50.2 kDa, 
respectively. The predicted size of full-length H-protein is 15.2 kDa (see Table 3.1). 
  
  
 
Table 3.4 Predicted- and proven molecular masses of α-KADH E2 subunits and the H-protein of the GCC in L. major, H. sapiens and M. musculus 
Predicted (full-length, FL) protein sequences of human (Hs), M. musculus (Mm) and L. major (Lmj) α-KADH E2 proteins and the H-protein of the GCC were obtained as 
described in Section 2.3. Predicted cleavage sites for mitochondrial transit were made by MitoProt and TargetP, and the subsequent processed protein sizes were 
recorded. Where possible, the proven molecular weights of the different apoproteins are given, along with the associated authors who published the data. The proven sizes 
for L. major are based upon α-LA antibody-probed western blots, and the range of potential sizes given are based upon results obtained from western blots of both 
promastigote and amastigote protein lysates with α-LA antibody (see Figure 3.1B and C). The presence of a lipoylated E2pL protein (which could be E3BP) in amastigotes 
is questionable, and as such is marked with '?' after the calculated protein size. 
 
Predicted protein sizes (kDa) 
Lipoylated protein Species Accession number FL MitoProt TargetP Proven size (kDa) Reference
Lm LmjF35.4720 15.2 13.1 13.1 13.4 - 15.5 This work (western blots with α -LA antibody)
H-protein Mm NP_080848 18.6 12.3 14.7 N/A N/A
Hs NP_004474 18.9 12.3 16.8 N/A N/A
Lm LmjF28.2420 41.7 39.9 33.4 39.4 - 41.4 This work (western blots with  α -LA antibody) 
E2k Mm NP_084501 49.0 43.8 41.6 N/A N/A
Hs NP_001924 48.8 41.9 34.8 48 Migliaccio et al. (1998)
Lm LmjF36.2660 48.7 45.9 45.7 47.3 - 47.8 This work (western blots with  α -LA antibody) 
E2p Mm NP_663589 67.9 66.6 58.8 67 Nakagome et al. (2007)
Hs NP_001922 69.0 N/A 59.6 70 Yeaman et al.  (1988), Migliaccio et al. (1998)  
Lm LmjF05.0180 50.2 44.3 39.8 55 This work (western blots with α -LA antibody)
E2b Mm NP_034152 53.2 46.8 49.7 N/A N/A
Hs NP_001909 53.5 46.3 50.9 52 Migliaccio et al. (1998)
Lm LmjF21.0550 46.1 N/A 37.9 39.4 - 41.4? This work (western blots with α -LA antibody)
E3BP/E2p-L Mm NP_780303 54.0 50.0 49.0 N/A N/A
Hs NP_001128496 51.5 49.8 N/A 50 Jilka et al . (1996)
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3.4 Sequence analyses of lipoylating proteins 
Given that lipoylation of α-KADHs and the GCC occurs in promastigotes, the next 
question to be addressed was whether lipoylating proteins are found within the L. 
major genome. Potential homologues for biosynthesis enzymes LIPB and LIPA 
and the salvage enzyme LPLA were identified (as described in Section 2.3) (see 
Table 3.5).  
3.4.1 LIPB 
LIPB catalyses the first step involved in the biosynthesis of LA from octanoyl-acyl 
carrier protein; the transfer of an octanoyl-group from a phosphopantetheine-
bound cofactor of ACP onto E2- and H-protein apoproteins to form E2/H-protein-
octanoamide.   
Searching the L. major genome revealed the presence of three potential genes 
encoding LIPB (LmjLIPB); LmjF36.3080, LmjF07.1060 and LmjF31.1070. 
LmjF07.1060 is most likely to be LPLA (LmjLPLA) (see Section 3.4.3), 
LmjF31.1070 is most similar to biotin protein ligase (bpl), and LmjF36.3080 is the 
most likely candidate for LmjLIPB. LmjLIPB (29.5 kDa) is similar in size to H. 
sapiens LIPB (HsLIPB) (25.2 kDa) and E. coli LIPB (EcLIPB) (23.9 kDa) (see 
Table 3.5). Compared to HsLIPB and EcLIPB, LmjLIPB (and T. brucei LIPB 
(TbLIPB)) has a circa 20 amino acid C-terminal extension (see Figure 3.2). Both 
HsLIPB and LmjLIPB (and TbLIPB) have approximately 5-10 amino acid N-
terminal extensions, which contain targeting signals for mitochondrial transit (see 
Figure 3.2). LmjLIPB has reasonable sequence identity to HsLIPB (21 %) and 
EcLIPB (21 %). LmjLIPB is predicted to be mitochondrial by MitoProt and TargetP 
programmes, with confidence values of 60 % and 82 %, respectively (see Table 
3.5). 
The crystal structure of M. tuberculosis LIPB (MtLIPB) complexed with decanoic 
acid (DA) highlighted residues that are important in the binding of DA/octanoic acid 
(OA) to form the LIPB-DA/OA intermediate (Ma et al., 2006). ClustalW alignment 
of LmjLIPB with MtLIPB, HsLIPB and EcLIPB illustrated the presence of strictly 
conserved residues in LmjLIPB (see Figure 3.2). Firstly, residues that form a 
hydrophobic tunnel for binding of the aliphatic portion of DA/OA in MtLIPB (Ma et 
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al., 2006) are conserved in LmjLIPB. For example, the motif 80RGGx2TxHx7Y95 is 
present, although the importance of Tyr95 is questionable given that in HsLIPB the 
residue is instead His100 (see Figure 3.2). Most importantly, LmjLIPB possesses 
the strictly conserved Lys157 and Cys191 residues (see Figure 3.2). In MtLIPB, 
Cys176 (Cys191 in LmjLIPB) has been shown to form an essential covalent thioether 
linkage with the C3 atom of DA/OA, producing the LIPB-DA/OA intermediate (Ma 
et al., 2006). Importantly, LPLA enzymes lack this Cys residue, and this is indeed 
also the case for the predicted LmjLPLA (see Section 3.4.3). The Lys142 residue in 
MtLIPB (Lys157 in LmjLIPB) is conserved in all biotin protein ligases (BPL), LPLA 
and LIPB proteins (Reche, 2000). However, the role of the invariable lysine 
residues is thought to differ in LIPB and LPLA enzymes (Ma et al., 2006). 
 
Mt_LIPB         ---MTG-SIR-SKLSAIDVRQLGTVDYRTAWQLQRELADARVAGGADTLLLLEHPA--VY 53 
Hs_LIPB         ---MRQPAVRLVRLGRVPYAELLGLQDRWLRRLQAEPGIEAPSGTEAGALLLCEPAGPVY 57 
Lmj_LIPB        ---MKAFFIGKREYRRVLSLQETIFNAKIARQVSVRRGASKLPLLPDVVILVEHST-PVY 56 
Tb_LIPB         MNGMRAYNLGSRRYHDVLRLQEAIFRKKIDRQMRYIRGDKSARLIPNVVLLVEHSS-PVY 59 
Ec_LIPB         -----------MYQDKILVRQLGLQPYEPISQAMHEFTDTRDDSTLDEIWLVEHYP--VF 47 
                                :   :      .   :                  *: . .  *: 
 
Mt_LIPB         TAGRR-----TETHERPIDGTPVVDTDRGGKITWHGPGQLVGYPIIGLAEP--------- 99 
Hs_LIPB         TAGLRGGLTPEETARLRALGAEVRVTGRGGLATFHGPGQLLCHPVLDLRRLG-------- 109 
Lmj_LIPB        TIGRRD----TTHGLPPHCSIDVVKTRRGGGITYHGPGQLTMYPIANIQLLWKDCTAE-K 111 
Tb_LIPB         TIGRRD----TSNGIKAGCAAEVVKTRRGGGVTFHGPGQVTMYPIVNVQVLWKQCTASDK 115 
Ec_LIPB         TQGQAG----KAEHILMPGDIPVIQSDRGGQVTYHGPGQQVMYVLLNLKRRK-------- 95 
                * *                   *  : ***  *:*****   : : .:             
 
Mt_LIPB         --LDVVNYVRRLEESLIQVCADLGLHAGRVDGR--SGVWLPGRPARKVAAIGVRVSRATT 155 
Hs_LIPB         --LRLRMHVASLEACAVRLCELQGLQDARARPPPYTGVWLDDR---KICAIGVRCGRHIT 164 
Lmj_LIPB        PRSPIEWFSWALEEAMIQTAAMYHIPTHRFKTGVWADQYKDIPA-QKLGAVGLQLGSWVS 170 
Tb_LIPB         PRSPIEWFSSVLEQAMINVAGEYNIPAHRGRVGVWSDSWGDVAP-RKMGFVGLQLGNWVS 174 
Ec_LIPB         --LGVRELVTLLEQTVVNTLAELGIEAHPRADAP--GVYVGEK---KICSLGLRIRRGCS 148 
                    :      **   :.      :           . :       *:  :*::     : 
 
Mt_LIPB         LHGFALNCDCDLAAFTAIVPCGISDAAVTSLSAELGRTVTVDEVRATVAAAVCAALDGVL 215 
Hs_LIPB         SHGLALNCSTDLTWFEHIVPCGLVGTGVTSLSKELQRHVTVEEVMPPFLVAFKEIYKCTL 224 
Lmj_LIPB        MHGAGLNVASDLHFFDDIIMCELPDRRATSLSNEMQHRGVAESPPLVQATAPVLLQKFIE 230 
Tb_LIPB         MHGAGLNVSNNLLYFNDIVMCEMPNEAATSLVEELRLRGLSGAEPTPHVIAPRLLHHFLL 234 
Ec_LIPB         FHGLALNVNMDLSPFLRINPCGYAGMEMAKISQWKPEATTNNIAPRLLENILALLNNPDF 208 
                 ** .**   :*  *  *  *   .   :.:                         .    
 
Mt_LIPB         PVGDRVPSHAVPSPL--------------------                          230 
Hs_LIPB         ISED--------SPN--------------------                          231 
Lmj_LIPB        SLHQQPSCAAPQLVDLSADADWHERVIDTAGISTP                          265 
Tb_LIPB         SMQQQESVVNTELVDLSIDGSWERSILCELE----                          265 
Ec_LIPB         EYITA------------------------------                          213 
                                                 
 
Figure 3.2 LIPB protein alignment 
ClustalW alignment of L. major LIPB (LmjLIPB) (accession number LmjF36.3080) with homologues 
in T. brucei (TbLIPB) (accession number Tb11.01.1160), H. sapiens (HsLIPB) (accession number 
A6NK58), E. coli (EcLIPB) (accession number AAC73731) and M. tuberculosis (MtLIPB) 
(accession number CAA94273) was carried out. The alignment indicates identical residues (*), 
conserved residues (:) and homologous residues (.). Red residues highlight the strictly conserved 
lysine and Cys residues that comprise the catalytic dyad within the active site of LIPB enzymes (Ma 
et al., 2006). Blue residues are those that are involved in binding decanoic acid in MtLIPB (Ma et 
al., 2006). Green residues highlight residues in HsLIPB that are not conserved in other species. 
MitoProt programme predicts the targeting peptide for mitochondrial transit as being 34 amino 
acids (green arrow, LIPBT1) (see Section 3.5.2). 
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3.4.2 LIPA 
LIPA is an [4Fe – 4S] + cluster-containing protein that catalyses the second step 
involved in the biosynthesis of LA; via a radical S-adenosylmethionine (SAM)-
dependent mechanism LIPA catalyses the replacement of two hydrogen atoms 
with sulphur atoms, at positions C6 and C8 of octanoamide-E2/H-protein, to form 
lipoamide-E2/H-protein (Booker et al., 2007). 
Searching the L. major genome revealed the presence of one potential gene 
encoding LIPA (LmjLIPA). LmjLIPA (45.9 kDa) is similar in size to H. sapiens LIPA 
(HsLIPA) (41.9 kDa), yet 10 kDa larger than the E. coli homologue (EcLIPA) (36.1 
kDa) (see Table 3.5). Compared to HsLIPA and EcLIPA, LmjLIPA has a circa 17 
amino acid C-terminal extension that is rich in hydrophobic amino acids alanine 
and glycine (see Figure 3.3). Both HsLIPA and LmjLIPA (and TbLIPA) have 
approximately 40 amino acid N-terminal extensions, which contain targeting 
signals for mitochondrial transit (see Figure 3.3 and Section 5.2). LmjLIPA has 
reasonable sequence identity to HsLIPA (40 %) and EcLIPA (33 %). LmjLIPA is 
predicted to be mitochondrial by MitoProt and TargetP programmes, with 
confidence values of 75 % and 54 %, respectively (see Table 3.5). 
ClustalW alignment of LmjLIPA with human and bacterial homologues indicates 
that LmjLIPA possesses two motifs that are integral to its function: 133Cx4Cx5C144 
and 165Cx3Cx2C172 (see Figure 3.3 and Section 1.4.3.1). The Cx3Cx2C motif is 
present in all radical S-adenosylmethionine (SAM) proteins. The cysteine residues 
nucleate a [4Fe – 4S] + cluster, which binds SAM. LIPA catalyses the reductive 
cleavage of SAM to produce [4Fe – 4S] 2+-Met and the 5'-deoxyadenosyl radical 
(5'-dA●). 5'-dA● abstracts hydrogen atoms linked to C6 and C8, of the octanoyl 
substrate (Douglas et al., 2006). The motif Cx4Cx5C is specific to LIPA enzymes. 
After hydrogen abstraction by 5'-dA●, C6- and C8 alkyl radicals are formed, which 
attack µ-sulphido atoms attached to the Cx4Cx5C cluster; the final result is 
production of a lipoyl-group (Cicchillo et al., 2004b).  
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Tb_LIPA         MFQRWSFALCR--------PIVAAAQVSQQQVPPSEEPRNESGAANPPLVKEEFLRQFRE 52 
Lmj_LIPA        MLRCCSALMCPTAVPSRVSPVAAAAAADIAGSSESTVSLVADVDKKNSQYKQIFLERFRK 60 
Hs_LIPA         MSLRCGDAARTLG------PRVFGRYFCSPVRPLSSLP----DKKKELLQNGPDL--FVS 50 
Ec_LIPA         ------------------------------------------------MSKPIVMERGVK 12 
                                                                  :   :.   . 
 
Tb_LIPA         RLANDKTGRNSLEGFLDLPENLPPTAASIGPLKRGKEPLPPWLKLKVPMGASRQPRFNKI 112 
Lmj_LIPA        KLQSDKTGMNNLESFVELPEGVAPSAASIGPIKRGSEPLPPWIKLKVPKGMTHRPRFNRI 120 
Hs_LIPA         GDLADRSTWDEYKGNLKRQK---------GERLR----LPPWLKTEIPMGKN----YNKL 93 
Ec_LIPA         YRDADKMALIPVKNVATERE----------ALLR----KPEWMKIKLPADSTR---IQGI 55 
                    *:      :.     :             *     * *:* ::* . .     : : 
 
Tb_LIPA         RRNMREKRLATVCEEAKCPNIGECWGGGDEEGDGTATATIMVMGAHCTRGCRFCSVMTSR 172 
Lmj_LIPA        RRSMREKNLSTVCEEAKCPNIGECWGGSDEEG--TATATIMVMGSHCTRGCRFCSVLTSR 178 
Hs_LIPA         KNTLRNLNLHTVCEEARCPNIGECWGGGEYAT---ATATIMLMGDTCTRGCRFCSVKTAR 150 
Ec_LIPA         KAAMRKNGLHSVCEEASCPNLAECFNHG--------TATFMILGAICTRRCPFCDVAHGR 107 
                :  :*:  * :***** ***:.**:. .        ***:*::*  *** * **.*  .* 
 
Tb_LIPA         TPPPLDPEEPRKTADAVADMGVEYIVMTMVDRDDLADGGAAHVVRCVTAVKERNPGLLLE 232 
Lmj_LIPA        RPPPLDPEEPEKVAAAVHEMGVDYIVMTMVDRDDLPDGGASHVCCCIHTIKKKNPELMLE 238 
Hs_LIPA         NPPPLDASEPYNTAKAIAEWGLDYVVLTSVDRDDMPDGGAEHIAKTVSYLKERNPKILVE 210 
Ec_LIPA         -PVAPDANEPVKLAQTIADMALRYVVITSVDRDDLRDGGAQHFADCITAIREKSPQIKIE 166 
                 * . *..** : * :: : .: *:*:* *****: **** *.   :  ::::.* : :* 
 
Tb_LIPA         ALVGDFHGDLK-LVEMVAGSPLNVYAHNIECVERITPNVRDRRASYRQSLKVLEHVNNFT 291 
Lmj_LIPA        ALVGDFHGDLK-LVEQLAVTPLSVYAHNIECVERITPRVRDRRASYRQSLQTLEHVTKWT 297 
Hs_LIPA         CLTPDFRGDLK-AIEKVALSGLDVYAHNVETVPELQSKVRDPRVNFDQSLRVLKHAKKVQ 269 
Ec_LIPA         TLVPDFRGRMDRALDILTATPPDVFNHNLENVPRIYRQVR-PGADYNWSLKLLERFKEAH 225 
                 *. **:* :.  :: :: :  .*: **:* * .:  .**   ..:  **: *:: .:   
 
Tb_LIPA         KGAMLTKSSIMLGLGEKEEEVRQTLRDLRTAGVSAVTLGQYLQPSRTRLKVSRYAHPKEF 351 
Lmj_LIPA        NGNMLTKSSIMLGLGEEEAEVRQTLRDLRTAGVSAVTLGQYLQPSHTRLKVSRYAHPKEF 357 
Hs_LIPA         P-DVISKTSIMLGLGENDEQVYATMKALREADVDCLTLGQYMQPTRRHLKVEEYITPEKF 328 
Ec_LIPA         P-EIPTKSGLMVGLGETNEEIIEVMRDLRRHGVTMLTLGQYLQPSRHHLPVQRYVSPDEF 284 
                   : :*:.:*:**** : ::  .:: **  .*  :*****:**:: :* *..*  *.:* 
 
Tb_LIPA         EMWEKEALDMGFLYCASGPMVRSSYRAGEYYIKNILKQRETVEAPSVSDGGNEPKDSE-- 409 
Lmj_LIPA        EMWEKEAMDMGFLYCASGPMVRSSYRAGEYYIKNILKQRQSAEGGKAAAAATAVNAGTAI 417 
Hs_LIPA         KYWEKVGNELGFHYTASGPLVRSSYKAGEFFLKNLVAKRKTKDL---------------- 372 
Ec_LIPA         DEMKAEALAMGFTHAACGPFVRSSYHA------DLQAKGMEVK----------------- 321 
                .  :  .  :** : *.**:*****:*      ::  :    .                  
 
Tb_LIPA         - 
Lmj_LIPA        A                  418 
Hs_LIPA         - 
Ec_LIPA         -                  
 
 
Figure 3.3 LIPA protein alignment 
ClustalW alignment of L. major LIPA (LmjLIPA) (accession number LmjF19.0350) with homologues 
in T. brucei (TbLIPA) (accession number Tb10.61.1530), H. sapiens (HsLIPA) (accession number 
NP_006850) and E. coli (EcLIPA) (accession number AAC73729) was carried out. The alignment 
indicates identical residues (*), conserved residues (:) and homologous residues (.). Red residues 
highlight strictly conserved Cys residues that belong to the Cx4Cx5C motif that is specific to LIPA 
enzymes (Cicchillo et al., 2004b). Blue residues represent strictly conserved Cys residues 
belonging to the Cx3Cx2C motif, which is specific to radical SAM proteins (Cicchillo et al., 2004b). 
Bold letters represent strictly conserved residues and 'x' represents any amino acid. TargetP and 
MitoProt programmes predict the targeting peptide for mitochondrial transit as being five amino 
acids (black arrow, LIPAT1) and 15 amino acids (green arrow, LIPAT2), respectively. However, in 
order to produce soluble recombinant protein, an N-terminal 62 amino acid truncated version of 
LIPA was constructed (purple arrow, LIPAT3) (see Section 3.5.1). 
 
  
Predicted Sizes (kDa) Systematic Name (GeneDB) Targeting Predictions Identity (%) to other species
Enzyme E. coli H. sapiens L. major L. major Mitoprot Target P H. sapiens E. coli
LIPA 36.1 (AAC73729) 41.9 (NP_006850) 45.9 LmjF19.0350 75 % MT 54 % MT 40 33
LIPB 23.9 (AAC73731) 25.2 (A6NK58) 29.5 LmjF36.3080 60 % MT 82 % MT 21 21
LPLA 37.9 (AAC77339) 42.5 (LT) (NP_057013) 55.2 LmjF07.1060 63 % MT 76 % MT 26 (LT)* 29*
 
Table 3.5 Sequence analyses of lipoic acid synthase (LIPA) and lipoyl/octanoyl transferase (LIPB and LPLA) proteins 
L. major homologues of LIPA, LIPB and LPLA were identified as described in Section 2.3. In the 'Protein Size' column, accession numbers of E. coli and H. sapiens 
proteins are shown in brackets. Mitochondrial targeting predictions were carried out by analysing L. major protein sequences with MitoProt or TargetP. The results obtained 
indicate the percent likelihood of mitochondrial targeting (MT). Amino acid sequence identity of L. major LIPA, LIPB and LPLA proteins to E. coli and H. sapiens 
homologues was determined using Vector NTI. In the case of LPLA sequence identities, only the N-termini of L. major LPLA (1-222 amino acids), E. coli LPLA (1-182) and 
H. sapiens LT (1-250) were aligned(*).  
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3.4.3 LPLA 
As described in Section 1.4.3.2, salvage of LA in most bacteria, plants and 
protozoans requires one enzyme, LPLA, whereas mammals necessitate the 
sequential action of two enzymes, ACSM1 and LT (see Table 3.5). Crystal 
structure data indicate that E. coli LPLA (EcLPLA) (Fujiwara et al., 2005), T. 
acidophilum LPLA (TaLPLA) (Kim do et al., 2005; McManus et al., 2005) and B. 
taurus LT (BtLT) (Fujiwara et al., 2007) have relatively high sequence identities in 
their N-terminal domains, especially within the hydrophobic lipoyl-AMP binding 
site. However, unlike EcLPLA, TaLPLA and BtLT cannot activate LA with ATP to 
form lipoyl-AMP. TaLPLA completely lacks a C-terminal domain, and it is proposed 
that another enzyme may be required to catalyse the activation of LA to lipoyl-
AMP (McManus et al., 2005). In contrast, BtLT possesses a C-terminal domain 
with similar folds to that of EcLPLA, however the domain is shifted 180° relative t o 
the C-terminal domain of EcLPLA (Fujiwara et al., 2007). The authors hypothesise 
that the more ordered conformation of the BtLT C-terminal domain results in 
stabilisation of the adenylate-binding loop, which consequently increases the 
binding affinity for LA, yet excludes the bulkier ATP (Fujiwara et al., 2007). The 
steric exclusion of ATP is the current hypothesis as to why LT cannot activate LA, 
and yet the less bulky lipoyl-AMP can enter the active site and be ligated to the 
apoprotein. 
Searching the L. major genome resulted in the discovery of three potential 
lipoate/biotin protein ligases, LmjF36.3080, LmjF07.1060 and LmjF31.1070. As 
mentioned in Section 3.4.1, LmjF36.3080 most likely corresponds to the LmjLIPB 
gene, LmjF31.1070 corresponds to the LmjBPL gene, and LmjF07.1060 could 
encode LmjLPLA or LmjLT. The predicted LmjF07.1060 protein is 55.2 kDa, and 
as such is substantially larger than EcLPLA (37.9 kDa) and H. sapiens LT (HsLT) 
(42.5 kDa) (see Table 3.5). Both LmjF07.1060 and HsLT have approximately 37 
amino acid N-terminal extensions compared to EcLPLA, which contain residues 
involved in mitochondrial targeting (see Figure 3.4 and Table 3.5). However, 
LmjF07.1060 has a C-terminus that is 137 amino acids longer than that of 
EcLPLA, and 127 amino acids longer than that of HsLT (see Figure 3.5). The 
LmjF07.1060 protein is predicted to be mitochondrial by MitoProt and TargetP 
(with confidence values of 63 % and 76 %, respectively) (see Table 3.5). In order 
to analyse sequence identities, only the N-terminal domains of LPLA proteins were 
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aligned (see Figure 3.4), since inter-species sequence variation within LPLA C-
terminal domains is common. Firstly, EcLPLA and LmjF07.1060 share 25 % and 
26 % sequence identity, respectively, with HsLT (see Table 3.5). LmjF07.1060 has 
29 % sequence identity to E. coli LPLA (see Table 3.5). 
ClustalW alignment of the N-termini of putative trypanosomatid LPLA proteins, 
EcLPLA, BtLT and HsLT were carried out in order to determine whether 
LmjF07.1060 is most likely to be LPLA or LT. The key motif 
108RRx2GGGxV(F/Y)HD119 that forms the lipoyl-AMP binding pocket in all LPLA 
and LT proteins (Kim do et al., 2005; McManus et al., 2005) is conserved in 
LmjF07.1060 and all other trypanosomatid homologues (see Figure 3.4). 
Additionally, the invariant (Fujiwara et al., 2007; Reche, 2000) Lys172 is present in 
LmjF07.1060 and all other trypanosomatid homologues (see Figure 3.4). Lastly, in 
EcLPLA, the motif 177GITSVR182 which has been shown to bind to LA is instead 
217SVGSVR222 in LmjF07.1060, and is similar in other trypanosomatid putative 
LPLA proteins. In HsLT and BtLT the motifs are instead 204ATASIPS210 and 
204ATASTPA210, respectively. Although the trypanosomatid motifs share more 
sequence identity and similarity to the EcLPLA motif than to the HsLT and BtLT 
motif, it is not possible to categorically label LmjF07.1060 as LPLA instead of LT. 
It is apparent that alignment of the N-termini does not result in an obvious 
conclusion as to whether LmjF07.1060 is LPLA or LT, since lipoyl-AMP binding 
and transferase functions that are shared by LPLA and LT appears to be a highly 
conserved property of their N-termini (Fujiwara et al., 2007; Reche, 2000). The 
recent analysis of the structure of BtLT infers that although the C-terminal domains 
of EcLPLA and BtLT have the same overall fold, they are rotated approximately 
180° relative to one another, which is thought to permit LPLA but not LT, to 
accommodate ATP and thus activate LA (Fujiwara et al., 2007). Unfortunately, 
since trypanosomatid C-terminal domains are 120 – 140 residues longer than the 
C-terminal domains of EcLPLA and HsLT and BtLT proteins (see Figure 3.5), 
modelling the LmjLPLA C-terminal domain was not an option. BLAST analyses 
indicate that the C-terminal extensions of trypanosomatid putative LPLA proteins 
have no known homologues, although they share approximately 22 % to one 
another (see Figure 3.5). 
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Lmj_LPLA        MWQTVVRRYRLQPT-SLAAFLESNCMVAKPPTAALHSDSNLVVAETNSLSIFENLAAEES 59 
Li_LPLA         MWQTVVQRYRLQPT-SLATFLESNCMVAKPPTAALHSGSNLVVAETNSLSIFENLAAEES 59 
Lb_LPLA         MWQTLRQRYRLQPT-SLAAFLESNCTVSKSPTAALHRNSSLVVAETNSLCIFENLVAEES 59 
Tb_LPLA         ---MRAARLSLRPTISLLDFVNRHGASIRS-DRLLSDKQRSVALISNSDVIYDNLATEEA 56 
Tc_LPLA         --MMRRMGWCLCPTTTLFSFLTRHATATHS-ERQLTEARASVALVSNSRCIFENLAVEEA 57 
Hs_LT           ----------MLIPFSMKNCFQLLCNCQVPAAGFKKTVKNGLILQSISNDVYQNLAVEDW 50 
Bt_LT           ----------MLIPFSMKNCFQLLCNLKVPAAGFKNTVKSGLILQSISNDVYHNLAVEDW 50 
Ec_LPLA         -------------------------------------MSTLRLLISDSYDPWFNLAVEEC 23 
                                                             : *   : **..*:  
 
Lmj_LPLA        LIRGLSLDTKQRLLLFYVNRPCVVVGRNQNIFQEVSLRRAAADGVCVARRASGGGAVFHD 119 
Li_LPLA         LIRGLSLDTKQRLLLFYVNRPCVVVGRNQNIFQEVSLRRAAADGVCLARRASGGGAVFHD 119 
Lb_LPLA         LARGLSLDKTQRLLLFYVNRPCVVVGRNQNLFQEVALRRAAADGVSVARRASGGGAVFHD 119 
Tb_LPLA         LLRGVVLRRQEALLLMYVNKPCVVVGRNQNIFSEVALRAAHHDGVSIARRNSGGGAVYHD 116 
Tc_LPLA         LLRGVILPPGQQLLFSYVNRPCVVIGRNQNYLQEVAVSAARRDGVPIARRSSGGGAVYHD 117 
Hs_LT           IHDHMNLEGKP-ILFFWQNSPSVVIGRHQNPWQECNLNLMREEGIKLARRRSGGGTVYHD 109 
Bt_LT           IHDHMNLEGKP-VLFLWRNSPTVVIGRHQNPWQECNLNLMREEGVKLARRRSGGGTVYHD 109 
Ec_LPLA         IFRQMPATQR--VLFLWRNADTVVIGRAQNPWKECNTRRMEEDNVRLARRSSGGGAVFHD 81 
                :   :       :*: : *   **:** **  .*        :.: :*** ****:*:** 
 
Lmj_LPLA        EGNLCFSFITHRTRYAPEKTIQLVRLGLCASYAIDPARLTTTGRHDLFLD----GRKITG 175 
Li_LPLA         EGNLCFSFLTHRTCYAPEKTIQLVRLGLCASYAIDPARLTTTGRHDLFLD----GRKITG 175 
Lb_LPLA         EGNLCLCFITHRTRYAPEKTIQLIRLGLCVNYAIDPARLTTTRRHDLFLD----GKKITG 175 
Tb_LPLA         LGNVSFSVFTHRDTYEPKRSIQLLRWHLCREFGIGPERITTTKRHDLFLD----EMKITG 172 
Tc_LPLA         TGNVCFSFFTHRSAYHPERTIEIIRLFLCCAFDICPERLTTTFRHDLFLD----RKKITG 173 
Hs_LT           MGNINLTFFTTKKKYDRMENLKLIVRALNAVQPQ--LDVQATKRFDLLL---DGQFKISG 164 
Bt_LT           MGNINLTFFTTKKKYDRMENLKLVVRALKAVHPH--LDVQATKRFDLLL---DGQFKISG 164 
Ec_LPLA         LGNTCFTFMAGKPEYDKTISTSIVLNALNALG----VSAEASGRNDLVVKTVEGDRKVSG 137 
                 **  : .:: :  *    . .::   *            :: * **.:       *::* 
 
Lmj_LPLA        SAMRVQRDIAYHHCTLLVDTPHASVGRYLRPEGDYVAFKTSSVGSVRS             223 
Li_LPLA         SAMRVQRDIAYHHCTLLVDTTHASVSRYLRPEGDYVAFETSSVGSVRS             223 
Lb_LPLA         SAMRVQREIAYHHCTLLVDTPLASLGRYLHPEGEYVAFKTSSVGSVRS             223 
Tb_LPLA         SAMRVQRDIACHHFTLLVSSSGSRLGKYLKREGDYISFTTAAVGSVRS             220 
Tc_LPLA         SAMRVQRDIACHHCTLLVKSCSERLSAYLQPEGQYVFFTTSSIGSVRS             221 
Hs_LT           TASKIGRTTAYHHCTLLCSTDGTFLSSLLKS--PYQGIRSNATASIPS             210 
Bt_LT           TASKIGRNAAYHHCTLLCGTDGTFLSSLLKS--PYQGIRSNATASTPA             210 
Ec_LPLA         SAYRETKDRGFHHGTLLLNADLSRLANYLNP--DKKKLAAKGITSVRS             183 
                :* :  :  . ** ***  :    :.  *.       : : .  *  : 
 
Figure 3.4 Alignment of LPLA and LT N-terminal domains 
ClustalW alignment of the N-terminal domains of L. major LPLA (LmjLPLA) (accession number 
LmjF07.1060) was carried out with homologues in L. infantum (LiLPLA) (accession 
LinJ07_V3.1230), L. braziliensis (LbLPLA) (accession LbrM07_V2.1130), T. brucei (TbLPLA) 
(accession Tb927.8.630), T. cruzi (TcLPLA) (accession unknown) and E. coli (EcLPLA) (accession 
number AAC77339), and with H. sapiens LT (HsLT) (accession number NP_057013) and B. taurus 
LT (BtLT) (accession number NP_77720) (see Table 3.5 also). Only the N-terminal domains were 
aligned, since trypanosomatid LPLA C-termini are considerably longer than LPLA and LT in other 
organisms. The alignment indicates identical residues (*), conserved residues (:) and homologous 
residues (.). Red residues represent the most highly conserved amino acids within the 
RRx2GGGxV(F/Y)HD motif of a disordered loop, which forms the hydrophobic pocket in which the 
lipoyl-domain of lipoyl-AMP is buried (Kim do et al., 2005). In E. coli LPLA, LA binds to the motif 
177GITSVR182 (green letters), within a second disordered loop (McManus et al., 2005). A lysine 
residue strictly conserved in all LPLA, BPL and LT enzymes is highlighted in blue (Kim do et al., 
2005). Bold letters represent strictly conserved residues, 'x' represents any amino acid, and 'h' 
represents any hydrophobic amino acid. The targeting peptide for mitochondrial transit is predicted 
by programme TargetP as being 12 amino acids (green arrow, LPLAT1). However, in order to 
produce soluble recombinant protein, an N-terminal 36 amino acid truncated version of LPLA was 
constructed (purple arrow, LPLAT2) (see section 3.5.3). 
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Lmj_LPLA        SPVTSLAESGCIADGP---------GAVAALKGNMADFFLAEGDRVLNAATPWELDAVEL 51 
Li_LPLA         SPVTSLAESGCIAGGP---------GAVAALKRNMADFFLAEGDRVLDAATPWELDAVKL 51 
Lb_LPLA         SPVTTLAESVHIASGQ---------GAMASLKRNMAEFFLTEGDRVLEAAAPWELDVREL 51 
Tb_LPLA         SRTTTLKEAGVLTDSASADP-------VNFILRSMAGFFVEHSWDILAHKAPWETNPLNF 53 
Tc_LPLA         SSVTTLQMAGVLPEGYCSDENINGEDVVHCTQRSLADFFVRHVGVITAHSAPWEIDPSIF 60 
                * .*:*  :  :. .            :     .:* **: .   :    :*** :   : 
 
Lmj_LPLA        R-------QRFTTARHRCANAPLFALDVVGAVAADMPFIEREGRQPARGDAATLGEAVHK 104 
Li_LPLA         R-------QSFATSRHRCENAPLFALDVVGAVAADMPFFEGEGRRPTRGDAATLGEAVRK 104 
Lb_LPLA         R-------QSFATARHCCADTPLFSLDVVGAVAADMSFIEGEGRRAASGDLATLGEAVHK 104 
Tb_LPLA         G--DNVDTVESKRTRECRETAAVFTLDTTKAIADGTVMIDGENRRPCAGASKTVREECVR 111 
Tc_LPLA         LSKRNEETKGSEEKTLHPSNESVFLLDVVGALRENTRIVDGEGRRPAAGSSKTVLEEVDR 120 
                                     .:* **.. *:  .  :.: *.*:.  *   *: *   : 
 
Lmj_LPLA        AASKEWAYAMPTFTSTVFLSDSELRRRLKTLSVRQHVALLCSLAEEELLAVLQRCVLEGS 164 
Li_LPLA         TASKDWAYAMPSFTSTVLLSGSELRRRLKTLSMWQDVASLCSLAEEELLAVLQRCVLEGS 164 
Lb_LPLA         AASKDWAYAMPAFTSTVLLSSGELQRRLQALSVWPDVVRLSSLAEEQLLAALQQCVFADL 164 
Tb_LPLA         LQSLGWLFNMPKFETRVAITLADILASEETFSKHAALP---PSLIAWLLQSCTRVDIITL 168 
Tc_LPLA         LRSADWMFSMPKFTTCVAVTAKDLLAWENDTIVRSCVP---PGVVTYLMQGRTRFDITTV 177 
                  *  * : ** * : * ::  ::    :       :    .     *:    :  :    
 
Lmj_LPLA        EGPEAVAG-TEAGLHLVTTVEHRLVTSVVVRRVAPTTATASAVAPSSASSGGWVQRYLSA 223 
Li_LPLA         EGLEEVAAGTEAGLHLITTVEHRLVTSVVVRRAASTTSTASAVAPSSGSSGGWVQRCLSA 224 
Lb_LPLA         VGCGEVVAETEVGLHLLTTVEHRLVTSVTVRRAPSTDAATRAVAPLGGYSGGWVERYLSA 224 
Tb_LPLA         IENRRVTSITAYWIKQGEPAPEQPWFSCLLRYLVEGRYVDNVFADMGG------KCSVLA 222 
Tc_LPLA         VECRHITKLTACWAENAAGDVDEMWCAAILRVLLEGVRVDDPTVDVSE------ENAVLV 231 
                     :.  *    .      ..   :  :*       .    .  .       :  : . 
 
Lmj_LPLA        LLVGHPCDAAIEGLECVGDTTAVVQGLVHEAGSLCPDLPDAVG--DAALLMVARVLLDVW 281 
Li_LPLA         LLVGQPCDAAVEGLERTGDTTAVMQGLVHEAGSLCLDLPDLAG--DAALLMVTRVLLDVW 282 
Lb_LPLA         LLVGHACDAAVEGLESLGDITAVVQGLLHETGSLCPELPDVAR--DAALLMVARVLLNVW 282 
Tb_LPLA         AAIDLECSQIISGLPAIISQLSAGGSRNGEAVGSVISLAEERERSHDVIQRFLQAVLDVW 282 
Tc_LPLA         AALQLECRSLMDGMPLSAREENIACDENGSG-----SLDEQ-----SALLLFMRAVLSVW 281 
                  :   *   :.*:           .   .      .* :       .:  . :.:*.** 
 
Lmj_LPLA        RDKNVFDIAT--                                                 291 
Li_LPLA         RDKNVFDIAT--                                                 292 
Lb_LPLA         RDKNVFDLSR--                                                 292 
Tb_LPLA         RRKNVFYPISY-                                                 293 
Tc_LPLA         RVKNVFIPVISQ                                                 293 
                * ****                    
 
Figure 3.5 Alignment of trypanosomatid LPLA C-terminal domains 
ClustalW alignment of the N-terminal domains of L. major LPLA (LmjLPLA) with homologues in L. 
infantum (LiLPLA) (accession LinJ07_V3.1230), L. braziliensis (LbLPLA) (accession 
LbrM07_V2.1130), T. brucei (TbLPLA) (accession Tb927.8.630) and T. cruzi (TcLPLA) (accession 
unknown) was carried out. Only the C-termini of trypanosomatid LPLA proteins were aligned as 
they are circa 120-140 residues longer than the C-termini of EcLPLA and BtLT. The alignment 
indicates identical residues (*), conserved residues (:) and homologous residues (.). 
3.5 Expression and functionality of lipoylating proteins 
In order to determine whether the lipoylating proteins identified in silico were 
functional, and in order to produce polyclonal antibodies against these proteins, it 
was necessary to clone the genes for LIPA, LIPB and LPLA into a protein 
expression plasmid – pASK-IBA3 – adding a Strep-tag to the 3' end.  
Expression of eukaryotic proteins in E. coli lines can be difficult, especially if the 
genes in question have hydrophobic targeting sequences. All three L. major 
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lipoylating proteins were predicted to be mitochondrial by MitoProt and TargetP 
(see Table 3.5), and the programs predicted the number of amino acids 
comprising the potential targeting peptide. Based on these predictions, constructs 
were made corresponding to full-length genes or truncated versions (see arrows in 
Figure 3.2, Figure 3.3 and Figure 3.4). All proteins were successfully expressed, 
purified and polyclonal antibodies generated (see Section 3.5.4). 
3.5.1 LIPA  
3.5.1.1 Cloning and expression of LIPA 
DNA of full-length (FL) LIPA and three 5' truncated versions (T1, T2 and T3) (see 
Figure 3.3) were cloned into the pASK-IBA3 plasmid, resulting in constructs 
LIPAFLIBA3, LIPAT1IBA3, LIPAT2IBA3 and LIPAT3IBA3, as described in Section 
2.5.6.1 (see Figure 3.6A for LIPAT3IBA3 cloning). Constructs encoding LIPAT1 and 
LIPAT2 result in LIPA proteins that are truncated at the N-terminus by 5 amino 
acids and 15 amino acids (see Figure 3.3); the respective constructs were 
designed as such based upon the mitochondrial targeting peptide cleavage sites 
predicted by TargetP and MitoProt, respectively. The LIPAT3 construct was 
designed such that the LIPAT3 protein would be truncated by 63 amino acids at the 
N-terminus (see Figure 3.3). The rationale was that LIPAT3 would lack all of the 
associated hydrophobic targeting sequence and as such possibly be expressed to 
a higher degree in the soluble fraction. Relative to the predicted start of the 
EcLIPA protein, LIPAT3 lacks 14 amino acids (see Figure 3.3). However, the aim 
was to purify soluble protein and not to characterise the LmjLIPA enzyme, and as 
such this truncation was deemed acceptable. 
Trial expressions identified that the optimal conditions for protein expression were 
using the LIPAT3IBA3 construct in BLR (DE3) E. coli, shaking at 37 °C 250 rpm for 
one hour, post induction. LIPAFLIBA3, LIPAT1IBA3 and LIPAT2IBA3 constructs 
expressed in the same E. coli line did not result in the production of sufficient 
quantities of soluble protein for protein purification at any of the conditions tested 
(see Section 2.5.6.2) (data not included). 
Purification of LIPAT3-Strep protein via affinity chromatography on a Strep-tactin 
column was subsequently carried out. SDS-PAGE analysis resulted in the 
identification of a band potentially corresponding to LIPAT3-Strep (40.6 kDa) in 
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elution fractions two, three and four (see Figure 3.6B). In addition, contaminating 
bands were observed at approximately 60 kDa and 65 kDa, which were 
consistently co-purified with LIPAT3-Strep. Western blotting with α-Strep antibody 
confirmed the circa 40 kDa band to be LIPAT3-Strep, and some cross-reactivity is 
observed in elution fraction 3 (see Figure 3.6C). 
 
Figure 3.6 Cloning, expression and purification of LIPA 
A, LIPAT3 (see Figure 3.3) was amplified from gDNA with primer pair Lm28-29 (see Section 2.1.4). 
The insert was cloned into expression vector pASK-IBA3, generating construct LIPAT3IBA3 (I). 
Correct cloning was verified by XbaI / HindIII digest, releasing a 1.1 kb insert corresponding to 
LIPAT3, and vector backbone of 3.1 kb (II). B, LIPAT3IBA3 was expressed in E. coli BLR (DE3) cells, 
and LIPAT3-Strep protein purified via affinity chromatography on a Strep-tactin column. 10 µl of 
fractions collected during purification were subjected to 10 % SDS-PAGE and stained with 
Coomassie-blue. C, Western blotting with α-Strep antibody at 1/7,500 on elution fractions 2 – 4 
verifies the 40.6 kDa band as purified LIPAT3-Strep. 
3.5.1.2 Functionality of LIPA 
An E. coli line lacking the endogenous lipA gene (KER176) was transformed with 
LIPAT1IBA3, LIPAT2IBA3 or LIPAT3IBA3 constructs, or uncut plasmid pASK-IBA3 
(negative control). All were plated on minimal medium without- or with 
supplementation of 10 µM LA. In the presence of LA, growth was apparent in all 
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cases. Without LA, growth was only supported by the LIPAT1IBA3 construct (see 
Figure 3.7). 
 
Figure 3.7 Functionality of LIPA 
Functionality of L. major LIPA was assessed by complementation of lipA deficient bacteria, 
KER176 (Reed & Cronan, 1993). Bacteria were transformed with LIPAT1IBA3 (1), LIPAT2IBA3 (2), 
LIPAT3IBA3 (3) (see Figure 3.3) or pASK-IBA3 uncut plasmid negative control (4), and plated on 
minimal medium without- or with supplementation of 10 µM LA. Plates were incubated at 37 °C for 
48 – 72 h and growth recorded by photographing plates. 
3.5.2 LIPB 
3.5.2.1 Cloning and expression of LIPB 
DNA of full-length (FL) LIPB and one 5' truncated version (T1) (see Figure 3.2) 
were cloned into pASK-IBA3 plasmid, resulting in constructs LIPBFLIBA3 and 
LIPBT1IBA3, as described in Section 2.5.6.1 (see Figure 3.8A for LIPBFLIBA3 
cloning). The construct encoding LIPBT1-Strep results in LIPB protein that is 
truncated at the N-terminus by 34 amino acids (see Figure 3.2); the construct was 
designed as such based upon the mitochondrial targeting peptide cleavage site 
predicted by MitoProt. TargetP did not predict a cleavage site which explains why 
only one truncated construct was designed. 
Trial expressions identified the optimal conditions for protein expression with the 
LIPBFLIBA3 construct in BLR (DE3) E. coli cells, shaking at 37 °C 250 rpm for two 
hours, post induction. Expression of LIPBT1IBA3 was not tested, since it was 
possible to express a relatively high level of soluble LIPBFL-Strep protein.  
Subsequently, LIPBFL-Strep protein was purified via affinity chromatography on a 
Strep-tactin column. SDS-PAGE analysis resulted in the identification of a band 
potentially corresponding to LIPBFL-Strep (30.7 kDa) in elution fractions three, four 
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and five (see Figure 3.8B). In addition, a contaminating band was observed at 
approximately 60 kDa, which was consistently co-purified with LIPBFL-Strep. The 
contaminant was excised from a Coomassie-Blue-stained SDS-PAGE and shown 
by tandem MS / MS analysis to be the E. coli GroEL large subunit (accession 
number AAC77103) (Dr R. Burchmore, University of Glasgow). Western blotting 
with α-Strep antibody confirmed the 30 kDa band to be LIPBFL-Strep (see Figure 
3.8C). An additional cross-reacting band is apparent at circa 48 kDa, although the 
nature of the band is unknown. 
 
Figure 3.8 Cloning, expression and purification of LIPB 
A, LIPBFL (see Figure 3.2) was amplified from gDNA with primer pair Lm30-33 (see Section 2.1.4). 
The insert was cloned into expression vector pASK-IBA3, generating construct LIPBFLIBA3 (I). 
Correct cloning was verified by XbaI/HindIII digest, releasing a 0.9 kb insert corresponding to 
LIPBFL, and vector backbone of 3.1 kb (II). B, LIPBFLIBA3 was expressed in E. coli BLR (DE3) cells, 
and LIPBFL-Strep protein purified via affinity chromatography on a Strep-tactin column. 10 µl of 
fractions collected during purification were subjected to 10 % SDS-PAGE and stained with 
Coomassie-blue. C, Western blotting with α-Strep antibody at 1/7,500 on elution fractions 3 – 5 
verifies the 31 kDa band as purified LIPBFL-Strep. 
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3.5.3 LPLA 
3.5.3.1 Cloning and expression of LPLA 
DNA of full-length (FL) LPLA and two 5' truncated versions (T1 and T2) (see 
Figure 3.4) were cloned into pASK-IBA3 plasmid, resulting in constructs 
LPLAFLIBA3, LPLAT1IBA3 and LPLAT2IBA3, as described in Section 2.5.6.1 (see 
Figure 3.9A for LPLAT2IBA3 cloning). Constructs encoding LPLAT1Strep and 
LPLAT2Strep result in LPLA proteins that are truncated at the N-terminus by 12 
amino acids and 36 amino acids (see Figure 3.4); the respective constructs were 
designed as such based upon the mitochondrial targeting peptide cleavage site 
predicted by TargetP and to align with the start of EcLPLA, respectively.  
Trial expressions identified the optimal conditions for protein expression with the 
LPLAT2IBA3 construct in BLR (DE3) E. coli cells, shaking at 15 °C 250 rpm 
overnight, post induction. Under all conditions tested (see Section 2.5.6.2), 
LPLAFLIBA3 and LPLAT1IBA3 constructs did not produce soluble protein to the 
same degree as did the LPLAT2IBA3 construct (data not shown). 
Purification of LPLAT2-Strep protein via affinity chromatography on a Strep-tactin 
column was subsequently carried out. SDS-PAGE analysis resulted in the 
identification of a band potentially corresponding to LPLAT2-Strep (52.4 kDa) in 
elution fractions three and four (see Figure 3.9B). In addition, contaminating bands 
were observed at approximately 60 and 65 kDa, which were consistently co-
purified with LPLAT2-Strep. Western blotting with α-Strep antibody confirmed the 
circa 52 kDa band to be LPLAT2-Strep (see Figure 3.9C). 
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Figure 3.9 Cloning, expression and purification of LPLA 
A, LPLAT2 (see Figure 3.4) was amplified from gDNA with primer pair Lm36-37 (see Section2.1.4). 
The insert was cloned into expression vector pASK-IBA3, generating construct LPLAT2IBA3 (I). 
Correct cloning was verified by XbaI/HindIII digest, releasing a 1.5 kb insert corresponding to 
LPLAT2, and vector backbone of 3.1 kb (II). B, LPLAT2IBA3 was expressed in E. coli BLR (DE3) 
cells, and LPLAT2-Strep protein purified via affinity chromatography on a Strep-tactin column. 10 µl 
of fractions collected during purification were subjected to 10 % SDS-PAGE and stained with 
Coomassie-blue. C, Western blotting with α-Strep antibody at 1/7,500 on elution fractions 3 – 4 
verifies the 52 kDa band as purified LPLAT2-Strep. 
3.5.3.2 Functionality of LIPB and LPLA 
In order to test the functionality of L. major LIPB and LPLA enzymes, the E. coli 
line KER184 which lacks the endogenous lipB gene, was transformed with 
LIPBFLIBA3, LPLAT1IBA3, LPLAT2IBA3 or P. falciparum LPLA1FLIBA3 (positive 
control) constructs, or uncut plasmid pASK-IBA3 (negative control) (see Figure 
3.10). All were plated on minimal medium without- or with supplementation of 10 
µM LA. 
Growth was supported in all cases except with LPLAT2IBA3. Growth of 
LPLAT1IBA3 was considerably lower than that of P. falciparum LPLA1FLIBA3 
positive control. LIPBFLIBA3 complemented growth of KER184 in the absence of 
LA to a higher extent than did LPLAT1IBA3. As explained in Section 3.5.3.1, under 
all conditions tested, expression of the LPLAT2IBA3 construct produced more 
soluble protein than did LPLAFLIBA3 or LPLAT1IBA3. Although expression was not 
analysed in KER184 cells, a possible explanation for the unexpected results with 
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regards to complementation of KER184 is that LPLAT2-Strep protein is non-
functional and overexpression is toxic to E. coli. In contrast, LPLAT1-Strep is likely 
to be at least partially functional because it supports colony growth of KER184 E. 
coli in LA-depleted medium (see Figure 3.10). Potential reasons why LPLAT1-Strep 
may be functional yet LPLAT2-Strep is toxic to KER184 cell growth will be 
discussed in Section 6.3.3.1. 
 
Figure 3.10 Functionality of LIPB and LPLA 
Functionalities of L. major LIPB and LPLA were assessed by complementation of LIPB deficient 
bacteria, KER184 (Morris et al., 1995). Bacteria were transformed with LIPBFLIBA3 (1) (see Figure 
3.2), LPLAT1IBA3 (2), LPLAT2IBA3 (3) (see Figure 3.4), P. falciparum LPLA1FLIBA3 positive control 
(4) or pASK-IBA3 uncut plasmid negative control (5), and plated on minimal medium without- or 
with supplementation of 10 µM LA. Plates were incubated at 37 °C for 48 – 72 h and growth 
recorded by photographing plates. 
3.5.4 Polyclonal antibody generation and purification 
Two rabbits were inoculated with SDS-PAGE-purified LIPAT3-Strep, LIPBFL-Strep 
or LPLAT2-Strep antigen (see Sections 2.5.6 and 2.5.7). Western blotting with the 
antisera resulted in extensive background signal, however it was possible to 
discern which antisera recognised the appropriate antigen. In all cases, the 
antisera also detected co-purified contaminants from the recombinant protein 
elution fractions. It was possible to purify specific antibodies raised against LIPAT3-
Strep and LIPBFL-Strep antigens from the antisera. Unfortunately, the yield of α-
LmjLPLA antibodies was poor. Albeit multiple attempts to purify α-LmjLPLA 
antibodies from the two antisera, it was not possible to reliably use the antibodies 
for western blot analysis of recombinant protein or L. major protein lysate. 
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3.5.4.1 Purification of α-LmjLIPA antibodies  
α-LmjLIPA antibodies were purified from the antiserum via a two-step procedure. 
Firstly, α-LmjLIPA antibodies were separated from antibodies recognising 
contaminating proteins in the purified LIPAT3-Strep elution fractions, by incubating 
5 ml of α-LmjLIPA antiserum on agarose beads cross-linked to LPLAT2-Strep 
recombinant protein. Given that the contaminants in LPLAT2-Strep purification 
were the same size (and thus probably the same proteins) as those in LIPAT3-
Strep purification, the rationale was that contaminating antibodies in α-LIPA 
antiserum would bind to the column, whereas α-LmjLIPA-specific antibodies would 
be collected in the flow-through. 
Subsequently, α-LmjLIPA antibodies were purified using a LIPAT3-Strep 
recombinant protein column. Proteins in the antiserum that resulted in high 
background in western blots would be lost in the flow-through fraction, and then α-
LmjLIPA-specific antibodies could be eluted from the column (see Figure 3.11). 
 
Figure 3.11 Purification of α-LmjLIPA antibodies from α-LmjLIPA antiserum 
In order to purify α-LmjLIPA antibodies from α-LmjLIPA antiserum, two affinity chromatography 
steps were carried out. Purified recombinant LIPAT3-Strep was subjected to SDS-PAGE and then 
stained with Coomassie Blue. The overall yield of the elution fraction shown is 0.2 µg µl-1, and 10 µl 
was loaded on the gel. LIPAT3-Strep band is barely visible, and as such it was not possible to 
determine the quantity loaded. The same quantity of material was used for western blot analyses. 
Western blotting with α-LmjLIPA antiserum before purification was carried out at 1/20,000 (lane 1). 
After two rounds of purification, western blotting was carried using α-LmjLIPA antibody at 1/500 
(lane 2). 
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3.5.4.2 Purification of α-LmjLIPB antibodies 
Two rabbits were inoculated with the SDS-PAGE-purified antigen (see Sections 
2.5.6 and 2.5.7). One of the two antisera was found to recognise LIPBFL-Strep 
recombinant protein by western blotting, although the background signal was high. 
α-LmjLIPB antibodies were purified from the antiserum using a LIPBFL-Strep 
recombinant protein column. Compounds in the antiserum that resulted in high 
background in western blot were lost in the flow-through fraction, and then α-
LmjLIPB-specific antibodies were eluted from the column (see Figure 3.12).  
 
Figure 3.12 Purification of α-LmLIPB antibodies from α-LmLIPB antiserum 
In order to purify α-LmjLIPB antibodies from α-LmjLIPB antiserum, one affinity chromatography 
step was carried out. Purified recombinant LIPBFL-Strep was subjected to SDS-PAGE and then 
stained with Coomassie Blue. The overall yield of the elution fraction shown is 0.2 µg µl-1, and 10 µl 
was loaded on the gel, and since LIPBFL-Strep corresponds to approximately 1/3 of the total 
protein, 666 ng of LIPBFL-Strep protein is present in 10 µl of the elution fraction. The same quantity 
of material was used for western blot analyses. Western blotting with α-LmjLIPB antiserum before 
purification was carried out at 1/50,000 (lane 1). After one round of purification, western blotting 
was carried using α-LmjLIPB antibody at 1/1,000 (lane 2). 
3.6 Effects of LA analogues on promastigotes 
Having established that L. major possesses active lipoylating enzymes, and that α-
KADH and GCC components are lipoylated throughout promastigote development, 
I next determined the effect of LA analogues on promastigote cell growth and 
lipoylation patterns. The analogues octanoic acid (OA) and 8'-bromooctanoic acid 
(8-BOA) were used, since data has already been published in other parasites – T. 
gondii and P. falciparum – with regards to their effects on growth and lipoylation 
patterns (Allary et al., 2007; Crawford et al., 2006). In these experiments, parasites 
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were grown in lipid-depleted medium in order to minimise competition of 
exogenous LA with LA analogues. 
The hypothesis was that a lower concentration of 8-BOA than OA would be 
required to detrimentally affect parasite growth, and that addition of just 1 µM LA 
would rescue the phenotype, as is the case in T. gondii and P. falciparum (Allary 
et al., 2007; Crawford et al., 2006). The rationale behind this result is that 
octanoylation of apoproteins is a natural cellular process ordinarily catalysed by 
LIPB, and the octanoyl-moiety can be converted to an active lipoyl-group by the 
action of LIPA. However, 8-BOA is an analogue of LA which when ligated to 
apoproteins, renders them inactive. The toxicity of a similar LA analogue, 
selenolipoic acid (SeLA), has been demonstrated in E. coli (Fujiwara et al., 1997b; 
Jordan & Cronan, 2002; Morris et al., 1994; Reed et al., 1994). 
In order to remain consistent with previously published data, L. major 
promastigotes were grown in lipid-depleted medium for two sub-passages 
(equating to 1/100 dilution of lipids from the original HOMEM + 10 % FCS medium) 
before adding LA analogues alone or with 1 µM LA supplementation. Alamar blue 
assays were carried out in order to determine the effects of LA analogues on L. 
major promastigote growth. 
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Figure 3.13 Growth and lipoylation patterns of promastigotes incubated with different 
concentrations of LA analogues 
Alamar blue assay was used in order to determine the effect of LA analogues, OA (A) and 8-BOA 
(B and C), on promastigote cell growth. Fluorescence at OD590nm was recorded and all values 
normalised against negative EtOH (solvent) controls to give percentage growth relative to the 
control. D, In order to determine the effect of LA analogues on lipoylation patterns, promastigotes 
were grown in lipid-depleted medium, and supplemented with either 10 µM LA or 10 µM 8-BOA. 
Stationary phase promastigotes (120 h) were lysed and the soluble protein fraction isolated. 10 µg 
of each lysate was subjected to SDS-PAGE. Western blotting was carried out using α-LA antibody 
at 1/6,000 and α-CS antibody to assess loading, at 1/5,000. Lane 1 represents a typical lipoylation 
pattern at 120 h growth in normal HOMEM + 10 % FCS medium (see Figure 3.1B lane 4, for 
derivation of lane 1 in the current figure). 
Figure 3.13A demonstrates that OA concentrations up to 150 µM do not affect 
promastigote growth. 300 µM OA reduces growth to 16 % relative to the negative 
control. In T. gondii, the IC50 for OA is approximately 500 µM, yet 1 µM LA 
completely restored growth to wild-type levels (Crawford et al., 2006). In L. major, 
1 µM LA does not alleviate the effects of 300 µM OA (Figure 3.13A). Addition of 
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LA or 8-BOA to the growth medium did not cause an alteration in lipoylation 
intensity/patterns (Figure 3.13D), and as such it is difficult to discern whether these 
compounds are not efficiently taken up, or whether parasites rely on biosynthesis 
of LA and as such do not incorporate LA or 8-BOA into α-KADHs or the GCC. 
Figure 3.13B & C illustrate that the IC50 for 8-BOA is 90.5 µM (± 9.2 µM) and the 
IC50 for 8-BOA with 1 µM LA supplementation is 92.3 µM (± 10.8 µM). These 
values are relatively high, compared to those published for T. gondii, whereby 10 
µM 8-BOA inhibits cell growth by 95 %, and 1 µM LA is sufficient to completely 
rescue the growth defect (Crawford et al., 2006). In P. falciparum red blood cell 
stage, 8-BOA at 25 µM – 400 µM results in growth defects, and addition of 2 µM 
LA significantly rescued the phenotype (Allary et al., 2007). Possible explanations 
for the discrepancy between the results observed in T. gondii and P. falciparum 
versus L. major will be discussed in Section 6.3.3.2. 
3.7 Summary 
• In silico searches show that L. major possesses all potential components of α-
KADHs and the GCC, although some potentially interesting differences are 
apparent. 
• Lipoylation of α-KADH E2-subunits and H-protein occurs during promastigote 
growth, and lipoylation patterns are consistent throughout: E2k is predominantly 
lipoylated, and during stationary phase E2p, E2b and H-protein become 
lipoylated. Purified metacyclic promastigotes only lipoylate E2k. Amastigotes 
may possess lipoylated E2p, E2k, H-protein and not E2b. 
• L. major has genes corresponding to LIPA and LIPB from the LA biosynthesis 
pathway, and both contain motifs that are pivotal to activity of these enzymes. 
• L. major has a gene for LPLA from the salvage pathway. The LmjLPLA protein 
possesses all of the key motifs within the N-terminus that are required for 
transferase activity; however these motifs are also conserved in the mammalian 
LT enzyme. LmjLPLA has a circa 140 amino acid C-terminal extension relative 
to the C-terminal domains of EcLPLA and mammalian LT enzymes, the nature 
of which is unclear.   
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• L. major LIPA, LIPB and LPLA were cloned into expression construct pASK-
IBA3, and the proteins were expressed and purified. 
• Antibodies were generated for all three proteins, and α-LmjLIPA and α-LmjLIPB 
antibodies were successfully purified for use in western blot analyses. 
• The functionality of lipoylating genes from L. major was tested by functional 
complementation of E. coli lacking lipA (KER176) or lipB (KER184) genes. 
LmjLIPA, LmjLIPB and LmjLPLA rescued bacterial growth. LmjLPLA did not 
complement KER184 bacteria as efficiently as did the PfLPLA1 positive control, 
perhaps indicating that LmjLPLA does not utilise octanoyl-ACP as efficiently as 
does PfLPLA1, and it could also be due to the extended C-terminal extension 
not found in E. coli. 
• In lipid-depleted medium, analogues of LA – OA and 8-BOA – affected L. major 
promastigote cell growth at higher concentrations than those published for T. 
gondii and P. falciparum, and supplementation with 1 µM LA did not rescue the 
growth phenotype. Addition of 10 µM LA or 8-BOA did not cause an alteration in 
lipoylation patterns. 
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4 Genetic manipulation of LPLA 
4.1 Introduction 
L. major encodes a putative LPLA enzyme, which was shown to be functional by 
complementation of E. coli deficient in lipB, as described in Section 3.4.3. In the 
study reported in this chapter, the aims were to determine the subcellular 
localisation of LPLA and the role that LPLA plays in L. major. The former question 
was addressed by expressing a LPLA-green fluorescent protein (GFP) fusion 
protein in promastigotes, and establishing the subcellular localisation of LPLA-
GFP by live cell fluorescence microscopy. In order to elucidate the function of 
LPLA in promastigotes, attempts were made to ablate both gene copies by 
homologous recombination. Additionally, wild-type LPLA and an active site mutant 
of LPLA were ectopically expressed in promastigotes, with the aim of perturbing 
the normal balance of lipoylation, to investigate whether this results in a decrease 
in parasite fitness. 
4.2 Localisation of LPLA 
To generate a L. major line expressing a C-terminal fusion protein of LPLA with 
GFP, the full-length LPLA gene was amplified by PCR using primer pair Lm23-24 
(see Section 2.1.4). The resulting 1.5 kb fragment was digested with NdeI/BglII 
before cloning into NdeI/BglII-digested pGL1132 vector (Tetaud et al., 2002) to 
yield construct LPLA-GFP (see Figure 4.1A). The destination vector pGL1132 
contains the required control elements that allow constitutive expression of the 
proteins in L. major as well as the neomycin phosphotransferase (NEO) selectable 
marker (see Section 2.2.6) (Cruz & Beverley, 1990; Tetaud et al., 2002). The 
LPLA-GFP construct was transfected into wild-type promastigotes (WT) to give 
rise to the WT[LPLA-GFP] line, which was grown in the presence of 50 µg ml-1 
G418 to select for parasites that possess ectopic copies of the LPLA-GFP plasmid 
(see Section 2.2.8). 
In order to verify that the LPLA-GFP fusion protein is expressed in the WT[LPLA-
GFP] line, western blotting with α-GFP monoclonal antibody was carried out. 
Figure 4.1B shows that a 79.5 kDa band is found in the WT[LPLA-GFP] line but 
not in wild-type, which corresponds to the LPLA-GFP fusion protein. The size of 
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LPLA after processing of its target peptide can be calculated by subtraction of the 
known size of GFP (27.1 kDa) from that observed for the LPLA-GFP band (79.5 
kDa), which equals 52.4 kDa. This is an intermediate between the LPLAT1 (53.7 
kDa) and LPLAT2 (50.3 kDa) constructs created for expression in E. coli (see 
Sections 3.4.3 and 3.5.3). The calculated size of the T. brucei elongation factor 1-
α (TbEF1-α) loading control was 52.4 kDa, which is in accordance with previously 
published data that reported TbEF1-α to be 53 kDa (Kaur & Ruben, 1994). 
Fluorescence microscopy to detect the LPLA-GFP reporter, in combination with 
Mitotracker CMXRos mitochondrial stain, revealed that LPLA-GFP is a 
mitochondrial protein (see Figure 4.1C). This result is in accordance with 
subcellular targeting predictions using MitoProt and TargetP (see Section 3.4.3).  
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Figure 4.1 Subcellular localisation of LPLA-GFP 
A, The LPLA gene (see Section 3.4.3) was amplified from gDNA with primer pair Lm23-24 (see 
Section 2.1.4). The insert was cloned into expression vector pGL1132, generating construct LPLA-
GFP (I). Correct cloning was verified by NdeI/BglII digest, releasing a 1.54 kb insert corresponding 
to LPLA, and vector backbone of 6.96 kb (II). B, The LPLA-GFP construct was expressed in 
promastigotes to give rise to the WT[LPLA-GFP] line, and expression verified by western blotting of 
10 µg wild-type protein lysate and 10 µg LPLA-GFP protein lysate with α-GFP antibody at 1/5,000. 
Equal loading was verified by probing with α-TbEF1-α antibody at 1/10,000.The calculated sizes of 
LPLA-GFP and TbEF1-α are 79.5 kDa and 52.4 kDa, respectively (see Section 2.5.5) for method 
of calculating molecular sizes from SDS-PAGE). C, The mitochondrion of WT[LPLA-GFP] 
promastigotes was stained with Mitotracker CMXRos, and images of live cells were attained by 
fluorescence microscopy with DIC (for phase), FITC (for LPLA-GFP), rhodamine (for Mitotracker) 
or DAPI filters. 
4.3 Knockout studies  
In order to study the in vivo role of LPLA, a gene replacement strategy was 
employed. Knockout cassettes LPLA-SAT and LPLA-HYG were generated and 
transfected into promastigotes, as described in Sections 2.2.4–2.2.9.  
Chapter 4  118 
 
Figure 4.2 is representative of the results obtained from LPLA knockout attempts, 
a summary of which is provided in Table 4.1. Two independent heterozygous lines 
for LPLA – ∆lplAHYG/LPLA and ∆lplASAT/LPLA – were created by replacement of 
one LPLA allele with either LPLA-HYG or LPLA-SAT constructs, respectively. 
Based on growth data generated in duplicate, ∆lplAHYG/LPLA and ∆lplASAT/LPLA 
lines reached significantly lower cell densities at stationary phase than did the 
wild-type control (see Figure 4.3). 
Subsequently, attempts were made to replace the remaining LPLA allele in 
∆lplAHYG/LPLA and ∆lplASAT/LPLA lines. ∆lplAHYG/LPLA was transfected with the 
LPLA-SAT knockout cassette on three independent occasions (see Table 4.1); a 
total of nine clones proliferated during the first cloning step in 96-well plates. 
However, upon sub-passaging into fresh medium, all nine clones failed to grow, 
and no genotypic data were retrieved. 
On the other hand, three independent transfections of ∆lplASAT/LPLA with the 
LPLA-HYG knockout cassette resulted in viable clones. Correct integration of the 
second knockout cassette was achieved for 30/63 clones analysed (see Table 
4.1). However, as indicated by Southern blot analysis of one such clone, 
∆lplASAT/lplAHYG/LPLA, the endogenous gene is still present (see Figure 4.2, lane 
4). In fact, as shown by FACS analysis (Figure 4.4) the ∆lplASAT/lplAHYG/LPLA line 
is tetraploid, meaning that non-dividing cells possess four copies of each 
chromosome, instead of the normal two copies in diploid cells. This indicates that 
the double integrant ∆lplASAT/lplAHYG/LPLA still possesses two copies of the 
endogenous LPLA allele, despite having correct integration of LPLA-SAT and 
LPLA-HYG knockout cassettes. This is the case for all clones isolated, as 
determined by PCR (data not shown). It can be determined that for 
∆lplASAT/lplAHYG/LPLA, genome duplication must have occurred during the 
selection process for LPLA-HYG integration, since the parent line, ∆lplASAT/LPLA, 
is diploid (see Figure 4.4). In addition, LPLA ∆lplASAT/lplAHYG/LPLA seems to have 
growth defects compared to wild-type, including slower logarithmic development, 
and premature entry into stationary phase (see Figure 4.3). 
In order to provide more convincing evidence that LPLA is an essential/very 
important gene, a complementation construct, LPLA-pRB, was generated and 
transfected into ∆lplASAT/LPLA and ∆lplAHYG/LPLA lines to give rise to 
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∆lplASAT/LPLA::PrRNALPLA and ∆lplAHYG/LPLA::PrRNALPLA lines, respectively (see 
Sections 2.2.4–2.2.9). Clones were tested for LPLA-pRB integration by Southern 
blot analysis. The pRB construct is designed to integrate into any of the six 18S 
SSU rRNA gene copies present on chromosome 27 (Misslitz et al., 2000). 
Therefore, depending upon the site of LPLA-pRB integration, a Southern blot 
probed with a LPLA gene probe on NruI-digested gDNA would result in a band 
size of 8.4 kb, 6.3 kb, 6.4 kb, 9.0 kb, 7.4 kb or 5.5 kb (see Figure 4.2B). Figure 
4.2C shows a 6.3 kb/6.4 kb band for ∆lplAHYG/LPLA::PrRNALPLA. However, the 
band size for ∆lplASAT/LPLA::PrRNALPLA is larger than 9 kb. In this case, LPLA-
pRB could have integrated non-specifically into the L. major genome. Alternatively, 
LPLA-pRB could have integrated correctly, and subsequently duplicated within the 
18S SSU rRNA locus, resulting in a band size double that of 5.5 kb or 6.3 kb/6.4 
kb. However, the nature of the > 9 kb band was not investigated further. 
Finally, ∆lplASAT/LPLA::PrRNALPLA and ∆lplAHYG/LPLA::PrRNALPLA lines were 
transfected with LPLA-HYG or LPLA-SAT knockout cassettes, respectively, in 
order to create null mutants of the endogenous LPLA allele (∆lplA::PrRNALPLA). 
Analysis of a total of 43 clones from both transfections (see Table 4.1) revealed 
only one endogenous gene knockout, whereas the remaining clones retained the 
LPLA gene. Figure 4.2C shows one clone with gene ablation, 
∆lplASAT/lplAHYG::PrRNALPLA. Another clone has correct second-round integration 
but still retains at least one endogenous gene copy 
(∆lplAHYG/lplASAT/LPLA::PrRNALPLA). These results indicate that replacement of the 
LPLA allele is possible when LPLA is ectopically expressed. 
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Figure 4.2 Knockout attempts of LPLA gene, and complementation to permit gene ablation 
A, Schematic representation of the endogenous LPLA locus (I), and the locus after LPLA-SAT (II) 
or LPLA-HYG (III) integration. B, Complementation of a knockout necessitated replacement of one 
of the six 18S SSU rRNA gene copies (I) with the LPLA gene, under puromycin selection (II). Sizes 
in kb represent the expected band sizes to be observed by Southern blot (C). *Depending upon 
which of the six 18S SSU rRNA gene copies is replaced by the LPLA re-expressor, NruI-digested 
gDNA and Southern blot with LPLA gene probe may yield either 8.4 kb, 6.3 kb, 6.4 kb, 9 kb, 7.4 kb 
or 5.5 kb bands. C, Southern blot of 2 µg gDNA digested with NruI and probed with HYG-, SAT- 
and LPLA gene probes, with expected bands shown in A and B. 'LPLA-re-expressor' represents 
LPLA-pRB integration into the 18S SSU rRNA locus. 
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Figure 4.3 Growth of LPLA knockout mutants  
Growth analysis of different LPLA knockout mutants was carried out by diluting all cultures to 5 x 
105 parasites ml-1, and recording parasite density circa every 24 h. All lines were cultured in 
duplicate. A, Average and standard deviation values were calculated for each line at individual time 
points. Values were normalised to wild-type values and plotted as a bar chart. One-way ANOVA 
with Tukey post-tests were performed at each time point. Values that are significantly different from 
wild-type values (p-value < 0.05) are depicted with the '*' symbol. B, Growth of parasite lines 
represented by a line graph with logarithmic Y-axis. 
 
Figure 4.4 Ploidy of LPLA knockout mutants 
FACS was used in order to determine the ploidy of different LPLA knockout mutants. Cells were 
fixed in 70 % methanol and incubated with propidium iodide. Incorporation of propidium iodide into 
DNA was detected with a Becton Dickinson FACS Calibur using FL2-A (detecting fluorescence 
emissions between 585 – 642 nm). Data were interpreted using the CellQuestPro software. 
Histograms show cell count relative to FL2 fluorescence (arbitrary units). Peaks at 200-, 400- and 
800 FL2 arbitrary units represent diploid, tetraploid and octaploid DNA contents, respectively. 
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Total numbers analysed
Transfections Clones Transfections Integration Gene knockout
∆lplA HYG/LPLA  + LPLA- SAT 9* 3 N/A N/A
∆lplA SAT/LPLA  + LPLA- HYG 63 3 30/63 0/63
∆lplA HYG/LPLA ::P rRNA LPLA  + LPLA- SAT 23 2 2/2 0/23
∆lplA SAT/LPLA ::P rRNA LPLA  + LPLA- HYG 20 2 3/3 1/20
 
Table 4.1 Summary table of LPLA knockout attempts 
The information provided illustrates the total number of second round knockout attempts on LPLA 
heterozygotes, and those carried out using heterozygotes re-expressing LPLA within the 18S SSU 
rRNA locus. All values were obtained through PCR-based knockout screens. *Only nine clones 
were attained from three transfections of ∆lplAHYG/LPLA + LPLA-SAT, and all were non-viable after 
sub-passaging into larger volumes of HOMEM + 10 % FCS. As such, gDNA was not attained from 
these lines, and therefore, integration or gene knockout determination is not applicable (N/A). 
4.4 Overexpression of LPLA-His 
Given that it was not possible to study the function of LPLA by gene knockout, an 
alternative approach was taken; LPLA-His expression/overexpression in 
promastigotes. Wild-type LPLA (LPLA) and LPLA containing a single point 
mutation resulting in a H118A amino acid mutation (LPLAH118A), were sub-cloned 
into the pGL1137 plasmid from the pGL1132 plasmid (see Section 4.2). When 
expressed in L. major, the constructs result in the translation of LPLA proteins with 
C-terminal 6x His-tags (see Section 2.2.6). The reason for expressing LPLA-His 
proteins instead of untagged versions was in order to be able to detect ectopic 
protein expression, since (as explained in Section 3.5.4) antibodies that detect 
LmjLPLA were not available. 
As discussed in Section 3.4.3, LPLA is a member of a larger family encompassing 
LPLA, LT and BPL proteins, all of which share a structurally- and catalytically 
similar N-terminal domain (Fujiwara et al., 2005; Fujiwara et al., 2007; Kim do et 
al., 2005; McManus et al., 2005; Wilson et al., 1992). The rationale for introducing 
the mutation LPLAH118A was based on the fact that in all LPLA and LT proteins 
His118 (LmjLPLA numbering) is one of the key residues involved in forming the 
hydrophobic crevice to which the lipoyl-AMP intermediate binds, and is found 
within the strictly conserved 108RRx2GGGxV(F/Y)HD119 motif (see Figure 3.4) 
(Fujiwara et al., 2005; Kim do et al., 2005; McManus et al., 2005). Specifically, the 
side-chain of His118 is thought to form van der Waals interactions with the lipoyl-
moiety of the lipoyl-AMP intermediate (Fujiwara et al., 2007). Published data 
highlight the importance of the ATP-binding pocket in E. coli BPL (EcBPL) (Choi-
Rhee et al., 2004; Cronan, 2005; Kwon & Beckett, 2000; Reche, 2000; Wilson et 
Chapter 4  123 
 
al., 1992). EcLplA and EcBPL enzymes operate in a similar fashion; via a two-step 
biotin/LA activation and transfer mechanism (see Section 3.4.3) (Fujiwara et al., 
2005; Wilson et al., 1992). Ordinarily in E. coli, the post-translational ligation of 
biotin (biotinylation) is highly specific to a single apoprotein, biotin carboxyl carrier 
protein (BCCP) (Beckett & Matthews, 1997; Cronan, 1989). However, a mutant 
within the ATP-binding domain, EcBPLR118G, biotinylates substrates other than 
BCCP (Choi-Rhee et al., 2004; Cronan, 2005). The most likely explanation for this 
"promiscuous biotinylation" was found to be due to the activated biotin 
intermediate (biotinoyl-AMP) escaping more easily from the EcBPLR118G active site 
and  biotinylating lysine residues on non-specific substrates by chemical (not 
enzymatic) acylation, in a concentration-dependent manner (of both enzyme and 
substrate) (Choi-Rhee et al., 2004; Cronan, 2005). Given that LplA and BPL 
enzymes share a similar mechanism of catalysis, the question was asked as to 
whether ectopic expression of LPLAH118A in L. major promastigotes would result in 
growth and/or lipoylation pattern phenotypes. 
WT[LPLA-His] and WT[LPLAH118A-His] lines were analysed by determining 
parasite growth rates relative to those of wild-type and WT[uncut pGL1137] 
negative controls. In addition, soluble protein was isolated during logarithmic 
growth and stationary phase and western blotting carried out with α-His-, α-LA-, α-
HASPB- and α-LmjLIPA antibodies, and α-cysteine synthease (α-CS) antibody to 
verify equal loading. At the final time point in stationary phase, in addition to 
harvesting mixed promastigotes, metacyclic promastigotes were isolated by a 
peanut agglutination protocol (see Section 2.2.2). All parasite lines were cultured 
in duplicate, and each experiment was independently repeated. Repetitions 
yielded very similar results; a representative set of which are shown. 
Firstly, LPLA-His expressing lines grown on 10 µg ml-1 or 50 µg ml-1 G418 drug 
selection pressures exhibited growth phenotypes; relative to the WT[uncut 
pGL1137] negative control, LPLA-His expressing lines enter stationary phase at a 
significantly earlier density (p<0.05) (see Figure 4.5). In terms of growth, both 
LPLA-His lines exhibit similar phenotypes, irrespective of G418 concentration (see 
Figure 4.5). Secondly, western blot analyses show that LPLA-His and LPLAH118A-
His proteins are expressed at similar levels, irrespective of whether the mutant 
lines were cultured in the presence of 10 µg ml-1 or 50 µg ml-1 G418 drug selection 
pressure (see Figure 4.6). The calculated molecular size of LPLA-His and 
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LPLAH118A-His proteins from SDS-PAGE was 56.1 kDa (see Section 2.5.5 for basis 
of calculations). Given that the LPLA proteins are fused to a His-tag that is 3.1 
kDa, the actual molecular size of the two proteins is 53.0 kDa (56.1 kDa minus 3.1 
kDa), which is similar to the predicted size of processed LPLA from the LPLA-GFP 
fusion protein (52.4 kDa) (see Section 4.2). It is likely therefore that the wild-type 
LPLA-His and mutant LPLA-His proteins are N-terminally processed for 
mitochondrial transit. Based on the sizes of LPLA calculated from LPLA-GFP (see 
Section 4.2) and LPLA-His data, it can be estimated that the mitochondrial 
targeting peptide for LPLA is between 19 – 24 amino acids, instead of 12 amino 
acids (LPLAT1) predicted by TargetP or 36 amino acids (LPLAT2) (see Figure 3.4 
for LPLA alignment). 
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Figure 4.5 Growth of LPLA-His expressing lines 
Growth analysis of LPLA-His expressing lines was carried out by diluting all cultures to 5 x 105 
parasites ml-1, and recording parasite density circa every 24 h. All lines were cultured in duplicate. 
WT[uncut pGL1137], WT[LPLA-His] and WT[LPLAH118A-His] lines were maintained on 10 µg ml-1 (A 
& B) or 50 µg ml-1 (C & D) G418 drug pressure. A & C, Average and standard deviation values 
were calculated for each parasite line at individual time points. Values were normalised to wild-type 
and plotted as a bar chart. One-way ANOVA with Tukey post-tests were performed at each time 
point, with uncut pGL1137 values as control. Values that are significantly different from uncut 
pGL1137 values (p-value < 0.05) are depicted with the '*' symbol. B, Growth of parasite lines 
represented by a line graph with logarithmic Y-axis. 
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Figure 4.6 Protein expression levels of LPLA-His expressing lines 
10 µg soluble protein samples from wild-type, WT[LPLA-His] and WT[LPLAH118A-His] lines 
maintained on 10 µg ml-1 or 50 µg ml-1 G418 drug pressure, from 96 h growth (see Figure 4.5), 
were subjected to SDS-PAGE and western blot analysis with α-HIS antibody at 1/10,000. The two 
blots were subsequently stripped of antibody and re-probed with α-CS antibody at 1/7,500 in order 
to check for equal loading. All lines were grown in duplicate, and both replicates are tested by 
western blot. The calculated size for both LPLA-His and LPLAH118A-His is 56.1 kDa (see Section 
2.5.5 for method of calculating molecular sizes from SDS-PAGE). 
As illustrated in Section 3.3, the lipoylation patterns of α-KADH E2 subunits and 
the H-protein of the GCC can be traced, in a repeatable way, throughout 
promastigote development in vitro. As such, the question was asked as to whether 
lipoylation patterns would be affected in WT[LPLA-His] and/or WT[LPLAH118A-His] 
lines. G418 concentration has no obvious effect on lipoylation pattern; as such, a 
representative set of data are shown, and the protein used for western blotting 
was derived from mutant lines grown in the presence of 50 µg ml-1 G418. Figure 
4.7 shows lipoylation patterns of wild-type and WT[uncut pGL1137] negative 
control lines, and WT[LPLA-His] and WT[LPLAH118A-His] lines. Protein loading is 
comparable in all lanes of each blot, lipoylation patterns of replicate treatments are 
consistent, and lipoylation patterns of the WT[uncut pGL1137] control are similar 
to those in wild-type. Figure 4.7 shows that the lipoylation pattern in WT[LPLA-His] 
is comparable to that in the WT[uncut pGL1137] line. The only difference between 
lipoylation patterns in these two lines compared to wild-type is that E2k, E2p and 
E2b are lipoylated in wild-type at 116 h mixed promastigote culture, yet only E2k is 
lipoylated in WT[LPLA-His] and WT[uncut pGL1137] lines (see Figure 4.7). 
In contrast, lipoylation of all three α-KADH E2 subunits and H-protein is up-
regulated in the WT[LPLAH118A-His] line at all time points. A very large increase in 
Chapter 4  127 
 
lipoylation of the H-protein is apparent at all time points except in purified 
metacyclic promastigotes. This is in contrast to LPLA-His expression (see Figure 
4.7) and LIPB-His expression (see Section 5.4.2), which do not result in an 
increase in H-protein lipoylation relative to the control lines. Perhaps the most 
intriguing finding is that metacyclic promastigotes in the WT[LPLAH118A-His] line 
possess lipoylated E2k, E2p and E2b subunits, whereas all other lines only have 
lipoylated E2k and H-protein (see Figure 4.7). 
 
Figure 4.7 Lipoylation patterns of LPLA-His expressing lines  
Approximately 1 e8 cells were lysed at four different time points from cultures maintained on 50 µg 
ml-1 G418 drug pressure (see Figure 4.5). Soluble protein was harvested and subjected to SDS-
PAGE. Western blots were carried out with α-LA antibody at 1/6,000 to determine lipoylation 
patterns, and with α-CS antibody at 1/7,500 to check for equal loading. All lines were grown in 
duplicate, and both replicates are tested by western blot. 
Purified metacyclic promastigotes at the 116 h time point from wild-type and LPLA-
His expressing lines grown on different G418 selection pressures were tested by 
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western blotting for a metacyclic-specific marker, hydrophilic acylated surface 
protein  (HASPB, kind gift from Professor D.F. Smith) (Flinn et al., 1994). Figure 
4.8 shows that LPLA-His expressing lines have significantly less HASPB protein 
than does the wild-type control (p<0.05), suggesting that LPLA-His expression 
could affect metacyclogenesis. A possible explanation is that since LPLA-His 
expressing lines enter stationary phase at an earlier time point (see Figure 4.5), 
and that this time point is most correlated to the production of HASPB-positive 
metacyclic promastigotes, 116 h was not a suitable time to probe LPLA-His and 
LPLAH118A-His protein lysates with α-HASPB antibody. This option was ruled out 
by western blotting with α-HASPB antibody at all time points, which revealed that 
levels of HASPB expression are consistently lower in LPLA-His expressing lines 
compared to wild-type (data not shown). 
 
Figure 4.8 Metacyclogenesis of LPLA-His expressing lines 
A, 10 µg soluble protein of metacyclic promastigotes (at 116 h time point) purified from LPLA-His 
expressing lines maintained on 10 µg ml-1 or 50 µg ml-1 G418 drug pressure, was subjected to 
SDS-PAGE. Western blotting was subsequently carried out with α-HASPB antibody at 1/4,000 and 
α-CS antibody at 1/7,500, to assess loading. All lines were grown in duplicate, and both replicates 
are tested by western blot. B, Band areas (shown in A) were determined using Scion Image 
program, averages and standard deviations were calculated and a bar chart plotted. Subsequently, 
one-way ANOVA with a Tukey post-test was performed to determine whether band areas in 
WT[LPLA-His] and WT[LPLAH118A-His] lines were significantly different from those in wild-type, 
where p-value < 0.05 is indicated by the '*' symbol. 
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In order to determine whether expression of LPLA-His and LPLAH118A-His proteins 
resulted in up-regulation of the LA biosynthesis pathway, western blotting was 
carried out using the α-LmjLIPA antibody (see Section 3.5.4.1). Given that the 
most notable differences in lipoylation pattern (with regards to the WT[LPLAH118A-
His] line) were observed in metacyclic promastigotes (see Figure 4.7), only protein 
lysates from this time point were probed with α-LmjLIPA by western blotting. 
Figure 4.9 shows that in all parasite lines, a band of 45.8 kDa is apparent. The fact 
that this band corresponds to LIPA is corroborated by the fact that western blotting 
with α-LmjLIPA antibody on protein lysate from the WT[LIPA-GFP] line reveals a 
45.3 kDa band, which is most likely to represent degradation of LIPA-GFP into 
LIPA and GFP (see Figure 5.1). According to prediction programmes TargetP and 
MitoProt, the expected molecular size of LIPA after cleavage of the N-terminal 
mitochondrial targeting peptide is 44.1 kDa (LIPAT1) or 45.5 kDa (LIPAT2), 
respectively (see Section 3.4.2). The average of the bands observed at 45.3 kDa 
and 45.8 kDa gives 45.5 kDa, which would be in line with the prediction made by 
MitoProt. Figure 4.9 shows that LIPA band intensity is similar in wild-type and 
WT[LPLA-His] lines, yet perhaps lower in the WT[LPLAH118A-His] line. However, 
the level of CS protein in protein lysates from the WT[LPLAH118A-His] line is lower 
than in the other two lines, and as such it is probable that the level of LIPA protein 
is similar in all lanes. This implies that any phenotypes, such as alterations in 
lipoylation patterns, are probably due to expression of LPLA-His/LPLAH118A-His 
proteins and not because of up-regulation of LA biosynthesis. 
 
Figure 4.9 LIPA expression levels in LPLA-His expressing lines 
Western blotting of protein lysates of purified metacyclic promastigotes from the 116 h time point 
(only lines grown on 50 µg ml-1 G418 selection pressure) using α-LmjLIPA antibodies at 1/20 to 
determine LIPA expression levels in LPLA-His expressing lines relative to the wild-type control. 
Blots were also probed with α-CS antibody at 1/7,500 to check for equal loading. All lines were 
grown in duplicate, and both replicates are tested by western blot. 
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4.5 Summary 
• LPLA-GFP is a mitochondrial protein, as shown by fluorescence microscopy in 
which LPLA-GFP (FITC filter) and Mitotracker CMXRos (Rhodamine filter) 
overlay. 
• LPLA is essential/very important to promastigote survival, since 0/72 clones from 
six independent transfections resulted in gene ablation. 
• Both LPLA alleles can be replaced, although all clones with double allele 
replacement still possessed at least one copy of the endogenous LPLA gene; 
apparently achieved by the parasites becoming tetraploid. 
• A permissive knockout strategy using an integrating LPLA re-expressor 
construct allowed complete gene replacement. The LPLA knockout with re-
expressor grew significantly slower than wild-type and entered stationary phase 
at a substantially lower cell density. 
• Expression of C-terminally His-tagged LPLA and active site mutant LPLAH118A 
resulted in the onset of stationary phase markedly earlier than in control lines. 
• The lipoylation pattern in WT[LPLA-His] was very similar to the usual wild-type 
pattern, whereas expression of LPLAH118A-His resulted in higher lipoylation of all 
three α-KADH E2 subunits and the H-protein of the GCC at all time points. 
Intriguingly, metacyclic promastigotes in the WT[LPLAH118A-His] line lipoylated 
E2p and E2b in addition to E2k and H-protein, which was not observed in wild-
type, WT[uncut pGL1137] or WT[LPLA-His] lines. 
• Expression of LPLA-His or LPLAH118A-His resulted in the isolation of a lower 
proportion of HASPB-positive non-procyclic promastigotes, suggesting that 
LPLA-His expression could affect metacyclogenesis. 
• There is no noticeable increase in LIPA protein in LPLA-His expressing lines 
relative to the wild-type control, indicating that the changes in lipoylation patterns 
observed in the WT[LPLAH118A-His] line are most likely a result of LPLAH118A-His 
expression and not due to up-regulation of LA biosynthesis. This increase in 
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lipoylation could be due to promiscuous lipoylation of the LPLAH118A-His mutant 
enzyme. 
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5 Biosynthesis of lipoic acid 
5.1 Introduction 
L. major encodes putative LIPA and LIPB enzymes, which were shown to be 
active by functional complementation of E. coli deficient in lipA and lipB, 
respectively, as described in Section 3.5. In the study reported in this chapter, the 
aims were to determine the sub-cellular localisations of LIPA and LIPB and to 
discern the roles that each plays in L. major. The former question was addressed 
by expressing a LIPA-GFP fusion protein in promastigotes, and establishing the 
sub-cellular localisation of LIPA-GFP by live cell fluorescence microscopy. An 
alternative approach was taken to determine the sub-cellular localisation of LIPB, 
which involved a pre-fractionation technique using digitonin titration. In order to 
elucidate the function of LIPA in promastigotes, attempts were made to ablate both 
gene copies by homologous recombination. In order to study the function of LIPB, 
wild-type LIPB with a C-terminal His-tag was ectopically expressed in 
promastigotes, with the aim of perturbing the normal balance of lipoylation, which 
would perhaps incite a decrease in parasite fitness. 
5.2 Localisation of LIPA 
To generate a L. major line expressing a C-terminal fusion protein of LIPA with 
GFP, the full length LIPA gene was amplified by PCR using primer pair Lm19-20 
(see Section 2.1.4). The resulting 1.3 kb fragment was digested with NdeI/KpnI 
before cloning into NdeI/KpnI digested pGL1132 vector (Tetaud et al., 2002) to 
yield the construct LIPA-GFP (see Figure 5.1A). The destination vector pGL1132 
contains the required control elements that allow constitutive expression of the 
proteins in L. major as well as the neomycin phosphotransferase (NEO) selectable 
marker (see Sections 2.2.6 and 2.2.7) (Cruz & Beverley, 1990; Tetaud et al., 
2002). The LIPA-GFP construct was transfected into wild-type to give rise to the 
WT[LIPA-GFP] line, which was grown in the presence of 10 µg ml-1 G418 to select 
for parasites that possess ectopic copies of the LIPA-GFP plasmid (see Section 
2.2.7). It is interesting to note that unlike the WT[LPLA-GFP] line, which grew 
efficiently when selecting with 50 µg ml-1 G418 (see Section 4.2), the WT[LIPA-
GFP] line was only able to proliferate when the concentration of G418 was 
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lowered to 10 µg ml-1; suggesting that expression of LIPA-GFP is not as well 
tolerated as that of LPLA-GFP. 
In order to verify that the LIPA-GFP fusion protein was expressed in the WT[LIPA-
GFP] line, western blotting with α-GFP monoclonal antibody and with α-LmjLIPA 
antibody was carried out. Figure 5.1B shows that both antibodies recognised a 
band with a calculated molecular size of 72.2 kDa. Unlike in the WT[LPLA-GFP] 
line where no GFP degradation was apparent, a clear 26.9 kDa band was 
detected in WT[LIPA-GFP] protein lysate using α-GFP antibody, with an expected 
GFP band size of 27.1 kDa (see Figure 5.1B). Probing WT[LIPA-GFP] protein 
lysate with α-LmjLIPA antibody resulted in a 45.3 kDa band on a western blot. 
Probing wild-type protein lysate with α-LmjLIPA antibody resulted in the 
recognition of a 45.8 kDa band (see Section 4.4, Figure 4.9). According to 
prediction programmes TargetP and MitoProt, the expected molecular size of 
LmjLIPA after cleavage of the N-terminal mitochondrial targeting peptide would be 
45.5 kDa (LmjLIPAT1) or 44.1 kDa (LmjLIPAT2), respectively (see Section 3.4.2). 
The average of the bands observed at 45.3 kDa and 45.8 kDa is 45.5 kDa, which 
would be in line with the prediction made by TargetP, and would equate to a 
targeting peptide of five amino acids. 
Fluorescence microscopy to detect the LIPA-GFP reporter, in combination with 
Mitotracker CMXRos mitochondrial stain, revealed that LIPA-GFP is a 
mitochondrial protein (see Figure 5.1C). This result is in accordance with sub-
cellular targeting predictions using MitoProt and TargetP (see Section 3.4.2). 
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Figure 5.1 Sub-cellular localisation of LIPA-GFP  
A, The LIPA gene (see Section 3.4.2) was amplified from gDNA with primer pair Lm19-20 (see 
Section 2.1.4). The insert was cloned into expression vector pGL1132, generating construct LIPA-
GFP (I). Correct cloning was verified by NdeI/KpnI digest, releasing a 1.26 kb insert corresponding 
to LIPA, and vector backbone of 6.94 kb (II). B, The LIPA-GFP construct was expressed in 
promastigotes to give rise to the WT[LIPA-GFP] line, and expression verified by western blotting of 
10 µg LIPA-GFP protein lysate with α-GFP antibody at 1/5,000 or α-LmjLIPA antibody at 1/20. 
Equal loading was verified by probing with α-CS antibody at 1/7,500. The band observed for LIPA-
GFP has a calculated size of 72.2 kDa. The calculated sizes of LIPA and GFP are 45.3 kDa and 
26.9 kDa, respectively (see Section 2.5.5 for method of calculating molecular weights from SDS-
PAGE). C, The mitochondrion of WT[LIPA-GFP] promastigotes was stained with Mitotracker 
CMXRos, and images of live cells were attained by fluorescence microscopy with DIC (for phase), 
FITC (for LIPA-GFP), rhodamine (for Mitotracker) or DAPI filters. 
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5.3 Knockout studies of LIPA 
In order to study the in vivo role of LIPA, a gene replacement strategy was 
employed. Knockout cassettes LIPA-SAT and LIPA-HYG were generated, and 
LIPA-SAT was transfected into promastigotes, as described in Section 2.2.4. 
Figure 5.2 is representative of the results obtained from LIPA knockout attempts, a 
summary of which is provided in Table 5.1. Two independent heterozygous lines 
for LIPA (∆lipASAT/LIPA) were created by replacement of one LIPA allele with the 
LIPA-SAT knockout cassette (see Figure 5.2C, lane 2 for one of the two 
heterozygotes). Based on growth data generated in duplicate from one of the 
heterozygous lines (other heterozygote exhibits the same phenotype; data not 
shown), ∆lipASAT/LIPA reached a significantly lower cell density at stationary phase 
than did the wild-type control (see Figure 5.3) 
Attempts were made to replace the remaining LIPA allele with the LIPA-HYG 
knockout cassette, and in all three transfections carried out 10 µM LA was 
included in the medium at all steps of the selection process. Therefore, if LA 
salvage and LA biosynthesis pathways are redundant, the theory was that 
supplementation with LA could permit LIPA gene ablation. In total, 61 clones from 
three independent transfections of ∆lipASAT/LIPA lines transfected with the LIPA-
HYG knockout cassette were analysed by PCR for the presence of the gene and 
for LIPA-HYG integration. 33/61 clones had correct LIPA-HYG integration yet 0/61 
had gene knockout (See Table 5.1, PCR data not shown). Southern blot analysis 
of one such double integrant (∆lipASAT/lipAHYG/LIPA) with LIPA, SAT and HYG 
gene probes showed that this clone indeed has LIPA-SAT and LIPA-HYG 
integration, and still possesses the endogenous gene (see Figure 5.2, lane 3). 
This clone was analysed by FACS, which illustrated that ∆lipASAT/lipAHYG/LIPA is 
tetraploid, meaning that non-dividing cells possess four copies of each 
chromosome, instead of the normal two copies in diploid cells (see Figure 5.4). In 
addition, ∆lipASAT/lipAHYG/LIPA seems to have growth defects compared to wild-
type, including slower logarithmic development, and premature entry into 
stationary phase (see Figure 5.3). 
In order to provide more convincing evidence that LIPA is an essential/very 
important gene, a complementation construct, LIPA-pRB, was generated and 
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transfected into one of the two ∆lipASAT/LIPA lines to give rise to the 
∆lipASAT/LIPA::PrRNALIPA line (see Sections 2.2.4-2.2.9). As discussed in Section 
4.3, the pRB construct is designed to integrate into any of the six 18S SSU rRNA 
gene copies present on chromosome 27 (Misslitz et al., 2000). Therefore, 
depending upon the site of LIPA-pRB integration, a Southern blot probed with a 
LIPA gene probe on NruI-digested gDNA would result in a band size of 13.2 kb, 
11.0 kb, 11.2 kb, 13.8 kb, 12.2 kb or 10.3 kb (see Figure 5.2B). Figure 5.2C (lane 
4) shows that Southern blotting with LIPA gene probe on NruI-digested gDNA from 
the ∆lipASAT/LIPA::PrRNALIPA line resulted in a band size >10 kb. It is not possible 
to interpret which of the six 18S SSU rRNA gene copies has been replaced by 
LIPA-pRB integration, since the DNA ladder does not surpass 10 kb. 
Subsequently, two independent transfections were carried out in order to attempt 
the replacement of the remaining endogenous LIPA allele in the 
∆lipASAT/LIPA::PrRNALIPA line, with the LIPA-HYG knockout cassette. A total of 23 
clones were analysed by PCR for the presence of the endogenous LIPA gene as 
well as for integration of the LIPA-HYG knockout cassette (data not shown); it was 
found that 14/23 clones had correct integration of LIPA-HYG, yet 0/23 clones were 
lacking the endogenous LIPA gene (see Table 5.1). Southern blot analysis 
indicated that one such clone possessed an unexpected band above 10 kb instead 
of the expected band for LIPA-HYG integration (see Figure 5.2C, lane 5). The 
reason why this clone (and presumably other clones) appears to have correct 
LIPA-HYG integration by PCR (using primers amplifying from outside of the 5' FR 
used in the construct to within the HYG gene) and not by Southern blot is unclear. 
         Total numbers analysed
Transfections Clones Transfections Integration Gene knockout
lipA SAT/LIPA  + LIPA -HYG 61 3 33/61 0/61
lipA SAT /LIPA ::P rRNA LIPA + LIPA- HYG 23 2 14/23 0/23
 
Table 5.1 Summary table of LIPA knockout attempts 
The information provided illustrates the total number of second round knockout attempts on LIPA 
heterozygotes, and those carried out using heterozygotes re-expressing LIPA within the 18S SSU 
rRNA locus. All values were obtained through PCR-based knockout screens. 
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Figure 5.2 Knockout attempts of LIPA gene, and complementation in an attempt to permit 
gene ablation 
A, Schematic representation of the endogenous LIPA locus (I), and the locus after LIPA-SAT (II) or 
LIPA-HYG (III) integration. B, Complementation of a knockout necessitated replacement of one of 
the six 18S SSU rRNA gene copies (I) with the LIPA gene, under puromycin selection (II). Sizes in 
kb represent the expected band sizes to be observed by Southern blot (C). *Depending upon which 
of the six 18S SSU rRNA gene copies is replaced by the LIPA re-expressor, NruI-digested gDNA 
and Southern blot with LIPA gene probe may yield either 13.2 kb, 11.0 kb, 11.2 kb, 13.8 kb, 12.2 
kb, 10.3 kb bands. C, Southern blot of 2 µg gDNA digested with NruI and probed with HYG-, SAT- 
and LIPA gene probes, with expected bands shown in A and B. 'LPLA-re-expressor' represents 
LPLA-pRB integration into the 18S SSU rRNA locus. The '**' symbol represents an unknown band, 
which could correspond to unexpected LIPA-HYG integration (see text for explanation). 
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Figure 5.3 Growth of LIPA knockout mutants 
Growth analysis of different LIPA knockout mutants was carried out by diluting all cultures to 5 x 
105 parasites ml-1, and recording parasite density circa every 24 h. All lines were cultured in 
duplicate. A, Average and standard deviation values were calculated for each line at individual time 
points. Values were normalised to wild-type values and plotted as a bar chart. One-way ANOVA 
with Tukey post-tests were performed at each time point. Values that are significantly different from 
wild-type values (p-value < 0.05) are depicted with the '*' symbol. B, Growth of parasite lines 
represented by a line graph with logarithmic Y-axis. 
 
Figure 5.4 Ploidy of LIPA knockout mutants 
FACS was used in order to determine the ploidy of different LIPA knockout mutants. Cells were 
fixed in 70 % methanol and incubated with propidium iodide. Incorporation of propidium iodide into 
DNA was detected with a Becton Dickinson FACS Calibur using FL2-A (detecting fluorescence 
emissions between 585 – 642 nm). Data were interpreted using the CellQuestPro software. 
Histograms show cell count relative to FL2 fluorescence (arbitrary units). Peaks at 200-, 400- and 
800 FL2 arbitrary units represent diploid, tetraploid and octaploid DNA contents, respectively. 
5.4 Overexpression of LIPB-His 
5.4.1 Localisation of LIPB-His 
Figure 5.1 illustrates that the LIPA-GFP fusion protein is targeted to the 
mitochondrion, which infers that LIPA is a mitochondrial protein. Given that LipA 
has been shown to be dependent upon the action of LipB in E. coli (Zhao et al., 
2005), and due to the fact that the two proteins co-localise to the apicoplast 
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compartment in P. falciparum (Wrenger & Muller, 2004) and in T. gondii 
(Thomsen-Zieger et al., 2003), it was hypothesised that LmjLIPA and LmjLIPB 
would also be found within the same organelle. In order to determine whether 
LmjLIPB is a mitochondrial protein, an alternative approach to the GFP reporter 
system was adopted; determination of the sub-cellular localisation of a LIPB-His 
fusion protein in promastigotes by cellular pre-fractionation.  
To generate a L. major line expressing a C-terminal fusion protein of LIPB with 
His-tag, the full length LIPB gene was amplified by PCR using primer pair Lm21-
22 (see Section 2.1.4). The resulting 0.8 kb fragment was digested with NdeI/KpnI 
before cloning into NdeI/KpnI digested pGL1137 vector to yield construct LIPB-His 
(see Figure 5.5A). The destination vector pGL1137 is derived from pGL1132, and 
as such contains the required control elements that allow constitutive expression 
of the proteins in L. major as well as the neomycin phosphotransferase (NEO) 
selectable marker (see Section 2.2.6 and 2.2.7) (Cruz & Beverley, 1990; Tetaud et 
al., 2002). The LIPB-His construct was transfected into wild-type to give rise to the 
WT[LIPB-His] line. 
In order to determine the sub-cellular localisation of LIPB, parasites from wild-type 
and WT[LIPB-His] lines were permeabilised with increasing quantities of digitonin 
in order to pre-fractionate (that is, to concentrate) different cellular compartments. 
Previous digitonin-titration experiments in L. mexicana showed that cytosolic-, 
glycosomal- or mitochondrial protein markers could be detected by western blot 
when cells were treated with 0.3 mg ml-1, 1.5 mg ml-1 or 3.0 mg ml-1 to 5.0 mg ml-1 
digitonin, respectively (Leroux et al., 2006). Similar experiments have been 
reported in T. brucei (Coustou et al., 2005; Marche et al., 2000), T. cruzi (Bouvier 
et al., 2006; Maugeri et al., 2003; Miranda et al., 2008), Trypanoplasma borelli (T. 
borelli) (Wiemer et al., 1995) and L. donovani and L. infantum (Foucher et al., 
2006). 
The rationale for using the pre-fractionation technique was in order to obtain a 
semi-pure- and concentrated mitochondrial protein lysate fraction that could be 
probed with α-LmjLIPB antibody. The different protein lysate fractions were also 
probed with α-LA antibody, which served as a mitochondrial protein marker 
control. Figure 5.5B shows that no protein is detected when wild-type protein 
lysate is probed with α-LmjLIPB antibody, indicating that endogenous LmjLIPB is 
either expressed at levels that are undetectable to the α-LmjLIPB antibody, or the 
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protein is not expressed in promastigotes. Figure 5.5B illustrates that the LIPB-His 
protein is detected by the α-LmjLIPB antibody, yet only in fractions in which protein 
was solubilised by 3.0 mg ml-1 or 5.0 mg ml-1 digitonin and not in the 1.5 mg ml-1 
digitonin fraction. As shown in Figure 5.5B, this pattern coincides with that 
observed when WT[LIPB-His] protein lysate is probed with α-LA antibody, 
whereby lipoylated E2k, E2p, E2b and H-protein are concentrated in 3.0 mg ml-1 
and 5.0 mg ml-1 digitonin fractions. There is some leakage of E2k and H-protein 
from cells treated with 1.5 mg ml-1 digitonin. Overall, the results indicate that LIPB-
His is a mitochondrial protein. 
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Figure 5.5 Sub-cellular localisation of LIPB-His in the WT[LIPB-His] line 
A, The LIPB gene (see Section 3.4.1) was amplified from gDNA with primer pair Lm21-22 (see 
Section 2.1.4). The insert was cloned into expression vector pGL1137, generating construct LIPB-
His (I). Correct cloning was verified by NdeI/KpnI digest, releasing a 0.8 kb insert corresponding to 
LIPB, and vector backbone of 6.3kb (II). B, The LIPB-His construct was expressed in 
promastigotes to give rise to the WT[LIPB-His] line. In order to determine the sub-cellular 
localisation of LIPB, wild-type and WT[LIPB-His] lines from stationary phase were sequentially 
treated with increasing concentrations of digitonin ([DG]) varying from 1.5 – 5.0 mg ml-1 (see 
Section 2.2.3.3). The three protein lysate fractions for each line were subjected to SDS-PAGE and 
western blotting was carried out using α-LmjLIPB antibody (top panel) at 1/1,000 or α-LA antibody 
(bottom panel) at 1/6,000. LIPB-His was detected in LIPB-His lysate and was calculated to be 33.3 
kDa (see Section 2.5.5 for method of calculating molecular weights from SDS-PAGE). 
LIPB is expected to be expressed in promastigotes given that LIPA was shown to 
be expressed (see Figure 4.9). Given that LIPB is not detected in concentrated 
mitochondrial protein lysate from promastigotes (see Figure 5.5B), combined with 
the knowledge that E. coli LipB is expressed at levels that are undetectable 
(Jordan & Cronan, 2003), an experiment was carried out to determine the 
concentration of LIPB-His protein in the WT[LIPB-His] overexpressing line. 
Quantities of LIPBFL-Strep recombinant protein ranging from 0.2 – 3.2 ng and 10 
µg of WT[LIPB-His] protein lysate were subjected to SDS-PAGE and western 
blotting with α-LmjLIPB antibody (see Figure 5.6A). Band density was measured 
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using Quantity One software and a standard curve produced with band intensity as 
a function of quantity of LIPBFL-Strep recombinant protein (as described in Section 
2.5.5) (see Figure 5.6B). Using the standard curve, it was determined that LIPB-
His protein is present at a concentration of 50 pg per µg of WT[LIPB-His] soluble 
protein lysate. This equates to approximately 27,000 copies of LIPB-His 
polypeptide per cell (given that there are 3.7 x 105 cells per 1 µg of soluble protein 
lysate). Considering that E. coli express < 10 copies of LipB per cell (Jordan & 
Cronan, 2003), and that LmjLIPB is not detectable in concentrated promastigote 
mitochondrial protein lysate, it can be concluded that the WT[LIPB-His] line 
drastically overexpresses the LIPB-His protein relative to endogenous LIPB.  
In addition to analysing band density, the molecular sizes of LIPBFL-Strep and 
LIPB-His were calculated (see Section 2.5.5 for method of calculating molecular 
sizes from SDS-PAGE). The molecular sizes of LIPBFL-Strep and LIPB-His are 
30.8 kDa and 32.2 kDa, respectively (see Figure 5.6A). The expected molecular 
size of LIPBFL-Strep is 30.7 kDa, and since the protein will not be processed for 
mitochondrial transit in E. coli, the observed 30.8 kDa band corresponds well to 
the predicted size. The expected molecular size of full-length LIPB-His is 32.3 
kDa, and based on TargetP mitochondrial targeting prediction (see Figure 3.2), the 
size of LIPB-His after cleavage of the mitochondrial targeting peptide would be 
28.8 kDa. The fact that the observed LIPB-His protein is 32.2 kDa indicates that 
the mitochondrial targeting peptide is likely to be considerably shorter than that 
predicted by TargetP. 
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Figure 5.6 Quantification of the level of LIPB-His expression in the WT[LIPB-His] line 
A, In order to quantify the amount of LIPB-His in the WT[LIPB-His] line, mid-log growth phase 
promastigote cells were harvested and 10 µg of soluble protein lysate subjected to SDS-PAGE. 
Different quantities of recombinant LIPBFL-Strep protein were loaded on the same gel. Western 
blotting was carried out with α-LmjLIPB antibody at 1/1,000 and chemiluminescence signal 
detected using a BioRad ChemiDoc XRS machine. The calculated sizes for LIPB-His and LIPBFL-
Strep are 32.2 kDa and 30.8 kDa, respectively (see Section 2.5.5 for method of calculating 
molecular sizes from SDS-PAGE). B, Band density was measured using the Quantity One software 
program and the linear phase was plotted on a graph. Using the linear equation, the quantity of 
LIPB-His protein in 10 µg of WT[LIPB-His] soluble protein lysate was determined to be 0.5 ng (as 
depicted in A). 
5.4.2 Effects of LIPB-His overexpression on promastigotes 
As discussed in Section 5.4.1, the WT[LIPB-His] line dramatically overexpresses 
the LIPB-His protein, relative to endogenous LmjLIPB expression in wild-type 
promastigotes. The effects of LIPB-His overexpression were analysed by 
employing the same assays used to study the effects of LPLA-His and LPLAH118A-
His expression (see Section 4.4). That is, the WT[LIPB-His] line was analysed by 
determining parasite growth rate relative to those of wild-type and WT[uncut 
pGL1137] controls. In addition, soluble protein was isolated during logarithmic 
growth and stationary phase and western blotting carried out with α-His, α-LA, α-
HASPB and α-LmjLIPA antibodies, and α-CS antibody to verify equal loading. All 
parasite lines were cultured in duplicate, and each experiment was independently 
repeated. Repetitions yielded very similar results; a representative set of which are 
shown. 
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Firstly, whether grown on 10 µg ml-1 or 50 µg ml-1 G418 drug selection pressure, 
the WT[LIPB-His] line exhibited a growth phenotype; relative to the WT[uncut 
pGL1137] control, WT[LIPB-His] entered stationary phase at a significantly earlier 
density (p<0.05) (see Figure 5.7). Secondly, western blot analysis with α-His 
antibody showed that LIPB-His protein expression was not affected by culturing 
parasites in the presence of different concentrations of G418 (see Figure 5.8). 
 
Figure 5.7 Growth of the WT[LIPB-His] line 
Growth analysis of the LIPB-His over-expressing line was carried out by diluting all cultures to 5 x 
105 parasites ml-1, and recording parasite density circa every 24 h. All lines were cultured in 
duplicate. WT[uncut pGL1137] and WT[LIPB-His] lines were maintained on 10 µg ml-1 (A & B) or 50 
µg ml-1 (C & D) G418 drug pressure. A & C, Average and standard deviation values were 
calculated for each parasite line at individual time points. Values were normalised to wild-type and 
plotted as a bar chart. One-way ANOVA with Tukey post-tests were performed at each time point, 
with uncut pGL1137 values as control. Values that are significantly different from uncut pGL1137 
values (p-value < 0.05) are depicted with the '*' symbol. B, Growth of parasite lines represented by 
a line graph with logarithmic Y-axis. 
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Figure 5.8 LIPB-His expression levels in the WT[LIPB-His] line 
10 µg soluble protein samples from wild-type or the WT[LIPB-His] line maintained on 10 µg ml-1 or 
50 µg ml-1 G418 drug pressure, from 96 h growth (see Figure 5.7), were subjected to SDS-PAGE 
and western blot analysis with α-HIS antibody at 1/10,000. The blot was subsequently stripped of 
antibody and re-probed with α-CS antibody at 1/7,500 in order to check for equal loading. 
Figure 5.9 illustrates the lipoylation patterns of wild-type and the WT[LIPB-His] 
lines cultured in the presence of 50 µg ml-1 G418 (the lipoylation patterns do not 
differ in LIPB-His overexpressing lines grown in the presence of either 10 µg ml-1 
or 50 µg ml-1 G418, and therefore only the latter data are shown). It should be 
noted that lipoylation of E2p and E2b are not as pronounced as that which is 
normally observed in wild-type parasites during stationary phase (72 h onwards) 
(see Figure 3.1). Throughout promastigote growth, lipoylation patterns in the 
WT[LIPB-His] line are very similar to those observed in the wild-type control. The 
only notable difference is that whereas metacyclic promastigotes in wild-type do 
not possess lipoylated E2p and E2b subunits, lipoylation of these acceptor 
proteins is apparent in WT[LIPB-His] protein lysate (see Figure 5.9), which is 
similar to the phenotype observed in the WT[LPLAH118A-His] line but not in the 
WT[LPLA-His] line (see Section 4.4, Figure 4.7). 
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Figure 5.9 Lipoylation patterns of the WT[LIPB-His] line 
Approximately 1 e8 cells were lysed at four different time points from cultures maintained on 50 µg 
ml-1 G418 drug pressure. Soluble protein was harvested and subjected to SDS-PAGE. Western 
blots were carried out with α-LA antibody at 1/6,000 to determine lipoylation patterns, and with α-
CS antibody at 1/7,500 to check for equal loading. All lines were grown in duplicate, and both 
replicates are tested by western blot. 
In terms of the capacity to undergo metacyclogenesis as determined by the 
detection of the metacyclic protein marker HASPB at 116 h growth, the WT[LIPB-
His] line grown in the presence of either concentration of G418 showed a marked 
decrease, indicating that metacyclogenesis is possibly impaired (see Figure 5.10). 
A possible explanation is that since the WT[LIPB-His] line enters stationary phase 
at an earlier time point (see Figure 5.7), and this time point is most correlated to 
the production of HASPB-positive metacyclic promastigotes, 116 h was not a 
suitable time point to probe WT[LIPB-His] protein lysates with α-HASPB antibody. 
This possibility was ruled out by western blotting with α-HASPB antibody at all 
time points, which revealed that levels of HASPB expression are consistently 
lower in WT[LIPB-His] lines compared to wild-type (data not shown). 
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Figure 5.10 Metacyclogenesis of the WT[LIPB-His] line 
A, 10 µg soluble protein from metacyclic promastigotes (at 116 h time point) purified from the LIPB-
His overexpressing line maintained on 10 µg ml-1 or 50 µg ml-1 G418 drug pressure, was subjected 
to SDS-PAGE. Western blotting was subsequently carried out with α-HASPB antibody at 1/4,000 
and with α-CS antibody at 1/7,500, to assess loading. All lines were grown in duplicate, and both 
replicates were tested by western blot. All treatments were carried out in duplicate B, Band areas 
(shown in A) were determined using Scion Image program, averages and standard deviations were 
calculated and a bar chart plotted. Subsequently, one-way ANOVA with a Tukey post-test was 
performed to determine whether band areas in the WT[LIPB-His] line were significantly different 
from those in wild-type, where p-value < 0.05 is indicated by the '*' symbol.  
Given that the WT[LIPB-His] line demonstrates a high overexpression of LIPB-His 
relative to endogenous LIPB, it was hypothesised that LIPA might consequently be 
up-regulated also. In order to test the hypothesis, wild-type and WT[LIPB-His] 
protein lysates from metacyclic promastigotes were probed with α-LmjLIPA 
antibody by western blotting. The reason for using this time point to analyse the 
levels of LIPA protein was due to the fact that the most notably difference in 
lipoylation pattern between the two lines is observed at this point. Figure 5.11 
shows that the level of LIPA protein is not higher in the WT[LIPB-His] line grown 
on 50 µg ml-1 G418 drug selection. This result indicates that the expression levels 
of endogenous LIPA and LIPB are low, and probably tightly regulated, and that 
overexpression of LIPB-His does not result in a concomitant increase in LIPA. 
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Figure 5.11 LIPA expression levels in the WT[LIPB-His] line 
Western blotting of protein lysates from purified metacyclic promastigotes from the 116 h time point 
(only lines grown on 50 µg ml-1 G418 selection pressure) using α-LmjLIPA antibodies at 1/20 to 
determine LIPA expression levels in the WT[LIPB-His] line relative to the wild-type control. Blots 
were also probed with α-CS antibody at 1/7,500 to check for equal loading. All lines were grown in 
duplicate, and both replicates are tested by western blot. 
5.5 Summary 
• LIPA-GFP is a mitochondrial protein, as shown by fluorescence microscopy in 
which LIPA-GFP (FITC filter) and Mitotracker CMXRos (Rhodamine filter) 
overlay. 
• LIPA is essential/very important to promastigote survival, since none of the 61 
clones from three independent transfections lacked the gene. 
• Both LIPA alleles can be replaced, although all clones with double allele 
replacement still possess at least one copy of the endogenous LIPA gene. 
• A permissive knockout strategy using an integrating LIPA re-expressor construct 
did not lead to gene knockout in any of the 23 clones examined. 
• A LIPB-His fusion protein was shown to localise to the mitochondrial fraction by 
a digitonin pre-fractionation experiment. 
• Endogenous LIPB is expressed at sub-picomolar levels, since it could not be 
detected by western blotting of concentrated mitochondrial soluble protein lysate 
from wild-type parasites with α-LmjLIPB antibody.  
• Overexpression of LIPB-His resulted in the onset of stationary phase markedly 
earlier than in control lines. 
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• The lipoylation pattern in WT[LIPB-His] was very similar to the typical wild-type 
pattern, except that metacyclic promastigotes in the WT[LIPB-His] line lipoylated 
E2p and E2b in addition to E2k and H-protein. 
• Overexpression of LIPB-His resulted in the isolation of a lower proportion of 
HASPB-positive non-procyclic promastigotes, suggesting that LIPB-His 
overexpression could affect metacyclogenesis. 
• There is no noticeable increase in LIPA protein levels in the WT[LIPB-His] line 
relative to the wild-type control. 
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6 Discussion 
6.1 Introduction 
LA metabolism has been most extensively studied in E. coli, and a wealth of data 
have also been generated in other organisms including the bacteria M. 
tuberculosis (Ma et al., 2006; Rachman et al., 2006; Sassetti et al., 2003) and L. 
monocytogenes (Keeney et al., 2007; O'Riordan et al., 2003), the archaebacterium 
T. acidophilum (Kim do et al., 2005; McManus et al., 2005), the mammals H. 
sapiens (Feng et al., 2009a), M. musculus (Morikawa et al., 2001; Yi & Maeda, 
2005; Yi et al., 2009) and B. taurus (Fujiwara et al., 2007; Witkowski et al., 2007), 
the plants A. thaliana (Ewald et al., 2007), Oryza sativa L. (Kang et al., 2007) and 
P. satisvum (Wada et al., 1997), the fungus N. crassa (Wada et al., 1997), the 
yeast S. cerevisiae (Hiltunen et al., 2009) and Kluyveromyces lactis (Chen, 1997), 
and the protozoan parasites P. falciparum (Allary et al., 2007; Gunther et al., 2005; 
Gunther et al., 2007; Gunther et al., 2009a; Gunther et al., 2009b; Wrenger & 
Muller, 2004) and T. gondii (Crawford et al., 2006; Mazumdar et al., 2006; 
Thomsen-Zieger et al., 2003). 
Some of these studies have investigated enzymes involved in LA metabolism, 
whereas others have researched type II FAS, and many have concluded that LA is 
essential for aerobic respiration, mitochondrial genome stability (in eukaryotes) 
and cell survival. The principal aim of this thesis was to investigate LA metabolism 
in L. major, because there is little information regarding the role of the cofactor in 
this or any other trypanosomatid. 
The first aim of this thesis was to identify the components of multienzyme 
complexes that require to be lipoylated for activity, by taking an in silico approach. 
This work was carried out using the L. major genome, the sequence of which is 
available (Ivens et al., 2005) in an online database (GeneDB). Subsequently, 
experimental evidence was gathered to show that these complexes are lipoylated 
in vivo. Furthermore, the question was asked as to which complexes are 
preferentially lipoylated at different stages of the L. major life cycle. After 
establishing that lipoylation of apo-E2 and apo-H-protein occurs, I set out to 
identify the genes involved in LA metabolism in L. major, and again an in silico 
approach was taken to address the question. Subsequently, the function(s) of L. 
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major gene products involved in LA metabolism were studied using several 
assays; namely, complementation of E. coli lines lacking certain genes involved in 
LA metabolism, observing the effect of LA analogues on LA metabolism, as well 
as gene replacement and protein overexpression. The results obtained will be 
discussed in this order below, with reference to published data. 
6.2 α-KADHs and the GCC 
6.2.1 In silico predictions 
From bacteria to mammals, α-KADHs are central to energy metabolism (Cronan et 
al., 2005; Mooney et al., 2002; Perham, 2000), and the GCC is important for the 
provision of one-carbon (C1) units, which can be used to synthesise purines, 
thymidylate, serine, methionine and formylmethionyl- transfer RNA (tRNA) 
(Cossins & Chen, 1997; Douce et al., 2001). 
There are a plethora of published data with regards to the α-KADH and GCC 
multienzyme complexes, in terms of subunit compositions and crystal structures. 
These complexes are presumed to exist in Leishmania, based upon biochemical 
evidence, and the first aim of this thesis was to identify genes in the L. major 
genome encoding all of the putative subunits comprising PDH, α-KGDH, BCKDH 
and GCC complexes, and to compare the amino acid sequences of the L. major 
predicted proteins with the known protein sequences in E. coli and H. sapiens (see 
Table 3.1). It should be noted that genes encoding all of the subunits comprising 
the GCC in L. major have previously been identified (Scott et al., 2008), and the 
role of the P-protein was evaluated by a gene disruption strategy. The results 
indicated that the GCC is active in L. major, and that the promastigote and 
amastigote forms lacking the P-protein exhibit a slow growth phenotype (Scott et 
al., 2008). 
Potential genes encoding all of the subunits comprising the three α-KADHs and 
the GCC were identified in the L. major genome. Sequence alignments were 
carried out, and most of the components were found to contain conserved 
residues that have been shown to be important in catalytic activity or in substrate 
binding. Importantly, the PDH E2 (E2p), KGDH E2 (E2k), BCKDH E2 (E2b) and H-
protein from the GCC, all possess lipoyl-domains containing a strictly conserved 
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lysine residue that has been shown to be essential for lipoylation (see Section 
3.2). All of the predicted E2 proteins also contain a strictly conserved histidine 
residue at the C-terminus, which is required for acyltransferase activity. Lastly, all 
of the components of α-KADHs and the GCC were predicted with high confidence 
by TargetP and MitoProt to possess mitochondrial-targeting peptides, which would 
be in line with the fact that these complexes also localise to mitochondria in yeast 
and human. 
Given that the in silico results were explained in depth in Section 3.2, and that one 
would predict that L. major possesses all genes necessary to encode functional 
components of α-KADHs and the GCC, the aim of this section is to highlight the 
potentially interesting differences that were mentioned in Section 3.2. 
Firstly, L. major has genes encoding two potential KGDH E1 (E1k) proteins 
(referred to as LmjE1k-A and LmjE1k-B), whereas E. coli, for example, encodes a 
single E1k, which forms a homodimer (Frank et al., 2007) (see Section 3.2.1.1). 
Interestingly, recent sequence analyses have resulted in the identification of a 
second human E1k, which is referred to as E1k-like (E1k-L) (Bunik & Degtyarev, 
2008). The E1k-L protein shares all motifs characteristic of E1k enzymes (Bunik & 
Degtyarev, 2008), and is the most common isomer in human heart tissue (Bunik et 
al., 2008). In addition, it was shown that another E1k-like protein exists in human – 
dehydrogenase E1 and transketolase domain-containing 1 (DHTDK1) – and is 
more like bacterial E1k enzymes, since it lacks the three pivotal Ca2+-binding 
motifs that are characteristic of vertebrate E1k proteins (Bunik et al., 2008; Lawlis 
& Roche, 1981; Rutter et al., 1989). LmjE1k-A and LmjE1k-B share only 36 % 
sequence identity with each other, and although they contain most of the required 
motifs necessary for E1k activity, such as lipoyl-domain-binding motifs and TPP-
binding motifs, they lack all three conserved motifs required for binding of Ca2+. In 
terms of known motifs involved in α-KGDH activity, it would appear unlikely that 
LmjE1k-A and LmjE1k-B complement one another, and as such LmjE1k-A and 
LmjE1k-B are more likely to be E1k isomers, rather than E1k heteromers that are 
dependent upon one another for full E1k function. This could have implications in 
terms of substrate specificity of the α-KGDH, and it is tempting to hypothesise that 
L. major possesses two E1k subunits that are able to recognise different 
substrates or that the two proteins are expressed in different life cycle/cell cycle 
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stages, although experimental evidence would be required to make any 
conclusions. 
The second potentially interesting observation from in silico analyses regards the 
E2p subunit. Querying the L. major genome database with the E. coli protein 
sequence for E2p resulted in the identification of two potential E2p subunits; 
LmjE2p and LmjE2p-like (LmjE2p-L) (see Section3.2.2.2). It is most likely that the 
annotations provided by GeneDB are correct, since LmjE2p possesses the strictly 
conserved C-terminal histidine residue, whereas LmjE2p-L lacks this residue, and 
as such is unlikely to be catalytically active. Interestingly, both LmjE2p and 
LmjE2p-L possess lipoyl-domains containing the strictly conserved lysine residue, 
which is the target of lipoylation. Notably, LmjE2p has a single lipoyl-domain with 
the conserved lipoylation motif 60TDKA63, and LmjE2p-L potentially has two lipoyl-
domains with lipoylation motifs 80TDKA83 and 177TDKA180. E. coli E2p (EcE2p) and 
H. sapiens E2p (HsE2p) contain three lipoyl-domains (Reed & Hackert, 1990), 
although it has been demonstrated in E. coli that only one is required for activity 
and that lipoylation of all three domains does not increase acyltransferase activity 
(Guest et al., 1985). 
The fact that LmjE2p-L has putative lipoyl-domains and is likely to be catalytically 
inactive indicates that it is most likely to correspond to E3-binding protein (E3BP), 
which is also found in mammals (De Marcucci & Lindsay, 1985) and some yeast 
(Maeng et al., 1994), but not in bacteria. The function of E3BP is to bind to E3, and 
insert E3 into the E2 scaffold, since in these organisms, E3 cannot bind E2 directly 
(Sanderson et al., 1996a; Sanderson et al., 1996b). In terms of the evolutionary 
justification of E3BP, one reason might be to add an extra level of control of the 
PDH, whereby if E3BP is not expressed (or inhibited), E3 will not be able to bind to 
the PDH complex, thus rendering it inactive. Interestingly, in T. brucei BSF, in 
which the mitochondrion is poorly formed and the majority of enzymes involved in 
the TCA cycle are not expressed, E3 has been shown to localise to the inner 
surface of the plasma membrane (Danson et al., 1987). This might appear to be a 
very strange observation, however there are published data implicating E3 and LA 
in the E. coli protein-dependent transport of galactose and maltose (Richarme & 
Heine, 1986), as well as the involvement of dithiols in hexose transport in 3T3-L1 
adipocytes (Frost & Lane, 1985). However, the physiological relevance of the 
observed E3 localisation to the plasma membrane in T. brucei has not been 
investigated further. Another interesting and surprising study in L. major concluded 
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that of the proteins that are potentially secreted/excreted from promastigotes, 
LmjE2p-L is one of them (Chenik et al., 2006). This is possible, given that TargetP 
predicts with high confidence (85 %) that LmjE2p-L possesses a secretory signal 
sequence. Also, MitoProt predicts with low confidence (23 %) that E3 has a 
mitochondrial targeting peptide, although TargetP predicts with high confidence 
that E3 possesses a mitochondrial targeting peptide. Is it possible that E3 and/or 
E3BP are dually-targeted to the mitochondrion and plasma membrane, and if so 
how would these proteins bind to the membrane, and what would be the 
physiological significance? To answer these questions is out of the scope of this 
thesis, yet these are potentially interesting questions which have not been 
addressed at all in recent studies regarding LA and α-KADHs. 
6.2.2 Regulation of α-KADHs by phosphorylation 
Mammals encode four PDH kinases (PDK), PDK-1-4 (Roche et al., 2001; Roche & 
Hiromasa, 2007), and one BCKDH kinase (BCKDK) (Machius et al., 2001; Wynn 
et al., 2000), which act on PDH and BCKDH, respectively, to down-regulate 
activity of these complexes. In addition, they also possess two PDH phosphatases 
(PDP), which contain the same regulatory subunit (PDPr) but differ in the catalytic 
subunit (PDP-1c or PDP-2c) (Huang et al., 1998; Lawson et al., 1993; Lawson et 
al., 1997; Teague et al., 1982), as well as a single BCKDH phosphatase (BCKDP 
or PTMP) (Damuni et al., 1984; Damuni & Reed, 1987; Joshi et al., 2007). The 
role of PDP and BCKDP is to catalyse the dephosphorylation of their respective 
enzyme complexes, and as such repress the down-regulation caused by 
phosphorylation of PDH and BCKDH by PDK and BCKDK, respectively. 
Querying the L. major genome database with human PDK and BCKDK protein 
sequences resulted in the identification of two potential PDK/BCKDK proteins, 
which were annotated in GeneDB as PDH kinase (lipoamide) (LmjF24.0010) and a 
phosphoprotein-like protein (LmjF20.0280) (see Table 3.2). Both predicted protein 
sequences, corresponding to LmjF24.0010 and LmjF20.0280 genes, are highly 
likely to contain mitochondrial targeting peptides, as predicted by TargetP and 
MitoProt. The predicted protein sequence of the LmjF20.0280 gene contains the 
strictly conserved N-, G1- and G2 boxes that constitute the ATP-binding domain 
that is a key feature of the ATPase/kinase superfamily (Bilwes et al., 1999). 
However, the protein completely lacks the F-box, which is present in all known 
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human PDK and BCKDK enzymes (Bowker-Kinley & Popov, 1999; Wynn et al., 
2000). The LmjF24.0010 predicted protein lacks strictly conserved residues within 
the N-, G1- and G2 boxes, and as such is unlikely to correspond to PDK, contrary 
to the annotation found in GeneDB. Lastly, both LmjF24.0010 and LmjF20.0280 
predicted proteins lack the C-terminal domain found in PDK, which is involved in 
binding the second lipoyl-domain (L2) of E2p (Kato et al., 2005). Nevertheless, 
BCKDP in humans also lacks this C-terminal portion. In conclusion, of the two 
predicted PDK/BCKDK enzymes in the L. major genome database, it is not 
possible to conclude with any confidence that either acts to phosphorylate either 
the PDH or BCKDH. However, based on sequence comparisons with human PDK 
and BCKDK, it is more likely that LmjF20.0280 has the capacity to phosphorylate 
proteins, and experimental data would be required to show this, as well as the 
specificity of this kinase towards either (or both) of PDH or BCKDH. 
If L. major possesses a kinase(s) to down-regulate certain α-KADHs, it would also 
be necessary to encode a phosphatase(s) that can release this inhibition by 
dephosphorylation of the α-KADH. Querying the L. major genome database with 
human PDP subunits and with BCKDP resulted in the identification of seven 
putative phosphatase genes. The seven corresponding predicted proteins have a 
high degree of conservation within motifs known to be important in members of the 
PPM family (Barford et al., 1998; Bork et al., 1996), which includes mammalian 
PDP and BCKDP. Of the seven predicted proteins, only two – LmjF30.0380 and 
LmjF32.1690 – are predicted with high confidence by TargetP and MitoProt to 
contain mitochondrial targeting peptides (see Section 3.2.6.2). Given that PDH 
and BCKDH are likely to be mitochondrial, these two predicted proteins are the 
best two candidates for being PDP/BCKDP. 
Overall, sequence analyses did not give a clear answer as to whether L. major is 
likely to possess genes encoding kinase(s) and phosphatase(s) that are known in 
mammals to regulate PDH and BCKDH activities. It has been possible however to 
narrow down the potential list of genes that could play this role in L. major, and 
experimental evidence in the form of biochemical characterisation would be 
required to verify whether any of these predicted proteins possess kinase or 
phosphatase activity, and if they do, to what extent they possess α-KADH-
specificity. 
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6.2.3 Lipoylation as a mechanism of regulating α-KADHs and the 
GCC 
Bacteria do not possess kinases and phosphatases to regulate activity of α-
KADHs, and also, a kinase (s) and phosphatase (s) that regulates α-KADH activity 
has not been documented. Also, given that mitochondrial proteins typically turn 
over slowly and the half-life of the PDH in rat is one week (Weinberg & Utter, 
1980), there must be a post-translational mechanism other than phosphorylation, 
to regulate α-KADHs. Given that LA is pivotal to activity of α-KADHs, it is likely 
that controlling the relative levels of lipoylation of different α-KADHs is an 
important mechanism to regulate their activities. Indeed, it has been shown in 
human HEK293 T cells that lipoyl-moieties are rapidly turned over (Feng et al., 
2009a). Work in human (Hayakawa & Oizumi, 1988; Oizumi & Hayakawa, 1989), 
rat, Lactobacillus casei (Shirota) (Hayakawa et al., 2006) and Enterococcus 
faecalis (Jiang & Cronan, 2005) has indicated the presence of an amidase enzyme 
called lipoamidase, which catalyses the removal of LA from E2 subunits and H-
protein. It is interesting to note that querying the L. major genome database with 
the E. faecalis lipoamidase protein sequence resulted in the identification of one 
potential homologue; LmjF16.1360. In the L. major genome database, this gene is 
annotated as a hypothetical gene. 
There are surprisingly few published data characterising the differential lipoylation 
intensities of the three α-KADHs and H-protein of the GCC under different stages 
of cell development or in different environmental conditions. The aim of this 
section of my thesis was to determine whether lipoylation patterns of the different 
α-KADHs and GCC change during promastigote growth in vitro, and in the 
amastigote stage, in order to establish whether the analysis of lipoylation patterns 
could be a useful diagnostic tool for studying metabolic responses. 
In order to address this question, western blot analysis was carried out on soluble 
protein extracts from L. major using a polyclonal antibody that recognises protein-
bound LA. This antibody has been used in previous studies in L. monocytogenes 
(O'Riordan et al., 2003), S. cerevisiae (Schonauer et al., 2008), A. thaliana (Ewald 
et al., 2007), P. falciparum (Allary et al., 2007; Gunther et al., 2007), T. gondii 
(Crawford et al., 2006), T. brucei (Stephens et al., 2007) and H. sapiens (Feng et 
al., 2009a). In L. major, a total of four lipoylated protein species were identified. 
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Based on predicted sizes after cleavage of the mitochondrial targeting peptide by 
MitoProt and TargetP, three of the bands were designated as H-protein, E2k, E2p 
and E2b (see Section 3.3). These predictions are not perfect however. For 
example, the molecular mass of the predicted full-length E2b protein is 50.2 kDa, 
and yet the observed molecular mass of the putative E2b is 55 kDa (see Table 
3.4). Also, E2k and E2p-L proteins were predicted to be a similar size after 
cleavage of the mitochondrial targeting peptide. It is much more likely however 
that the observed band of molecular mass 39.1 – 41.4 kDa is E2k and not E2p-L, 
since E2p-L is likely to be catalytically inactive and correspond to E3BP (see 
Section 6.2.1), and there have been no published studies using the α-LA antibody 
that have identified lipoylated E3BP, despite it possessing a lipoyl-domain. One 
possibility is that both proteins are lipoylated, and that the prominent band 
designated as E2k in western blots probed with α-LA antibody (see Figure 3.1) is 
masking a band of a similar size that could represent E2p-L. However, even when 
α-LA western blot films were exposed for less time to minimise the intensity of the 
putative E2k band, a second band was never observed. Nevertheless, in order to 
verify the predictions made above, it would be necessary to immunoprecipitate 
lipoylated proteins from L. major promastigote lysate, and to subsequently carry 
out mass spectrometry analysis. Please note that this is acknowledged as a 
limitation, however from henceforth the four lipoylated proteins will be referred to 
as H-protein, E2k (and not E2p-L), E2p and E2b, and potential reasons will be 
given to justify their differential lipoylation with regards to parasite energy 
metabolism. 
The results generated by western blotting with α-LA antibody illustrated that 
lipoylation patterns change throughout L. major promastigote growth in vitro, and 
that the changes in lipoylation patterns are consistent from one sub-passage to the 
next. Unfortunately, I did not have antibodies recognising E2k, E2k, E2b or H-
protein, and those raised against P. falciparum recombinant E2 proteins did not 
cross-react with L. major soluble protein extract (data not shown). As such, it was 
not possible to correlate lipoylation of E2 subunits with the levels of E2 protein, 
although the half-life of the PDH, for example, has been shown to be one week in 
rat (Weinberg & Utter, 1980). Nevertheless, since lipoylation is required for α-
KADH activity, it is possible to make putative conclusions with regards to the 
relative activities of these different protein complexes at any time point. 
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My results highlight several interesting and notable differences in terms of 
lipoylation intensities in promastigotes. Firstly, the E2k is constitutively lipoylated at 
all time points studied, from early-log growth to late stationary phase (see Figure 
3.1). α-KGDH catalyses the oxidative decarboxylation of α-ketoglutarate, one 
source of which is proline (another sources is glutamine) (see Figure 1.4). Given 
the importance of proline as a carbon source for energy production in the sandfly 
vector (Bringaud et al., 2006), combined with the fact that Leishmania 
promastigotes grown in vitro preferentially use amino acids as an energy source 
(Cazzulo et al., 1985) (see Section 1.2.2), could explain why E2k is highly 
lipoylated throughout promastigote in vitro culture. 
The E2p and E2b subunits are lipoylated during late-log growth and stationary 
phase, although never to the extent to which E2k is lipoylated (see Figure 3.1). 
However, E2p and E2b are not lipoylated in mid-log phase. These results could 
indicate that proline/glutamine is preferentially used as a carbon source, and once 
proline/glutamine becomes depleted (although this was not directly shown), the 
parasites start using additional energy sources. Up-regulation of PDH would allow 
pyruvate from glycolysis to be oxidatively decarboxylated to acetyl-CoA, which 
would most likely be converted to acetate via the ASCT, instead of being fed into 
the TCA cycle (see Section 1.2.3 & Figure 1.4) (Van Hellemond et al., 1998). 
There have not been any studies carried out with regards to the capacity of 
Leishmania to use branched-chain amino acids (BCAAs) as a carbon source, and 
these results are the first to show that a putative E2b is lipoylated, and that the 
BCKDH is thus likely to be active. BCAAs are converted to branched-chain 
ketoacids (BCKAs) by a branched-chain aminotransferase (BCAT), which is 
predicted to be present in the L. major genome database (LmjF27.2030). Genome 
data support the fact that Leishmania cannot synthesise branched-chain amino 
acids (Ivens et al., 2005), and the fact that they are used as an energy source 
could indicate that the parasites make use of exogenously-supplied branched-
chain amino acids as carbon sources. Indeed, in mammals, accumulating data 
suggests that BCKDH activity increases with exercise, as does oxidation of the 
BCAA leucine (Cynober & Harris, 2006; Norton & Layman, 2006). Although the 
midgut of the sandfly is likely to be sugar-rich, there is probably a limited supply of 
sugars as the parasites migrate towards the proboscis, and based on these results 
regarding lipoylation patterns, it could be that Leishmania are very adaptable to 
the carbon sources that they use to acquire energy. Interestingly, although mixed 
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culture promastigotes in late stationary phase lipoylate all three α-KADH E2 
subunits, metacyclic promastigotes purified from the same culture flask only 
lipoylate E2k (see Figure 3.1). It is worth noting that the method used to isolate 
metacyclic promastigotes is a negative selection procedure, whereby peanut lectin 
binds to a specific plasma membrane-bound protein found on procyclic 
promastigotes (which is not found on the plasma membrane of metacyclic 
promastigotes), and as such procyclic promastigotes can be pelleted by low-speed 
centrifugation, whilst metacyclic promastigotes remain in the supernatant fraction. 
The metacyclic promastigote is truly defined by the ability to infect human/mouse 
macrophages, and this assay was not carried out in conjunction with lipoylation 
experiments, nevertheless the term 'metacyclic promastigote' will be used 
henceforth for simplicity. Metacyclic promastigotes are non-dividing. The fact that 
this sub-population of parasites do not lipoylate PDH or BCKDH indicates that they 
do not use acetyl-CoA (derived from pyruvate in glycolysis) or BCAAs as an 
energy source, and must therefore rely upon glycolysis and amino acid oxidation. 
A potential explanation for this observation is that metacyclic promastigotes do not 
expend as much energy as dividing procyclic promastigotes, and as such down-
regulate PDH and BCKDH activities. This is intriguing because it potentially 
implies that lipoylation is a dynamic event, since 24 h beforehand, E2p and E2b 
were lipoylated (although it cannot be ruled out that the E2p and E2b proteins 
themselves are degraded). As mentioned already, L. major potentially encodes a 
lipoamidase which could cleave the amide bond between the lipoyl-moiety and the 
E2 subunit or H-protein. This could add an extra level of control to lipoylation, and 
it would be interesting to overexpress this protein, for example, to show whether it 
results in a decrease in lipoylation of the α-KADH and GCC. 
It would be interesting in future studies to alter the 
proline/glutamine/glucose/threonine concentrations in the growth medium, and to 
determine how this affects lipoylation patterns, and whether the two can be 
correlated. If the lipoylation pattern would be diagnostic of the relative activities of 
different α-KADHs, analysing lipoylation patterns would represent a simple and 
effective method to obtain a global picture of metabolic switching of cells treated 
under different nutritional conditions. For example, detailed molecular studies were 
recently carried out in PCF T. brucei which illustrated that these parasites have the 
capacity to rapidly switch their metabolism in response to the carbon sources 
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available (Coustou et al., 2008); it would be interesting to determine whether 
alterations in lipoylation patterns correlate with such metabolic switches. 
In promastigotes, lipoylation of the H-protein was observed in a pattern that 
mirrored E2p and E2b lipoylation patterns; H-protein was lipoylated during late-log 
growth and stationary phase, yet not during mid-log growth or in metacyclic 
promastigotes. A homozygous disruption of the L. major gene encoding the P-
protein (see Section 3.2.4.2) of the GCC was not lethal in the promastigote stage, 
as long as serine was present in the medium (Scott et al., 2008). The authors of 
this work hypothesise that an enzyme called serine hydroxymethyltransferase 
(SHMT) is able to compensate for the loss of the GCC, since SHMT catalyses the 
reversible conversion of serine and THF (tetrahydrofolate) to glycine and 5,10-
CH2-THF (methylene tetrahydrofolate). Two isoforms of SHMT are found in L. 
major promastigotes that localise to the cytosol and to the mitochondrion (Gagnon 
et al., 2006). The main role of the GCC is to provide C1 units in the form of 5,10-
CH2-THF, which are used by folate coenzymes to synthesise essential cellular 
compounds, including pyrimidines. Since metacyclic promastigotes are non-
dividing, one would hypothesise that these parasites do not require as much 
pyrimidine for DNA synthesis as do procyclic promastigotes, which could partially 
explain why H-protein is not lipoylated in metacyclic promastigotes. Also, given 
that there is redundancy between the GCC and SHMT, perhaps only the SHMT 
need be active in metacyclic promastigotes. 
In order to analyse the lipoylation pattern in the mammal-infective form, 
amastigotes were extracted from a mouse back lesion by dissecting out the lesion, 
crushing the tissue to release amastigotes, centrifuging the sample and then 
collecting the amastigote-containing supernatant fraction (work carried out by 
Denise Candlish, University of Glasgow). This is a crude method of cell isolation, 
and the amastigote-containing fraction inevitably contains host cell proteins. 
Western blotting of amastigote protein lysate with α-LA antibody revealed 
lipoylated proteins that potentially correspond to L. major-specific H-protein, E2k 
and E2p. However, lipoylation of the 55 kDa E2b band was not apparent in 
amastigotes. Interestingly, a lipoylated protein was observed that is of a very 
similar molecular mass to E2k, and I hypothesise that this could represent E2p-L, 
although it could be a cross-reacting mouse E2 subunit. The published molecular 
mass of mouse E2p after cleavage of the mitochondrial targeting peptide is 67 
kDa, and no such band was observed in the α-LA western blot. However, it cannot 
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be ruled out that lipoylated mouse E2p or E2b proteins do not contaminate the 
amastigote sample preparation, and that the bands observed at 41.4 kDa and 47.8 
kDa could represent these contaminating proteins. There are no published data 
regarding the molecular masses of mouse E2k and E2b after removal of the 
mitochondrial targeting peptide. Overall, it is more difficult to make any 
conclusions with regards to the lipoylation status of L. major amastigotes, and 
since L. major promastigotes cannot be differentiated into axenic amastigotes, this 
area remains elusive. 
6.3 Enzymes involved in LA metabolism 
6.3.1 In silico predictions 
Having established that α-KADHs and the GCC are lipoylated in L. major, the next 
step was to identify the enzymes involved in LA metabolism. In all organisms, LA 
can be synthesised from the type II FAS product octanoyl-ACP by LipB and LipA 
(in E. coli and mammals), and/or LA can be salvaged by LplA (in E. coli) or by 
ACSM1 and LT (in mammals).  
Crystal structure data on MtLipB (Ma et al., 2006) and biochemical analysis of 
EcLipB (Zhao et al., 2005) have shown that the LipB-catalysed reaction proceeds 
through an acyl-LipB intermediate, in which the octanoyl-moiety forms a thioester 
bond with the thiol of Cys169 (EcLipB numbering). This residue is only found in 
LipB enzymes, and not in LplA, LT or BPL. The reason for this is because LplA, LT 
and BPL-catalysed reactions proceed through a non-covalently bound acyl-
adenylate intermediate, whereas LipB forms a covalently bound acyl thioester 
intermediate, which requires the thiol group of Cys169. LipB, LplA, LT and BPL 
enzymes share one common residue, Lys135 (EcLipB numbering). In all of these 
enzymes, this residue has been proposed to be important in the transfer of the 
lipoyl-AMP/octanoyl intermediate to the target lysine residue on the lipoyl-domain 
of an apo-E2 or apo-H-protein. In LipB, Lys135 (EcLipB numbering) is essential for 
formation of the octanoyl-LipB intermediate (Ma et al., 2006), potentially by 
activating the octanoyl-moiety for thioester formation with Cys169 (EcLipB 
numbering) (Kim do et al., 2008; Ma et al., 2006). 
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Putative genes encoding LmjLIPB and LmjLPLA were identified in the L. major 
genome database (see Section 3.4). LmjF36.3080 is the most likely candidate for 
LmjLIPB since the predicted gene product possesses the strictly conserved 
cysteine residue that defines LipB enzymes (Cys191 in LmjLIPB). LmjF07.1060 is 
most likely to be LPLA, since the N-terminal domain of the predicted gene product 
has all of the key motifs that are essential for binding LA, ATP and lipoyl-AMP (see 
Section 3.4.3). Recent structural data indicate that despite LPLA and LT being 
similar in terms of amino acid sequence identity within the N-terminal domain, their 
C-terminal domains differ at the structural level, which has very important 
implications in their catalytic qualities. For example, BtLT and HsLT contain the 
motifs that are characteristic of LPLA, however are unable to activate LA due to 
steric hindrance of ATP access to the LA/ATP/lipoyl-AMP binding site, which is 
due to the fact that the C-terminal domain of LT is rotated 180 °C relative t o that of 
LplA (Fujiwara et al., 2007). As such, although LmjF36.3080 has been named 
LmjLPLA, it is possible that this gene in fact encodes LT and not LPLA. The C-
terminal domains of LplA proteins from different organisms share little sequence 
homology. However, it is interesting to note the size difference of LmjLPLA 
compared to LplA proteins in other organisms; LmjLPLA has a C-terminal domain 
that is 137 amino acids longer than that of EcLPLA, and 127 amino acids longer 
than that of HsLT (see Figure 3.5). In fact, this anomalously long C-terminal 
domain is not restricted to LmjLPLA, but is a common feature amongst all 
trypanosomatid putative LPLA proteins. The reason for possessing a significantly 
longer C-terminal domain is not known, and was not investigated during this 
thesis. 
A gene (LmjjF19.0350) that potentially encodes LmjLIPA was also identified in the 
L. major genome database. This predicted protein contains two motifs – 
133Cx4Cx5C144 and 165Cx3Cx2C172 (see Figure 3.3) – that are known to be essential 
for the LipA-catalysed insertion of two sulphur atoms into the octanoyl-moiety of 
octanoyl-E2/octanoyl-H-protein (Cicchillo et al., 2004a; Cicchillo et al., 2004b; 
Cicchillo & Booker, 2005; Douglas et al., 2006). 
6.3.2 Localisation of lipoylating enzymes 
All three predicted proteins, LIPB, LIPA and LPLA, were predicted with high 
confidence to contain mitochondrial targeting peptides by TargetP and MitoProt 
(see Section 3.4). Two approaches were taken in order to verify the subcellular 
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localisation of these proteins. Firstly, full-length LIPA-GFP and LPLA-GFP reporter 
constructs were expressed in promastigotes, giving rise to the respective lines 
WT[LIPA-GFP] and WT[LPLA-GFP], and live fluorescence microscopy was carried 
out using Mitotracker CMXRos as a marker for mitochondrial staining. In both 
lines, the green fluorescent fusion protein co-localised with Mitotracker CMXRos 
staining, indicating that LIPA-GFP and LPLA-GFP are mitochondrial. It is likely 
therefore that endogenous LIPA and LPLA proteins are mitochondrial.  
The second approach involved the concentration of various organelles by 
treatment with digitonin, and subsequently probing the soluble protein from these 
different fractions with α-LmjLIPB antibody. In the LIPB-His overexpressing line 
WT[LIPB-His], LIPB-His protein was found primarily in fractions that coincided with 
the highest levels of lipoylated protein. Given that α-KADHs and the GCC are 
predicted with high confidence to be mitochondrial, combined with the fact that 
these complexes are mitochondrial in all other eukaryotes, this was taken as good 
evidence that LIPB-His is mitochondrial. However, endogenous LIPB was not 
detected in any of the fractions when probed with α-LmjLIPB antibody. This was 
the expected result, given that endogenous LipB protein detection by western 
blotting has not been documented in any other organism due to its very low 
expression levels (Jordan & Cronan, 2003; Vaisvila et al., 2000). 
Overall, I experimentally illustrated that the predictions of LIPB, LIPA and LPLA to 
be mitochondrial were correct. The next question to answer would be 'are these 
proteins functional?' 
6.3.3 Functionality of lipoylating enzymes 
6.3.3.1 Bacterial complementation 
In order to determine whether the L. major genes encoding putative enzymes 
involved in LA metabolism were functional, a complementation approach was 
taken. Two E. coli insertion mutant lines were used, KER176 and KER184, which 
contain inactive lipA and lipB genes respectively. These bacteria do not grow on 
minimal medium, unless supplemented with either LA or succinate and acetate 
(Vanden Boom et al., 1991). However, the growth can be rescued to almost 
normal levels when complementing heterologous genes are expressed in these 
bacterial mutants. 
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My results indicate that N-terminally truncated versions of L. major LIPA-Strep 
proteins complement the growth defect of KER176 in the absence of LA, indicating 
that L. major encodes a functional LIPA protein (see Section 3.5.1.2). In addition, 
full-length LIPB-Strep complemented the growth defect of KER184 in the absence 
of LA (see Section 3.5.3.2), and thus it is possible to conclude that both enzymes 
comprising the LA biosynthesis pathway are likely to be functional in L. major.  
When interpreting the complementation results of KER184 E. coli, it is important to 
appreciate that this line is 'leaky', because in the absence of LA a small amount of 
growth is still apparent. The reason for this residual colony formation is that LplA 
can catalyse the ligation of the octanoyl-moiety from octanoyl-ACP to apoproteins, 
albeit much less efficiently than LipB (Morris et al., 1995). Only one of the two N-
terminal truncated versions of LPLA-Strep, LPLAT1-Strep, rescued the growth of 
KER184 in the absence of LA (see Section 3.5.3.2). Interestingly, in the presence 
of exogenous LA, the expression of LPLAT1-Strep resulted in colony formation, 
whereas expression of LPLAT2-Strep resulted in a decrease in colony formation 
relative to the negative control (empty pASK-IBA3 vector) (see Section 3.5.3.2). 
This phenomenon has been observed before, whereby expression of the L. 
monocytogenes LplA1 protein in an E. coli line lacking lipA and lplA (KER131) 
resulted in a reduction in colony formation in the presence of succinate and 
acetate, when compared to the empty vector negative control (Keeney et al., 
2007). The authors did not comment on this result (Keeney et al., 2007), however 
one would interpret the result as signifying that expression of the recombinant L. 
monocytogenes LplA1 in KER131 E. coli has a negative impact upon cell growth in 
the bypass medium. The LPLA complementation results obtained in my thesis 
indicate that not only does LPLAT2-Strep not support growth of KER184, but also 
causes a decrease in cell growth. The difference between LPLAT1-Strep and 
LPLAT2-Strep is that the former has an N-terminal truncation of 12 amino acids, 
whereas the latter has a 36 amino acid N-terminal truncation. One possible 
explanation for the no-growth phenotype is that the shortened N-terminus of 
LPLAT2-Strep renders this protein catalytically inactive, yet still permits the protein 
to bind LA. This sequestration of LA could have a dominant negative effect, 
whereby the inactive LPLAT2-Strep would compete for LA with the endogenous E. 
coli LplA. Indeed, purified recombinant LPLAT2-Strep was never found to be active 
when using P. falciparum E2 subunits and H-protein as apoproteins in an in vitro 
lipoylation assay, and western blotting with α-LA antibody showed that instead of 
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lipoylating apoproteins, instead LPLAT2-Strep was itself strongly lipoylated (data 
not shown). 
6.3.3.2 Effect of LA analogues on parasite growth 
In the presence of 30-50 ng ml-1 of a LA analogue, selenolipoic acid (SeLA), E. coli 
growth is completely inhibited (Reed et al., 1994). The isolation of a spontaneous 
mutant that was resistant to SeLA at concentrations up to 5 µg ml-1 (Reed et al., 
1994) resulted in the identification of the lplA gene, and a single point mutation in 
the LplA protein was attributed to the SeLA resistance phenotype (Morris et al., 
1995). Interestingly, a second mutant was also identified that was resistant to 
SeLA and which could proliferate in the absence of exogenous LA, even after 
ablation of the lipA gene (Morris et al., 1995). Later studies revealed that this 
mutant had a duplication of the segment of the E. coli chromosome containing the 
lipA and lipB genes (Jordan & Cronan, 2002). Therefore, resistance to SeLA in E. 
coli can be attained by relying upon LA biosynthesis, or by reducing LplA activity. 
Since these initial studies, experiments have been carried out using a similar 
analogue, 8-BOA, with the aim of discerning the relative importance of LplA in LA 
metabolism in T. gondii (Crawford et al., 2006) and P. falciparum (Allary et al., 
2007). Another analogue that has been used to study the role of LplA is OA (Allary 
et al., 2007; Crawford et al., 2006; Jordan & Cronan, 2003). Free OA is not used 
by E. coli LipB as substrate for acylation of apo-E2 and apo-H-protein (Jordan & 
Cronan, 2003), since ligation of OA to lipoyl-domains necessitates the thioester 
octanoylation of LipB by OA-ACP (Jordan & Cronan, 2003; Zhao et al., 2005). 
However, E. coli LplA can octanoylate lipoyl-domains using either free OA (in the 
presence of ATP) or OA-ACP, albeit with a significantly reduced efficiency 
compared to the classical lipoylation reaction involving LA and ATP (Jordan & 
Cronan, 2003). Therefore, LplA is the only enzyme capable of catalyzing the 
octanoylation or 8'-bromooctanoylation of E2 and H-protein apoproteins (Allary et 
al., 2007; Crawford et al., 2006; Jordan & Cronan, 2003). As such, any effects 
resulting from OA or 8-BOA treatment (at physiologically-relevant concentrations) 
are attributable to the low efficiency action of LplA.  
8-BOA and OA were used in this thesis in order to understand the importance of 
LPLA in the survival of promastigotes. In accordance with previous studies, the 
parasites used in this experiment were grown in lipid-depleted medium in order to 
minimise competition of LA found in FBS, with exogenously added 8-BOA as a 
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LPLA substrate. Specifically, promastigotes were grown for two sub-passages in 
lipid-depleted medium before starting the alamar blue assay (see Section 3.6), and 
any attempt to culture promastigotes for subsequent sub-passages in lipid-
depleted medium resulted in a reduction of cell growth and by sub-passage five in 
lipid-depleted medium, growth was no longer apparent (data not shown). My 
results indicate that the IC50 for 8-BOA is five to tenfold higher in L. major 
promastigotes than it is in T. gondii and P. falciparum, and the IC50 of OA is similar 
to that in T. gondii. Interestingly, whereas supplementation of 1-2 µM LA in media 
containing the IC50 dose of 8-BOA or OA completely restored growth in T. gondii 
and P. falciparum, addition of 1 µM LA to the media did not positively affect L. 
major promastigotes. 
A possible explanation for the inter-species differences observed could be due to 
the differential compartmentalisation of α-KADH complexes and GCC in T. gondii 
(and P. falciparum) and L. major. Biosynthesis enzymes LipA and LipB lipoylate 
the sole PDH located in the apicoplast (Gunther et al., 2005; Gunther et al., 2007; 
Gunther et al., 2009b; Wrenger & Muller, 2004). Salvage enzyme LplA is 
mitochondrial and is required for lipoylation of E2k, E2b or H-protein (Allary et al., 
2007; Crawford et al., 2006; Gunther et al., 2009b). Therefore, treatment with 8-
BOA and OA specifically impedes LplA-dependent α-KGDH, BCKDH and GCC 
complexes within the mitochondrion of T. gondii and P. falciparum. Lipoylation of 
the apicoplast PDH probably remains unaffected, since LipB does not use 8-BOA 
as a substrate (Crawford et al., 2006). In L. major, it is highly likely that all three α-
KADHs and the GCC are located in the same organelle (see Sections 6.2.1 and 
5.4.1). Therefore, if one hypothesised that L. major promastigotes grown in lipid-
depleted medium rely solely upon biosynthesis of LA, one would expect they be 
resistant to higher concentrations of LA analogues. Indeed, western blotting with 
α-LA antibody indicates that lipoylation patterns are not altered in the presence of 
10 µM 8-BOA. Unlike in T. gondii and P. falciparum, 1 µM LA was not sufficient to 
rescue the growth defects caused by 8-BOA or OA, indicating that the inhibitory 
effects on L. major at high concentrations of 8-BOA and OA are probably 
attributable to interactions of this compound with other pathways operating in L. 
major and therefore cannot be alleviated by addition of LA. An interesting follow-up 
experiment would be to determine the expression levels of LA biosynthesis and LA 
salvage enzymes when promastigotes are incubated with different concentrations 
of LA analogues. If the above theory is correct, LA biosynthesis enzymes would be 
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up-regulated in lipid-depleted medium and LPLA down-regulated, and addition of 
OA or 8-BOA should not affect LIPB or LIPA expression levels under these 
conditions. 
6.3.3.3 Gene replacement in L. major 
The results obtained from LA analogue experiments indicate that in L. major 
promastigotes, LA biosynthesis and salvage pathways might be redundant. In 
order to test this possibility further, a gene replacement strategy was taken, with 
the hypothesis that it would be possible to replace genes encoding either LIPA or 
LPLA. The results were very surprising, since every attempt to replace either gene 
in L. major promastigotes resulted in the duplication of the target gene by genome 
amplification. Leishmania are renowned for their genomic plasticity (Cruz et al., 
1993), and it is known that although Leishmania are mostly diploid, some 
chromosomes are aneuploid, such as chromosome 1 in L. major (Martinez-Calvillo 
et al., 2005; Sunkin et al., 2000). Also, it has been established in attempted 
knockout studies of L. major dihydrofolate reductase-thymidylate synthase (DHFR-
TS) (Cruz et al., 1993), a hypothetical gene (LmjF01.0750) (Martinez-Calvillo et 
al., 2005), L. mexicana cdc2-related kinase 1 (CRK1) (Mottram et al., 1996) and L. 
tarentolae J-binding protein 1 (JBP1) (Genest et al., 2005) that targeting of 
essential genes in Leishmania frequently results in aneuploidy for the 
chromosome in question, tetraploidy, or the creation of ectopic DNA fragments 
called amplicons (Feng et al., 2009b; Genest et al., 2005). 
The efficiency of correct targeting of the LIPA and LPLA genes was high, which 
rules out the possibility of either gene occupying a non-recombinogenic region of 
chromosomal DNA. Indeed, after integration of a stable re-expressing copy of 
LPLA into the 18S SSU RNA locus it was possible to obtain a LPLA null mutant, 
which suggests that the endogenous LPLA gene is essential in promastigotes. 
However, despite the expression of an ectopic copy of LPLA, the growth of the 
LPLA null mutant is significantly slower than that of wild-type at all time points on 
the growth curve. Unfortunately, the immunogenic response raised against 
recombinant LPLA protein in rabbit was poor, and as such the α-LmjLPLA 
polyclonal antibody generated was not useful in western blot analyses, despite 
multiple attempts to purify and concentrate the antibody (data not shown). It is 
therefore not possible to make any conclusions with regards to the expression 
level of LPLA under normal conditions or in the null mutant containing an ectopic 
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copy of LPLA. In terms of LIPA, it was not possible to generate a null mutant, even 
in the presence of an integrated ectopic copy of the gene. It is likely that LIPA is 
essential, however it is not possible to make as firm a conclusion as it is for LPLA. 
The obvious question is, why would both LIPA and LPLA proteins be essential for 
survival of L. major promastigotes? In E. coli, LA biosynthesis and salvage 
pathways are redundant (Morris et al., 1995), and based on the results gained 
from the effect of LA analogue experiments in this thesis, I expected the same to 
be true in L. major. The first possible explanation is that in L. major promastigotes, 
LIPA and LPLA are important but not essential, and that the inability to 
successfully replace both alleles could be due to limitation(s) in the methods used 
to achieve this. For example, promastigotes may be able to survive without 
salvage of LA, yet after replacement of the second LPLA allele, the parasites may 
take some time to up-regulate the biosynthesis pathway. The procedure I followed 
involved incubating transfected parasites for 24 h before cloning. Upon cloning it is 
clear that competition with other parasites is not an issue, however it could be that 
during the 24 h period preceding the initiation of cloning, the LPLA null mutants 
are out-competed/over-grown by parasites with duplicated genomes that do not 
need to switch metabolic pathways to survive. I would argue against this because 
promastigotes do not grow exponentially during the 24 h post transfection (data 
not shown). In terms of the attempted creation of a LIPA null mutant, 10 µM LA 
was included in each step of selection of the second-round allele replacement, yet 
it was still not possible to replace the remaining allele without the parasites 
duplicating their genome. This again provides support for the notion that both LIPA 
and LPLA are essential, since as explained above, if LPLA is important when LA is 
not limiting, replacement of the LIPA gene should be feasible. 
A second possibility to explain the essentiality of both LIPA and LPLA is that only 
one of the two pathways used to acquire LA is active at any one time, and that the 
expression of the genes involved in these pathways is regulated by LA availability 
in the medium. It seems peculiar that if an organism has the genetic capacity to 
encode a compensatory enzyme/set of enzymes to complement a growth defect, it 
would not do so. For example, an ACP knock-down mutant in human HEK293 T 
cells resulted in decreased cell growth and eventually death by 72 h in culture, and 
the principal cause was due to an almost complete loss of protein lipoylation (Feng 
et al., 2009a). This study highlighted the importance of LA biosynthesis in 
lipoylation of α-KADHs and the GCC (Feng et al., 2009a). Also, it has previously 
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been shown in mouse that deletion of lipA has an embryonic-lethal phenotype (Yi 
& Maeda, 2005; Yi et al., 2009), which further emphases the importance of LipA in 
mammals. Nevertheless, in the HEK293 T cell ACP knock-down line, addition of 2 
µM exogenous LA in the growth medium did not rescue growth or result in 
increased lipoylation of α-KADHs and H-protein (Feng et al., 2009a). This result 
argues against the possibility that LA availability in the medium was a limiting 
factor affecting the capacity of LA salvage to compensate for lack of LA 
biosynthesis. Also, in this thesis 10 µM LA was included in the growth medium at 
all steps during the selection of a LIPA null mutant, and yet LA salvage could still 
not compensate for a loss of LIPA protein. This fact thus opposes the theory that 
the LA salvage pathway is 'switched off' in LA-poor conditions. 
A third possibility to explain the essentiality of both LIPA and LPLA is that the 
pathways for LA biosynthesis and salvage are indeed redundant in terms of 
lipoylating α-KADHs and the GCC, yet the enzymes involved could have essential 
roles other than catalysing lipoylation reactions. For example, in E. coli, LipB has a 
surprising additional role as a negative regulator of dam gene expression. The 
dam gene encodes a DNA methyltransferase which transfers methyl groups from 
SAM to adenine residues in the sequence 5'-GATC-3' in double stranded DNA, 
and has a large impact on the chromosome replication, gene expression and 
mismatch repair (Barras & Marinus, 1989). Also, in P. falciparum, an unexpected 
result was obtained whereby LipB null mutants exhibited a faster growth 
phenotype that was mainly due to accelerated progression through the 
intraerythrocytic cell cycle (Gunther et al., 2007). Again, it could be that LipB has a 
role other than octanoylation of the PDH in P. falciparum (although it cannot be 
ruled out that in the P. falciparum LipB null line, increased growth rate is due to an 
increase in myristate production through type II FASI) (Gunther et al., 2007). 
A body of data is also accumulating that implicates LA biosynthesis in 
mitochondrial RNA processing (Hiltunen et al., 2009). In 1993, a screen for 
mutants with altered mitochondrial tRNA precursor/product ratios resulted in the 
identification of the lip5 mutant (Sulo & Martin, 1993). The lip5 mutant had a non-
functional lipA gene and as a result completely lacked lipoylated α-KADHs and 
GCC. Other phenotypes included accumulation of mitochondrial tRNA precursors, 
destabilisation of the mitochondrial genome and poor cell growth, which was not 
rescued by the addition of 2 µM LA (Sulo & Martin, 1993). In S. cerevisiae, 
Chapter 6  170 
 
mutants in type II FAS genes lack lipoylated α-KADHs and GCC (Schonauer et al., 
2008). It had been hypothesised that the main role of type II FAS is the provision 
of octanoyl-ACP as a substrate for LA biosynthesis (Brody et al., 1997; Hiltunen et 
al., 2009; Wada et al., 1997), however this particular study went a step further to 
show that FASII mutants had similar RNA processing phenotypes to that of the 
lip5 mutant (Schonauer et al., 2008). The authors illustrated that mutants of the 
pdh, α-kgdh and gcc genes did not cause RNA processing phenotypes, and it was 
proposed that biosynthesis of LA is not just involved in lipoylating α-KADHs and 
the GCC, but is also somehow implicated in RNA processing (Schonauer et al., 
2008). Interestingly, a similar phenotype of LA depletion and changes in 
mitochondrial ultrastructure was observed in a T. brucei PCF ACP knock-down 
line (Stephens et al., 2007). A follow-up study subsequently showed that RNAi of 
ACP resulted in malformation of the mitochondrial membrane, and the authors 
concluded that the principle cause of the RNAi phenotype was due to a change in 
phospholipid composition of the mitochondrial membrane (Guler et al., 2008). It 
would be interesting to determine whether RNA processing is also affected in this 
line, and whether LA is also the cause of this phenotype. Unfortunately, it was 
outside the scope of this thesis to investigate the exciting possibility that enzymes 
involved in LA metabolism play key roles in cellular functions other than lipoylation 
of α-KADHs and the GCC. 
A fourth and final possibility to explain the essentiality of both LIPA and LPLA in L. 
major is that the LA biosynthesis and salvage pathways lipoylate their apoproteins 
in a substrate-specific manner. Given that all four apoproteins (H-protein, E2k, E2p 
and E2b) are lipoylated (and assumedly active) during logarithmic growth phase in 
L. major (see Figure 3.1), there is a possibility that three of them are essential to 
parasite survival (excluding the H-protein, which has been shown to be 
dispensable in L. major promastigotes (Scott et al., 2008)). If LA biosynthesis and 
salvage have differential substrate specificities for the α-KADHs, one would then 
expect that these genes be essential to promastigote survival. An interesting 
observation in E. coli is that the lipB null mutant KER184 can grow on any medium 
that bypasses the need for the α-KGDH (for example, on succinate-containing 
medium), however acetate-containing minimal medium is not sufficient to sustain 
growth. This result infers that in the absence of LipB, LplA is not able to sufficiently 
lipoylate the α-KGDH to permit cell growth, yet can lipoylate the PDH enough to 
allow colony formation (Reed & Cronan, 1993). Another interesting study showed 
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that in L. monocytogenes, which encodes two LplA enzymes (LplA1 and LplA2) 
but lacks LA biosynthesis enzymes, LplA1 is essential for intracellular survival of 
the bacterium, and that LplA1 and LplA2 are not redundant (O'Riordan et al., 
2003). This interesting phenomenon was shown to be due to the fact that LplA1 
can use lipoyl-peptides and ATP as substrates for lipoylation, whereas LplA2 
requires free LA and ATP (Keeney et al., 2007). 
6.3.3.4 Ectopic expression of lipoylating enzymes 
Since it was not possible to study the functions of LIPA or LPLA by gene 
replacement, an alternative approach was taken. LIPB-His, LPLA-His and 
LPLAH118A-His constructs were expressed in promastigotes and the effect of 
protein expression was assessed in terms of growth and lipoylation patterns at 
different stages. Unfortunately, it was not possible to express the LIPA-His 
construct in promastigotes, even when the G418 selection pressure was lowered 
to 10 µg ml-1 from the standard 50 µg ml-1 (data not shown). One possible 
explanation is that high ectopic expression of LIPA is not tolerated in 
promastigotes. 
My results indicate that there is a dramatic overexpression of LIPB-His relative to 
endogenous LIPB in the WT[LIPB-His] line, since it was not possible to detect 
endogenous LIPB protein in wild-type promastigotes, whereas in the mutant line 
LIPB was readily detected by the α-His antibody (see Figure 5.5). Expression of 
LPLA-His and LPLAH118A-His is easily detectable in the WT[LPLA-His] and 
WT[LPLAH118A-His] lines using an α-His antibody, respectively (see Figure 4.6). 
The endogenous expression levels of LPLA remain unknown because the 
antibody raised against the recombinant protein proved to be cross-reactive with 
numerous other parasite proteins and no protein of the expected size of LmjLPLA 
was detected in the blots. Growth rates were significantly slower in all three mutant 
lines compared to that observed in the empty vector control line, and this slow-
growth phenotype was observed when G418-resistant lines were grown in the 
presence of either 10 µg ml-1 or 50 µg ml-1 selection pressure (see Figure 4.5 and 
Figure 5.7). The reason why G418-resistant lines were cultured in the presence of 
two different drug concentrations was because it had been shown before in L. 
major that overexpression levels of an ATPase protein VPS4, were correlated with 
the concentration of G418 included in the growth medium (Besteiro et al., 2006). In 
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the experiments carried out in this thesis, expression levels of LIPB-His, LPLA-His 
and LPLAH118A-His did not differ when the mutant lines were grown in the presence 
of either 10 µg ml-1 or 50 µg ml-1 G418 drug selection pressure (see Figure 4.6 and 
Figure 5.8). 
It was hypothesised that the cause of reduced growth rate in the three mutant lines 
would be due to alterations in lipoylation patterns, which could impact on cell 
metabolism and growth. However, the lipoylation patterns in the WT[LIPB-His] and 
WT[LPLA-His] lines were comparable to those observed in the empty vector 
control lines (see Figure 4.7 and Figure 5.9). This potentially indicates that 
overexpression of LIPB-His and LPLA-His interferes with pathways other than 
lipoylation, although investigation of these options was not within the scope of this 
thesis. Interestingly, lipoylation of the H-protein was higher in the WT[LPLAH118A-
His] line at all time points investigated apart from in purified metacyclic 
promastigotes. Also, in WT[LIPB-His] and WT[LPLAH118A-His] lines, but not in the 
WT[LPLA-His] line, E2p and E2b were lipoylated in metacyclic promastigotes (see 
Figure 4.7 and Figure 5.9). I consistently found in multiple independent 
experiments carried out with the wild-type line, that metacyclic promastigotes had 
lipoylated E2k, but I had never observed lipoylation of E2p or E2b (for a 
representative result see Figure 3.1), and as such this was a potentially interesting 
phenotype. Based on sequence alignments with LplA and LT enzymes in other 
organisms whose three-dimensional structures have been determined, the His118 
residue in L. major is likely to be one of the key residues involved in forming the 
hydrophobic crevice to which the lipoyl-AMP intermediate binds (Fujiwara et al., 
2005; Kim do et al., 2005; McManus et al., 2005). As explained in Section 4.4, the 
justification for creating the LPLAH118A-His mutant was based on the published 
observation that an E. coli BPL mutant, EcBPLR118G, biotinylates substrates other 
than BCCP (Choi-Rhee et al., 2004; Cronan, 2005). Given that the EcBPLR118G 
protein also bears a mutation within the ATP-binding domain, I hypothesised that 
the LPLAH118A-His mutant protein would lipoylate substrates other than the 
endogenous substrates of wild-type LPLA. Therefore, one possibility is that 
'promiscuous lipoylation' is the cause of the observed lipoylation of E2p and E2b in 
metacyclic promastigotes in the WT[LPLAH118A-His] line. In addition, the fact that 
expression of LPLA-His does not result in lipoylation of E2p and E2b in metacyclic 
promastigotes suggests that LPLA may not normally lipoylate E2p and E2b. The 
fact that LIPB-His overexpression results in lipoylation of E2p and E2b in 
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metacyclic promastigotes is also interesting, and suggests that LIPB may have a 
substrate-specificity for E2p an E2b, and in wild-type metacyclic promastigotes, 
perhaps LIPB is not expressed and as such does not lipoylate E2p and E2b. 
6.4 Conclusions and future directions 
The overall aim of this thesis was to initiate an understanding of LA metabolism in 
L. major. I illustrated that L. major likely possesses genes that encode all subunits 
of the α-KGDH, PDH, BCKDH and GCC. All of the complexes are likely to be 
mitochondrial, although it is noteworthy that the subcellular localisations of the E3 
and E3BP were not entirely predictable. As such, it would be interesting to 
determine the sub-cellular localisation of E3 (and E3BP), and perhaps the protein 
has dual localisation, as has been reported in T. brucei BSF (Danson et al., 1987). 
L. major was shown to possess a functional biosynthesis pathway consisting of 
LIPB and LIPA enzymes. Bacterial complementation studies did not yield a 
satisfactory answer regarding the functionality of LPLA; future studies would focus 
on optimising the expression and purification of LPLA to a high purity, such that it 
could be biochemically characterised. All three enzymes were shown to localise to 
the mitochondrion, which itself reinforces the likelihood that the α-KADH and GCC 
complexes are also localised to this organelle. In E. coli, LA salvage and 
biosynthesis pathways are redundant, and this was hypothesised to be the case in 
L. major also, because similarly to E. coli, both LA metabolism pathways are 
localised to the same organelle. Unexpectedly, LIPA and LPLA appear to have an 
essential function in L. major, since it was not possible to ablate either gene. 
Evidence is accumulating in other organisms that LipA and LipB may have roles 
other than lipoylation of α-KADHs and the GCC. Future work will be aimed at 
unravelling the seemingly complex role(s) that LipA and LipB play in the 
intersection between energy metabolism, type II FAS and mitochondrial RNA 
processing (Hiltunen et al., 2009). Another hypothesis to explain the essentiality of 
LIPA and LPLA in L. major promastigotes is that LA salvage and biosynthesis 
enzymes may have differential substrate specificities. Preliminary results from 
overexpression of different enzymes involved in LA metabolism indicate that this 
could indeed be the case, and it would be of interest to build upon these results by 
determining whether LIPB and LPLA exhibit substrate-specificities for 
octanoylation/lipoylation in vitro. The potential for substrate-specificity between the 
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two different LA metabolic pathways is something that has not been addressed in 
the literature. However, one must pose the question, what is the purpose of having 
a LA salvage pathway when the LA biosynthesis pathway enables the cell to be 
completely self-sufficient? 
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Rn_E1k          -----MFHLRTCAAKLRPLTASQTVKTFSQNKPAAIRTFQQIRCYSAPVAAEP-FLSGTS 54 
Mm_E1k          -----MFHLRTCAAKLRPLTASQTVKTFSQNKPAAIRTFQQIRCYSAPVAAEP-FLSGTS 54 
Hs_E1k          -----MFHLRTCAAKLRPLTASQTVKTFSQNRPAAARTFQQIRCYSAPVAAEP-FLSGTS 54 
Rn_E1kL         -----MSQLRLLLFRLG----PQARKLLATR---DIAAFGGRRRSSGPPTTIPRSRGGVS 48 
Mm_E1kL         -----MSQLRLLPFRLG----PRATKLLATR---AIPVFSGCRRSSGPPTTIPRSRSGVS 48 
Hs_E1kL         -----MSQLRLLPSRLG----VQAARLLAAH---DVPVFGWRSRSSGPPATFPSSKGGGG 48 
Rn_DHTKD1       ------------------------------------------------MASATVAAAGRA 12 
Mm_DHTKD1       -----------------------------------------------MASAATVAAAGRA 13 
Hs_DHTKD1       ------------------------------------------------MASATAAAARRG 12 
Lm_E1kB         MMRR--ALSGVVAVR-----ASAMRSYTDARTIRKPN-------------PYDQLVNAEN 40 
Lm_E1kA         MMRRLVPVRGVVSCGSAVAPTSAFPCASHAALIMGRRRAAEAVPERQLLFDNDSFLSGSS 60 
                                                                             
 
Rn_E1k          SNYVEEMYCAWLENPKSVHKSWDIFFRNTNAGAPPGTAYQSPLSLSRSSLATMAHAQSLV 114 
Mm_E1k          SNYVEEMYCAWLENPKSVHKSWDIFFRNTNAGAPPGTAYQSPLSLSRSSLATMAHAQSLV 114 
Hs_E1k          SNYVEEMYCAWLENPKSVHKSWDIFFRNTNAGAPPGTAYQSPLPLSRGSLAAVAHAQSLV 114 
Rn_E1kL         PSYVEEMYFAWLENPQSVHKSWDNFFQRATKEASVGPAQPQPP-------AVIQESRASV 101 
Mm_E1kL         SSYVEEMYFAWLENPQSVHKSWDSFFQRASKEASVGPAQPQLP-------AVLQESRTSV 101 
Hs_E1kL         SSYMEEMYFAWLENPQSVHKSWDSFFREASEEAFSGSAQPRPP-------SVVHEGRSAV 101 
Rn_DHTKD1       LRRAVPLLRRSYQTERGVYGYRP---RKAGSGEPRGDR-----------------ARPSV 52 
Mm_DHTKD1       LRRAVLLLRRGYQTERGVYGYRP---RKAKSGEPRGDR-----------------ARPSV 53 
Hs_DHTKD1       LGRALPLLWRGYQTERGVYGYRP---RKPESREPQGAL-----------------ERPPV 52 
Lm_E1kB         QHYVEDLMRQYEADSALVDPSWVPVLEAIRSGSDDSPVVAT--------------FSRPT 86 
Lm_E1kA         AMYMDGLYQQWKKDPASVDASWAELFSRSDLGNYNHALLDTPI----------CVLPAKS 110 
                      :          *                                           
 
Rn_E1k          EAQPNVDKLVEDHLAVQSLIRAYQIRGHHVAQLDPLGILDADLDSSVPAD------IISS 168 
Mm_E1k          EAQPNVDKLVEDHLAVQSLIRAYQIRGHHVAQLDPLGILDADLDSSVPAD------IISS 168 
Hs_E1k          EAQPNVDKLVEDHLAVQSLIRAYQIRGHHVAQLDPLGILDADLDSSVPAD------IISS 168 
Rn_E1kL         SSCTKTSKLVEDHLAVQSLIRAYQIRGHHVAQLDPLGILDADLDSFVPSD------LITT 155 
Mm_E1kL         SSCTKTSKLVEDHLAVQSLIRAYQIRGHHVAQLDPLGILDADLDSFVPSD------LITT 155 
Hs_E1kL         SSRTKTSKLVEDHLAVQSLIRAYQIRGHHVAQLDPLGILDADLDSFVPSD------LITT 155 
Rn_DHTKD1       DHG------------LARLVTVYCEHGHKAAQINPLFPGQALLDTVPEIQ------ALVQ 94 
Mm_DHTKD1       DHG------------LARLVTVYCEHGHKAAQINPLFPGQALLDTVPEIQ------ALVR 95 
Hs_DHTKD1       DHG------------LARLVTVYCEHGHKAAKINPLFTGQALLENVPEIQ------ALVQ 94 
Lm_E1kB         DAKSLSEKQRHDNMRLSWMIREYERFGHHMANVDPLSGYHADNCILG-SR------TLAP 139 
Lm_E1kA         SDEAVVKQSLADCGRLIRMIHTFEDRGHLMAQTDPLNYVDTDVTERTPSRRYKEMVRLDL 170 
                .              :  ::  :   **  *: :**   .:                :   
 
Rn_E1k          TDKLGFYGLHESDLDKVFHLPTTTFIGGQEPALPLREIIRRLEMAYCQHIGVEFMFINDL 228 
Mm_E1k          TDKLGFYGLHESDLDKVFHLPTTTFIGGQEPALPLREIIRRLEMAYCQHIGVEFMFINDL 228 
Hs_E1k          TDKLGFYGLDESDLDKVFHLPTTTFIGGQESALPLREIIRRLEMAYCQHIGVEFMFINDL 228 
Rn_E1kL         IDKLAFYDLQEADLDKEFRLPTTTFIGGSENTLSLREIIRRLESTYCQHIGLEFMFINDV 215 
Mm_E1kL         IDKLAFYDLQEADLDKEFRLPTTTFIGGPENTLSLREIIRRLESTYCQHIGLEFMFINDV 215 
Hs_E1kL         IDKLAFYDLQEADLDKEFQLPTTTFIGGSENTLSLREIIRRLENTYCQHIGLEFMFINDV 215 
Rn_DHTKD1       TLQGPFT--------------TTGLLNMGKEEASLEEVLAYLNHIYCGPISIETAQLQSQ 140 
Mm_DHTKD1       TLQGPFT--------------TTGLLNLGKEAASLEEVLAYLNHIYCGPISIETAQLQSQ 141 
Hs_DHTKD1       TLQGPFH--------------TAGLLNMGKEEASLEEVLVYLNQIYCGQISIETSQLQSQ 140 
Lm_E1kB         EEFGFTKDDLTHVFNVTFGASHEATFVSGGTAMTLQQIIDQLRRLYCGPIGFEFMSSGFF 199 
Lm_E1kA         AYFGFSDKDLDRVVRVGFQNQMGGIYDTSSPQLTIRQLHELLTERYCGRIGFELVHLTDG 230 
                                                 .:.::   *   **  *..*        
 
Rn_E1k          EQCQWIRQKFETPGIMQFTN-----EEKRTLLARLVRSTRFEEFLQRKWSSEKRFGLEGC 283 
Mm_E1k          EQCQWIRQKFETPGIMQFTN-----EEKRTLLARLVRSTRFEEFLQRKWSSEKRFGLEGC 283 
Hs_E1k          EQCQWIRQKFETPGIMQFTN-----EEKRTLLARLVRSTRFEEFLQRKWSSEKRFGLEGC 283 
Rn_E1kL         EQCQWIRQKFETPGVMKFSI-----EEKRTLLARLVRSMRFEDFLARKWSSEKRFGLEGC 270 
Mm_E1kL         EQCQWIRQKFETPGVMQFSV-----EEKRTLLARLVRSMRFEDFLARKWSSEKRFGLEGC 270 
Hs_E1kL         EQCQWIRQKFETPGVMQFSS-----EEKRTLLARLVRSMRFEDFLARKWSSEKRFGLEGC 270 
Rn_DHTKD1       EEKDWFARRFEELKKETFTT-----EERKHLSKLLLESQEFDHFLATKFATVKRYGGEGA 195 
Mm_DHTKD1       EERDWFARRFEELKKETFTT-----EERKYLSKLLLESQEFDHFLATKFATVKRYGGEGA 196 
Hs_DHTKD1       DEKDWFAKRFEELQKETFTT-----EERKHLSKLMLESQEFDHFLATKFSTVKRYGGEGA 195 
Lm_E1kB         ELRNWFR--QEVMDSLQSLP----TEERRLYYNDVVKACGFEKFLQLKYATKHRFGLDGG 253 
Lm_E1kA         DAKRFVRSQIELKDGCSALHRPMSREERLRIWDTVASAVFFEDFFKRKYSTQKRFGCDGA 290 
                :   :.    *              **:      :  :  *:.*:  *::: :*:* :*  
 
Rn_E1k          EVLIPALKTIIDMSSANGVDYVIMGMPHRGRLNVLANVIRKELEQIFCQFDSKLEAAD-- 341 
Mm_E1k          EVLIPALKTIIDMSSANGVDYVIMGMPHRGRLNVLANVIRKELEQIFCQFDSKLEAAD-- 341 
Hs_E1k          EVLIPALKTIIDKSSENGVDYVIMGMPHRGRLNVLANVIRKELEQIFCQFDSKLEAAD-- 341 
Rn_E1kL         EVMIPALKTIIDKSSEMGVENVILGMPHRGRLNVLANVIRKDLEQIFCQFDPKLEAAD-- 328 
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Mm_E1kL         EVMIPALKTIIDKSSEMGIENVILGMPHRGRLNVLANVIRKDLEQIFCQFDPKLEAAD-- 328 
Hs_E1kL         EVMIPALKTIIDKSSEMGIENVILGMPHRGRLNVLANVIRKDLEQIFCRFDPKLEAAD-- 328 
Rn_DHTKD1       ESMMGFFHELLKLSAYGGITDIIIGMPHRGRLNLLTGLLQLPPELMFRKMRGLSEFPENV 255 
Mm_DHTKD1       ESMMGFFHELLKLSAYGGITDIIIGMPHRGRLNLLTGLLQLPPELMFRKMRGLSEFPENV 256 
Hs_DHTKD1       ESMMGFFHELLKMSAYSGITDVIIGMPHRGRLNLLTGLLQFPPELMFRKMRGLSEFPENF 255 
Lm_E1kB         EALIPALKAAILTSSDLGVQSAIIGMPHRGRLNVLANVLRKSLRAILNEFEGR--VAIED 311 
Lm_E1kA         ESMVAGLRALLEKSSELGVQAINLGMPHRGRLNVLCHVIGKPFEVILKEFVGVTGQELHP 350 
                * ::  ::  :  *:  *:    :**.******:*  ::    . :: .:           
 
Rn_E1k          EGSGDMKYHLGMYHRRINRVTDRNITLSLVANPSHLEAADPVVMGKTKAEQFYCGDTE-- 399 
Mm_E1k          EGSGDMKYHLGMYHRRINRVTDRNITLSLVANPSHLEAADPVVMGKTKAEQFYCGDTE-- 399 
Hs_E1k          EGSGDMKYHLGMYHRRINRVTDRNITLSLVANPSHLEAADPVVMGKTKAEQFYCGDTE-- 399 
Rn_E1kL         EGSGDMKYHLGMYHERINRVTNRNITLSLVANPSHLEAVDPVVQGKTKAEQFYRGDAQ-- 386 
Mm_E1kL         EGSGDMKYHLGMYHERINRVTNRNITLSLVANPSHLEAVDPVVQGKTKAEQFYRGDAQ-- 386 
Hs_E1kL         EGSGDMKYHLGMYHERINRVTNRNITLSLVANPSHLEAVDPVVQGKTKAEQFYRGDAQ-- 386 
Rn_DHTKD1       AAIGDVLSHLTSSVD-LDFGAHRPLHVTMLPNPSHLEAINPVAVGKTRGRQQSQEDGDYS 314 
Mm_DHTKD1       ATIGDVLSHLTSSVD-LDFGAHQPLHVTMLPNPSHLEAVNPVAVGKTRGRQQSREDGDYS 315 
Hs_DHTKD1       SATGDVLSHLTSSVD-LYFGAHHPLHVTMLPNPSHLEAVNPVAVGKTRGRQQSRQDGDYS 314 
Lm_E1kB         AHLTGDVEYHLGKRKHVSLPNNKSIELDLLPNPSHLEAVNPLVLGKARARQTYTNDVE-- 369 
Lm_E1kA         FQIQSDVKYHLGYRGQLKLNSGKVMETEMLFNPSHLEAVNPFVQGYTRAMQVSLGEKG-- 408 
                    .   :       :     : :   :: ******* :*.. * ::. *    :     
 
Rn_E1k          -------GKKVMSILLHGDAAFAGQGIVYETFHLSDLPSYTTHGTVHVVVNNQIGFTTDP 452 
Mm_E1k          -------GKKVMSILLHGDAAFAGQGIVYETFHLSDLPSYTTHGTVHVVVNNQIGFTTDP 452 
Hs_E1k          -------GKKVMSILLHGDAAFAGQGIVYETFHLSDLPSYTTHGTVHVVVNNQIGFTTDP 452 
Rn_E1kL         -------GRKVMSILVHGDAAFAGQGVVYETFHLSDLPSYTTNGTVHVVVNNQIGFTTDP 439 
Mm_E1kL         -------GRKVMSILVHGDAAFAGQGVVYETFHLSDLPSYTTNGTVHVVVNNQIGFTTDP 439 
Hs_E1kL         -------GKKVMSILVHGDAAFAGQGVVYETFHLSDLPSYTTNGTVHVVVNNQIGFTTDP 439 
Rn_DHTKD1       PNGSAQPGDKVICLQVHGDASFCGQGIVLETFTLSNLPHFRIGGSIHLIVNNQLGYTTPA 374 
Mm_DHTKD1       PNGSAQPGDKVICLQVHGDASFCGQGIVLETFTLSNLPHFRIGGSIHLIVNNQLGYTTPA 375 
Hs_DHTKD1       PDNSAQPGDRVICLQVHGDASFCGQGIVPETFTLSNLPHFRIGGSVHLIVNNQLGYTTPA 374 
Lm_E1kB         -------CTAVLPILIHGDAAFAGQGSCYETMGFCELENFHVGGTLHLVINNQIGFTTNP 422 
Lm_E1kA         -------REKVLPIEIHGDAAFAGQGVAFETMCISEVGEQDTGGTVHVVCNNQIGFTTDP 461 
                          *: : :****:*.***   **: :.::      *::*:: ***:*:** . 
 
Rn_E1k          RMARSSPYPTDVARVVNAPIFHVNSDDPEAVMYVCKVAAEWRNTFHKDVVVDLVCYRRNG 512 
Mm_E1k          RMARSSPYPTDVARVVNAPIFHVNSDDPEAVMYVCKVAAEWRNTFHKDVVVDLVCYRRNG 512 
Hs_E1k          RMARSSPYPTDVARVVNAPIFHVNSDDPEAVMYVCKVAAEWRSTFHKDVVVDLVCYRRNG 512 
Rn_E1kL         RMARSSPYPTDVARVVNAPIFHVNADDPEAVIYVCSVAAEWRNTFNKDVVVDLVCYRRRG 499 
Mm_E1kL         RMARSSPYPTDVARVVNAPIFHVNADDPEAVIYVCSVAAEWRNTFNKDVVVDLVCYRRRG 499 
Hs_E1kL         RMARSSPYPTDVARVVNAPIFHVNADDPEAVIYVCSVAAEWRNTFNKDVVVDLVCYRRRG 499 
Rn_DHTKD1       ERGRSSLYSSDIGKLVGCAIIHVNGDSPEEVVRATRLAFEYQRQFRKDVIIDLLCYRQWG 434 
Mm_DHTKD1       ERGRSSLYSSDIGKLVGCAIIHVNGDSPEEVVRATRLAFEYQRQFRKDVIVDLLCYRQWG 435 
Hs_DHTKD1       ERGRSSLYCSDIGKLVGCAIIHVNGDSPEEVVRATRLAFEYQRQFRKDVIIDLLCYRQWG 434 
Lm_E1kB         KDSRASAYCTDLSKVNNAPVMHVNGDDVDACVKAAKIAARFRQQFHHDIIIDLVCYRRYG 482 
Lm_E1kA         KSSRSSAYCSDLGRVYNCPILHVNGDYPEEVIRVFEFAAEYRARFHKSVVIDLVCYRRFG 521 
                . .*:* * :*:.:: ...::***.*  :  : .  .* .::  *.:.:::**:***: * 
 
Rn_E1k          HNEMDEPMFTQPLMYKQIRKQKPVLQKYAELLVSQGVVNQPEYEEEISKYDKICEEAFTR 572 
Mm_E1k          HNEMDEPMFTQPLMYKQIRKQKPVLQKYAELLVSQGVVNQPEYEEEISKYDKICEEAFTR 572 
Hs_E1k          HNEMDEPMFTQPLMYKQIRKQKPVLQKYAELLVSQGVVNQPEYEEEISKYDKICEEAFAR 572 
Rn_E1kL         HNEMDEPMFTQPLMYKQIHKQVPVLKKYADKLIAEGTVTLQEFEEEIAKYDRICEEAYGR 559 
Mm_E1kL         HNEMDEPMFTQPLMYKQIHKQVPVLKKYADKLIAEGTVTLQEFEEEIAKYDRICEEAYGR 559 
Hs_E1kL         HNEMDEPMFTQPLMYKQIHRQVPVLKKYADKLIAEGTVTLQEFEEEIAKYDRICEEAYGR 559 
Rn_DHTKD1       HNELDEPFFTNPVMYKIIRARKSIPDTYAEHLIASGLMTQEEVSDIKASYYAKLNGHLAN 494 
Mm_DHTKD1       HNELDEPFFTNPVMYKIIRARKSIPDTYAEHLIASGLMTQEEVSDIKTSYYTKLNDHLAN 495 
Hs_DHTKD1       HNELDEPFFTNPIMYKIIRARKSIPDTYAEHLIAGGLMTQEEVSEIKSSYYAKLNDHLNN 494 
Lm_E1kB         HNELDEPFFTNPQLYHQIRQHPSVVDIYTKTLIKDGVLTAEEAKAKDKDWEGVLRQAYDR 542 
Lm_E1kA         HNENDDPSITQPLMYERVRAMPDVFRRYTDALITQGILTPQQSTQKAID-EKARYGSYQE 580 
                *** * *  *:* :*. ::    :   *:. *:  * :.  :      .          . 
 
Rn_E1k          SKDEK---------ILHIKHWLDSPWPGFFTLDGQPRSMTCPSTGLEEDILTHIGNVASS 623 
Mm_E1k          SKDEK---------ILHIKHWLDSPWPGFFTLDGQPRSMTCPSTGLEEDVLFHIGKVASS 623 
Hs_E1k          SKDEK---------ILHIKHWLDSPWPGFFTLDGQPRSMSCPSTGLTEDILTHIGNVASS 623 
Rn_E1kL         SKDKK---------ILHIKHWLDSPWPGFFNVDGEPKSMTYPTTGIPEDTLSHIGNVASS 610 
Mm_E1kL         SKDKK---------ILHIKHWLDSPWPGFFNVDGEPKSMTCPTTGIPEEMLTHIGSVASS 610 
Hs_E1kL         SKDKK---------ILHIKHWLDSPWPGFFNVDGEPKSMTCPATGIPEDMLTHIGSVASS 610 
Rn_DHTKD1       VAHYS---------PPAPH--LQARWQGLVQP---AACVTTWDTGVPLELLRFVGVKSVE 540 
Mm_DHTKD1       VAHYS---------PPATN--LQARWQGLVQP---EACVTTWDTGVPLELLRFIGVKSVE 541 
Hs_DHTKD1       MAHYR---------PPALN--LQAHWQGLAQP---EAQITTWSTGVPLDLLRFVGMKSVE 540 
Lm_E1kB         MNSAQNFVKVMPVFDPESENTSADLSSAKIAATRVPPPVSAVDTGVETQTLRAAGLRLAS 602 
Lm_E1kA         AAAQVNYAEYLKKSIPD-KWKCMKYSDELGNVTQHP-------TAITQETVDKVLKALKT 632 
                                  .                        *.:  : :          
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Rn_E1k          VPVENFTIHGGLSRILKTRRELVTNRT-VDWALAEYMAFGSLLKEGIHVRLSGQDVERGT 682 
Mm_E1k          VPVENFTIHGGLSRILKTRRELVTNRT-VDWALAEYMAFGSLLKEGIHVRLSGQDVERGT 682 
Hs_E1k          VPVENFTIHGGLSRILKTRGEMVKNRT-VDWALAEYMAFGSLLKEGIHIRLSGQDVERGT 682 
Rn_E1kL         VPLEDFKIHTGLSRILRGRADMTKKRT-VDWALAEYMAFGSLLKEGIHVRLSGQDVERGT 669 
Mm_E1kL         VPLEDFKIHTGLSRILRGRADMTKKRT-VDWALAEYMAFGSLLKEGIHVRLSGQDVERGT 669 
Hs_E1kL         VPLEDFKIHTGLSRILRGRADMTKNRT-VDWALAEYMAFGSLLKEGIHVRLSGQDVERGT 669 
Rn_DHTKD1       VPEELQLHSHLLKMYVQSRMEKVKNGTNLDWATAETLALGSLLAQGFNVRLSGQDVERGT 600 
Mm_DHTKD1       VPEELQVHSHLLKMYVQSRMEKVKNGSGLDWATAETLALGSLLAQGFNVRLSGQDVERGT 601 
Hs_DHTKD1       VPRELQMHSHLLKTHVQSRMEKMMDGIKLDWATAEALALGSLLAQGFNVRLSGQDVERGT 600 
Lm_E1kB         IPKEMQKPHPVVERTYAARKKGTEQGDAIEWCQAELMALATLSMQGVPIRLTGEDVERGT 662 
Lm_E1kA         YPEGFQL-HPKLKAVLDRRNETIETGEGIEWGTAEALAFGSLLLEGHQVRVTGEDVERGT 691 
                 *         :.     * .       ::*  ** :*:.:*  :*  :*::*:** *** 
 
Rn_E1k          FSHRHHVLHDQNVDKRTCIPMNHLWPNQAPY-TVCNSSLSEYGVLGFELGFAMASPNALV 741 
Mm_E1k          FSHRHHVLHDQNVDKRTCIPMNHLWPNQAPY-TVCNSSLSEYGVLGFELGFAMASPNALV 741 
Hs_E1k          FSHRHHVLHDQNVDKRTCIPMNHLWPNQAPY-TVCNSSLSEYGVLGFELGFAMASPNALV 741 
Rn_E1kL         FSHRHHVLHDQDVDRRTCVPMNHLWPDQAPY-TVCNSSLSEYGVLGFELGYAMASPNALV 728 
Mm_E1kL         FSHRHHVLHDQEVDRRTCVPMNHLWPDQAPY-TVCNSSLSEYGVLGFELGYAMASPNALV 728 
Hs_E1kL         FSHRHHVLHDQEVDRRTCVPMNHLWPDQAPY-TVCNSSLSEYGVLGFELGYAMASPNALV 728 
Rn_DHTKD1       FSQRHAMVVCQNTDD-VYIPLNHMDPNQKGFLEVSNSPLSEEAVLGFEYGMSIESPKLLP 659 
Mm_DHTKD1       FSQRHAMVVCQDTDD-AYIPLNHMDPNQKGFLEVSNSPLSEEAVLGFEYGMSIESPTLLP 660 
Hs_DHTKD1       FSQRHAIVVCQETDD-TYIPLNHMDPNQKGFLEVSNSPLSEEAVLGFEYGMSIESPKLLP 659 
Lm_E1kB         FTQRHAGITDMKTNL-KYFPVKMLSPS-QALITISNSSLSELGVCGFEMGYNMENTRSIT 720 
Lm_E1kA         FAQRHAVIHDQSQER-TYVPLAHISDT-QGRMIINNSPLSEYGMLGYAAGYSLYDPTSLV 749 
                *::**  :   . :    .*:  :         : **.*** .: *:  *  : ..  :  
 
Rn_E1k          LWEAQFGDFNNMAQCIIDQFICPGQAKWVRQNGIVLLLPHGMEGMGPEHSSARPERFLQM 801 
Mm_E1k          LWEAQFGDFNNMAQCIIDQFICPGQAKWVRQNGIVLLLPHGMEGMGPEHSSARPERFLQM 801 
Hs_E1k          LWEAQFGDFHNTAQCIIDQFICPGQAKWVRQNGIVLLLPHGMEGMGPEHSSARPERFLQM 801 
Rn_E1kL         LWEAQFGDFHNTAQCIIDQFISTGQAKWVRHNGIVLLLPHGMEGMGPEHSSARPERFLQM 788 
Mm_E1kL         LWEAQFGDFHNTAQCIIDQFISTGQAKWVRHNGIVLLLPHGMEGMGPEHSSARPERFLQM 788 
Hs_E1kL         LWEAQFGDFHNTAQCIIDQFISTGQAKWVRHNGIVLLLPHGMEGMGPEHSSARPERFLQM 788 
Rn_DHTKD1       LWEAQFGDFFNGAQIIFDTFISGGEAKWLLQSGLVILLPHGYDGAGPDHSSCRIERFLQM 719 
Mm_DHTKD1       LWEAQFGDFFNGAQIIFDTFISGGEAKWLLQSGLVILLPHGYDGAGPEHSSCRIERFLQM 720 
Hs_DHTKD1       LWEAQFGDFFNGAQIIFDTFISGGEAKWLLQSGIVILLPHGYDGAGPDHSSCRIERFLQM 719 
Lm_E1kB         IWEAQFGDFANGAQVIFDQFLSCCEEKWNEHSSLVLSLPHGYSGAGPEHSSARVERFLQL 780 
Lm_E1kA         IWEAQYGDFANGATIVFDQFLSAGESKWNQQQSCIVTLPHGYDGKGAEHSSGRLERFLQM 809 
                :****:*** * *  ::* *:.  : **  :.. :: **** .* *.:*** * *****: 
 
Rn_E1k          CNDDPDVLP---NLQEENFDISQLYDCNWIVVNCSTPGNFFHVLRRQILLPFRKP----- 853 
Mm_E1k          CNDDPDVLP---DLQEENFDINQLYDCNWIVVNCSTPGNFFHVLRRQILLPFRKP----- 853 
Hs_E1k          CNDDPDVLP---DLKEANFDINQLYDCNWVVVNCSTPGNFFHVLRRQILLPFRKP----- 853 
Rn_E1kL         SNDDSDAYP---VFTED-FEVSQLYDCNWIVVNCSTPASYFHVLRRQVLLPFRKPGWMWG 844 
Mm_E1kL         SNDDSDAYP---VFTED-FEVSQLYDCNWIVVNCSTPASYFHVLRRQILLPFRKP----- 839 
Hs_E1kL         SNDDSDAYP---AFTKD-FEVSQLYDCNWIVVNCSTPANYFHVLRRQILLPFRKP----- 839 
Rn_DHTKD1       CDSAEEGVD---SDTVN-----------MFVVHPTTPAQYFHLLRRQMMRNFRKP----- 760 
Mm_DHTKD1       CDSAEEGVD---SDTVN-----------MFVVHPTTPAQYFHLLRRQMIRNFRKP----- 761 
Hs_DHTKD1       CDSAEEGVD---GDTVN-----------MFVVHPTTPAQYFHLLRRQMVRNFRKP----- 760 
Lm_E1kB         SDDSDRVPSDFRHFPNDQALEIRIRRHNWQVTYPSTPANYFHLLRRQGLREFAKP----- 835 
Lm_E1kA         SSEDVTTP--------AYSKEERAHRINWEITYPSTPAQYFHLLRRHQKRNFRKA----- 856 
                ...                           :.  :**..:**:***:    * *.      
 
Rn_E1k          --------------LIVFTPKSLLRHPEARTSFDEMLPGTHFQRVIPEDGPAAQNPDKVK 899 
Mm_E1k          --------------LIVFTPKSLLRHPEARTSFDEMLPGTHFQRVIPENGPAAQDPHKVK 899 
Hs_E1k          --------------LIIFTPKSLLRHPEARSSFDEMLPGTHFQRVIPEDGPAAQNPENVK 899 
Rn_E1kL         PIDGAPGGWLFAFQLIVFTPKSLLRHPDAKSSFDQMVSGTSFQRMIPEDGPAAQSPERVE 904 
Mm_E1kL         --------------LIVFTPKSLLRHPDAKSSFDQMVSGTSFQRLIPEDGPAAHSPEQVQ 885 
Hs_E1kL         --------------LIIFTPKSLLRHPEAKSSFDQMVSGTSFQRVIPEDGAAARAPEQVQ 885 
Rn_DHTKD1       --------------LIVASPKMLLRYPVAVSTLEEMAPGTAFKPVIGD---SSVDPKNVK 803 
Mm_DHTKD1       --------------LIVASPKMLLRYPAAVSTLEEMAPGTAFKPVIGD---SSVDPKNVK 804 
Hs_DHTKD1       --------------LIVASPKMLLRLPAAVSTLQEMAPGTTFNPVIGD---SSVDPKKVK 803 
Lm_E1kB         --------------LINLFSKARLRAPN-LSKLSDMTQGTSFKAVIDT---ARAKDTVAR 877 
Lm_E1kA         --------------LVIFFSKKYLRAPN-VSTLEELTSG-EFQPVIPD---LSVPASQAR 897 
                              *:   .*  ** *   :.:.::  *  *: :*            .. 
 
Rn_E1k          RLLFCTGKVYYDLTRER----KARDMAE-EVAITRIEQLSPFPFDLLLKEAQKYPN---- 950 
Mm_E1k          RLLFCTGKVYYDLTRER----KARNMEE-EVAITRIEQLSPFPFDLLLKEAQKYPN---- 950 
Hs_E1k          RLLFCTGKVYYDLTRER----KARDMVG-QVAITRIEQLSPFPFDLLLKEVQKYPN---- 950 
Rn_E1kL         RLIFCTGKVYYDLVKER----SSQGLEK-QVAITRLEQISPFPFDLIMREAEKYSG---- 955 
Mm_E1kL         RLIFCTGKVYYDLVKER----SSQGLEQ-QVAITRLEQISPFPFDLIMREAEKYSG---- 936 
Hs_E1kL         RLIFCTGKVYYDLVKER----SSQDLEE-KVAITRLEQISPFPFDLIKQEAEKYPG---- 936 
Rn_DHTKD1       TLIFCSGKHFYALLKQR----ESLGAKKRDFAIIRLEELCPFPLDSLQQEMGKYKHV--- 856 
Mm_DHTKD1       TLIFCSGKHFYALLKQR----ESLGTKKHDFAIIRLEELCPFPLDALQQEMSKYKHV--- 857 
Hs_DHTKD1       TLVFCSGKHFYSLVKQR----ESLGAKKHDFAIIRVEELCPFPLDSLQQEMSKYKHV--- 856 
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Lm_E1kB         KVVFCSGQIESIVNDAKTAMQKETPGVHDDVVLVTVEQLAPFPWEEVADVMEKYAQRNPN 937 
Lm_E1kA         RLVMCTGQIYHYLNKYR-----ETKGVKD-VALVRVEELSPFPVAEVQQLLAEYEK---- 947 
                 :::*:*:    :   :             ..:  :*::.***   :     :*       
 
Rn_E1k          AELAWCQEEHKNQGYYDYVKPRLRTTIDRAK----PVWYAGRDPAAAPATGNKKTHLTEL 1006 
Mm_E1k          AELAWCQEEHKNQGYYDYVKPRLRTTIDRAK----PVWYAGRDPAAAPATGNKKTHLTEL 1006 
Hs_E1k          AELAWCQEEHKNQGYYDYVKPRLRTTISRAK----PVWYAGRDPAAAPATGNKKTHLTEL 1006 
Rn_E1kL         AELVWCQEEHKNMGYYDYISPRFMTLLGHSR----PIWYVGREPAAAPATGNKNTHLVSL 1011 
Mm_E1kL         AELVWCQEEHKNMGYYDYISPRFMTLLGHSR----PIWYVGRDPAAAPATGNKNAHLVSL 992 
Hs_E1kL         AELAWCQEEHKNMGYYDYISPRFMTILRRAR----PIWYVGRDPAAAPATGNRNTHLVSL 992 
Rn_DHTKD1       QDIIWSQEEPQNMGPWSFVYPRFEKQLACK------LRLVSRPPLPAPAVGIGTVHQQQH 910 
Mm_DHTKD1       RDVIWSQEEPQNMGPWSFVSPRFEKQLACR------LRLVSRPPLPAPAVGIGTVHQQQH 911 
Hs_DHTKD1       KDHIWSQEEPQNMGPWSFVSPRFEKQLACK------LRLVGRPPLPVPAVGIGTVHLHQH 910 
Lm_E1kB         TEFVWLQEEPRNMGMWTHMRPRMNSLMRHLGLKQTRVNVVSRPSAASPSTGYGSVHVAEE 997 
Lm_E1kA         AELMWAQEEPKNMGSWAHVEPRIEDYTK----GERELRYAGRSITAAPSTGYKSKHEKEQ 1003 
                 :  * *** :* * : .: **:             :  ..*   . *:.*  . *  .  
 
Rn_E1k          QRFLDTAFDLDAFKKFS-                                           1023 
Mm_E1k          QRFLDTAFDLDAFKKFS-                                           1023 
Hs_E1k          QRLLDTAFDLDVFKNFS-                                           1023 
Rn_E1kL         RKFLDTAFNLKAFEGKTF                                           1029 
Mm_E1kL         RRFLDTAFNLKAFEGKTF                                           1010 
Hs_E1kL         KKFLDTAFNLQAFEGKTF                                           1010 
Rn_DHTKD1       EAILFKTFTS--------                                           920 
Mm_DHTKD1       EDILSKTFTQ--------                                           921 
Hs_DHTKD1       EDILAKTFA---------                                           919 
Lm_E1kB         KKLIAETLA---------                                           1006 
Lm_E1kA         EIICEMVFH---------                                           1012 
                . :   .:           
 
Figure 7.1 Alignment of E1k, E1k-like and DHTKD1 protein sequences 
ClustalW alignment of L. major E1k-A and E1k-B (LmE1k-A and LmE1k-B) (see Table 3.1) with: R. 
norvegicus E1k (RnE1k) (accession number NP_001017461); M. musculus E1k (MmE1k) 
(accession number CAI24405); H. sapiens E1k (HsE1k) (accession number NP_002532); R. 
norvegicus E1k-like (RnE1kL) (accession number NP_001099532); M. musculus E1k-like 
(MmE1kL) (accession number AAI57971); H. sapiens E1k-like (HsE1kL) (accession number 
NP_060715); R. norvegicus DHTKD1 (RnDHTKD1) (accession number NP_001099532); M. 
musculus DHTKD1 (MmDHTKD1) (accession number AAI57971); H. sapiens DHTKD1 (Hs 
DHTKD1) (accession number NP_061176). The alignment indicates identical residues (*), 
conserved residues (:) and homologous residues (.). Red residues indicate conserved amino acids 
within different motifs that fulfil various roles within E1k enzymes. Blue residues and green residues 
are those that are conserved in E1k/E1kL proteins but not in DHTKD1 or LmE1kA/LmE1kB, 
respectively. Refer also to Table 7.1. 
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Signature specific motif 
Functiona E1k consensusa Hs E1ka Hs DHTKD1a Lm E1kAb Lm E1kBb
Lipoyl domain
complementarity KRF(G/s)(L/i)EG KRFGLEG KRYGGEG KRFGCDG HRFGLDG
2-Oxo substrate side chain
binding pocket GM(A/p)HRGRLN GMPHRGRLN GMPHRGRLN GMAHRGRLN GMPHRGRLN
ThDP interaction
2-Oxo substrate side chain
binding pocket GD(V/m)KYH(L/m,q)G GDVKYHLG GDVLSHLT SDVKYHLG GDVEYHLG
Stabilization of ThDP binding
Shielding S of ES from the
solvent
NPSHLE NPSHLE NPSHLE NPSHLE NPSHLE
Binding of ThDP
pyrophosphate group G(Q/e)G GQG GQG GQG GQG
Binding of ThDP
pyrophosphate group and
thiazole ring GFTT GFTT GYTT GFTT GFTT
Hydrogen bond network
Interaction with ThDP
through loop 1
Catalysis of decarboxylation
and reductive acylation
GHNExD(E/q)PxxTQ GHNEMDEPMFTQ GHNELDEPFYTN GHNENDDPSITQ GHNETDLPDFTQ
Lipoyl domain interaction
Lipoyl domain
complementarity Wxx(A/g)E WALAE WATAE WGTAE WCQAE
Lipoyl domain
complementarity G(Q/e)DxxRGTF GQDVERGTF GQDVGRGTF GEDVERGTF GEDVERGTF
ThDP binding WEAQ(F/y)GDF WEAQFGDF WEAQFGDF WEAQYGDF WEAQFGDF
Catalysis
Shielding leaving
carboxylate from solvent LPHG(Y/m)(E/d)GxGPEHSS LPHGMEGMGPEHSS LPHGYDGAGPDHSS LPHGYDGKGAEHSS LPHGYSGAGPEHSS
Lipoyl domain interaction
Lipoyl domain
complementarity LLR LLR LLR YLR RLR
Ca2+ binding DxDxDx DADLDS QALLEN DTDVTE HADNCI
ExDxDx ESDLDK - FSDKDL ?
NDDxDx NDDPDV MCDSAE? SEDVTT SDDSDR
 
Table 7.1 Summary of conserved motifs in LmE1k-A and LmE1k-B 
This table summarises which motifs contribute to specific activities within E1k enzymes (Bunik & 
Degtyarev, 2008)a. Based upon ClustalW alignment (see Figure 7.1), conservation of sequences 
comprising these motifs was determined for LmE1k-A and LmE1k-Bb. Blue residues and green 
residues are those that are conserved in E1k/E1kL motifs in other species but not in HsDHTKD1 or 
LmE1kA/LmE1kB, respectively. 
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Hs_E1p-α          MRKMLAAVSRVLSGASQKPASRVLVASRNFANDATFEIKKCDLHRLEEGPPVTTVLTRED 60 
Rn_E1p-α          MRKMLAAVSHVLAGAAQKPASRVLVASRNFANDATFEIKKCDLHRLEEGPPVTTVLTRED 60 
Lm_E1p-α          ---MFKCATRCLLDTKTVP----LKPQR------PFKLHTAGRTDMAP-LPTQAVYDAEQ 46 
                     *: ..:: * .:   *    * ..*      .*:::...   :    *. :*   *: 
 
Hs_E1p-α          GLKYYRMMQTVRRMELKADQLYKQKIIRGFCHLCDGQEACCVGLEAGINPTDHLITAYRA 120 
Rn_E1p-α          GLKYYRMMQTVRRMELKADQLYKQKIIRGFCHLCDGQEACCVGLEAGINPTDHLITAYRA 120 
Lm_E1p-α          LKQSLALMFRIRRMESLCDQSYKLKKIRGFCHLYIGQEAIPAGMENVLTFEDPIITGYRD 106 
                    :   :*  :****  .** ** * *******  ****  .*:*  :.  * :**.**  
 
Hs_E1p-α          HGFTFTRGLSVREILAELTGRKGGCAKGKGGSMHMYAKN--FYGGNGIVGAQVPLGAGIA 178 
Rn_E1p-α          HGFTFTRGLPVRAILAELTGRRGGCAKGKGGSMHMYAKN--FYGGNGIVGAQVPLGAGIA 178 
Lm_E1p-α          HGWYISRGGKPEDVFAEMFGRQGGCSKGKGGSMHMYRVDNGFYGGNGIVGAQVSIGAGLA 166 
                  **: ::**   . ::**: **:***:**********  :  ************.:***:* 
 
Hs_E1p-α          LACKYNGKD---EVCLTLYGDGAANQGQIFEAYNMAALWKLPCIFICENNRYGMGTSVER 235 
Rn_E1p-α          LACKYNGKD---EVCLTLYGDGAANQGQIFEAYNMAALWKLPCIFICENNRYGMGTSVER 235 
Lm_E1p-α          WRFAMENRDSPKHVAVTFYGDGAANQGQIYESMNIAALQRLPVIFAVENNHFGMGTSAAR 226 
                       :.:*   .*.:*:***********:*: *:*** :** **  ***::*****. * 
 
Hs_E1p-α          AAASTDYYKRGDFIPGLRVDGMDILCVREATRFAAAYCRSGKGPILMELQTYRYHGHSMS 295 
Rn_E1p-α          AAASTDYYKRGDFIPGLRVDGMDILCVREATKFAAAYCRSGKGPILMELQTYRYHGHSMS 295 
Lm_E1p-α          GSYQAEFYRRGDYIPGIKVDGMDVLAVQEGTRYARDYCMSGKGPIVMELDCYRYMGHSMS 286 
                  .: .:::*:***:***::*****:*.*:*.*::*  ** ******:***: *** ***** 
 
Hs_E1p-α          DPGVSYRTREEIQEVRSKSDPIMLLKDRMVNSNLASVEELKEIDVEVRKEIEDAAQFATA 355 
Rn_E1p-α          DPGVSYRTREEIQEVRSKSDPIMLLKDRMVNSNLASVEELKEIDVEVRKEIEDAAQFATA 355 
Lm_E1p-α          DPDNQYRTKSDIQHVKQERDCIRKMREFMATEGIMTEDEMSKMEKDVKKEVDQDLQKAQK 346 
                  **. .***:.:**.*:.: * *  ::: *....: : :*:.::: :*:**:::  * *   
 
Hs_E1p-α          DPEPPLEELGYHIYSSDPPFEVRGANQWIKFKSVS                          390 
Rn_E1p-α          DPEPPLEELGYHIYSSDPPFEVRGANQWIKFKSVS                          390 
Lm_E1p-α          QPMTKLDELFTDIYVG-EQYEHRTCQGTVYHKP--                          378 
                  :* . *:**  .** .   :* * .:  : .*.   
 
Figure 7.2 Alignment of E1p-α protein sequences 
ClustalW alignment of L. major E1p-α (LmE1p-α) (see Table 3.1) with homologues in R. 
norvegicus (RnE1p-α) (accession number CAA78146) and H. sapiens (HsE1p-α) (accession 
number NP_000275). The alignment indicates identical residues (*), conserved residues (:) and 
homologous residues (.). Red residues indicate conserved amino acids within different motifs that 
fulfil various roles within E1p-α enzymes. Green residues are those that are conserved in E1p-α 
proteins found in other species but not in LmE1p-α. Refer also to Table 7.2. 
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Hs_E1p-β         MAAVSGLVRRPLREVSGLLKRRFHWTAPAALQVTVRDAINQGMDEELERDEKVFLLGEEV 60 
Rn_E1p-β         MAAVAGLVRGPLRQASGLLKRRFHRSAPAAVQLTVREAINQGMDEELERDEKVFLLGEEV 60 
Lm_E1p-β         ---MRRFASRALFSASAAMAARCATTN-----MTVRDAIHSALDEELAREEKVFVIGEEV 52 
                    :  :.  .* ..*. :  *   :      :***:**:..:**** *:****::**** 
 
Hs_E1p-β         AQYDGAYKVSRGLWKKYGDKRIIDTPISEMGFAGIAVGAAMAGLRPICEFMTFNFSMQAI 120 
Rn_E1p-β         AQYDGAYKVSRGLWKKYGDKRIIDTPISEMGFAGIAVGAAMAGLRPICEFMTFNFSMQAI 120 
Lm_E1p-β         AQYQGAYKVTKGLMDKYGKDRIIDMPITEHGFAGMAVGAALSGLRPVCEFMTFNFAMQAI 112 
                 ***:*****::** .***..**** **:* ****:*****::****:********:**** 
 
Hs_E1p-β         DQVINSAAKTYYMSGGLQPVPIVFRGPNGASAGVAAQHSQCFAAWYGHCPGLKVVSPWNS 180 
Rn_E1p-β         DQVINSAAKTYYMSAGLQPVPIVFRGPNGASAGVAAQHSQCFAAWYGHCPGLKVVSPWNS 180 
Lm_E1p-β         DQLVNSAGKSLYMSGGQMKCPIVFRGPNGASAGVGAQHSQCFGPWYASVPGLKVIAPYNC 172 
                 **::***.*: ***.*    **************.*******..**.  *****::*:*. 
 
Hs_E1p-β         EDAKGLIKSAIRDNNPVVVLENELMYGVPFEFLPEAQSKDFLIPIGKAKIERQGTHITVV 240 
Rn_E1p-β         EDAKGLIKSAIRDDNPVVMLENELMYGVAFELPTEAQSKDFLIPIGKAKIERQGTHITVV 240 
Lm_E1p-β         EDARGMIKAAIRDDNAVVVLEHELLYSESFPVTDEAADKNFVIPFGKAKIEREGKDITLI 232 
                 ***:*:**:****:*.**:**:**:*. .* .  ** .*:*:**:*******:*..**:: 
 
Hs_E1p-β         SHSRPVGHCLEAAAVLSKEGVECEVINMRTIRPMDMETIEASVMKTNHLVTVEGGWPQFG 300 
Rn_E1p-β         AHSRPVGHCLEAAAVLSKEGIECEVINLRTIRPMDIEAIEASVMKTNHLVTVEGGWPQFG 300 
Lm_E1p-β         GFSRGVDLCLKAAEKLAAEGVQAEVINLRSLRPLDRHTILSSIKKTHRAVTVDESFPVCN 292 
                 ..** *. **:**  *: **::.****:*::**:* .:* :*: **:: ***: .:*  . 
 
Hs_E1p-β         VGAEICARIMEGPAFNFLDAPAVRVTGADVPMPYAKILEDNSIPQVKDIIFAIKKTLNI 359 
Rn_E1p-β         VGAEICARIMEGPAFNFLDAPAVRVTGADVPMPYAKILEDNSIPQVKDIIFAIKKTLNI 359 
Lm_E1p-β         IGAEICACVMESDTFDYLDAPIERVSCADCPTPYSKDIEMASQPQVADVMAAAKRVLS- 350 
                 :****** :**. :*::****  **: ** * **:* :*  * *** *:: * *:.*.  
 
Figure 7.3 Alignment of E1p-β protein sequences 
ClustalW alignment of L. major E1p-β (LmE1p-β) (see Table 3.1) with homologues in R. norvegicus 
RnE1p-β) (accession number NP_001007621) and H. sapiens (HsE1p-β) (accession number 
NP_000916). The alignment indicates identical residues (*), conserved residues (:) and 
homologous residues (.). Red residues indicate conserved amino acids within different motifs that 
fulfil various roles within E1p-α enzymes. Green residues are those that are conserved in E1p-β 
proteins found in other species but not in LmE1p-β. Refer also to Table 7.2. 
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Signature specific motif 
Functiona E1p consensusa Hs E1p-alphaa Lm E1p-alphab Hs E1p-betaa Lm E1p-betab
Lipoyl domain
complementarity IRGFCHL IRGFCHL IRGFCHL - -
2-Oxo substrate side chain
binding pocket IT(A/s)YR ITAYR ITGYR - -
ThDP interaction
2-Oxo substrate side chain
binding pocket GKGGSMH GKGGSMH GKGGSMH - -
Stabilization of ThDP binding
Shielding S of ES from the
solvent
FYGG(N/h)GIVGAQ FYGGNGIVGAQ FYGGNGIVGAQ - -
Binding of ThDP
pyrophosphate group NQGQ NQGQ NQGQ - -
Binding of ThDP
pyrophosphate group and
thiazole ring GMGT GMGT GMGT - -
Hydrogen bond network
Interaction with ThDP
through loop 1
Catalysis of decarboxylation
and reductive acylation
TYRY(H/g)GHSMSDPG TYRYHGHSMSDPG CYRYMGHSMSDPD - -
Lipoyl domain interaction
Lipoyl domain
complementarity TVR(D/e)A(L/i)N - - TVRDAIN TVRDAIH
Lipoyl domain
complementarity GEEVxQYxGAYK - - GEEVAQYDGAYK GEEVAQYQGAYK
ThDP binding EFM(T/s)FNFSMQAID - - EFMTFNFSMQAID EFMTFNFAMQAID
Catalysis
Shielding leaving
carboxylate from solvent VFRGPNGAxxGVxAQHSQ - - VFRGPNGASAGVAAQHSQ VFRGPNGASAGVGAQHSQ
Lipoyl domain interaction
Lipoyl domain
complementarity (L/m)YG - - MYG LYS
 
Table 7.2 Summary of conserved motifs in LmE1p-α and LmE1p-β 
This table summarises which motifs contribute to specific activities within E1p enzymes (Bunik & 
Degtyarev, 2008)a. Based upon ClustalW alignments (see Figure 7.2 and Figure 7.3), conservation 
of sequences comprising these motifs was determined for LmE1p-αand LmE1p-βb. Green residues 
are those that are conserved in E1p-α/E1p-β motifs in other species but not in LmE1p-αand 
LmE1p-β. 
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Hs_E1b-α          ------------MAVAIAAARVWRLNRGLSQAALLLLRQPG---ARGLARSHPPRQQQQ- 44 
Rn_E1b-α          ------------MAVAMSAAKIWRPSRGLRQAALLLLGRPG---ARGLARFHPSRQQQQQ 45 
Lm_E1b-α          MFHISRAVRCNALATAIAGRTSLSDAIRQVQKVWNLDFKDGPVITSTLAFNDEPDPAAPI 60 
                              :*.*::.           * .  *  : *   :  **  . .       
 
Hs_E1b-α          FSSLDDK-PQFPGASAEFIDKLEFIQPNVISGIPIYRVMDRQGQIINPSEDPH--LPKEK 101 
Rn_E1b-α          FPSLDDK-PQFPGASAEFVDKLEFIQPNVISGIPIYRVMDRQGQIINPSEDPH--LPQEE 102 
Lm_E1b-α          FHVLDLQGRVFVEDKADSRAAAATPSTVNEAGKMESQSADVGEVFRYHAEDEMSVITREV 120 
                  *  ** :   *   .*:        ..   :*    :  *    :   :**    :.:*  
 
Hs_E1b-α          VLKLYKSMTLLNTMDRILYESQRQGRISFYMTNYGEEGTHVGSAAALDNTDLVFGQYREA 161 
Rn_E1b-α          VLKLYRSMTLLNTMDRILYESQRQGRISFYMTNYGEEGTHVGSAAALERTDLVFGQYREA 162 
Lm_E1b-α          AQGMMSAMLTHNTMDKIMLEAQRQGRISFYMTMFGEEAAVIGAAAGLASNDELFAQYREA 180 
                  .  :  :*   ****:*: *:*********** :***.: :*:**.*  .* :*.***** 
 
Hs_E1b-α          GVLMYRDYPLELFMAQCYGNISDLGKGRQMPVHYGCKERHFVTISSPLATQIPQAVGAAY 221 
Rn_E1b-α          GVLMYRDYPLELFMAQCYGNVSDPGKGRQMPVHYGCKERHFVTISSPLATQIPQAVGAAY 222 
Lm_E1b-α          GILTYRGYTIPEFIAQCMGNCECDAKGRQMPIHYGSKRLHAQMVSSPLATQIPHGAGAGY 240 
                  *:* **.*.:  *:*** ** .  .******:***.*. *   :*********:..**.* 
 
Hs_E1b-α          AAKRAN-----------------ANRVVICYFGEGAASEGDAHAGFNFAATLECPIIFFC 264 
Rn_E1b-α          AAKRAN-----------------ANQIVICYFGEGAASEGDAHAGFNFAATLECPIIFFC 265 
Lm_E1b-α          AFRLENQALERRLPAGTLLSTIPEARICATFFGEGAASEGDFHAGLNFASTVGSHTLFFV 300 
                  * :  *                   ::   :********** ***:***:*: .  :**  
 
Hs_E1b-α          RNNGYAISTPTSEQYRGDGIAARGPGYGIMSIRVDGNDVFAVYNATKEARRRAVAENQPF 324 
Rn_E1b-α          RNNGYAISTPTSEQYRGDGIAARGPGYGIMSIRVDGNDVFAVYNATKEARRRAVAENQPF 325 
Lm_E1b-α          RNNGYAISTPTHSQYMGDGILSRAVGYGIPAARVDGLDALAVYHTVRKAREMILNSHRPV 360 
                  *********** .** **** :*. **** : **** *.:***::.::**.  : .::*. 
 
Hs_E1b-α          LIEAMTYRIGHHSTSDDSSAYRSVDEVNYWDKQDHPISRLRHYLLSQGWWDEEQEKAWRK 384 
Rn_E1b-α          LIEAMTYRIGHHSTSDDSSAYRSVDEVNYWDKQDHPISRLRQYLLNQGWWDEEQEKAWRK 385 
Lm_E1b-α          LVEALTYRLSHHSTSDDSTAYRSRDEIEHFAETFSPIERFEHFVTARGWWTPEQSREVVE 420 
                  *:**:***:.********:**** **:::: :   **.*:.:::  :***  **.:   : 
 
Hs_E1b-α          QSRRKVMEAFEQAERKPKPNPNLLFSDVYQEMPAQLRKQQESLARHLQTYGEHYPLDHFD 444 
Rn_E1b-α          QSRKKVMEAFEQAERKLKPNPSLLFSDVYQEMPAQLRRQQESLARHLQTYGEHYPLDHFD 445 
Lm_E1b-α          RTRSEVLSELRRQEKLPAWPVSTLCDDVFEHLTPELERQRTQLVEHYQAHRSIYDQEKL- 479 
                  ::* :*:. :.: *:      . * .**::.:..:*.:*: .*..* *:: . *  :::  
 
Hs_E1b-α          K          445 
Rn_E1b-α          K           446 
Lm_E1b-α          -                   
 
Figure 7.4 Alignment of E1b-α protein sequences 
ClustalW alignment of L. major E1b-α (LmE1b-α) (see Table 3.1) with homologues in R. 
norvegicus (RnE1b-α) (accession number NP_036914) and H. sapiens (HsE1b-α) (accession 
number NP_000700). The alignment indicates identical residues (*), conserved residues (:) and 
homologous residues (.). Red residues indicate conserved amino acids within different motifs that 
fulfil various roles within E1b-α enzymes. Green residues are those that are conserved in E1b-α 
proteins found in other species but not in LmE1b-α. Refer also to Table 7.3. 
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Hs_E1b-β         MAVVAAAAGWLLRLRAAGAEGHWRRLPGAGLARGFLHPAATVEDAAQRRQVAHFTFQPDP 60 
Rn_E1b-β         MAAVAARAGGLLRLGAAGAERRRRGLRCAALVQGFLQPA--VDDASQKRRVAHFTFQPDP 58 
Lm_E1b-β         ----------MRRLFDASATAVVAASSAAAKRHGSVQPS-------------EFVFAPAP 37 
                           : **  *.*         *.  :* ::*:             .*.* * * 
 
Hs_E1b-β         -EPREYGQTQKMNLFQSVTSALDNSLAKDPTAVIFGEDVAFGGVFRCTVGLRDKYGKDRV 119 
Rn_E1b-β         -ESLQYGQTQKMNLFQSVTSALDNSLAKDPTAVIFGEDVAFGGVFRCTVGLRDKYGKDRV 117 
Lm_E1b-β         GEEEAMRNGVKMNLFQAVNSGLDHALSKE-RTVLLGEDVAFGGVFRCTLDLRKKHGPQKV 96 
                  *     :  ******::.*.**::*:*:  :*::*************:.**.*:* ::* 
 
Hs_E1b-β         FNTPLCEQGIVGFGIGIAVTGATAIAEIQFADYIFPAFDQIVNEAAKYRYRSGDLFNCGS 179 
Rn_E1b-β         FNTPLCEQGIVGFGIGIAVTGATAIAEIQFADYIFPAFDQIVNEAAKYRYRSGDLFNCGS 177 
Lm_E1b-β         FDSPLTEQGIVGFAVGMAAVGWHPIAEVQFADYIFPAFDQIVNEAAKYRFRTGSNFHCG- 155 
                 *::** *******.:*:*..*  .***:*********************:*:*. *:**  
 
Hs_E1b-β         LTIRSPWGCVGHGALYHSQSPEAFFAHCPGIKVVIPRSPFQAKGLLLSCIEDKNPCIFFE 239 
Rn_E1b-β         LTIRAPWGCVGHGALYHSQSPEAFFAHCPGIKVVIPRSPFQAKGLLLSCIEDKNPCIFFE 237 
Lm_E1b-β         MLIRAPCSAVGHGGIYHSQSVEGYFTHCPGLKIVMPSSPSEAKGLLLKCVEENDPCIFFE 215 
                 : **:* ..****.:***** *.:*:****:*:*:* ** :******.*:*:::****** 
 
Hs_E1b-β         PKILYRAAAEEVPIEPYNIPLSQAEVIQEGSDVTLVAWGTQVHVIREVASMAKEKLGVSC 299 
Rn_E1b-β         PKILYRAAVEQVPVEPYKIPLSQAEVIQEGSDVTLVAWGTQVHVIREVASMAQEKLGVSC 297 
Lm_E1b-β         PKILYRSAVEEVNPDYYTLPLGKGRILVEGRDVTMVTYGSQVYVAAKAAEMARKE-GISV 274 
                 ******:*.*:*  : *.:**.:..:: ** ***:*::*:**:*  :.*.**::: *:*  
 
Hs_E1b-β         EVIDLRTIIPWDVDTICKSVIKTGRLLISHEAPLTGGFASEISSTVQEECFLNLEAPISR 359 
Rn_E1b-β         EVIDLRTIVPWDVDTVCKSVIKTGRLLISHEAPLTGGFASEISSTVQEECFLNLEAPISR 357 
Lm_E1b-β         ELIDLRSLLPWDRQLVADSVKKTGKVIVTHEAPKTSGYGAELVSSITEDCFLSLEAPPTR 334 
                 *:****:::*** : :..** ***:::::**** *.*:.:*: *:: *:***.**** :* 
 
Hs_E1b-β         VCGYDTPFPHIFEPFYIPDKWKCYDALRKMINY                            392 
Rn_E1b-β         VCGYDTPFPHIFEPFYIPDKWKCYDALRKMINY                            390 
Lm_E1b-β         VCGLDTPFP-LHERLYLPNELKLLDAIKSVVHF                            366 
                 *** ***** :.* :*:*:: *  **::.:::: 
 
Figure 7.5 Alignment of E1b-β protein sequences 
ClustalW alignment of L. major E1b-β (LmE1b-β) (see Table 3.1) with homologues in R. norvegicus 
(RnE1b-β) (accession number NP_062140) and H. sapiens (HsE1b-β) (accession number 
NP_000047). The alignment indicates identical residues (*), conserved residues (:) and 
homologous residues (.). Red residues indicate conserved amino acids within different motifs that 
fulfil various roles within E1b-β enzymes. Green residues are those that are conserved in E1b-β 
proteins found in other species but not in LmE1b-β. Refer also to Table 7.3. 
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Signature specific motif 
Functiona E1b consensusa Hs E1b-alphaa Lm E1b-alphab Hs E1b-betaa Lm E1b-betab
Lipoyl domain
complementarity - - - - -
2-Oxo substrate side chain
binding pocket YR(D/e,q) YRE YRE - -
ThDP interaction
2-Oxo substrate side chain
binding pocket (K/s)G(G)RQ(M/l)P KGRQMP KGRQMP - -
Stabilization of ThDP binding
Shielding S of ES from the
solvent
- - - - -
Binding of ThDP
pyrophosphate group (N/t)FA NFA NFA - -
Binding of ThDP
pyrophosphate group and
thiazole ring AIS AIS AIS - -
Hydrogen bond network
Interaction with ThDP
through loop 1
Catalysis of decarboxylation
and reductive acylation
(P/h)H(S/t)xx(G)DD(P/d,s) HHSTSDDS HHSTSDDS - -
Lipoyl domain interaction
Lipoyl domain
complementarity (Q/d)(A/s)xxxA - - QSVTSA QAVNSG
Lipoyl domain
complementarity G(E/q)DVxxxGGVF - - GEDVAFGGVF GEDVAFGGVF
ThDP binding E(I/m)QF - - EIQF EVQF
Lipoyl domain
complementarity (L/a)Y(R/n) - - LYR LYR
 
Table 7.3 Summary of conserved motifs in LmE1b-α and LmE1b-β 
This table summarises which motifs contribute to specific activities within E1b enzymes (Bunik & 
Degtyarev, 2008)a. Based upon ClustalW alignments (see Figure 7.4 and Figure 7.5), conservation 
of sequences comprising these motifs was determined for LmE1b-αand LmE1b-βb. Green residues 
are those that are conserved in E1b-α/E1b-β motifs in other species but not in LmE1b-αand 
LmE1b-β. 
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Ec_P-protein      ------------------------------------------------MTQTLSQLE-NS 11 
Hs_P-protein      MQSCARAWGLRLGRGVGGGRRLAGGSGPCWAPRSRDSSSGGGDSAAAGASRLLERLLPRH 60 
Lm_P-protein      --VSALPSGFTP--------------PPFLSPACARMLRRLLRVHGVPAPAGLARYT-ST 43 
                                                                   .  * :      
 
Ec_P-protein      GAFIERHIGPDAAQQQEMLNAVGAQSLNALTGQIVPKDIQLATPPQVGAPATEYAALAEL 71 
Hs_P-protein      DDFARRHIGPGDKDQREMLQTLGLASIDELIEKTVPANIRLKRPLKMEDPVCENEILATL 120 
Lm_P-protein      DAYLNRHIGPTRKETAEMLKTVGKESLADLMTTVLPSDI-LRTPLNNFKCLSETAALSYL 102 
                  . : .*****   :  ***:::*  *:  *    :* :* *  * :      *   *: * 
 
Ec_P-protein      KAIASRNKRFTSYIGMGYTAVQLPPVILRNMLENPGWYTAYTPYQPEVSQGRLEALLNFQ 131 
Hs_P-protein      HAISSKNQIWRSYIGMGYYNCSVPQTILRNLLENSGWITQYTPYQPEVSQGRLESLLNYQ 180 
Lm_P-protein      KSLGAQNKVLKSMIGQGYYECIVPSAIMRNVLENPMWYTPYTPFQSEIAQGRLESLLNFQ 162 
                  :::.::*:   * ** **    :* .*:**:***. * * ***:*.*::*****:***:* 
 
Ec_P-protein      QVTLDLTGLDMASASLLDEATAAAEAMAMAKRVSKLKNANRFFVASDVHPQTLDVVRTRA 191 
Hs_P-protein      TMVCDITGLDMANASLLDEGTAAAEALQLCYRHNKRR---KFLVDPRCHPQTIAVVQTRA 237 
Lm_P-protein      TMVTDLTKMDISNASLLDQATAAGECLYLALNQHRHKR-RKFFVSRDVFLSSIEMIRTRA 221 
                   :. *:* :*::.*****:.***.*.: :. .  : :   :*:*    . .:: :::*** 
 
Ec_P-protein      ETFG-FEVIVDDAQKVLDHQDVFGVLLQQVGTTGEIHDYTALISELKSRKIVVSVAADIM 250 
Hs_P-protein      KYTGVLTELKLPCEMDFSGKDVSGVLFQYPDTEGKVEDFTELVERAHQSGSLACCATDLL 297 
Lm_P-protein      HPLGAQVIVGDVQSLDLDDAELSGIFVQTPDAKGELHDFTTIFARAKANGVVCCAGVDLM 281 
                  .  *    :    .  :.  :: *::.*  .: *::.*:* :. . :    : . ..*:: 
 
Ec_P-protein      ALVLLTAPGKQGADIVFGSAQRFGVPMGYGGPHAAFFAAKDEYKRSMPGRIIGVSKDAAG 310 
Hs_P-protein      ALCILRPPGEFGVDIALGSSQRFGVPLGYGGPHAAFFAVRESLVRMMPGRMVGVTRDATG 357 
Lm_P-protein      ASCLVKPAGEMGADVVVGCAQRFGTPLGYGGPHAAFMATTDNLKRLSPGRIVGISKDNAG 341 
                  *  :: ..*: *.*:..*.:****.*:*********:*. :.  *  ***::*:::* :* 
 
Ec_P-protein      NTALRMAMQTREQHIRREKANSNICTSQVLLANIASLYAVYHGPVGLKRIANRIHRLTDI 370 
Hs_P-protein      KEVYRLALQTREQHIRRDKATSNICTAQALLANMAAMFAIYHGSHGLEHIARRVHNATLI 417 
Lm_P-protein      DPAIRVALQTREQHIKRERATSNICTAQALLANMNAFYAIYHGPEGLKQLAREIHQKAKL 401 
                  . . *:*:*******:*::*.*****:*.****: :::*:***. **:::*..:*. : : 
 
Ec_P-protein      LAAGLQQKGLKLRHAHYFDTLCVEV----ADKAGVLTRAEAAEINLRSD-ILNAVGITLD 425 
Hs_P-protein      LSEGLKRAGHQLQHDLFFDTLKIQCG---CSVKEVLGRAAQRQINFRLF-EDGTLGISLD 473 
Lm_P-protein      FAVGMESLGFSPVNTTYFDTLSFSMEAAPMTAADYAQRCVERGINLFVDGSTNQVSVSLD 461 
                  :: *::  * .  :  :**** ..             *.    **:      . :.::** 
 
Ec_P-protein      ETTTRENVMQLFNVLLGDNHGLDIDTLDKDVAHDSRSIQPAMLR-DDEILTHPVFNRYHS 484 
Hs_P-protein      ETVNEKDLDDLLWIFGCESS---AELVAESMGEECRGIPGSVFKRTSPFLTHQVFNSYHS 530 
Lm_P-protein      EATTEQHIAALLQAAGMPTP--KIEALTR-VADTICVIPEALLR-KSKFLQSTVFNSHKS 517 
                  *:...:.:  *:      .     : : . :..    *  ::::  . :*   *** ::* 
 
Ec_P-protein      ETEMMRYMHSLERKDLALNQAMIPLGSCTMKLNAAAEMIPITWPEFAELHPFCPPEQAEG 544 
Hs_P-protein      ETNIVRYMKKLENKDISLVHSMIPLGSCTMKLNSSSELAPITWKEFANIHPFVPLDQAQG 590 
Lm_P-protein      ETELMRYAQHLQRKDYGLTHGMIPLGSCTMKLNSAAAMRALSWPEYTALHPYAPEDQARG 577 
                  **:::** : *:.** .* :.************::: : .::* *:: :**: * :**.* 
 
Ec_P-protein      YQQMIAQLADWLVKLTGYDAVCMQPNSGAQGEYAGLLAIRHYHESRNEGHRDICLIPASA 604 
Hs_P-protein      YQQLFRELEKDLCELTGYDQVCFQPNSGAQGEYAGLATIRAYLNQKGEGHRTVCLIPKSA 650 
Lm_P-protein      YHTLLADLKQKLCDITGMAACSIQPNSGAQGEYAGLRIIRAYHESRGEAHRDVCFIPISA 637 
                  *: :: :* . * .:**    .:*************  ** * :.:.*.** :*:** ** 
 
Ec_P-protein      HGTNPASAHMAGMQVVVVACDKNGNIDLTDLRAKAEQAGDNLSCIMVTYPSTHGVYEETI 664 
Hs_P-protein      HGTNPASAHMAGMKIQPVEVDKYGNIDAVHLKAMVDKHKENLAAIMITYPSTNGVFEENI 710 
Lm_P-protein      HGTNPASAVLAGLKVVTVKCLDDGSVDMVDLETKCVKHARDLACLMITYPSTYGLYDQNI 697 
                  ******** :**:::  *   . *.:* ..*.:   :   :*:.:*:***** *::::.* 
 
Ec_P-protein      REVCEVVHQFGGQVYLDGANMNAQVGITSPGFIGADVSHLNLHKTFCIPHGGGGPGMGPI 724 
Hs_P-protein      SDVCDLIHQHGGQVYLDGANMNAQVGICRPGDFGSDVSHLNLHKTFCIPHGGGGPGMGPI 770 
Lm_P-protein      RKITSMVHEHGGQCYIDGANLNALVGYTGPGFIGGDVCHINMHKTFSIPHGGGGPGLGPI 757 
                   .: .::*:.*** *:****:** **   ** :*.**.*:*:****.*********:*** 
 
Ec_P-protein      GVKAHLAPFVPGHSVVQIEG--MLTRQGAVSAAPFGSASILPISWMYIRMMGAEGLKKAS 782 
Hs_P-protein      GVKKHLAPFLPNHPVISLKRNEDACPVGTVSAAPWGSSSILPISWAYIKMMGGKGLKQAT 830 
Lm_P-protein      TVRPHLAPFLPNSTYGPAVG--GSQAFGQVSQAGNGSASIATISYAFMMMLGSHGLKTCT 815 
                   *: *****:*. .             * ** *  **:** .**: :: *:*..*** .: 
 
Ec_P-protein      QVAILNANYIASRLQDAFPVLYTGRDGRVAHECILDIRPLKEETGISELDIAKRLIDYGF 842 
Hs_P-protein      ETAILNANYMAKRLETHYRILFRGARGYVGHEFILDTRPFKKSANIEAVDVAKRLQDYGF 890 
Lm_P-protein      EYAVLNANYLKKRLEEHYTICFLDHSQFCAHEFILDIRPFKKTAHIDAEDVAKRLIDYGF 875 
                  : *:*****: .**:  : : : .     .** *** **:*: : *.  *:**** **** 
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Ec_P-protein      HAPTMSFPVAGTLMVEPTESESKVELDRFIDAMLAIRAEIDQVKAGVWPLEDNPLVNAPH 902 
Hs_P-protein      HAPTMSWPVAGTLMVEPTESEDKAELDRFCDAMISIRQEIADIEEGRIDPRVNPLKMSPH 950 
Lm_P-protein      HAPTLAFPVEGTLMIEPTESESKRELDRLADALISIRREIAAVERGDQPKDNNVLTNAPH 935 
                  ****:::** ****:******.* ****: **:::** **  :: *      * *  :** 
 
Ec_P-protein      -IQSELVAEWAHPYSREVAVFPAGVA---DKYWPTVKRLDDVYGDRNLFCSCVPISEYQ- 957 
Hs_P-protein      SLTCVTSSHWDRPYSREVAAFPLPFVKPENKFWPTIARIDDIYGDQHLVCTCPPMEVYES 1010 
Lm_P-protein      TAKCVTADEWNRPYSRQLAAYPTRHQYR-EKFWPSVGRVDNTYGDRNLMCSCAPLEFY-- 992 
                     .    .* :****::*.:*       :*:**:: *:*: ***::*.*:* *:. *   
 
Ec_P-protein      ---------- 
Hs_P-protein      PFSEQKRASS         1020 
Lm_P-protein      ---------- 
 
Figure 7.6 Alignment of P-protein sequences 
ClustalW alignment of L. major P-protein (LmP-protein) (see Table 3.1) with homologues in E. coli 
(EcP-protein) (accession number AAC75941) and H. sapiens (HsP-protein) (accession number 
NP_000161). The alignment indicates identical residues (*), conserved residues (:) and 
homologous residues (.).Red residues indicate conserved amino acids within different motifs that 
fulfil various roles within P-proteins. Green residues are those amino acids that are not conserved 
in L. major, but which are strictly conserved in other species. 
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Hs_E2k          LSRSHCVPGVQHSLSAFQKGNCPLGRHSLPGVSLCQGPGYPNSRKVVINNSVFSVRFFRT 60 
Lm_E2k          ----------------FRR----VSTRVLP--TACSAAHNLN------------LRFC-- 24 
Ec_E2k          ------------------------SS---------------------------------- 2 
                                        .                                    
 
Hs_E2k          TTVCKYDLVTVKTPAFAEPVTEGDVR-WEKAVGDTVAEDEVVCEIETDKTLVQVPSPANG 119 
Lm_E2k          --------LSINVPTIAESISTGKVVNWTKKVGDAVAEDEVICQIESDKLNVDVRAPANG 76 
Ec_E2k          --------VDILVPDLPESVADATVATWHKKPGDAVVRDEVLVEIETDKVVLEVPASADG 54 
                        : : .* :.*.:: . *  * *  **:*..***: :**:**  ::* :.*:* 
 
Hs_E2k          MIEALFVPDGGKVEGGTPLFTLRKTGAAPAKAKPAEAPAAAAPKAE-----------PIA 168 
Lm_E2k          VITKINFEEGADVEVGAQLSTMKEGPAPAAAAPKAAEVKLDAPKAE-----------PPK 125 
Ec_E2k          ILDAVLEDEGTTVTSRQILGRLREGNSAGKETSAKSEEKASTPAQRQQASLEEQNNDALS 114 
                ::  :   :*  *     *  :::  :.   :         :*  .           .   
 
Hs_E2k          AAVPPRAAPIPTQMPPVPSP---------------SQPPSSK-PVSAVKPTAVPPLAEPG 212 
Lm_E2k          AAAPAASAPA---APAAPAA---------------AAKPAMH-TIAGADPRTKS------ 160 
Ec_E2k          PAIRRLLAEHNLDASAIKGTGVGGRLTREDVEKHLAKAPAKESAPAAAAPAAQPALAAR- 173 
                .*     *      ..  ..               :  *: . . :.. * : .       
 
Hs_E2k          AGKGLHSEHREKMNRMRQCIAQRLKEAQNTVPMLTIFNEIDVSNIQKMRARHKEAFLKKH 272 
Lm_E2k          ----------VRISSMRRRIADRLKASQNTCAMLTTFNEIDMTPLFQLRDKYKDEFHKRH 210 
Ec_E2k          ------SEKRVPMTRLRKRVAERLLEAKNSTAMLTTFNEVNMKPIMDLRKQYGEAFEKRH 227 
                            :. :*: :*:**  ::*: .*** ***:::. : .:* :: : * *:* 
 
Hs_E2k          NLKLGFMSASVKASAFALQEQPVVNAVIDDITKEVVYRDYIDISVAVATPQGLVVPVIRN 332 
Lm_E2k          DVKLGLMSPFVKASAIALKDVPIVNASFG--KDTIDYHEFVDIAIAVATPRGLVVPVIRD 268 
Ec_E2k          GIRLGFMSFYVKAVVEALKRYPEVNASID--GDDVVYHNYFDVSMAVSTPRGLVTPVLRD 285 
                .::**:**  *** . **:  * *** :.   . : *:::.*:::**:**:***.**:*: 
 
Hs_E2k          VEAMNYADIEQTITELGEKARKNEFAIEDMDGGTFTISNGGVFGSLFEHPLS-TPLSAIL 391 
Lm_E2k          VQNMNLANIETAIADYAARARINKLTMAEMTGGTFTISNGGVFGSWMGTPIINPPHSAIL 328 
Ec_E2k          VDTLGMADIEKKIKELAVKGRDGKLTVEDLTGGNFTITNGGVFGSLMSTPIINPPQSAIL 345 
                *: :. *:**  * : . :.* .:::: :: **.***:******* :  *:  .* **** 
 
Hs_E2k          GMHGIFDKPVAIGGKVEVRPMMYVALTYDHRLIDGREAVTFLRKIKAAVEDPRVLLFDL- 450 
Lm_E2k          GMHAIKKKPWVVGNEIKIRDIMAVALTYDHRLIDGSDAVTFLVKVKNLIEDPARMVLDLS 388 
Ec_E2k          GMHAIKDRPMAVNGQVEILPMMYLALSYDHRLIDGRESVGFLVTIKELLEDPTRLLLDV- 404 
                ***.* .:* .:..::::  :* :**:******** ::* ** .:*  :***  :::*:  
 
Figure 7.7 Alignment of E2k protein sequences 
ClustalW alignment of L. major E2k (LmE2k) (see Table 3.1) with homologues in E. coli (EcE2k) 
(accession number AAA23898) and H. sapiens (HsE2k) (accession number NP_000161). The 
alignment indicates identical residues (*), conserved residues (:) and homologous residues (.).Red 
residues indicate conserved amino acids within different motifs that fulfil various roles within E1k 
enzymes. Green residues are those that are conserved in E1k proteins found in other species but 
not in LmE1k. 
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Hs_E2p          MWRVCARRAQNVAPWAGLEARWTALQEVPGTPRVTSRSGPAPARRNSVTTGYGGVRALCG 60 
Hs_E3BP         ----------MAASWR-----------LGCDPRLLRYLVGFPGRRS-----VGLVKGALG 34 
Lm_E2p          -----------------------------------------------------MLRCRAV 7 
Ec_E2p          -MAIEIKVPDIGADEVEITEILVKVGDKVEAEQSLITVEGDKASMEVPSPQAGIVKEIKV 59 
Lm_E2pL         -----------------------------------------------------MMRRTLL 7 
                                                                      ::     
 
Hs_E2p          WTPSSGATPRNRLLLQLLGSPGRRYYSLPPHQKVPLPSLSPTMQAGT------------- 107 
Hs_E3BP         WSVSRGANWRWFHSTQWLRGD---------PIKILMPSLSPTMEEGN------------- 72 
Lm_E2p          SKLATLAALRFLTITP-----------------IPMPALSPTMEKGK------------- 37 
Ec_E2p          SVGDKTQTGALIMIFDSADGAADAAPAQAEEKKEAAPAAAPAAAAAKDVNVPDIGSDEVE 119 
Lm_E2pL         WLVNFEP--------------------------VFMPALSPSMETGT------------- 28 
                                                    *: :*:   ..              
 
Hs_E2p          IARWEKKEGDKINEGDLIAEVETDKATVGFE-SLEECYMAKILVAEGTRDVPIGAIICIT 166 
Hs_E3BP         IVKWLKKEGEAVSAGDALCEIETDKAVVTLD-ASDDGILAKIVVEEGSKNIRLGSLIGLI 131 
Lm_E2p          ITEWCKQPGDFIRPGDTFCNIETDKAVVSYDNATEEGFFARVITSPG-EETVVGQTVCLI 96 
Ec_E2p          VTEILVKVGDKVEAEQSLITVEGDKASMEVP-APFAGTVKEIKVNVGDKVSTGSLIMVFE 178 
Lm_E2pL         VVEWKKKIGELVKESDVFCTIQTDKAVVDYTNTFESGYLAKIYCGNGQSAPVAKTIAVMV 88 
                :..   : *: :   : :  :: *** :    :     . .:    *           :  
 
Hs_E2p          VGKPEDIEAFKNYTLDSSAAPTPQAAPAPTPAATAS--PPTPSAQAPGSSYPPHMQVLLP 224 
Hs_E3BP         VEEGE----------DWKHVEIPKDVGPPPPVSKPS--EPRPSPE-PQISIPVKKEHIPG 178 
Lm_E2p          VDEKEGVHS------DEVKNWKPEAEEAPAAAAEEA--PAAPAATTPVAAAPVAAS---- 144 
Ec_E2p          VAGEAGAAAP-----AAKQEAAPAAAPAPAAGVKEVNVPDIGGDEVEVTEVMVKVGDKVA 233 
Lm_E2pL         SDAADVSKAD----EYTPEGEVPAAEAEAPTAAAVAAAPAAGGASSKAPEGVTCEPVFMP 144 
                                      *     ...           .                  
 
Hs_E2p          ALSPTMTMGTVQRWEKKVGEKLSEGDLLAEIETDKATIGFEVQEEGYLAKILVPEGTRDV 284 
Hs_E3BP         TLRFRLSPAARNILEKHS--------------------------------LDASQGTATG 206 
Lm_E2p          GDRVKASPYARKMAAEKN---------------------------------VSLRGIKGT 171 
Ec_E2p          AEQSLITVEGDKASMEVPAPFAG-----------------------VVKELKVNVGDKVK 270 
Lm_E2pL         ALSPSMETGTVVEWKKKIG----------------------------------------- 163 
                               :                                             
 
Hs_E2p          PLGTPLCIIVEKEADISAFADYRPTEVTDLKPQVPPPTPPPVAAVPPTPQPLAPTPSAPC 344 
Hs_E3BP         PRG-----IFTKEDALKLVQLKQTGKITESRPTPAP------TATPTAPSPLQAT----- 250 
Lm_E2p          GGG------VGRITSKDVAAAVASGTASSAAEVAAP-------AKTAATAALAAP----- 213 
Ec_E2p          TGSLIMIFEVEGAAPAAAPAKQEAAAPAPAAKAEAP------AAAPAAKAEGKSEFAEND 324 
Lm_E2pL         --------ELVKESDVFCTIQTDKAVVDYTNTFESG------------------------ 191 
                         .                        .                          
 
Hs_E2p          PATPAGPKGRVFVSPLAKKLAVEKGIDLTQVKGTGPDGRITKKDIDSFVPSKVAPAPAAV 404 
Hs_E3BP         ---------------------------------SGPS------------------YPRPV 259 
Lm_E2p          ------------------------------------------------------------ 
Ec_E2p          AYVHATPLIRRLAREFG----------VNLAKVKGTGRKGRILREDVQAYVKEAIKRAEA 374 
Lm_E2pL         ------------------------------------------------------------ 
                                                                             
 
Hs_E2p          VPPTGPGMAP----------VPTGVFTDIPISNIRRVIAQRLMQSK-QTIPHYYLSIDVN 453 
Hs_E3BP         IPPVSTPGQP----------NAVGTFTEIPASNIRRVIAKRLTESK-STVPHAYATADCD 308 
Lm_E2p          AKPAAAKGTP----------PANPNFTDIPVTTMRSVIAKRLHQSKNLEIPHYYLFDDCR 263 
Ec_E2p          APAATGGGIPGMLPWPKVDFSKFGEIEEVELGRIQKISGANLSRNW-VMIPHVTHFDKTD 433 
Lm_E2pL         --------------------------------YLAKIYCGNGQSAPVAKTIAVMVSDAAD 219 
                                                 :  :   .                    
 
Hs_E2p          MGEVLLVRKELN---KILEGRSKISVNDFIIKASALACLKVPEANSSWM--DTVIRQNHV 508 
Hs_E3BP         LGAVLKVRQDL------VKDDIKVSVNDFIIKAAAVTLKQMPDVNVSWD--GEGPKQLPF 360 
Lm_E2p          VDNMLALIKQLN---AKGNGEYKITVNDYIVKAVARANTLVPEVNSSWQ--GDFIRQYAT 318 
Ec_E2p          ITELEAFRKQQNEEAAKRKLDVKITPVVFIMKAVAAALEQMPRFNSSLSEDGQRLTLKKY 493 
Lm_E2pL         VEKVANYYPEDA-----VGGPPASAADPSAAAAAAASARPAPSAASAKH-------YGGS 267 
                :  :     :              :       * * :    *    :              
 
Hs_E2p          VDVSVAVSTPAGLITPIVFNAHIKGVETIANDVVSLATKAREGKLQPHEFQG--GTFTIS 566 
Hs_E3BP         IDISVAVATDKGLLTPIIKDAAAKGIQEIADSVKALSKKARDGKLLPEEYQG--GSFSIS 418 
Lm_E2p          VDVSVAVATPTGLITPIIRNAQAKGLVEISKETKALAKKARDGTLQPSEFQG--GTCSVS 376 
Ec_E2p          INIGVAVDTPNGLVVPVFKDVNKKGIIELSRELMTISKKARDGKLTAGEMQG--GCFTIS 551 
Lm_E2pL         LDAAVAASGPS---------VARIAAGLETSTLAGIAPSGKGGRFLKSDFSGQPGFDYND 318 
                :: .**.             .   .    :     :: ..: * :   : .*  *    . 
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Hs_E2p          NLGMFGIKNFSAIINPPQACILAIGASEDKLVPADNEKG---FDVAS----MMSVTLSCD 619 
Hs_E3BP         NLGMFGIDEFTAVINPPQACILAVGRFRPVLKLTEDEEGNAKLQQRQ----LITVTMSSD 474 
Lm_E2p          NLGATGIPGFTAIINPPQAMILAVGSAKPRAEIVKSEETG-EFEMTGRVENVVSFSASFD 435 
Ec_E2p          SIGGLGTTHFAPIVNAPEVAILGVSKSAMEPVWNGKEFVP---------RLMLPISLSFD 602 
Lm_E2pL         TTPARAMQQKAAPAAAADEASKTAAKSAAPAAVSGDIYN------------VVLKPGPVY 366 
                .    .    :.   ..:      .          .               ::  . .   
 
Hs_E2p          HRVVDGAVGAQWLAEFRKYLEKPITMLL                                 647 
Hs_E3BP         SRVVDDELATRFLKSFKANLENPIRLA-                                 501 
Lm_E2p          HRIVDGALGAKWFQHFHDAMENPLSLLL                                 463 
Ec_E2p          HRVIDGADGARFITIINNTLSDIRRLVM                                 630 
Lm_E2pL         KSVSDTALLKKLMHTMHVPKPKLKKAAE                                 394 
                  : *     : :  :.    .       
 
Figure 7.8 Alignment of E2p and E3BP protein sequences 
ClustalW alignment of L. major E2p (LmE2p) and L. major E2p-like (LmE2pL) (see Table 3.1) with: 
E. coli E2p (EcE2p) (accession number AAC73226); H. sapiens E2p (HsE2p) (accession number 
NP_001922); H. sapiens E3BP (HsE3BP) (accession number NP_001128496). The alignment 
indicates identical residues (*), conserved residues (:) and homologous residues (.).Red residues 
indicate conserved motifs within E2p and E3BP enzymes. Green residues are those that are 
conserved in E1p proteins but not in E3BP or LmE2pL. 
Hs_E2b          --TPAVRRLAMENNIKLSEVVGSGKD-GRILKEDILNYLEKQTGA 42 
Rn_E2b          --TPAVRRLAMENNIKLSEVVGSGKD-GRILKEDILNFLEKQTGA 42 
Bs_E2b          --MPSVRKYAREKGVDIRLVQGTGKN-GRVLKEDIDAFLAGGAKP 42 
Ec_E2p          --TPLIRRLAREFGVNLAKVKGTGRK-GRILREDVQAYVKEAIKR 42 
Hs_E2p          FVSPLAKKLAVEKGIDLTQVKGTGPD-GRITKKDIDSFVP--SKV 42 
Mm_E2p          FVSPLAKKLAAEKGIDLTQVKGTGPE-GRIIKKDIDSFVP--SKA 42 
Sc_E2p          --SPLAKTIALEKGISLKDVHGTGPR-GRITKADIESYLEKSSKQ 42 
Lm_E2p          KASPYARKMAAEKNVSLRGIKGTGGGVGRITSKDVAAAVASGT-- 43 
Ec_E2k          --SPAIRRLLAEHNLDASAIKGTGVG-GRLTREDVEKHLAKAPAK 42 
Hs_E3BP         RLSPAARNILEKHSLDASQGTATGPR-GIFTKEDALKLVQLKQ-- 42 
Lm_E2b          -EECELTRLMEVRG-SLKDVVKERSK-GKAKLSFMPFFLKAASIA 42 
Lm_E2k          --LGLMSPFVKASAIALKDVPIVNASFGKDTID-YHEFVDIAIAV 42 
Lm_E2pL         --PSMETGTVVEWKKKIGELVKESDVFC-TIQTDKAVVDYTNTFE 42                                                             
 
Figure 7.9 Alignment of the E1/E3 binding sequences found within E2p and E3BP proteins, 
respectively 
ClustalW alignment of the E1/E3 binding domains of LmE2p, LmE2pL, HsE2p, HsE3BP, EcE2p 
(see Figure 7.8), LmE2b, HsE2b, RnE2b (see Figure 7.10), LmE2k, EcE2k (see Figure 7.7) and: B. 
stearothermophilus E2p (BsE2p) (accession number CAA37630); M. musculus E2p (MmE2p) 
(accession number NP_663589); S. cerevisiae E2p (ScE2p) (accession number NP_014328). Red 
residues are those in H. sapiens E3 that interact with E3BP. Replacement of Pro with a less 
constraining residue (blue residue), along with a positively charged residue instead of Ile (blue 
residue), is thought to permit E1 binding as well as E3 binding (Ciszak et al., 2006). Green residues 
represent those from L. major E2 proteins that do not conform to the consensus, but which could 
perform similar functions. For example, the Val in LmE2p does not align well with Pro and Lys 
residues due to insertion of two Gly residues, but could be homologous to the Val observed in 
EcE2k. LmE2b and LmE2k potentially fulfil E1 and E3 binding since they possess both Ser and Lys 
residues, instead of Lys and Arg.  
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Hs_E2b          MAAVRMLRTWSRNAGKLICVRYFQTCGNVHVLKPNYVCFFGYPSFKYSHPHHFLKTTAAL 60 
Rn_E2b          MAAARVLGTWSRNAVRLTCVRYFQTYNNVHILKPQHVCSVGYPLLKSSQPRHSLRTAAVL 60 
Lm_E2b          MRSARCMVRR--------CIGAAAGAATVAHAS-------GWPYTASR--RHLFATTCAP 43 
                * :.* :           *:       .*   .       *:*       :* : *:..  
 
Hs_E2b          RGQVVQFKLSDIGEGIREVTVKEWYVKEGDTVSQFDSICEVQSDKASVTITSRYDGVIKK 120 
Rn_E2b          QGQVVQFKLSDIGEGIREVTIKEWYVKEGDTVSQFDSICEVQSDKASVTITSRYDGVIKR 120 
Lm_E2b          LGRCIPYRLADIGEGITEVQVLGVCVKAGDTINEFDPICEVQSDKATVDITSRYTGVVKA 103 
                 *: : ::*:****** ** :    ** ***:.:**.*********:* ***** **:*  
 
Hs_E2b          LYYNLDDIAYVGKPLVDIETEALKDSEEDVVET-----PAVSHD---EHTHQEIK----- 167 
Rn_E2b          LYYNLDDIAYVGKPLIDIETEALKDSEEDVVET-----PAVAHD---EHTHQEIK----- 167 
Lm_E2b          VYLQPGATAKVGSVMLDIVPEGADDAPEAASPSRSAPPPSSAPDSAPQATYSASKPSSDA 163 
                :* : .  * **. ::** .*. .*: * .  :     *: : *   : *:.  *      
 
Hs_E2b          -GRKTLATPAVRRLAMENNIKLSEVVGSGKDGRILKEDILNYLEKQTGAILPPSPKVEIM 226 
Rn_E2b          -GQKTLATPAVRRLAMENNIKLSEVVGSGKDGRILKEDILNFLEKQTGAILPPSPKSEIT 226 
Lm_E2b          SAGKVLATPATRYLAREHKLDLAHVPATGKGGRVTKEDVLQFMDAGMSAAAAPSPPSTAS 223 
                 . *.*****.* ** *:::.*:.* .:**.**: ***:*::::   .*  .***      
 
Hs_E2b          PPPPKPKDMTVPILVSKPPVFTGKDKTEPIKGFQKAMVKTMSAALKIPHFGYCDEIDLTE 286 
Rn_E2b          PPPPQPRDRPFPTPVSKPPVFLGKDRTEPVTGFQKAMVKTMSAALKIPHFGYCDEVDLTE 286 
Lm_E2b          SAATAPPG----TVVSGLQTEAG-DTVMPITGVRRGMVKTMSQAASIPTFTFSEECELTR 278 
                .... * .      **   .  * * . *:.*.::.****** * .** * :.:* :**. 
 
Hs_E2b          LVKLREELKPIAFARG---IKLSFMPFFLKAASLGLLQFPILNASVDENCQNITYKASHN 343 
Rn_E2b          LVKLREELKPVALARG---IKLSFMPFFLKAASLGLLQFPILNASVDENCQSITYKASHN 343 
Lm_E2b          LMEVRGSLKDVVKERSKGKAKLSFMPFFLKAASIALQHHPDINAHCPVDCSALVRKAAHN 338 
                *:::* .** :.  *.    *************:.* :.* :**    :*. :. **:** 
 
Hs_E2b          IGIAMDTEQGLIVPNVKNVQICSIFDIATELNRLQKLGSVSQLSTTDLTGGTFTLSNIGS 403 
Rn_E2b          IGIAMDTERGLIVPNVKNVQVRSVFEIAMELNRLQKLGSLGQLSTTDLTGGTFTLSNIGS 403 
Lm_E2b          IGFAMDTPNGLIVPVVKHVERKSILDIANDMQVLIERGKSNKLTTQDMTGGTFTLSNIGV 398 
                **:**** .***** **:*:  *:::** ::: * : *. .:*:* *:***********  
 
Hs_E2b          IGGTFAKPVIMPPEVAIGALGSIKAIPRFNQKGEVYKAQIMNVSWSADHRVIDGATMSRF 463 
Rn_E2b          IGGTYAKPVILPPEVAIGALGAIKALPRFDQKGDVYKAQIMNVSWSADHRVIDGATMSRF 463 
Lm_E2b          IGATVTTPVLLPPQVAIGAIGRLQKLPRFDANGSLYAANLICVSFTADHRVIDGASMVRF 458 
                **.* :.**::**:*****:* :: :***: :*.:* *::: **::*********:* ** 
 
Hs_E2b          SNLWKSYLENPAFMLLDLK                                          482 
Rn_E2b          SNLWKSYLENPAFMLLDLK                                          482 
Lm_E2b          ANTYKQLLEHPENMLVDLR                                          477 
                :* :*. **:*  **:**: 
 
Figure 7.10 Alignment of E2b protein sequences 
ClustalW alignment of L. major E2b (LmE2b) (see Table 3.1) with homologues in H. sapiens 
(HsE2b) (accession number NP_001909) and R. norvegicus (RnE2b) (accession number 
NP_445764). The alignment indicates identical residues (*), conserved residues (:) and 
homologous residues (.). Red residues indicate conserved amino acids within different motifs that 
fulfil various roles within E2b enzymes. 
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Hs_H-protein      MALRVVRSVRALLCTLRAVPLPAAPCPPRPWQLGVGAVRTLRTGPALLSVRKFTEKHEWV 60 
Rn_H-protein      MSLRVVRSVRAVALQPALSPWP--PCPPRPWRRALAAVRSLRTGSALLSVRKFTEKHEWV 58 
Lm_H-protein      -----MR--RAFASVP------------------VAAAAYLRC----YATKHFTDSHEWV 31 
                       :*  **.                      :.*.  **      :.::**:.**** 
 
Hs_H-protein      TTENGIGTVGISNFAQEALGDVVYCSLPEVGTKLNKQDEFGALESVKAASELYSPLSGEV 120 
Rn_H-protein      TAKDGIGTVGISNFAQEALGDVVYCSLPEVGTKLKKQEEFGGLESVKAASELYSPLSGEV 118 
Lm_H-protein      MQCEDEITIGISSYAQENLGDVVYVSLPQVGDTVKEKDVIGEVESVKATSNVYSPVDGTV 91 
                     :.  *:***.:*** ****** ***:** .::::: :* :*****:*::***:.* * 
 
Hs_H-protein      TEINEALAENPGLVNKSCYEDGWLIKMTLSNPSELDELMSEEAYEKYIKSIEE 173 
Rn_H-protein      TEVNEALPENPGLVNKSMYEDGWLIKMTLSDPSELDELMSEEAYEKYVKSN-- 169 
Lm_H-protein      SAVNENLKDEPGLVNQSPEEKGWLIKVKCSEIP--KGLMDEAAYKKFLE---- 138 
                  : :** * ::*****:*  *.*****:. *: .  . **.* **:*:::     
 
Figure 7.11 Alignment of H-protein sequences 
ClustalW alignment of L. major H-protein (LmH-protein) (see Table 3.1) with homologues in H. 
sapiens (HsH-protein) (accession number NP_004474) and R. norvegicus (RnH-protein) 
(accession number CAB56621). The alignment indicates identical residues (*), conserved residues 
(:) and homologous residues (.).Red residues indicate conserved amino acids within different 
motifs that fulfil various roles within H-protein. Green residues are those that are conserved in H-
protein motifs in other species but not in LmH-protein. 
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Lm_T-protein-A      ----------------------------MSASLKKTALHLFHLAQQAKMDAFAGYHMPIS 32 
Lm_T-protein-B      ----------------------------MSASLKKTALHLFHLAQQAKMDAFAGYHMPIS 32 
Hs_T-protein        MQRAVSVVARLGFRLQAFPPALCRPLSCAQEVLRRTPLYDFHLAHGGKMVAFAGWSLPVQ 60 
Ec_T-protein        -------------------------------MAQQTPLYEQHTLCGARMVDFHGWMMPLH 29 
                                                     ::*.*:  *    .:*  * *: :*:  
 
Lm_T-protein-A      YGRLGVLKEHLYTREVAGIFDVSHVGQYEVRGADRERFLEHVTPVDLQRIR-AGHGALTM 91 
Lm_T-protein-B      YGRLGVLKEHLYTREVAGIFDVSHVGQYEVRGADRERFLEHVTPVDLQRIR-AGHGALTM 91 
Hs_T-protein        Y-RDSHTDSHLHTRQHCSLFDVSHMLQTKILGSDRVKLMESLVVGDIAELR-PNQGTLSL 118 
Ec_T-protein        Y--GSQIDEHHAVRTDAGMFDVSHMTIVDLRGSRTREFLRYLLANDVAKLTKSGKALYSG 87 
                    *   .  ..*  .*  ..:*****:   .: *:   .::. :   *: .:  ..:.  :  
 
Lm_T-protein-A      LTNAQGGIKDDCIVTKMAD-HLFLVLNAGCKEKDVAHMESVLRESAMKGADVQLVPLDRS 150 
Lm_T-protein-B      LTNAQGGIKDDCIVTKMAD-HLFLVLNAGCKEKDVAHMESVLRESAMKGADVQLVPLDRS 150 
Hs_T-protein        FTNEAGGILDDLIVTNTSEGHLYVVSNAGCWEKDLALMQDKVRELQNQGRDVGLEVLDNA 178 
Ec_T-protein        MLNASGGVIDDLIVYYFTEDFFRLVVNSATREKDLSWITQHAEPFGIEIT----VRDDLS 143 
                    : *  **: ** **   :: .: :* *:.  ***:: : .  .    :         * : 
 
Lm_T-protein-A      LIALQGPQAAAILSE-FMDDVPGMGFMQCRQRVNIKGMEVQVTRCGYTGEDGFELSVSNT 209 
Lm_T-protein-B      LIALQGPQAAAILSE-FMDDVPGMGFMQCRQRVNIKGMEVQVTRCGYTGEDGFELSVSNT 209 
Hs_T-protein        LLALQGPTAAQVLQAGVADDLRKLPFMTSAVMEVFGVSGCRVTRCGYTGEDGVEISVPVA 238 
Ec_T-protein        MIAVQGPNAQAKAAT-LFNDAQRQAVEGMKPFFGVQAGDLFIATTGYTGEAGYEIALPNE 202 
                    ::*:*** *       . :*     .        .      ::  ***** * *:::.   
 
Lm_T-protein-A      DIVALVELLMSR-KAEMIGLGARDSLRLEAGLNLYGHELTEDINPVAARFMWVISKRRMA 268 
Lm_T-protein-B      DIVALVELLMSR-KAEMIGLGARDSLRLEAGLNLYGHELTEDINPVAARFMWVISKRRMA 268 
Hs_T-protein        GAVHLATAILKNPEVKLAGLAARDSLRLEAGLCLYGNDIDEHTTPVEGSLSWTLGKRRRA 298 
Ec_T-protein        KAADFWRALVEA-GVKPCGLGARDTLRLEAGMNLYGQEMDETISPLAANMGWTIAWEP-A 260 
                      . :   ::.   .:  **.***:******: ***::: *  .*: . : *.:. .  * 
 
Lm_T-protein-A      EGGFIGYEPIKYLRDNASKGAVPRLRVGLVSTGPVAREKT---VIEVGGKPVGEVTSGCP 325 
Lm_T-protein-B      EGGFIGYEPIKYLRDNASKGAVPRLRVGLVSTGPVAREKT---VIEVGGKPVGEVTSGCP 325 
Hs_T-protein        AMDFPGAKVIVPQ----LKGRVQRRRVGLMCEGAPMRAHSP--ILNMEGTKIGTVTSGCP 352 
Ec_T-protein        DRDFIGREALEVQR---EHGTEKLVGLVMTEKGVLRNELPVRFTDAQGNQHEGIITSGTF 317 
                      .* * : :        :*      : :   *   .  .        .   * :***   
 
Lm_T-protein-A      SPCLKKNIAIGYLDRELAKDGVKVDLVVRGRRVAAVVVTPPFVPARYYRKPPVKGTEERR 385 
Lm_T-protein-B      SPCLKKNIAIGYLDRELAKDGVKVDLVVRGRRVAAVVVTPPFVPARYYRKPK-------- 377 
Hs_T-protein        SPSLKKNVAMGYVPCEYSRPGTMLLVEVRRKQQMAVVSKMPFVPTNYYTLK--------- 403 
Ec_T-protein        SPTLGYSIALARVPEGIG---ETAIVQIRNREMPVKVTKPVFVRNGKAVA---------- 364 
                    ** *  .:*:. :    .       : :* :.  . * .  **                  
 
Lm_T-protein-A      TPTIKNIAS                                                    394 
Lm_T-protein-B      --------- 
Hs_T-protein        --------- 
Ec_T-protein        --------- 
 
Figure 7.12 Alignment of T-protein sequences 
ClustalW alignment of L. major T-protein-A and -B (LmT-protein-A and -B) (see Table 3.1) with 
homologues in H. sapiens (HsT-protein) (accession number NP_000472) and E. coli (EcT-protein) 
(accession number AAC75943). The alignment indicates identical residues (*), conserved residues 
(:) and homologous residues (.).Red residues indicate conserved motifs within T-proteins. Green 
residues are those that are conserved in bacterial T-proteins but not in HsT-protein or LmT-protein-
A/B. 
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Lm_LipDH        VTTLSGPRSNTHTFPHFTHT----QAHTSMFRRNIAHLAS-YDVTVIGGGPGGYVAAIKA 55 
Hs_LipDH        MQSWSRVYCSLAKRGHFNRISHGLQGLSAVPLRTYADQPIDADVTVIGSGPGGYVAAIKA 60 
Ec_LipDH        -----------------------------------MSTEIKTQVVVLGAGPAGYSAAFRC 25 
                                                          :*.*:*.**.** **::. 
 
Lm_LipDH       AQLGLKTACIEKRGALGGTCLNVGCIPSKALLHATHLYHDAH-ANFAQYGLRGGENVTMD 114 
Hs_LipDH       AQLGFKTVCIEKNETLGGTCLNVGCIPSKALLNNSHYYHMAHGKDFASRGIEMSE-VRLN 119 
Ec_LipDH       ADLGLETVIVERYNTLGGVCLNVGCIPSKALLHVAKVIEEAK--ALAEHGIVFGE-PKTD 82 
                *:**::*. :*:  :***.*************: ::  . *:   :*. *:  .*    : 
 
Lm_LipDH       VSAMQAQKGKGVKALTGGVEYLFKKNKVTYYKGEGSFVNPNTIKVKGLDGKEETLESKKT 174 
Hs_LipDH       LDKMMEQKSTAVKALTGGIAHLFKQNKVVHVNGYGKITGKNQVTATKADGGTQVIDTKNI 179 
Ec_LipDH       IDKIRTWKEKVINQLTGGLAGMAKGRKVKVVNGLGKFTGANTLEVEGENGKT-VINFDNA 141 
                :. :   * . :: ****:  : * .**   :* *.:.. * : .   :*   .:: .:  
 
Lm_LipDH       IVATGSEPTELPFLPFDEKVVMSSTGALDLDHVPKKMIVVGGGVIGLELGSVWARLGAEV 234 
Hs_LipDH       LIATGSEVTPFPGITIDEDTIVSSTGALSLKKVPEKMVVIGAGVIGVELGSVWQRLGADV 239 
Ec_LipDH       IIAAGSRPIQLPFIPHEDPRIWDSTDALELKEVPERLLVMGGGIIGLEMGTVYHALGSQI 201 
                ::*:**.   :* :. ::  : .**.**.*..**::::*:*.*:**:*:*:*:  **::: 
 
Lm_LipDH       TVVEFASRCAAT-TDADVSKALTDALVKHEKMKIMTNTKVVSGTNNGSS-VTIEVEDKDG 292 
Hs_LipDH       TAVEFLGHVGGVGIDMEISKNFQRILQKQG-FKFKLNTKVTGATKKSDGKIDVSIEAASG 298 
Ec_LipDH       DVVEMFDQVIPA-ADKDIVKVFTKRISKKF--NLMLETKVTAVEAKEDG-IYVTMEGKKA 257 
                 .**: .:   .  * :: * :   : *:   ::  :***..   : .. : : :*  .. 
 
Lm_LipDH       -KHQTLEADALLCSVGRRPHTTGLNAEAINLQME-RGFICINDHFETNVPNVYAIGDVVN 350 
Hs_LipDH       GKAEVITCDVLLVCIGRRPFTKNLGLEELGIELDPRGRIPVNTRFQTKIPNIYAIGDVVA 358 
Ec_LipDH       -PAEPQRYDAVLVAIGRVPNGKNLDAGKAGVEVDDRGFIRVDKQLRTNVPHIFAIGDIVG 316 
                   :    *.:* .:** *  ..*.    .:::: ** * :: ::.*::*:::****:*  
 
Lm_LipDH       KGPMLAHKAEEEGVACAEILAGKPGHVNYSVIPGVIYTNPEVAQVGETEEQVKKRGIDYK 410 
Hs_LipDH       -GPMLAHKAEDEGIICVEGMAGGAVHIDYNCVPSVIYTHPEVAWVGKSEEQLKEEGIEYK 417 
Ec_LipDH       -QPMLAHKGVHEGHVAAEVIAGKKHYFDPKVIPSIAYTEPEVAWVGLTEKEAKEKGISYE 375 
                  ******. .**  ..* :**   :.: . :*.: **.**** ** :*:: *:.**.*: 
 
Lm_LipDH       VGKFPFSANSRAKAVGTEDGFVKVVTDKKTDRILGVQIVCTAAGEMIAEPTLAMEYGASS 470 
Hs_LipDH       VGKFPFAANSRAKTNADTDGMVKILGQKSTDRVLGAHILGPGAGEMVNEAALALEYGASC 477 
Ec_LipDH       TATFPWAASGRAIASDCADGMTKLIFDKESHRVIGGAIVGTNGGELLGEIGLAIEMGCDA 435 
                ...**::*..** :    **:.*:: :*.:.*::*  *: . .**:: *  **:* *... 
 
Lm_LipDH       EDLGRTCHAHPTMSEAVKEACMAC-FAQTINF---------                    501 
Hs_LipDH       EDIARVCHAHPTLSEAFREANLAASFGKSINF---------                    509 
Ec_LipDH       EDIALTIHAHPTLHESVGLA--AEVFEGSITDLPNPKAKKK                    474 
                **:. . *****: *:.  *  *  *  :*.           
 
Figure 7.13 Alignment of LipDH protein sequences 
ClustalW alignment of L. major LipDH (LmLipDH) (see Table 3.1) with homologues in H. sapiens 
(HsLipDH) (accession number NP_000099) and E. coli (EcLipDH) (accession number AAC73227). 
The alignment indicates identical residues (*), conserved residues (:) and homologous residues (.). 
Red residues indicate conserved motifs within LipDH proteins. 
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Hs_PDK-1        -ELFKNAMRATMEHHANR--------GVYPPIQVHVTLGN--EDLTVKMSDRGGGVPLRK 49 
Hs_PDK-2        -ELFKNAMRATVESHESS--------LILPPIKVMVALGE--EDLSIKMSDRGGGVPLRK 49 
Hs_PDK-3        -ELFKNSMRATVELYEDRK-------EGYPAVKTLVTLGK--EDLSIKISDLGGGVPLRK 50 
Hs_PDK-4        -ELFKNAMRATVEHQENQ--------PSLTPIEVIVVLGK--EDLTIKISDRGGGVPLRI 49 
Hs_BCKDK        PELLKNAMRATMESHLDTP-------YNVPDVVITIANND--VDLIIRISDRGGGIAHKD 51 
LmjF20.0280     LELMKNAFRATVDSHMKRNDVGMVTCADMPPVRVLINLQEGTEHACICISDEGMGMTDEA 60 
                 **:**::***::   .            . :   :   .   .  : :** * *:. .  
 
Hs_PDK-1        IDRLFNYMYSTAPR----PRV----------ETSRAVPLAGFGYGLPISRLYAQYFQGDL 95 
Hs_PDK-2        IERLFSYMYSTAPT----PQP----------GTG-GTPLAGFGYGLPISRLYAKYFQGDL 94 
Hs_PDK-3        IDRLFNYMYSTAPR----PSL----------EPTRAAPLAGFGYGLPISRLYARYFQGDL 96 
Hs_PDK-4        IDRLFSYTYSTAPT----PVM----------DNSRNAPLAGFGYGLPISRLYAKYFQGDL 95 
Hs_BCKDK        LDRVMDYHFTTAEASTQDPRISPLFGHLDMHSGAQSGPMHGFGFGLPTSRAYAEYLGGSL 111 
LmjF20.0280     LTMAMAYSYTSVSK----PALQLGESG-ERCASTAPSPLAGYGYGLPMSRVYAQSLGGDL 115 
                :   : * :::.      *                  *: *:*:*** ** **. : *.* 
 
Hs_PDK-1        KLYSLEGYGTDAVIYIKALSTDSIERLPVYNKAAWKHYNTNHEADDWCVPSREPKDMTTF 155 
Hs_PDK-2        QLFSMEGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGDWCVPSTEPKNTSTY 154 
Hs_PDK-3        KLYSMEGVGTDAVIYLKALSSESFERLPVFNKSAWRHYKTTPEADDWSNPSSEPRDASKY 156 
Hs_PDK-4        NLYSLSGYGTDAIIYLKALSSESIEKLPVFNKSAFKHYQMSSEADDWCIPSREPKNLAKE 155 
Hs_BCKDK        QLQSLQGIGTDVYLRLRHIDG---------REESFRI----------------------- 139 
LmjF20.0280     LLQTMEGYGTRAYYYIKIADAQP------LCDEETK------------------------ 145 
                 * ::.* ** .   ::  .           .   :                         
 
Hs_PDK-1        RSA-             158 
Hs_PDK-2        RVS-             157 
Hs_PDK-3        KAKQ             160 
Hs_PDK-4        VAM-             158 
Hs_BCKDK        ---- 
LmjF20.0280     ---- 
 
Figure 7.14 Alignment of the ATPase/kinase domains of known PDH kinase proteins with a 
potential L. major α-KADH kinase, LmjF20.0280 
ClustalW alignment of LmjF20.0280 (see Table 3.1) with: H. sapiens PDK-1 (HsPDK-1) (accession 
number NP_002601); H. sapiens PDK-2 (HsPDK-2) (accession number NP_002602); H. sapiens 
PDK-3 (HsPDK-3) (accession number NP_005382); H. sapiens PDK-4 (HsPDK-4) (accession 
number NP_002603); H. sapiens BCKDK (HsBCKDK) (accession number NP_005872). The 
alignment indicates identical residues (*), conserved residues (:) and homologous residues (.). Red 
residues indicate conserved motifs within PDK and BCKDK proteins. Orange residues are those 
required for binding of PDK proteins to the E2p lipoyl-domain 2 (L2) of the PDH complex. 
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Hs_PDK-1        -ELFKNAMRATMEHHANR-GVYPPIQVHVTLG--NEDLTVKMSDRGGGVPLRKIDRLFN- 55 
Hs_PDK-2        -ELFKNAMRATVESHESS-LILPPIKVMVALG--EEDLSIKMSDRGGGVPLRKIERLFS- 55 
Hs_PDK-3        -ELFKNSMRATVELYEDRKEGYPAVKTLVTLG--KEDLSIKISDLGGGVPLRKIDRLFN- 56 
Hs_PDK-4        -ELFKNAMRATVEHQENQ-PSLTPIEVIVVLG--KEDLTIKISDRGGGVPLRIIDRLFS- 55 
Hs_BCKDK        PELLKNAMRATMESHLDTPYNVPDVVITIANN--DVDLIIRISDRGGGIAHKDLDRVMD- 57 
LmjF24.0010     CAMLEDAVSANVDRQERTGKECTKIEVTLAQWPTNKRFVLRISDTAGGMTLRQASMQLSC 60 
                  :::::: *.::         . :   :.    .  : :::** .**:. :  .  :.  
 
Hs_PDK-1        -YMYSTAPR----PRV----------ETSRAVPLAGFGYGLPISRLYAQYFQGDLKLYSL 100 
Hs_PDK-2        -YMYSTAPT----PQP----------GTG-GTPLAGFGYGLPISRLYAKYFQGDLQLFSM 99 
Hs_PDK-3        -YMYSTAPR----PSL----------EPTRAAPLAGFGYGLPISRLYARYFQGDLKLYSM 101 
Hs_PDK-4        -YTYSTAPT----PVM----------DNSRNAPLAGFGYGLPISRLYAKYFQGDLNLYSL 100 
Hs_BCKDK        -YHFTTAEASTQDPRISPLFGHLDMHSGAQSGPMHGFGFGLPTSRAYAEYLGGSLQLQSL 116 
LmjF24.0010     WSLYRNIQG----------------HNQDTISTWTSSPIRLPYAYNAARVIGGNITLASI 104 
                   : .                          .  .    ** :   *. : *.: * *: 
 
Hs_PDK-1        EGYGTDAVIYIKALSTDSIERLPVYNKAAWKHYNTNHEADDWCVPSREPKDMTTFRSA- 158 
Hs_PDK-2        EGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGDWCVPSTEPKNTSTYRVS- 157 
Hs_PDK-3        EGVGTDAVIYLKALSSESFERLPVFNKSAWRHYKTTPEADDWSNPSSEPRDASKYKAKQ 160 
Hs_PDK-4        SGYGTDAIIYLKALSSESIEKLPVFNKSAFKHYQMSSEADDWCIPSREPKNLAKEVAM- 158 
Hs_BCKDK        QGIGTDVYLRLRHIDG---------REESFRI--------------------------- 139 
LmjF24.0010     EGYGTDRQLYLPSTGLAGVSL-------------------------------------- 125 
                .* ***  : :   .                                             
 
Figure 7.15 Alignment of the ATPase/kinase domains of known PDH kinase proteins with a 
potential L. major α-KADH kinase, LmjF24.0010 
ClustalW alignment of LmjF24.0010 (see Table 3.1) with: H. sapiens PDK-1 (HsPDK-1) (accession 
number NP_002601); H. sapiens PDK-2 (HsPDK-2) (accession number NP_002602); H. sapiens 
PDK-3 (HsPDK-3) (accession number NP_005382); H. sapiens PDK-4 (HsPDK-4) (accession 
number NP_002603); H. sapiens BCKDK (HsBCKDK) (accession number NP_005872). The 
alignment indicates identical residues (*), conserved residues (:) and homologous residues (.). Red 
residues indicate conserved motifs within PDK and BCKDK proteins. Green residues are those that 
are strictly conserved in PDK and BCKDK proteins but not in LmjF24.0010. Orange residues are 
those required for binding of PDK proteins to the E2p lipoyl-domain 2 (L2) of the PDH complex. 
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